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Prologue
“Cardiovascular Endocrinology, a new dimension in Medicine”
Sir-From daily clinical practice we are aware that only about40% of all cardiovascular events can be explained by theclassical cardiovascular risk factors (such as hypertension,
dyslipidaemia, and obesity). In line with James Parle and colleagues’
report (1) additional pathophysiological mechanisms need to be inves-
tigated, especially in relation to hormonal disturbances. 
We have noted increased concentrations of highly atherogenic
lipoprotein remnants in active acromegaly (2). Moreover, premature
atherosclerosis is a clinical feature in adult-onset growth hormone
(GH) deficiency syndrome. We have reported an improved postpran-
dial atherogenic lipoprotein remnant profile and endothelial function
after GH substitution (3).
Bengtsson and Johansson (4) summarised the beneficial effects of GH
therapy on early atherosclerotic changes in GH-deficient adults. The
cardiovascular importance of the GH/insulin-like growth factor
(IGF) axis and the efforts to treat disturbed activity is a further example
of endocrinological intervention in cardiovascular disease. Scientific
progress has been made in this area, in which left-ventricle dysfunction
improved after chronic subcutaneous Ghrelin administration in a rat
model (5). Ghrelin in treatment of chronic heart failure in men may,
therefore, become an option in the future.
Concordant with effects of disturbed activity of the GH/IGF axis in
cardiovascular function, we postulate that other disturbed hormonal
systems will have an effect on cardiovascular disease. Of course, this
hormonal-cardiovascular interaction needs to be studied more thor-
oughly. We believe these developments support the importance of a
new multidisciplinary approach, which may create a new dimension in
medicine-cardiovascular endocrinology.
Lancet 2002; 359:799
X
General Introduction
complex relationship exists between
disease of the cardiovascular system
and a spectrum of neural and
humoral factors. Recently, the modulating
role of hormones, such as thyroid hormone
(6-9), in the atherosclerotic process has been
emphasized. However, several other hor-
mones, in addition to thyroid hormone, may
contribute to atherogenesis, thereby consti-
tuting a key element in the concept of car-
diovascular endocrinology (10). Recently,
evidence has been provided to suggest that
disturbances of the pituitary growth hor-
mone (GH) axis and its mitogenic partners,
including insulin-like growth factor-1 (IGF-
1) and IGF-binding proteins (IGFBP), are
critical actors in the initiation of atheroscle-
rotic processes (4; 11; 12).
GH axis/IGF system
The GH axis originates in the cerebrum with
the brain structures, hypothalamus and pitu-
itary, as regulation centers (figure 1). Growth
hormone releasing hormone (GHRH)
releases, whereas insulin-like growth factor-I
(IGF-I) inhibits secretion of GH from the
somatotrope cells in the anterior lobe of the
pituitary. Recent evidence supports the
notion that GH release from the pituitary is
controlled not only by GH-RH and Somato-
statin from the hypothalamus, but also by
GHrelin from the stomach and hypothala-
mus. GH is secreted from the anterior pitu-
itary in an individual diurnal pattern, with the
highest serum peak levels early in the night.
In the circulation, GH is mostly bound to
GH binding protein (GHBP). Only
unbound GH has biological activity. The GH
axis is superimposed on the IGF system. The
insuline-like growth factors (IGF-I and IGF-
II) are important factors in the regulation of
somatic growth, cellular proliferation and
metabolism. This regulation is modulated
further by at least six distinctive insulin-like
growth factor binding proteins (IGF BPs)
and IGF BP proteases (13). Both IGF-I and
IGF-II are synthesized and secreted from the
liver and they are mainly bound to the IGF
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Figure 1. 
The G Haxis/ IGF system with its principal components.
BP-3. The total plasma pool of IGF-II is
twice that of IGF-I. The synthesis of IGF-I
and IGF BP-3, but not IGF-II, is under regu-
lation by GH and  environmental factors
(e.g. nutritional status)(14). Both IGF-I and
IGF-II are products of a single gene, located
on the arm of chromosome 12 (IGF-I), and
on the short arm of chromosome 11 (IGF-
II)(15) In addition, the proportion of vari-
ance attributable to genetic effects for the
concentration of IGF-I was 38%, IGF-II:
66% and IGF BP-3: 60%. Therefore a sub-
stantial genetic contribution is responsible
for the interindividual variation of circulating
IGF-I, IGF-II, and IGF BP-3 (16). 
The availability of biological active (free cir-
culating) IGF-I is determined by its binding
on the IGFBP complex, which consist of a
140 kDa, or a smaller 40 kDa IGF-IGF BP
complex. Most circulating IGF-1 and IGF-II
(in an equimolar ratio) is sequestered by IGF
BP-3 (38 kDa to 43 kDa, depending upon the
number of sites that are glycolsylated), asso-
ciated with the 80 kDa acid labile subunit
(ALS) in a GH-dependent large complex,
leading to an increased residence time in
plasma (17). The proteolytic enzymes that
are bound to the apical side of tissue capillar-
ies break down the large fraction into smaller
GH-independent 40 kDa fractions (consist-
ing only of IGF-I and IGF BP-3), that are
capable to transfer into extra capillary tis-
sues. This extravasation results in dissocia-
tion of IGF-I, and probably of IGF-II, from
the 40 kDa complex, thereby enabling its
biological activities in local tissues (18). The
local level of free exchangeable IGF-1 is of
biological importance for its paracrine/
autocrine effects, such as cell proliferation,
prevention from apoptosis and synthesis of
nitric oxide (NO). In addition to the synthe-
sis of IGF-1 in the liver, GH also stimulates
IGF-1 expression in other tissues; which has
local autocrine and paracrine actions (vide
infra). 
GH deficiency
The GH axis is one of the first hormonal axis
that is defective in pituitary disease. Nowa-
days, the effects of a relative deficiency in
GH axis/IGF system on metabolic processes
are recognized. A decreased GH secretion,
and subsequently, a decreased plasma level of
total IGF-1 is observed in ageing and in
patients with type 2 diabetes mellitus and/or
premature atherosclerosis. In the general
population, a low serum total IGF-1 level
(without the analysis of GH secretion) gives
rise to an increased risk on ischemic heart
disease (IHD)(19). In addition, disturbances
in the signalling of the GH receptor lead to a
GH resistant state (defined as: inappropri-
ately high serum GH with low serum total
IGF-1 and IGFBP-3 levels) that is mostly
associated with catabolic conditions, such as
General Introduction
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Table 1: Cardiovascular mortality in patients with adult-onset GH deficiency, due to panhy-
popituitarism
Authors Study Cardiovascular Remarks
design mortality
Bulow, et al (26) retrospective increased; SMR 1.4 F>M; cerebrovascular > 
cardiovascular
Nilsson, et al (23) retrospective increased; SMR 1.6 F>M; cerebrovascular > 
cardiovascular
Bates, et al (27) retrospective not increased; SMR 1.2
Tomlinson, et al (28) prospective increased; SMR 1.8 associated with androgen 
deficiency
SMR: standard mortality rate; F: female; Male:male
chronic heart failure, progressive cancer or
end-stage renal failure (20; 21). Taken togeth-
er, the term of GHD includes nowadays a
broader range of separate insufficiencies or
deficiencies in the GH axis IGF system than
a decade ago.
Acromegaly 
GH-secreting pituitary adenomas are the
most frequent cause of acromegaly. Chronic
high circulating GH levels (with plasma GH
levels in the range from 5 to 500 ng/mL)
result in an increased plasma IGF-I level,
which results in several metabolic distur-
bances, one of which is insulin resistance. 
Accelerated atherosclerotic disease
AGHD
In several retrospective studies, cardiovascu-
lar mortality in AGHD is increased in com-
parison with a matched healthy population.
The first report by Rosèn and Bengsston
showed an increased cardiovascular mortality
in subjects with panhypopituitarism substi-
tuted with adrenal, gonadal and thyroid hor-
mones, as compared to an age- and gender-
matched control population (standard
mortality rate, 1.8) (22). Subsequent reports
have confirmed this observation (23-
28)(Table 1).
No long term effects of GH therapy on the
vascular mortality are known at present,
although short term analysis of GH interven-
tion in AGHD patients shows a decrease in
the increased cardiovascular mortality. How-
ever, long term randomised follow-up GH
intervention trials will definitively answer
whether GH treatment in AGHD patients
will result in reduction of cardiovascular
mortality.
Acromegaly 
Intriguingly,  increased mortality from car-
diovascular disease is observed in acromegaly.
Although cardiomyopathy is presented as a
major cause of death, atherosclerotic disease
is equally reported as an underlying cause in
acromegaly. 
In general, the relationship between mortali-
ty due to cardiovascular diseases and distur-
bances in the GH axis/IGF system is best
represented by a U-curve: revealing an
increased mortality in both GH deficiency
and in GH excess.
Lipoprotein metabolism
Disturbances in the GH axis/IGF system
coincides with abnormalities in lipoprotein
metabolism. Lipoproteins which originates
from the intestine or liver, are major carriers
for lipids in the circulation. Dietary fatty
acids are absorbed in the small intestine,
packaged  into chylomicrons and secreted
into the circulation via the lympatic system
(exogenous lipid pathway).  Chylomicrons
display a size of 0.1 to 1.0 µM, and a chemical
composition in weight percentage of  TG
87%, cholesterol 3%, phospholipids 9% and
proteins 2%. The major structural protein of
chylomicrons is apolipoprotein B-48. In the
circulation, chylomicrons are enriched with
apo E which facilitate receptor-mediated
uptake in the liver. 
The liver secretes very low density lipopro-
teins (VLDL) that possess apo B-100 as their
major structural protein. This pathway is
called the endogenous lipid pathway. Major
functional apolipoproteins are apo C-I, apo
C-II, apo C-III and apo E. VLDL particles
have a size between 300 and 800 Å, and
chemical composition expressed as weight
percentage consists of: TG 50-60%, choles-
terol 17%, phospholipids 19% and proteins
10%. This pathway is called endogenous lipid
pathway. 
In the circulation, both chylomicrons- and
VLDL-triglycerides are hydrolysed by
lipoprotein lipase (LPL) via a so-called com-
mon saturable pathway (29). This enzyme is
attached to the luminal side of the endotheli-
um. Lipolysis is catalysed by apo C-II, and
inhibited by apo C-III. The  lipid particle
which remains after lipolysis and intravascu-
lar remodelling by hepatic lipase and CETP,
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is called a remnant particle. Apo B-48 con-
taining remnant particles are preferentially
taken up by apo B-48 receptors at the hepatic
surface (30), whereas apo B-100 containing
particles may either be taken up via the LDL-
receptor by hepatocytes or be further
processed into smaller lipid particles, such as
intermediate density lipoprotein (IDL) and
low density lipoproteins (LDL) that are
more enriched in cholesteryl-esters by cho-
lesteryl-ester transfer protein (CETP) (31).
High density lipoprotein (HDL) with apo
AI as principal protein, removes cholesterol
from the peripheral cells. HDL cholesterol is
esterified by lecithin: cholesterol acyltrans-
ferase (LCAT), forming cholesteryl esters
(CE). This HDL-CE is returned to the liver
by: 1. transfer of CE from HDL to triglyc-
eride-rich particles by CETP (as apo B-48
and apo B-100) or 2. by selective uptake by
scavenger receptor B1(32). 
Catabolic lipid pathways are mediated
through receptors that are expressed at the
hepatic surface. Apo B-48 lipid particles are
taken up by LDL-receptors, apo B-48 recep-
tors and LRP (LDL-receptor related protein)
receptors (33). The LDL-receptor expression
is dependent upon intracellular cholesterol
content; the more cholesterol in the hepato-
cyte, the less expression of LDL-receptors.
No relation is found between intracellular
cholesterol content and hepatic LRP expres-
sion. Apo E facilitates particle uptake by the
LDL receptor. 
Glucose homeostasis 
Glucose is a major substrate for metabolic
fuel. Some tissues and cells are completely
dependent on glucose  (e.g. erythrocytes and
brain) for their energy metabolism. Plasma
glucose levels are therefore strictly con-
trolled by several hormones. Dietary glucose
is absorbed by enterocytes and delivered to
insulin-sensitive tissues, such as liver and
skeletal muscles for storage of glucose in the
form of glycogen (glycogenesis). In the fast-
ing and postabsorptive period, glucose is
released by degradation of stored glycogen
(glycogenolysis), and by gluconeogenesis.
Glycogen stores are limited (150 g in the
liver, and 300 g in skeletal muscles). The
glycogene stores in skeletal muscles are
direct sources for energy substrate (e.g. dur-
ing exercise). Regulation of the glycogenoly-
sis metabolism is reciprocal and depends
upon two key enzymes: glycogen phospho-
rylase (glycogenolysis) and glycogene syn-
thase (glycogenogenesis). These enzymes are
activated by phosphorylation that is itself
regulated by hormones (such as adrenalin,
insulin and glucagon). Due to limited stores
of glycogen, gluconeogenesis (GNG) will
contribute most to the circulating glucose
after 24 to 36 hours of fasting. The process
of GNG takes place for 80% in the liver, and
20 % in the kidney. After a 10 day period of
fasting, both kidney and liver contribute
equally through GNG to the amount of cir-
culating glucose. For GNG, the precursors
are pyruvate and lactate (a total contribution
of 35%) that are derived from the red blood
cell and skeletal muscle, alanine (a total con-
tribution of 35%) that is derived from skele-
tal muscle, and glycerol (a total contribution
of 8 %) that is derived from adipose tissue.
Entry in the GNG pathway is at three levels:
1. through pyruvate (lactate and alanine), 2.
through phosphoenolpyruvate (glutamate)
and 3. through dihydroxyaceton phosphate
(glycerol). Its regulation occurs at different
levels in the GNG pathway, that depends
mostly upon glucagon, the substrate avail-
ability (alanine), the NADH/NAD+ bal-
ance and the level of available ATP. Fatty
acids degradation provides additional compo-
nents, such as acetyl-Co A and NADH/
NAD+, that facilitates GNG. 
Under physiological conditions, catabolism
of amino acids from the skeletal muscle to
supply substrate for GNG is quantitatively
not important. However, in pathological
conditions, the release of alanine by skeletal
muscle, as a precursor for GNG, results in an
increase in GNG (through pyruvate), but
also of an increase of urea synthesis through
glutamate (Felig Cyclus). Consequently,
General Introduction
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increased plasma glutamate levels are found.  
All steps that limit the availability of glucose
for degradation (glycolysis) are related to the
biological action of insulin. Insulin resistance
may be a manifestation of a defect in glucose
transport (GLUT4; in muscle and adipose
tissue), in decreased expression of enzymes
required in the glycolytic cascade (ie hexoki-
nase, glucokinase, fosfokinase I, pyruvate
dehydrogenase) or further downstream in
the glycolytic pathway.  In general, progres-
sive hyperglycemia, or finally type 2 diabetes
mellitus, is due to combination of peripheral
insulin resistance and impairment in insulin
secretion by the insulin-secreting β-cells in
the pancreas (34). The function of insulin
secreting beta cells is under influence of the
different receptors that are involved in the
action of insulin and the IGF system. The
capacity to compensate for hyperglycemia is
related to the maximal insulin secretion.
Indeed, in type 2 DM patients who are
unable to compensate for hyperglycemia, a
decrease in β-cell mass, due to increased
apoptosis of insulin secreting cells, was
detected (35). Local growth factors, such as
IGF-I and IGF-II, control apoptosis (in case
of IGF-I), and increase β-cell growth (in case
of IGF-I and IGF-II). Receptors for IGF-I
and IGF-II are present in the pancreas.
Knock-out mice for the IGF-I receptor in
the pancreas cell showed an absent first phase
and a blunted second phase insulin secretion
response (36). IGF-II is a part of the glucose
sensitising mechanism in the pancreas that
forms an autoregulatory loop to control the
definite insulin secretion; insulin secretion is
known to adapt to systemic needs for insulin,
and in systemic insulin profiles mostly reflect
peripheral sensitivity to insulin action in man
(37). 
GH/IGF and myocardial adaptation 
Both GH and IGF-I have trophic effects on
cardiac muscle. Receptors for GH and IGF-I
are found on the surface of cardiomyocytes,
but also in the endothelium of the coronary
artery. The expression of the IGF-I receptor
in cardiomyocytes is facilitated by GH. An
increase of systemic GH, due to hormonal
substitution in AGHD or in excess in
acromegaly, give rise to vasodilation of arter-
ies, with a decrease in cardiac afterload. The
ejection fraction of the left ventricle increas-
es after start of GH therapy in AGHD. In
excessive amounts of systemic GH, a
decreased after load increases heart frequen-
cy to maintain constant heart minute vol-
umes, and subsequently the work load of the
heart increase. Such long-term periods defi-
nitely result in diastolic dysfunction, with a
decrease in left ventricular function.  
In situations of an increased work or stress
load, the heart is in adaptation. During adap-
tation, cardiomyocytes express more local
tissue IGF-I. The expression of local IGF-I
is under influence of the GH axis that deter-
mine the level of IGF-I receptors on the car-
diomyocyte. The exact pathway that regu-
lates the local expression of IGF-I in tissue is
not elucidated yet. Downregulation of the
expression of IGF-I with a subsequent rise in
angiotensin-II gives maladaptation with heart
failure. Therefore, IGF-I has trophic effects,
controls apoptosis and hypertrophy of car-
diomyocytes. Hypertrophic adaptations of
the heart muscle are also found in cardiomy-
opathy, that most frequently results from
ischemic heart disease (38).  Indeed,
although results are not yet conclusive, inter-
vention with GH in patients with ischemic
heart disease gives rise to an increase in ejec-
tion force of the left ventricle, and GH sub-
stitution may therefore be beneficial in this
kind of patients (39). 
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7Outline of the thesis
To study metabolic disturbances in lipoprotein metabolism in thefasting and postprandial state, that may explain the increased car-
diovascular risk, observed in patients with disturbances in the GH
axis/IGF system (adult-onset growth hormone deficiency (AGHD) and
acromegaly). 
To study the suitability of a recently introduced immuno-separationmethod (remnant-lipoprotein particle; RLP) to further character-
ize the atherogenic lipoprotein phenotype in patients with disturbances
in the GH axis/IGF system, and in patients with heterozygous familial
hypercholesterolemia (FH).
To study disturbances in glucose homeostasis occurring during dys-function in the GH axis/IGF system.
To study the relationship between cardiac function and acromegaly.
8
General Discussion
ndothelial dysfunction, as a surrogate
marker for atherosclerotic disease
Previous studies in adult-onset GH
deficiency have revealed a significant associa-
tion with GH deficiency and the progression
atherosclerotic disease (4; 4; 22). Pfeifer et al
(40) showed an increased carotid intima-
media thickness in AGHD, which was
decreased by growth hormone treatment. In
addition, the function of the endothelium is
impaired (chapter 1.6). GH and IGF-1 both
have an inductive effect on the endothelial
nitric oxide (NO) system. In GH deficiency,
a deficit in NO production occurs in the
endothelium. This depletion in endothelial
NO is associated with endothelial dysfunc-
tion, and thus early atherogenic disease
(41;42). In chapter 1.6, the flow mediated
dilation (FMD) in AGHD patients was
decreased before the start of GH therapy
(5.9 ± 3.3%), and improved after substitu-
tion with GH to 10.2 ± 4.0%. An improve-
ment of endothelial function, arterial stiff-
ness and IMT in AGHD patients after the
start with GH therapy is supported by sever-
al recent studies (43; 44). Evans et al (45)
indicate that an increased oxidative stress,
measured as the concentration of lipid-
derived free radicals by paramagnetic reso-
nance, may influence endothelial function in
AGHD patients. Treatment with GH results
in improvement of these parameters. Baseline
FMD values (chapter 1.11), were impaired in
active acromegalic patients (5.4 ± 3.1 %,
Twickler et al, personal communication).
Although treatment of active acromegalic
patients will improve the FMD, the values
are still not in the range that are observed in
healthy subjects, matched for BMI, age and
sex (46). These observations confirm the
importance of the GH axis/IGF system in
endothelial dysfunction.    
Atherogenic Lipoprotein Phenotype in
AGHD
The origin of the “progressive”, but also to
some extent rapidly reversible,  atheroscle-
rotic disease in AGHD patients, as shown by
distinctive methods (such as IMT, FMD and
arterial impedance), remain a subject of dis-
cussion. It has been reported that the elevat-
ed plasma LDL-cholesterol levels in AGHD
patients (47) are the most prominent risk
factor. However, plasma LDL-cholesterol is
only marginally elevated (chapter 1.5, 1.6,
1.7) (3.37 - 4.12 mmol/L)(48). The clinical
impact of small elevations in LDL-choles-
terol levels is still under debate, and more-
over, no point is obtained for a borderline
high plasma LDL-cholesterol in the risk
assessment in the NCEP score sheet that
estimates the 10-year risk. During GH thera-
py, plasma LDL-cholesterol level in AGHD
patients decrease by 16% (chapter 1.6).
According to ATP III of the NCEP guide-
lines, in chapters 1.4, 1.5, 1.6 and 1.7 plasma
TG levels in AGHD patients are within the
borderline high range from 1.71 to 2.27
mmol/l. After starting GH therapy, plasma
TG levels in AGHD patients tend to
increase. Plasma HDL levels are in the nor-
mal range, and decrease only slightly during
GH treatment. LDL-cholesterol, TG, and
HDL-cholesterol do not completely explain
the progressive atherosclerotic disease and
increased cardiovascular mortality in distur-
bances in the GH axis/IGF system.
Triglyceride-rich remnant particles (TRP) are
of special interest in the assessment of an
atherogenic lipid phenotype. Several studies
have shown that the importance of smaller,
more atherogenic, TRPs (such as intermedi-
ate density lipoprotein; IDL), are related to
carotid artery IMT (MARS study (49)). The
calculated non-HDL cholesterol was a better
predictor for cardiovascular disease than
plasma levels of LDL-cholesterol. The mor-
tality after a first cardiovascular ischemic
event is dependent upon plasma RLP-C lev-
els at entry of the study (50). In an evalua-
tion of fasting and postprandial plasma RLP-
C levels in healthy subjects, the fasting
plasma RLP-C levels were <0.20 mmol/L,
and tended to be higher in male than in
female subjects (chapter 1.2). Postprandially
the RLP-C peak level was at 3 h, while the
peak level of retinyl ester, a marker for
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dietary fatty acid uptake and metabolism,
was 2 h later, thereby illustrating that both
markers represent different features of the
intravascular metabolism of the TG-rich par-
ticle fraction. Probably, RE that is isolated
from the Sf<1000 fraction, represent the fate
of larger-sized TG-rich chylomicron particles
(Sf<1000). Postprandial peak in RE Sf<1000
was higher in AGHD patients than in nor-
molipidemic control subjects. In line with
recent literature, RLP-C is considered to be
more closely related to the atherogenic
process in vivo, such as endothelial dysfunc-
tion, IMT and induction of pro-inflamma-
tion (chapter 1.8, 1.11). This recent focus on
lipoprotein remnants could be an important
development in defining more closely the
atherogenic lipid phenotype, in general and
in patients with disturbances in the GH
axis/IGF system in particular. 
Plasma RLP-C levels in AGHD patients are
1.5 fold increased, as compared to control
subjects (table 1). In acromegaly, plasma
RLP-C levels were even higher (0.40 ±( 0.13
mmol/l ). In Japanese patients, in whom nor-
mal plasma RLP-C levels are twofold lower
than in Caucasians, plasma RLP-C > 0.14
mmol/l are a strong predictor of subsequent
cardiovascular events (OR 6.38, 95% CL 2.3-
17.6; p<0.01), even after the inclusion of
high LDL-cholesterol (> 3.4 mmol/l) in the
Cox analysis (50). In a subanalysis of the
Framingham study in which the relationship
between plasma RLP-C levels and cardiovas-
cular events in postmenopausal women was
investigated, plasma RLP-C of more than
0.14 mmol/L were associated with an
increased cardiovascular mortality, independ-
ent from plasma levels of TG, HDL- and
LDL-cholesterol (51). In conclusion, plasma
RLP-C levels are part of the atherogenic pro-
file in AGHD patients. 
Knowledge of plasma RLP-C levels in pri-
mary dyslipidemic diseases, such as heterozy-
gous familiar hypercholesterolemia, is rare.
Familiar hypercholesterolemia is character-
ized by a defect in the function of the LDL-
receptor, leading to accumulation of LDL-
cholesterol. This defective removal of plasma
LDL-cholesterol may give rise to a disturbed
removal of lipoprotein remnants. Notably,
the LDL-receptor is also part of the lipopro-
Elevated Remnant-Like particle cholesterol (RLP-C) concentration
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Table 2: Plasma fasting and postprandial RLP-C levels in populations at elevated cardiovascular
risk.
Plasma RLP-C Area under the incremental
(mmol/L) postprandial RLP-C curve
levels (mmol/l/h)
Healthy control subjects 0.18 ± 0.06 1.14 ± 0.61
Patients
Familial Hypercholesterolemia (FH)
Before Statin therapy 1.09 ± 0.50a 3.14 ± 1.8a
During Statin therapy 0.26 ± 0.12b 0.34 ± 0.6b
Adult-onset GH deficiency (AGHD)
Before rhGH therapy 0.29 ± 0.14 2.13 ± 1.60a,b
During rhGH therapy 0.32 ± 0.09 0.73 ± 0.34
Acromegaly 0.40 ± 0.13a 2.14 ± 1.19a
All values are expressed as mean ± SD. a: P<0.05, compared to control subjects, b:P<0.05, patients treated vs. untreated.
tein remnant removal pathway. Ongoing dis-
cussion exists regarding the presence of
lipoprotein remnant accumulation in FH in
the postprandial period. In chapter 1.10 and
1.11, we showed that plasma RLP-C levels in
heterozygous FH patients are increased in
both baseline as well as in the postprandial
state (Table 2). Treatment with high dose
simvastatin (80 mg once a day) decreased,
but did not completely normalise plasma
RLP-C levels. Therefore, focussing on LDL-
cholesterol profile only in these patients may
limit the assessment of the atherogenic phe-
notype and the  interpretation of treatment
goals. To confirm the hypothesis that plasma
RLP-C is related to atherosclerotic disease,
IMT of the carotid artery was analysed
together with the RLP-C profile, in a subset
of FH patients (chapter 1.11). Indeed, the
carotid artery IMT was positively associated
with plasma RLP-C levels, but LDL-choles-
terol levels remain the major predictor for
IMT in a multivariate analysis. These obser-
vations strengthen the hypothesis that plas-
ma RLP-C levels complete the atherogenic
profile, even in the classic dyslipidemia FH.   
Previous studies have confirmed that increase
in postprandial RLP-C is related to abnor-
mality in endothelial  function. Reduction in
postprandial plasma levels of RLP-C by
statin treatment attenuates endothelial func-
tion (52;53). As stated previously, endothe-
lial dysfunction is one of the first key steps
in athrosclerotic diease. Postprandial plasma
RLP-C levels are increased in both AGHD
(chapter 1.6), and in active acromegalic
patients (chapter 1.12). In addition to distur-
bances in the GH axis/IGF system, these ele-
vated postprandial RLP-C levels increase the
atherogenic burden. This conclusion is con-
firmed by Doi et al who found that incuba-
tion of RLP in endothelial models shows a
dose-dependent effect of RLP on the
endothelial function (54). Further evidence
was obtained by Dichtl et al (55) showed
that an increase of arterial expression of NF-
κβ, VCAM-I, ICAM-I, and  TNF-α was
found in rats, but that this phenomenon
occurred after a lag time of 12 hours after
infusion of VLDL. A pro-inflammatory reac-
tion is recognized as one of the first steps in
the initiation of early atherosclerosis (56-58).
In chapter 1.8, an induction of the inflamma-
tory response with an increase in TNF-α and
IL-6 in AGHD patients was found in the
postprandial period.  The peak level of both
TNF-α and IL-6 was found between 10 and
12 hours after intake of the fat, and 6 to 8
hours after the peak level of RLP-C with a
positive association between the postprandial
IL-6 and RLP-C profile (r2=0.44, P<0.05). 
In the classic representation of initiation of
the atherosclerotic process, oxidation of
LDL is an important step. After retention of
LDL in the subendothelial space, oxidative
processes and oxidized LDL give rise to
inflammation (59). Huff et al (60) previously
showed that lipolysed triglyceride-rich parti-
cles (remnants) may be oxidized and taken
up in macrophages. In line with these results,
we found that RLP-C of type II-B dyslipi-
demic patients can be easily oxidized (chap-
ter 1.3). Moreover from FPLC analysis we
learned that  85 % of the RLP in type II-B
dyslipidemic patients is in the VLDL-1
range, and 15 % in the VLDL-2 and IDL size
range. A recent report noted that VLDL-1 is
a favourable substrate for lipid accumulation
in human monocyte-macrophages (61). The
in vitro experiments indicate that RLP is a
fraction that induces early atherogenic com-
ponents, such as oxidation and foam cell for-
mation (not shown in the present results),
and that induction of a postprandial inflam-
matory response in AGHD patients may be
caused by RLP related interactions with the
endothelium and components in the sub-
endothelial space. 
In GH deficiency,  the expression of the
hepatic LDL-receptors is decreased in both
human and in animal models (62). Decreased
removal of lipoprotein particles by the LDL-
receptor result in higher plasma levels of
LDL-cholesterol and RLP-C. (figure 2)
Additionally, a second receptor, LRP, is
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involved in the removal of lipoprotein rem-
nants so that the removal of RLP-C is only
partly inhibited. An increase in synthesis and
secretion of apo B-100 VLDL (enriched in
TG) in AGHD patients is found (63; 64).
However, the intravascular remodelling of
TG-rich lipoproteins by lipolysis in AGHD
patients remained unchanged because no
decrease in postheparin activity of both
lipoprotein lipase and hepatic lipase was
found (in contrast to rodents) (65). During
GH therapy, cholesterol synthesis, reflected
by plasma concentrations of cholesterol
intermediates as mevalonic acid, is still
increased, compared to control subjects
(chapter 1.7). However, plasma LDL-choles-
terol is decreased in AGHD patients due to
the up-regulation of the hepatic LDL recep-
tor (66). GH substitution in a LDL-receptor
knock-out model showed an increase in the
7-alpha hydroxylase pathway (67). This leads
to the hypothesis that a larger part of the
intrahepatic cholesterol pool will be released
into the bile acid pool, resulting in an
increased removal of cholesterol from the
circulation via LDL uptake. In humans,
depletion of intracellular cholesterol also
reduces synthesis of the VLDL-2 sub-frac-
tion (68). Thus, although plasma LDL-cho-
lesterol levels in AGHD patients decrease
during GH therapy, plasma RLP-C and
VLDL-1  remain elevated, due to the fact
that TG secretion is still elevated. 
In acromegaly, plasma RLP-C in both the
fasting and postprandial state was elevated.
The origin of this disturbed RLP-C profile is
related to a lower postheparin LPL activity in
active acromegalics (chapter 1.12). This
reduced LPL activity give rise to postprandial
accumulation of both intestinal and liver
derived TRP. Fasting plasma levels of TG was
positively related to the postprandial RLP-C
response. Besides the deficient intravascular
remodelling pathway, the increased insulin
resistance, that is reflected by an elevated
HOMA index, will give rise to a disturbed
postprandial lipoprotein metabolism, with an
increase in especially the VLDL-1 pool and
dense LDL. As previously stated, RLP frac-
tion is mostly within the size range of
VLDL-1, and this physical relation may
explain its increased baseline levels in active
acromegaly.  
The baseline plasma RLP-C levels are closely
associated with postprandial RLP response,
when studying postprandial mtabolism. Post-
prandial studies are time consuming and
laborious for both patient and clinician. Con-
sequently, Schaeffer et al (69) therefore ques-
tioned whether a postprandial approach is
necessary to define the atherogenic lipid phe-
notype, with a final negative conclusion
From our results, the RLP-C response was
associated with baseline RLP-C in both con-
trol subjects, as in studied patient groups
(AGHD, FH, and acromegaly). 
GH/IGF and pro-diabetic phenotype
Glucose homeostasis in GH deficient
patients is similar to that in normal subjects.
Several reports have shown a decreased
glycogen store in skeletal muscle, and a
decrease in insulin sensitivity. In contrast, we
and others were not able to find any differ-
ence in the insulin sensitivity. GH therapy in
Elevated Remnant-Like particle cholesterol (RLP-C) concentration
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Figure 2 The relastionship between the GH axis/IGF system
and the lipoprotein metabolism; the effect of GH therapy
AGHD patients is the cause of a shift in glu-
cose homeostasis with a decrease in insulin
sensitivity. The amount of rhGH substitu-
tion is directly associated with the insulin
sensitivity. Therefore, lower start dosages of
daily rhGH are not associated with major
changes in insulin sensitivity.  Indeed, we
have observed (chapters 1.5, 1.6, 2.4, 2.5) a
decrease in insulin sensitivity (as reflected by
HOMA index) in AGHD patients during
GH therapy. Although, fasting plasma
insulin increase as a consequence of GH
therapy, no hyperglycaemia occurs. The
decrease in insulin sensitivity during GH
therapy is therefore compensated by an
increased insulin secretion. In male AGHD
patients, the increase of HOMA index dur-
ing GH therapy was not significantly
increased. In our studies, the dosage of GH
was low (0.5 IU/day) at the start, and was
titrated to age and sex adjusted normal IGF-I
levels. In excessive increased GH levels, such
as in active acromegaly, insulin resistance
(reflected by HOMA) is higher and the
HOMA index is associated to the plasma
IGF-I levels. The insulin resistance in
AGHD patients, that is reached during GH
therapy (with equal amounts of GH adminis-
tered daily), is also related to pre-treatment
IGF-I levels (chapter 2.4).  
The major substrate for the energy supply in
humans is glucose, but glucose may be partly
replaced by fatty acids during decreased
insulin sensitivity. Glucose remains the prin-
cipal substrate for energy supply during GH
therapy, despite the increase in plasma FFA
levels. In our study, these changes from glu-
cose to fat as a preferable substrate for ener-
gy supply in AGHD male patients did not
reach a significant difference after a 12
months’ GH therapy. Glucose oxidation con-
tributes for 55 % of the total oxidation in
mild obese control subjects
In addition to glucose that is derived from
exogenous sources (diet), glucose is actively
formed in several tissues (muscle and liver)
through GNG and GL (Figure 3). Both
processes occur simultaneously. Several steps
in GL are pertubated in children with a GH
deficiency, and therefore a state of hypo-
glycemia develop during a fasting period. In
GHD in adulthood, GL contributed most to
total glucose turnover. During GH therapy,
the contribution of GNG increases. The
major precursor for the increased GNG is
pyruvate, that is derived from acetyl Co-A.
This last molecule is part of the fatty acid
oxidation pathway (β-oxidation), which is
induced by GH. 14
Oxaloacetate
Lactate, alanine and
other amino acids
Hepatocyte and
renal cell 
FFA
PDH
NADH
NAD
KREBS
Cycle
GNG
GL
Glucose
Insulin secreting
ß-cells
Insulin secretion
IGF-2
Acetyl-Co ß-oxidation
Mitochondrion
Cytosol
Pancreas
ATP
PEP
Glycerol
Oxaloacetate Citrate
Malate
NADH
pyruvate
1
3
4
5
2
GH therapy
GH therapy
Figure 3. Adipose tissue lipolysis increases due to GH thera-
py, with consequently higher plasma free fatty acid (FFA)
levels. In the liver, oxidation of FFA gives rise to an increase
of β-oxidation and formation of NADH. Increased mito-
chondrial levels of NADH lead to a decrease in the activity
of pyruvate dehydrogenase (1) with consequently less pro-
duction of acetyl Co-A, and therefore less substrate for the
Krebs cyclus (3). Equally, elevated NADH levels increase
pyruvate carboxylase with an increase in the production of
oxaloacetate (2); in addition, increased availability of
NADH favours conversion of oxaloacetate to malate (4).
Hereafter, cytosolic oxaloacetate is converted to phosphoenol
pyruvate (PEP), that results in increase of gluconeogenesis
(GNG). In the fasting state, glycogenolysis (GL) is the
principal glucose provider. A regulated balance exists
between GNG and GL, that is slightly in favour of GNG
during GH therapy (5). The increase in circulating glucose
is detected by pancreatic β-cells. An increase in intrapancre-
atic glucose level increases de-novo insulin synthesis and
secretion. This process is facilitated by IGF-2 (6). Within
this background, prenatal development of the capacity of the
insulin secreting cell may be determined by plasma levels of
IGF-2, that are highly genetically determined. The increase
in insulin secretion, which is dependent on the capacity of
the β-cell, normalises hyperglycaemia. 
Substitution of GH increases the efflux of
glutamate from the liver, that is part of a
nitrogen (N) sparing pathway. Indeed, in
chapter 2.5, plasma levels of glutamate in
AGHD patients were higher (with a decrease
in 24 h urine content) during GH therapy,
than in control subjects. The plasma gluta-
mate levels are increased in pre-treatment
AGHD patients, as compared to control
subjects.    
To overcome insulin resistance, insulin secre-
tion increases. The reserve capacity of insulin
secreting β-cells in the pancreas is therefore
of importance. In healthy non-diabetic
humans, a positive association was found
between insulin secretion and IGFBP-3
(chapter 2.2), and IGF-II (chapter 2.3). The
relationship with IGF BP-3 was decreased,
after correction for BMI. IGF BP-3 is the
principal transporters of both IGF-I and
IGF-II in circulation. The IGF-II pool is
larger that IGF-I pool in human adults. Plas-
ma levels of IGF-II are an important factor
for the development of the individual capaci-
ty to secrete insulin. In foetal life, IGF-II is
an essential component in the development
of the pancreas, and in tissues of mesodermal
origin. In line with Barkers’ hypothesis, it
may be argued that pancreatic insulin secre-
tion capacity is predetermined, because 66%
of the IGF-II levels are genetically deter-
mined as has been reported in human twin
studies. In adult life, the paracrine and
autocrine effect of IGF-II prevents apoptosis
of  pancreatic beta cells. An increased apop-
tosis of beta cells with a decrease in mass was
found in insulin dependent type II diabetes.
The biological effect of IGF-II is mediated
by IRS-2 pathway. The limited insulin secre-
tion capacity may therefore be mostly deter-
mined by the amount of circulating IGF-II.
Lower IGF-II levels may provoke a faster
expression of a prodiabetic phenotype. In
dorsal pancreas agenesis, a decrease in beta
cell mass results in a modest increase in
GNG, also a feature in the syndrome of
insulin resistance. Insufficiencies in beta cell
function accounts therefore for several key
symptoms in insulin resistance. Higher plas-
ma levels of IGF-II, therefore, improve the
capacity of the insulin secreting beta cells to
compensate for hyperglycaemic events. In
line with this conclusion, the negative associ-
ation that was found in a GH intervention in
AGHD male patients, compared to mild
obese matched control subjects, between
GNG and IGF-II may be a consequence of
an adequate insulin response. Type II dia-
betes has an increased GNG due to less inhi-
bition of the GNG process by insulin.       
GH/IGF and heart adaptation
The GH axis/IGF system, through an
autocrine and systemic effect, influence the
capacity of cardiomyocytes to adapt on both
volume and pressure stress. In a case report
(chapter 3.2), we described that a decrease in
plasma GH levels (and not IGF-I) was asso-
ciated with a decrease of chronic hyper-
trophic cardiomyopathy in a patient with
active acromegaly. Simultaneously, the ejec-
tion fraction improved. GH receptors are
abundantly present on the heart, and activa-
tion of these local GH receptors result in
trophic changes and a decrease in apoptosis.
If GH is chronically present in excess, the
expression of local GH receptors is disturbed
that lead to a GH resistant state. Less stimula-
tion of the GH receptor results in less induc-
tion of local IGF-I. Consequently, the heart
will enter in a maladaptation process, which
leads to overt heart failure (chapter 3.1).  
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To conclude, the data that are presented in this thesis  indicate that:
1. The assessment of RLP-C is essential in assessing the atherogenic lipoprotein phenotype.
2. RLP possess atherogenic properties, such as oxidizability and foam cell formation.
3. The metabolism of fasting and postprandial RLP-C in AGHD  is disturbed and post-
prandial RLP-C profile is improved during GH therapy. These disturbances in RLP
metabolism may be partly responsible for the high susceptibility to premature atheroscle-
rosis in AGHD. 
4. Endothelial dysfunction in AGHD patients improves during GH therapy. 
5. The postprandial RLP-C profile is related to a pro-inflammatory response.
6. In heterozygous FH patients, increased fasting plasma RLP-C levels are part of the
atherogenic lipid phenotype (independent from plasma LDL-cholesterol levels). Simvas-
tatin (80 mg) reduces RLP-C levels to within the normal range in a quarter of FH
patients. 
7. Postprandial RLP-C response in heterozygous FH patients decreases during Simvastatin
therapy.
8. Plasma RLP-C levels in heterozygous FH patients are associated with an increased
carotid IMT, but not independent of plasma LDL-cholesterol.
9. The fasting and postprandial RLP-C profile is disturbed, not only in GH deficiency, but
also in acromegaly, due to a decreased insulin sensitivity and decreased LPL activity.
10. Insulin secretion in adult healthy subjects is related to the IGF system through plasma
IGF-II.
11. Baseline plasma IGF-I levels in AGHD patients determine the decline in insulin sensitiv-
ity during GH therapy.
12. The contribution of GNG in AGHD patients increase with pyruvate as major GNG pre-
cursor 
13. In addition to insulin secretion capacity of adult pancreatic b-cells, plasma IGF-II levels
are inversely associated with the amount of GNG. The adult plasma levels of IGF-II,
which is mostly genetically determined, therefore link two major features of the insulin
resistance syndrome.
14. Severe dysfunction of the left ventricle in acromegaly is reversible, and is closely related
to plasma GH levels.
Prospectives
Clinical features that are related to disturbances in the GH axis/IGF system (such as disturbed
lipoprotein remnant metabolism, endothelial dysfunction, increased visceral fat with obesity,
hypertension, relation with insulin secretion and gluconeogenesis) resemble closely to the
entity syndrome X or the plurimetabolic syndrome. Analysis of the GH axis/IGF system will
therefore teach us more about insulin resistance, unravel the plurimetabolic syndrome, and
may give rise to novel therapeutic approaches. 
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Summary of the Thesis
therosclerosis is a major cause of pre-
mature cardiovascular morbidity and
mortality in the Western World. One
of the principal risk factors in atherosclerotic
disease is dyslipidemia with a major focus on
elevated plasma LDL-cholesterol levels.
However, triglyceride-rich particles also pos-
sess atherogenic properties and elevated fast-
ing (and postprandial) plasma levels of these
particles are therefore associated with an
increased cardiovascular morbidity and mor-
tality (Chapter 1.1). Postprandial levels of
lipoprotein remnants reflect the composition
and quantity of the diet and lipoprotein
metabolism itself. Because Western individu-
als eat at least three times a day, and intrinsic
defects in lipoprotein metabolism are fre-
quently present, most of these people are in
an accentuated postprandial state during the
day. In the recent NCEP ATP III guidelines,
the importance to treat high plasma triglyc-
eride-rich particle levels in order to reduce
cardiovascular disease was emphasized. It is
relevant that cardiovascular mortality is
increased in patients with disturbances in the
growth hormone (GH) axis/insulin-like
growth factor (IGF) system (such as in GH
deficiency and acromegaly). GH is secreted
from a small gland just down the brain; the
pituitary. GH induces IGF and IGF-related
proteins principally in the liver, and other
functional tissues. Probably, disturbances in
the complex GH IGF system are involved in
atherogenesis, via changes in lipoprotein
metabolism and in endothelial nitric oxide
synthesis (Chapter 1.4). The synthesis of
nitric oxide by endothelial cells leads to
vasodilatation and influence structures in the
subendothelial matrix (such as smooth mus-
cle cells).  Such an interaction between hor-
mones and/or hormone-like growth factors
and the pathophysiology of the cardiovascu-
lar system is encapsulated in a recently intro-
duced term, cardiovascular endocrinology.  
The presence of increased plasma triglyc-
eride-rich particle levels, and especially of
lipoprotein remnants (RLP), has been
assessed in several patient groups with an
increased risk of cardiovascular disease. In
Chapters 1.9 and 1.10, we showed that both
fasting and postprandial plasma RLP-C levels
were elevated in patients with a primary
atherogenic dyslipidemia: heterozygous
familial hypercholesterolemia [FH]. In addi-
tion, in Chapters 1.5, 1.6, 1.7 and 1.12 in
patients with a secondary dyslipidemia: overt
acromegaly, and growth hormone deficiency
[GHD]) displayed similar increased fasting
and postprandial levels, as compared to
healthy BMI, age and gender-matched con-
trol subjects (Chapter 1.2). 
Although plasma RLP levels were elevated in
all these patient groups, the origin of these
disturbances was detected at different levels;
1. in the postheparin lipoprotein lipase
activity (lower in overt acromegaly;
Chapter 1.12),
2. in the production of very low-density
lipoproteins (increased in GHD and FH;
Chapters 1.6, 1.7, and 1.9),
3. in the activity of cholesteryl ester trans-
fer protein (lower in GHD),
4. and in the expression of hepatic LDL-
receptors (decreased in FH and GHD;
Chapters 1.7 and 1.9). 
The atherogenic process consists of several
initial steps of which a key feature is
endothelial dysfunction. Treatment with
recombinant growth hormone (GH)
decreases the rise of plasma RLP levels after a
fatty meal, and improves endothelial dys-
function in adult-onset GHD (Chapter 1.6).
Moreover, such increased postprandial plas-
ma RLP levels induced a pro-inflammatory
state, a condition that is associated with pre-
mature atherosclerosis (Chapter 1.8). In
addition, fasting plasma RLP-C in FH
patients are associated with elevated carotid
artery intima media thickness, a surrogate
marker of atherosclerotic disease (Chapter
1.11). In in-vitro studies, RLP consist mostly
of cholesteryl ester and TG, have mostly the
size of VLDL-1 (85%), and could be easily
oxidized and give rise to formation of
macrophage foam cells (Chapter). With these
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results, we showed that RLP particles are
closely associated to atherogenic processes.
In line with this remark, elevated plasma RLP
levels make an individual more susceptible to
develop premature atherosclerotic disease.
Type 2 diabetes mellitus is generally due to a
combination of insulin resistance and impair-
ment in insulin secretion by the pancreatic β-
cell. Progression towards type II DM is relat-
ed to failure of insulin secreting cells to
compensate hyperglycaemia. Deterioration
of glucose homeostasis, although mostly lim-
ited and temporarily, is noted after the start
of GH therapy in AGHD patients (as pre-
sented in Chapters 1.5, 1.6, 1.7, and 2.4) and
more profoundly, in overt acromegaly
(Chapters 1.12 and 3.2). Besides a relation-
ship between the GH axis/ IGF system and
plasma RLP-C levels, a similar relationship
(but hitherto only observed in animal stud-
ies) is found with glucose homeostasis, and
insulin secretion (Chapter 2.1). A central
component of the IGF system, IGF-2, was
positively related to insulin secretion in
healthy adults, independent of IGF-I, IGF
BP-3 and BMI (Chapters 2.2 and 2.3). Recep-
tors of IGF-2 are found on the insulin secret-
ing cells in the pancreas, and IGF-2 is a prin-
cipal factor in the development of
mesodermal tissue, such as the pancreas,
muscle, liver and the heart. The variability of
GH independent plasma IGF-2 levels is
mostly genetically determined (66%), and
therefore the total capacity of insulin secre-
tion is partly determined in the prenatal peri-
od. A decline in insulin secretion is a key
symptom in type II diabetes mellitus, as is an
increase in glucose synthesis through the
gluconeogenic (GNG) pathway. Indeed, we
observed a negative correlation between plas-
ma IGF-2 levels and GNG in GHD patients
before and during GH therapy, in compari-
son to age and BMI matched control subjects
(Chapter 2.5). Moreover, the degree of
decrease in insulin sensitivity (as determined
by estimated HOMA index) due to GH
therapy is related to baseline plasma IGF-1
level (Chapter 2.4). The increase of GNG
during GH therapy has its origin in increased
oxidation of the higher circulating free fatty
acid levels, that supply energy to the GNG
pathway (with pyruvate as a dominant sub-
strate) (Chapter 2.5). The increase in plasma
glucose levels is almost completely compen-
sated by higher circulating insulin levels.
In addition to relationships between the IGF
system and insulin secretion, GNG and
lipoprotein metabolism, cardiomyocytes are
highly influenced by the local and systemic
GH/IGF system (Chapter 3.1). High plasma
levels of IGF-1, but more special GH, were
responsible for heart failure due to cardiomy-
opathy. After strict control of such increased
GH levels, the impaired heart function could
be progressively restored to normal (Chapter
3.2). 
In conclusion, plasma levels of lipoprotein
remnants, which are analysed with the
immuno-isolation method, are suitable in
testing the susceptibility to premature ather-
osclerotic disease. Moreover, several meta-
bolic (such as lipoprotein remnants and glu-
cose homeostasis) and endothelium-related
components that are considered as key fac-
tors in atherogenesis are related to distur-
bances in the GH axis/IGF system.  
Summary of the Thesis
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Résumé de la Thèse
’athérosclérose est la cause principale
de la morbidité et de la mortalité car-
dio-vasculaire précoce dans le monde
occidental. Un des facteurs de risque cardio-
vasculaire majeurs est la hyperlipoprotéiné-
mie, comportant une augmentation des taux
plasmatique de cholestérol-LDL. De plus, les
particules riches en triglycérides possèdent
aussi des actions pro-atherogènes et des taux
élevés (à’jeuns et postprandiaux) sont asso-
ciés à une morbidité et mortalité cardiovascu-
laire augmentée (Chapitre 1.1). Les taux
postprandiaux des lipoprotéines remnants
dans le sang sont la résultante conjointe de
l’alimentation, et du métabolisme lipidique
soi-même, tous les deux. Parce que l’homme
occidental mange au moins trois fois par jour,
et que les anomalies du métabolisme lipi-
dique sont fréquents, il se trouve la majeure
partie la journée en condition postprandiale.
Dans les recommandations de NCEP ATP
III l’importance du traitement des taux plas-
matique élevés des lipoprotéines riches en
triglycérides est soulignée pour la réduction
de la maladie cardiovasculaire. Une observa-
tion supplémentaire est l’augmentation des
maladies cardiovasculaires chez les patients
avec une pathologie de l’axe somatotrope
(comme en cas de déficit de GH et d’acromé-
galie). Les anomalies de l’axe GH/system
d’IGF peuvent démarrer l’athérogénèse, par
les modifications du métabolisme lipidique et
par une modification de la synthèse d’oxyde
nitrogène (NO) d’origine endothéliale (Cha-
pitre 1.4). L’endocrinologie cardiovasculaire
est un terme récent qui rassemble l’interaction
entre le système endocrine et cardiovasculaire.
La présence de taux plasmatiques élevés de
particules riches en triglycérides, et principa-
lement des remnants de lipoprotéines (RLP),
est déterminée dans plusieurs groupes de
patients dont le risque cardiovasculaire est
augmenté. Aux Chapitres 1.9 et 1.10, nous
avons montré que les taux plasmatiques RLP
(à’jeun et postprandiaux) sont élevés chez
des patients avec une hyperlipoprotéinémie
primaire: hypercholestérolémie familial hété-
rozygote [FH]. De plus, aux Chapitres 1.5,
1.6, 1.7 et 1.12 chez des patients avec une
hyperlipoprotéinémie secondaire: acroméga-
lie, et déficit en GH [GHD]) ont des taux
élevés, en comparaison avec des sujets en bon
santé (Chapitre 1.2). 
Bien que les taux plasmatiques RLP étaient
élevés dans ces groupes de patients, l’origine
de ces anomalies est reliée à plusieurs
niveaux différents;
1. à l’activité posthéparine de lipoprotéine
lipase (diminuée dans l’acromégalie; Cha-
pitre 1.12), 
2. à la sécrétion de very low-density lipo-
proteins (élevée dans GHD et dans FH;
Chapitres 1.6, 1.7, et 1.9), 
3. à l’activité de cholesteryl ester transfer
protein (CETP ; diminuée dans GHD),
4. et à  l’expression des récepteurs de LDL
dans le foie (diminué dans FH et dans
GHD; Chapitres 1.7 et 1.9). 
La processus d’athérogénèse comprends des
plusieurs étapes initiales dont l’une entre
elles est une dysfonction de l’endothélium.
Le traitement avec hormone de croissance
recombinante diminue l’augmentation des
taux plasmatiques RLP-C dans la période
postprandiale, et améliore la fonction d’en-
dothéliale dans GHD (Chapitre 1.6). De
plus, ces taux élèves induisent une réponse
inflammatoire, qui est une des caractéris-
tiques de l’athérosclérose (Chapitre 1.8). Les
taux plasmatiques RLP-C à’jeun chez les
patients FH sont associés à l’épaisseur de la
paroi artérielle (IMT, en anglais) des caroti-
des, qui est un marquer de l’athérosclérose
(Chapitre 1.11). Dans des études in-vitro, ces
RLP qui sont composées principalement de
cholestérol ester et de TG, ont une taille de
VLDL-1 (à 85%). Elles peuvent être oxydés
facilement et peuvent initier la formation des
cellules spumeuses (Chapitre 1.3). En compi-
lant ces résultants, nous avons montré que l’i-
solement de RLP est utile pour une définition
complète du phénotype lipidique proathéro-
gène. Ainsi, les taux plasmatiques élevés de
RLP sont associé à l’athérosclérose et qu’en
déroulant aux maladies cardiovasculaires.
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Le diabète de type 2, ou la résistance de l’in-
suline, est le résultat de la combinaison d’in-
sulinorésistance et la diminution de la sécré-
tion d’insuline par les cellules β pancréatique.
Le passage à l’insuline résistance dans les DM
type II est associé à un déficit total de la
sécrétion d’insuline par les cellules. Détério-
ration, dans la plupart des cas temporaire et
modérée, de la homéostasie glucidique est
notée après le début de traitement par l’hor-
mone de croissance chez les patients avec un
déficit de GH (comme présenté aux Chapit-
res 1.5, 1.6, 1.7 et 2.4) et plus profondément
en cas d’acromégalie active (Chapitres 1.12 et
3.2). Parallèlement, cette relation entre de
l’axe de GH/ système d’IGF et du taux plas-
matique de RLP-C, une relation similaire
(mais surtout décrite dans les études anima-
les) est retrouvée entre l’homéostasie gluci-
dique, et la sécrétion d’insuline (Chapitre
2.1). Parmi les composants du système
d’IGF, le taux d’IGF-2 est associé positive-
ment avec la sécrétion d’insuline chez les
sujets en bon santé, indépendamment d’IGF-
I, d’IGF BP-3 et du BMI (Chapitres 2.2 et
2.3). Des récepteurs d’ IGF-2 sont présents
au niveau des cellules pancréatiques qui
secrètent l’insuline. L’IGF-2 est un des fac-
teurs principaux dans le développement des
tissus de mésodermes, comme le pancréas, le
foie, et le cœur. La variation des taux plasma-
tiques d’IGF-2, non dépendant de l’hormone
de croissance, est déterminée principalement
par des facteurs génétiques  (66%), et par
conséquent la capacité totale de la sécrétion
d’insuline est déterminée pendant la période
prénatale. La diminution de la sécrétion d’in-
suline est un symptôme clé dans les diabètes
de type II, simultanément  avec l’augmenta-
tion de la synthèse glucidique par les voies
métaboliques de la néoglucogenèse (GNG).
Nous avons trouvé une corrélation négative
entre le taux plasmatiques d’IGF-2 et la
GNG chez des patients avec GHD, avant et
après leur traitement avec GH, en comparai-
son avec des sujets contrôlés pour l’âge et le
BMI (Chapitre 2.5). De plus, lors de traite-
ment avec GH la baisse de la sensibilité d’in-
suline (déterminé par l’index d’HOMA) est
relié aux taux plasmatiques d’IGF-1 avant le
traitement (Chapitre 2.4). L’augmentation de
la GNG est due à une augmentation de la
bêta oxydation mitochondriome des acides
gras circulant du faut de la lipolyse induit par
la GH et  qu’offrent l’énergie pour dérouler
des étapes successives dans la GNG (avec la
pyruvate comme substrat préféré) (Chapitre
2.5). Les élévations des taux plasmatiques de
glucides sont compensées par l’augmentation
des taux plasmatiques d’insuline.
Enfin à coté de la relation entre métabolisme
gluco-lipidique et système d’IGF, il existe
une autre et bien entre des cardiomyocytes et
le système d’IGF (Chapitre 3.1). Des taux
plasmatiques élevés d’IGF-1, mais plus prin-
cipalement de GH, sont associés avec une
insuffisance cardiaque dans la cardiomyopa-
thie des acromégalies. Apres traitement de
l’acromégalie et surtout de taux de GH, la
récupération de la fonction cardiaque peut
être rétabli (Chapitre 3.2). 
En bref, les taux plasmatiques des lipoprotéi-
nes remnants, mesurés grâce aux anticorps
anti-Apo B100 et anti-Apo AI, est prêts à
être introduit en clinique pour la détermina-
tion du phénotype lipidique proathérogène,
supplémentairement au taux de cholestérol-
LDL. Les affections du métabolisme gluco-
lipidique, lesquelles sont constatées dans la
pathologie de l’axe somatotrope sont aussi
associées avec une susceptibilité à l’athérogé-
nèse.  
Résumé de la These
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Samenvatting van het proefschrift
derverkalking is een veelvoorkomen-
de oorzaak van chronische hart- en
vaatziekten. Zelfs vroegtijdig overlij-
den aan aderverkalking in samenlevingen met
een Westerse georiënteerde leef- en voedings-
gewoonten hebben. Eén van de meest
belangrijke risicofactoren voor aderverkal-
king is een afwijkend vetspectrum in het
bloed (dyslipidemie). Een verhoogd LDL-
cholesterol, dat een van de vetten in het
bloed is, werd tot voor kort als belangrijkste
oorzaak van aderverkalking aangemerkt. Uit
recent onderzoek wordt steeds duidelijker
dat de lipoproteinen remnants, andere vet-
deeltjes dan het LDL-cholesterol in het
bloed, ook eigenschappen bezitten die tot
vervroegde aderverkalking kunnen leiden.
Lipoproteinen remnants zijn die triglyceride-
rijke deeltjes, die in het bloed deels afgebro-
ken en daardoor kleiner van formaat zijn.
Tevens wisselen de triglyceride-rijke en rem-
nant deeltjes, met de andere vetdeeltjes in het
bloed componenten uit. Door deze proces-
sen blijven de lipoproteinen remnant deeltjes
langer in het bloed. Door hun geringe for-
maat zijn ze in staat om door de vaatwand
heen te dringen en onder de vaatwand schade
aan te richten. Dit geheel van factoren kan
een eerste stap richting aderverkalking zijn.
In patiënten die verhoogde nuchtere als post-
prandiale (na de maaltijd) waarden van lipo-
proteinen remnant deeltjes hebben, is ver-
hoogde sterfte aan hart- en vaatziekten
vastgesteld. (Hoofdstuk 1.1). 
De postprandiale waarden van de lipoprotei-
nen remnants in het bloed zijn een resultaat
van de dagelijks genoten voeding, en van de
stoornissen die in vetstofwisseling zelf voor-
komen. De Westerse mens bevindt men zich
voor het grootste deel van de dag in een post-
prandiale staat vanwege zijn gewoonte om
minimaal driemaal per dag te eten en omdat
verstoringen van de vetstofwisseling met
regelmaat voorkomen. In de recent uitgeko-
men NCEP ATP III richtlijn werd het belang
van de behandeling van triglyceriden en tri-
glyceriden rijke deeltjes ter voorkoming van
hart- en vaatziekten benadrukt. Een interes-
sante observatie is dat de sterfte aan hart- en
vaatziekten verhoogd is bij patiënten met een
verstoring in de groeihormoon (GH) as/
“insulin-like growth factor” (IGF) systeem
(zoals in GH deficiëntie en in GH overschot;
acromegalie). Het GH wordt gemaakt in een
kleine klier die zich aan de schedelbasis
bevindt. Het in het bloed circulerende GH
stimuleert in de lever de productie van IGF-,
en aan IGF-, verbonden eiwitten. Waarschijn-
lijk hebben deze verstoringen een stimule-
rend effect op processen die tot aderverkal-
king leiden, zoals afwijkingen in de
vetstofwisseling en in de aanmaak van stik-
stofoxide (NO) in de vaatwand (Hoofdstuk
1.4). Dit NO is belangrijk voor een optimale
functie van de vaatwand, maar ook voor de
relatie met de directe omgeving, de subendo-
theliale matrix. Dit samenspel tussen hormo-
nen of hormoonachtige groeifactoren en de
pathofysiologie van het hart- en vaatstelsel
wordt samengevat onder de recent geïntrodu-
ceerde term, cardiovasculaire endocrinologie. 
De aanwezigheid van verhoogde waarden van
de lipoproteinen remnant deeltjes (RLP),
werd bepaald in het bloed van verscheidene
groepen patiënten met een verhoogd risico
op hart- vaatziekten. In de hoofdstukken 1.9
en 1.10 werd aangetoond dat nuchtere en
postprandiale RLP-C waarden verhoogd zijn
in het bloed van patiënten met een primaire
dyslipidemie: heterozygote familiaire hyper-
cholesterolemie [FH]. In de hoofdstukken
1.5, 1.6, 1.7 en 1.12, vonden we tevens ver-
hoogde nuchtere en postprandiale plasma
RLP-C waarden in patiënten met een secun-
daire dyslipidemie (onbehandelde acromega-
ly, en in patiënten met een groeihormoon
deficiëntie [GHD]), dit in vergelijking met
controle personen die een gelijke BMI, leef-
tijd en geslacht hadden (Hoofdstuk 1.2). 
Hoewel de plasma RLP-C waarden verhoogd
zijn in het bloed van al deze groepen patiën-
ten, ligt de oorsprong van de verhoging op
verschillende niveaus van het vetmetabo-
lisme. Deze verschillende niveaus zijn:
1. de  activiteit van het enzym lipoproteine
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lipase (dat verlaagd is bij acromegalie;
Hoofdstuk 1.12),
2. de secretie van het very low-density lipo-
proteins (dat verhoogd is bij GHD en
FH; Hoofdstukken 1.6, 1.7, en 1.9), 
3. de activiteit van het cholesteryl ester
transfer protein (CETP; dat is verlaagd
bij GHD), en
4. de expressie van de LDL receptoren op
de lever (dat verlaagd is bij FH en bij
GHD; Hoofdstukken 1.7 en 1.9). 
Het proces dat leidt tot aderverkalking
bestaat uit verscheidene stappen, waarvan
disfunctie van de vaatwand er een is. Behan-
deling van GHD patiënten met recombinant
groeihormoon (GH) verlaagt de plasma
RLP-C waarden na een vet inname en verbe-
tert de verminderde vaatwand functie in
AGHD patiënten (Hoofdstuk 1.6). De ver-
hoogde RLP-C waarden na een vet inname
leidt tot een ontstekingsrespons in het bloed,
een fenomeen dat ook gekoppeld is aan
vroegtijdige aderverkalking (Hoofdstuk 1.8).
De verhoogde nuchtere plasma RLP-C
waarden zijn verbonden aan de dikte van de
vaatwand van de halsslagader, hetgeen een
veelgebruikte indicator is voor het vaststellen
van de mate van aderverkalking (Hoofdstuk
1.11). In in-vitro onderzoek zijn de RLPs
grotendeels samengesteld uit cholesteryl
esters en triglyceriden. De RLPs hebben dan
grotendeels de omvang van het VLDL-1
(namelijk 85%), ze kunnen makkelijk geoxi-
deerd worden en geven aanleiding tot
schuimcelvorming (Hoofdstuk 1.3). 
Type 2 suikerziekte is in het algemeen te wij-
ten aan een combinatie van insuline resisten-
tie en een afname van de afgifte van insuline
door bèta-cellen in de alvleesklier (het pan-
creas). De uiteindelijke expressie van een
type II suikerziekte is gekoppeld aan het
falen van de insuline afgevende cellen in hun
poging de verhoogde plasma suiker waarden
te compenseren. Een verstoring van het sui-
ker evenwicht, die meestal beperkt en kort
van aard is, wordt in het bloed gevonden na
het begin van de GH behandeling bij patiën-
ten met een AGHD (zoals te zien in hoofd-
stukken 1.5, 1.6, 1.7, en 2.4). De verstoring
van het suiker evenwicht is nog duidelijker bij
patiënten met een onbehandelde acromegalie
(hoofdstukken 1.12 en 3.2). Naast een relatie
tussen de GH as/ IGF systeem en de plasma
RLP-C waarden, is er ook een relatie (maar
zover enkel geobserveerd in dier experimen-
teel onderzoek) in het bloed te vinden tussen
de GH as/ IGF systeem en het glucose even-
wicht. Deze relatie bestaat ook tussen de
secretie van het insuline door de alvleesklier
en de GH as/ IGF systeem (Hoofdstuk 2.1).
Een component van het IGF systeem, het
IGF-2, is positief gekoppeld aan de insuline
secretie bij gezonde volwassenen. Dit is onaf-
hankelijk van het IGF-I, het IGF BP-3 en de
BMI (hoofdstukken 2.2 en 2.3). Receptoren
voor IGF-2 zijn aangetoond op insuline secer-
nerende cellen in het pancreas. Het IGF-2 is
een belangrijke factor in de prenatale ontwik-
keling van het mesodermale weefsel, zoals het
pancreas, de skeletspier, de lever en het hart.
De variatie van de plasma IGF-2 waarden
worden grotendeels genetisch bepaald en
daardoor kan verondersteld worden dat de
capaciteit van de insuline secretie reeds voor
de geboorte wordt bepaald. Een afname van de
insuline secretie is een belangrijk symptoom
in type II suikerziekte, net als een toename
van de suikervorming door de lever middels de
zogenaamde gluconeogenese (GNG) route.
Inderdaad vonden we een negatieve correlatie
tussen de plasma IGF-2 waarden en de GNG
in GHD patiënten (Hoofdstuk 2.5). De mate
van afname van de insuline gevoeligheid
(bepaald met de HOMA index) door de GH
behandeling wordt bepaald door de waarden
voorafgaand aan de behandeling van het plas-
ma IGF-I (Hoofdstuk 2.4). De toename van
de GNG gedurende de GH behandeling heeft
zijn oorsprong in een toegenomen oxidatie
van het hogere aantal circulerende vrije vetzu-
ren dat de energie verschaft voor de GNG
route (met het pyruvaat als dominant sub-
straat) (Hoofdstuk 2.5). De verhoogde plas-
ma suikerwaarden worden nagenoeg volledig
gecompenseerd door de toegenomen hoeveel-
heid  insuline.
Samenvatting van het proefschrift
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Niet enkel de eerder besproken metabolis-
men (die van het suiker- en van het vetmeta-
bolisme) zijn gekoppeld aan het IGF
systeem. Ook functionele cellen van het hart
(cardiomyocytes) staan onder invloed van
het lokale en het systemische GH as/IGF
systeem (Hoofdstuk 3.1). Hoge plasma
waarden van het IGF-1, maar vooral van het
GH, zijn verantwoordelijk voor hartfalen als
gevolg van de cardiomyopathie bij patiënten
die niet voor hun acromegalie worden behan-
deld. Na adequate verlaging van het GH is de
afgenomen hartfunctie te herstellen in het
merendeel van de patiënten met acromegalie
(Hoofdstuk 3.2). 
Kortom, de plasma waarden van de lipopro-
tein remnants die geïsoleerd worden middels
de immuno-isolatie methode, zijn geschikt
voor de analyse van de vatbaarheid van perso-
nen voor vroegtijdige ziekten en overlijden
aan hart- en vaatziekten die worden veroor-
zaakt door aderverkalking. Afzonderlijke
metabole verstoringen (zoals in het lipopro-
tein remnant en in het glucose metabolisme)
en endotheel gerelateerde componenten die
beschouwd worden als belangrijke factoren
in het ontstaan van aderverkalking, zijn geas-
socieerd met verstoringen in de GH as en het
IGF systeem. 
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ardiovascular disease (CVD) is the
leading cause of morbidity and mor-
tality in the Western World.
Although an increase in plasma low-density
lipoprotein (LDL) concentration is an
important factor in the etiology of coronary
heart disease (CAD), oxidation of LDL is
believed to play a key role in the develop-
ment of atherosclerosis, based on in vitro
studies demonstrating a role of ox-LDL in
foam cell formation and endothelial dysfunc-
tion (1-4). Circulating levels of plasma ox-
LDL are however low, and ox-LDL is prima-
rily localized in the atheromatous plaque in
autopsy studies (5-7). Therefore, additional
circulating lipids and/or lipoproteins are like-
ly to contribute to the onset and develop-
ment of coronary atherosclerosis as well as
other cardiovascular complications. Recently,
in a large observational study, the calculated
non-HDL plasma cholesterol concentration
(LDL plus VLDL cholesterol) was a stronger
predictor of cardiovascular events than plas-
ma cholesterol alone (8-10). Improvement of
CAD predictability upon inclusion of VLDL
cholesterol emphasizes the proatherogenic
role of triglyceride-rich lipoproteins (TRL).
These lipoproteins may be directly athero-
genic by affecting lipid-accumulation by cells
in the artery wall. Alternatively, they may be
indirectly atherothrombogenic by affecting
the size and oxidizability of LDL, or by
affecting levels of plasma HDL, fibrinogen
or PAI-I. Smaller, partly lipolyzed TRL rem-
nants are considered to be more atherogenic
than larger newly secreted TRL since they
can more readily penetrate the endothelial
lining of the arterial wall. Disparity in the
atherogenicity of large versus small TRL is
best illustrated by the difference in preva-
lence of premature CAD in patients with dif-
ferent inherited forms of hypertriglyceride-
ma. Type I or type V hyperlipoproteinemic
patients have extremely high plasma triglyc-
eride levels due to a deficiency in lipoprotein
lipase or apo C-II. They characteristically
have an accumulation in plasma of very large
TRL, yet they are not at greatly increased
risk of CAD (11; 12). In contrast, type III
hyperlipoproteinemic patients have more
moderate hypertriglyceridemia and due to
defective remnant lipoprotein uptake by the
liver have an accumulation in plasma of
smaller TRL remnants (i.e. β-VLDL). These
patients do have increased risk of CAD and
also increased risk of peripheral vascular dis-
ease (13). TRL remnants are considered to be
atherogenic. Accurate quantification of TRL
remnants is, however, problematic (14),
since: 1) remnants are difficult to differenti-
ate from their larger and more triglyceride-
rich precursors; 2) their plasma concentra-
tion is very low compared to other
lipoproteins; and 3) they are biochemical dif-
ficult to isolate or detect because they repre-
sent a heterogeneous group of variable size
and composition. An immunoaffinity
method for isolation of TRL remnants has
recently been used in a number of clinical
and laboratory studies to study remnant
lipoprotein metabolism, atherogenicity (15),
and to asses its clinical 
Triglyceride rich particles in the atherogenic
phenotype
The importance of plasma TG as an inde-
pendent risk factor for CAD was recognized
after the publication of a meta analyses by
Austin et al (16; 17) showing that plasma
triglyceride levels predict relative risk for
CVD mortality in relatives of familial com-
bined hyperlipidemia (FCHL) patients. Epi-
demiological data from the Framingham
study already showed that plasma TG is an
important risk indicator of CAD in women
(18). Additional evidence was obtained from
by Yarnell et al in a ten-year follow-up study
(19), and confirmed in several other studies
(20; 21). The relationship between TG and
prevalence of cardiovascular disease was
dependent upon plasma HDL-cholesterol
concentration in the Procam study (22) and
was decreased when plasma TG levels were
above 800mg/dL, whereas Criqui et al (23)
could not demonstrate any relationship with
plasma TG.
The analyses of plasma TG are complicated
because of large inter- and intra-individual
36
C
variation, and heterogeneity of circulating
triglyceride-rich lipoprotein subclasses such
as intestinally derived apo B48-containing
chylomicrons, and chylomicron remants and
hepatic derived apo B100-containing very
low density lipoproteins (VLDL) and their
remnants. The remnant particles are the
atherogenic fraction, as illustrated by the
observation that fasting and postprandial
triglyceride-rich remnants are associated
with premature atherosclerosis (24-26). The
concentration of these circulating remnant
particles in-vivo have been determined with a
number of different methods, based on their
density, size charge, specific lipid compo-
nents, apolipoprotein composition or
apolipoprotein immunoaffinity (14). Isola-
tion of apo B100 and apo B48 lipoprotein
fractions was performed with the use of den-
sity-gradient ultracentrifugation based on the
assumption that lipoprotein subfractions dif-
fer in density (27-29). Apolipoproteins are
analysed by SDS-PAGE (28). Association
between increased levels of apo B-48 and apo
B-100 in Sf20-60 (small VLDL) and Sf 12-20
(IDL) and increased risk for cardiovascular
disease were found in a number of studies
(30-35). The fate of the fatty acid moiety of
intestinal derived chylomicron particles can
be analysed by in vivo labeling of the parti-
cles with retinyl esters (RE)(36) as a marker.
Several studies have shown an association
between abnormalities in the postprandial
response of TG, RE, and premature athero-
sclerosis (31; 33; 37-41) The problem with
this approach is that, at later time points in the
postprandial test, exchange of RE between the
different lipoprotein fractions occur (42-44).
All these techniques are very laborious and are
not useful in large clinical studies.
RLP-C analysis
Nakajima et al (45) introduced a new method
for estimation of lipoprotein remnants
(RLP) with specific monoclonal antibodies
directed against epitopes of apo A-I and apo
B-100, bound to Sepharose 4B gel. Plasma
samples are incubated with the immunoaffin-
ity gel. HDL, LDL and most of the VLDL
particles bind to the gel, whereas in the
unbound supernatant fraction, remnant-like
particle cholesterol is measured (remnant-
like particle cholesterol, RLP-C). The bind-
ing capacity of immunoaffnity sepharose gel
is high with a binding of > 95% of both plas-
ma HDL,LDL, and VLDL. The epitope of
apo B-100 that is recognized by the mono-
clonal antibody is localized in the amphipath-
ic helical region of the protein encompassing
residues 291-2318, approximately apo B-51.
The epitope for Mab JI-H (JIMRO-Havel)
was mapped to 81 residues (2251 to 2331), so
that all apo B-48 lipoprotein particles are
recovered in the RLP fraction. In addition, a
subfraction of TRL containing apo B-100 is
also included (46) The Ka value for the anti-
body to apo A-I is 4.2*108 mol/L. The Ka
value of the antibody directed to apo B-100
of LDL is 5.5*108 mol/L and that of VLDL
3.2*108 mol/L (15). Saturation of the coated
sepharose gel occurs at HDL-cholesterol lev-
els above 100 mg/dl, resulting in a rapid loss
of binding. For the monoclonal antibody
directed against apo B-100 no saturation could
be obtained so that 95% of LDL-cholesterol is
bound to the immuno-affinitygel at plasma
LDL-cholesterol levels up to 600 mg/dl (47).
RLP composition and Particle size
In fasting plasma of normolipidemic sub-
jects, RLP consists of an equal number of TG
and cholesterol molecules (3000 and 4000)
for each apo B molecule (>95% Apo B-100),
with an average of 33 molecules of apo C-III
and 7 molecules of apo E per apo-B molecule
(48;49). Separation of the RLP fraction by
size exclusion chromatography showed that
normolipidemic RLP was eluted at the size
large LDL (average particle size of 27 nm)
whereas 38% displayed a predominantly
VLDL size (average particle size 38
nm)(15;50).In normolipidemics the concen-
tration of plasma TG is determinant for its
size and composition. In those individuals
with low plasma TG the RLP is predomi-
nantly of LDL-size (46). With increasing lev-
els of plasma TG, the peak of RLP size
moves towards the larger VLDL fraction. In
Elevated Remnant-Like particle cholesterol (RLP-C) concentration; review
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normolipidemic individuals with low plasma
TG levels, the contribution of IDL + LDL
sized RLP is around 30% and depends upon
the LDL pattern A or B (46). To compare, in
the postprandial state, after a mixed meal,
TRPs in the Sf 60-400 density fraction (larger
TG-rich VLDL particles) that were subjected
to immunoaffinity chromotography (with
the use of specific monoclonal antibodies
4G3 and 5E11 against C terminal Apo B-
100), contained 2.0 molecules apo E and 25
molecules apo C-III per particle, with 25000
mol TG and 3500 mol cholesterol per parti-
cle. In the Sf 20-60 fraction (small VLDL,
IDL fraction) 2.0 mol apo E and 11 mol apo
C-III per particle were found, with 10000 mol
TG and 3000 mol cholesterol per particle (51).
RLP from type III patients contained
twofold higher triglycerides and cholesterol
molecules for each apo B molecule (50% of
apo B was apo B-48) than RLP in normolipi-
demic subjects ref. The content of apo CIII
and apo E molecules was slightly increased,
but not significantly different from nor-
molipidemic subjects. In type IV patients an
increased number of TG and apo CIII mole-
cules per apo B in RLP were found, but the
number of cholesterol and apo E molecules
were unchanged (48), and the RLP particle
size is on average larger than in normolipi-
demic subjects, and thus resembles that of
triglyceride-rich lipoproteins in the d<1.006
g/ml density fraction. (48).
Dynamics of TRL
Triglyceride-rich lipoprotein particles origi-
nate either from the intestine (apo B48-con-
taning chylomicrons) or from the liver (apo
B 100-containing VLDL). Upon secretion
into the circulation TRL undergoes lipolysis
by the enzyme lipoprotein lipase (LPL) that
is anchored in the endothelial lining of the
arterial wall (52). Most circulating TRL in
plasma contain apo B-100, while in the post-
prandial period an increase of 20 % of apo B-
48 containing TRL was observed. Catabolic
pathways are mediated through receptors
that are expressed at the hepatic surface. Apo
B-48-containing TRL are taken up by LDL -
and LRP receptors (53). Apo B-100 TRL are
precursors for the denser LDL fraction. Iso-
tope studies revealed that TG-rich VLDL-1,
in contrast to cholesterol-rich VLDL-2, is a
substrate for formation of intermediate den-
sity lipoproteins (IDL) and subsequently
LDL by further modulation through LPL
and hepatic lipase (HL) and by exchange of
TG for cholesterylesters from HDL by the
transfer protein: cholesterol ester transfer
protein (CETP). This small dense LDL frac-
tion possesses atherogenic properties (54). It is
of interest that the coronary system, the aortic
arch and the carotid arteries are the initial arte-
rial beds that are in contact with TRL and TRL
remnants, including lung and its alveolar
macrophages. Early atherosclerotic disease is
frequently found in these arterial regions.
Fasting plasma RLP-C levels in normolipi-
demic subjects
Normal levels of RLP-C are obtained from a
number of different studies and summarized
in Table 1.The mean level of RLP-C in a
healthy Caucasian population is less than
0.20 mmol/l. Despite the fact that anthropo-
metric and lipid parameters of normolipi-
demic Caucasian and Japanese control sub-
jects are similar, plasma RLP-C levels in
Caucasian populations are higher. A real
explanation for the differences can not be
deducted from the literature since no data on
life style were reported. Differences in plas-
ma RLP-C concentration between different
ethnic groups may account for the increased
prevalence of cardiovascular disease that is
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Figure 1. RLP isolation method. Free, unbound fraction
contains RLP. the bound fraction consists of ApoB-100 and
Apo A-I particles.
clustered in distinct ethnic populations, such
as in African Americans (55). A number of
studies have demonstrated significant differ-
ences between RLP-C levels in both men and
women, with higher levels in men (56;57). In
the Framingham study, fasting plasma RLP-C
levels in men were higher than in women
(0.21±0.10 mmol/L versus 0.18±0.06 mmol/L)
(56;58). Plasma RLP-C concentrations sig-
nificantly increase at older age as was shown
by Leary et al (57). Additional analysis of
RLP-C levels in postmenopausal women in
the Framingham study demonstrated plasma
RLP-C levels of 0.19 mmol/l and plasma
RLP-TG of 0.25 mmol/l (59). Plasma RLP-C
levels increase with age in both males and
females (for example: in men with age < 30
years, mean levels are 0.18±0.09 mmol/l; in
men aged between 50-59 years, 0.22±0.10
mmol/l and in men aged between 70-79
years, 0.22±0.12 mmol/l) (56).
In a large Framingham cohort of women
without CVD, of whom 57% were in a post-
menopausal state, plasma RLP-C and RLP-
TG levels were 16% and 27% lower than in
those women diagnosed with active CVD. In
the total cohort, the prevalence rate for CVD
in the upper quartile of plasma RLP levels with
an age adjusted estimate is 85 per 1000 women.
The lower three quartiles result in an age
adjusted estimate of 32-50 per 1000 women.
Moreover, plasma RLP-C levels, and not the
total plasma TG levels, were an independent
risk factor for cardiovascular disease (59).
Postprandial plasma RLP-C levels
Plasma triglyceride-rich lipoproteins (TRL)
and RLP accumulate in the postprandial peri-
od, with an abnormal lipid profile in dyslipi-
demic patients. Indeed, an increased post-
prandial accumulation of TRP is a feature of
the atherogenic lipid phenotype. With the
use of an oral fat load test with cream (50 g
fat/m2) or a mixed meal, the postprandial
lipid profile is estimated. Maximal postpran-
dial RLP-C levels in mildly obese normolipi-
demic subjects, aged 50 years, were reached
between 2 and 4 hours postprandial (0.48
mmol/l)(60;61). In healthy young male vol-
unteers plasma RLP-C levels increase from
0.15 mmol/l to 0.23 mmol/l 4 h postpandially
Elevated Remnant-Like particle cholesterol (RLP-C) concentration
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Table 1: Fasting plasma RLP-C levels in normolipidemic subjects.
N Age BMI C LDL-C TG RLP-C
Oda, H. etal (120) 106 30.2±5.6 np 3.9-6.0 1.9-4.2 0.4-1.8 0.07±0.03
Okazaki, M. et al (50) 49 np np 4.8±0.9 3.0±0.6 1.0±0.3 0.09±0.04
Marcoux, C. et al (49) 10 42.7±5.1 24.5±0.8 4.7±0.3 3.0±0.2 1.2±0.2 0.22±0.01
Marcoux, C. et al (48) 8 41.5±5 24±1 4.57±0.26 2.7±0.26 1.21±0.1 0.21±0.02
Devaraj, S. et al 1998 (95) 23 49.3±3.3 27.7±5.8 4.91±0.78 3.25±0.9 1.20±0.6 0.15±0.05
Ohnishi, H. et al (83) 352 64.4±10.0 22.6±2.7 5.21±0.80 3.14±0.9 1.21±0.6 0.09±0.06
Saigo, M. et al (121) 128 53.7±12.7 np 5.37±0.78 np 1.33±0.64 0.12±0.06
Koba, S. et al (122) 142 60±11 23.2±3.0 5.2±0.8 3.2±0.7 1.2±0.6 0.12±0.07
Schaefer, E.J. et al (58) 88 62±9 26±4 5.6±1.2 3.5±1.2 1.5±0.9 0.21±0.1
Ooi, T.C. et al (123) 10 55±4 24±1 4.55±0.15 2.75±0.10 1.34±0.13 0.17±0.01
Sakata, K. et al (98) 66 60±9 22.9±3.4 5.2±1.3 3.2±1.0 1.5±0.7 0.06±0.06
Ai, M. et al (63) 10 33±1 22.9±0.5 4.8±0.21 2.8±0.2 0.9±0.1 0.09±0.01
Twickler, Th.B. et al (61) 7 47.7±6.9 25.2±1.6 5.11±0.46 3.18±0.64 0.91±0.3 0.20±0.08
Abbreviations: np=not presented, TC: total cholesterol, LDL-C: LDL-cholesterol, TG: triglycerides.  Plasma levels are
expressed as mmol/l and as mean ± S.D.
(62), whereas atorvastatin intervention atten-
uates the postprandial RLP-C increase in
contrast to placebo and gemfibrozil treat-
ment. Ai et al (63) found an postprandial
RLP-C increase from 0.08 mmol/l to 0.13
mmol/l in normolipidemic Japanese subjects
after an oral fat load with only 17 g fat/m2. It
has been shown that the amount of fat given
orally will influence the height of the post-
prandial response. Chylomicron fatty acid
moiety (reprented as retinyl palmitate (RE)
in the <1.006 g/L density fraction) in nor-
molipidemic French, non-obese (BMI: 20-24
kg/m2) subjects did not increase 3 hours
after ingestion of either a non-fat or a 15
g/m2 low fat meal, whereas significant
increases in chylomicron RE were induced 3
hours after ingestion of meals with a fat con-
tent of 30, 40, and 50 g/m2 (64).
RLP-C levels in patients with dyslipidemia
Familial hypercholesterolemia (FH) is char-
acterized by mutations in the LDL-receptor
gene with a lipoprotein phenoype that is
characterized by elevated plasma cholesterol
and LDL-cholesterol levels. In a subset of
heterozygous FH patients elevated plasma
TG levels were found (65), and plasma RLP-
C levels were increased independent of plas-
ma LDL-cholesterol (FHExPRESS study,
(66)) with a median of 0.47 mmol/l. More-
over, a post-hoc analysis of the ExPRESS
study revealed a significant association
between baseline plasma RLP-C levels and
carotid artery intima media thickness, a sur-
rogate marker for atherosclerosis (Twickler
et al, unpublished data). Both plasma apo B-
48 and RLP-C levels were increased in het-
erozygous FH population in Australia (67).
Additional kinetic analyses using a stable iso-
tope breath test revealed no difference in
chylomicron catabolism in patients with FH
as compared to controls (68). Earlier studies
showed a delayed chylomicron remnant
clearance in the postprandial state (39; 69)
using ultracentrifugal analyses and RE as a
marker for chylomicron clearance. These
observations support the growing interest
for RLP as an atherogenic lipid component,
even in lipid disorders such as FH.
Patients with Type III dyslipidemia are char-
acterized by elevated plasma levels of rem-
nant particles. These patients have a geneti-
cally abnormal apo E genotype (apo E2/apo
E2) resulting in abnormal apoE mediated
TG-rich lipoprotein uptake via hepatic
lipoprotein receptors resulting in accumula-
tion of remnant particles in the circulation
(13). Only a small proportion of individual
40
Table 2: Postprandial plasma RLP-C in normolipidemic healthy subjects 
authors intervention age BMI Baseline Postprandial Baseline Postprandial
TG RLP-C
Twickler, Th.B. Cream 40% fat  48±7 25±2 0.91±0.3 1.66±0.53 0,20±0,08 0,34±0,05
et al (61) (50 g/m2 BSA)
Schaefer, E.J. Mixed meal, 57% fat 62±9 26±4 1.5±0.9 2.36±1.4 0.20±0.01 0.33±0.2
et al (124)
Wilmink, J. Cream 40% fat 25±4 23±3 1.1±0.5 2.0±1.0 0.15±0.06 0.23±0.07
et al (62) (50 g/m2 BSA)
Schaefer, E.J. Mixed meal, 57% fat 62±9 26±4 1.5±0.9 2.36±1.4 0.21±0.1 0.34±0.16
et al (58)
Schreuder, P.C.N.J. Cream 40% fat 49±9 25±3 0.9±0.4 1.8±1.2 0.18±0.06 0.48±0.31
et al (60) (50 g/m2 BSA)
Ai, M. et al (63) 17 g fat/m2 BSA 33±1 23±1 0.86±0.6 1.17±0.1 0.08±0.01 0.11±0.01
Results are expressed as mean ± SD (mmol/l)
with apo E2/E2 genotype will develop type
III hyperlipidemia. It is therefore necessary
to have an additional clinical marker. Mea-
surement of RLP-C and the RLP-C/TG
ratio, an estimation of the enrichment of
TRL in cholesterol (a characteristic of beta-
VLDL), provides an alternative for diagnosis
of lipid abnormalities in these patients
(70;71). The sensitivity 0.95 (0.85-1.00),
specificity 0.94 (0.85-1.00) and accuracy 0.94
(0.88-1.00) (with a cut off point of >0.23)
was much better in comparison to agarose
gel electrophoresis of the VLDL fraction
obtained after ultracentrifugation. Plasma
RLP-C was increased five-fold in type III
subjects (1,39 mmol/L). RLP in patients
with type III hyperlipidemia had a slow beta
VLDL mobility on agarose gels, but their
size was smaller (32 nm). In an Asian popula-
tion, plasma RLP-C levels in type III hyper-
lipidemia were increased compared to con-
trol subjects, but were lower than in
Caucasian subjects (72).
In patients with type IIb hyperlipidemia plas-
ma RLP-C levels were two-fold increased
(0,46 mmol/L) and in type IV subjects
almost threefold (0,53 mmol/L), as com-
pared to control subjects (14; 48; 70). Plasma
RLP particles were larger with a particle size
of 41 nm in patients with severe hyper-
triglyceridemia (TG>4,5 mmol/L) (73)
Patients with familial combined hyperlipi-
demia (FCHL) are characterized by elevated
levels of plasma TG, plasma apo B and/or
plasma cholesterol. Lipoprotein metabolism
in FCHL is disturbed, leading to remnant
accumulation in the circulation (74-76). The
level of plasma RLP-C may be an additional
marker for the characterization of patients
with FCHL. Male FCHL patients had a six-
fold increased plasma RLP-C concentration
than male normolipidemic controls (1.5
mmol/l vs 0.2 mmol/l), whereas the plasma
RLP-C concentration was only two-fold
higher in FCHL female patients as compared
to controls (0.4 mmol/l vs 0.2 mmol/l) (77).
No significant differences in plasma apo B,
HDL-C and total cholesterol levels were
found, but plasma TG was strongly correlat-
ed with plasma RLP-C in both the FCHL
men and women. Moreover, the waist hip
ratio was higher in the FCH men than in
FCH women and control subjects. No data
are available yet from a large study in FCHL.
Postprandial RLP-C abnormalities in patients
with primary hyperlipidemia
In patients with elevated plasma TG levels,
postprandial plasma TG increase after an oral
fat load was in the range of 30-50% in type
IIb, type III, and type IV dyslipidemic
patients, with no significant differences
between the maximal postprandial TG in all
the dyslipidemic groups. Although postpran-
dial RLP-C elevations at 4, 6 and 8 hours
from baseline in type III patients tended to
be smaller and in type IV patients tended to
have a greater postprandial RLP-C increase,
no significant differences between the groups
were found. The ratio RLP-C/ RLP-TG dur-
ing the postprandial period decreased due to
a relative increase in RLP-TG in patient with
Elevated Remnant-Like particle cholesterol (RLP-C) concentration
41
Table 3: Plasma RLP-C levels in primary dyslipidemie
Authors Type IIa Type IIb Type III Type IV
Okazaki, M. et al  (50) 0,11±0.04 0,21±0.11 0,78±0.13 0,33±0.23
Wang, T. et al (70) 0,46 [0.37, 0.63] 1,39 [1.04, 2.75] 0,53 [0.39,0.76]
Marcoux, C. et al (48) 0.21±0.01 0.50±0.07 0.58±0.11
Marcoux, C. et al  (125) 0.51±0.03 1.31±0.14 0.56±0.07
Ooi, T. et al (123) 0.29±0.02 0.67±0.1
Plasma levels are expressed as mmol/l and as mean ± S.D. or as median [95th percentile, 5th percentile].
type IIb and IV, and an concomitant enrich-
ment of cholesterol only in type III patients
at all postprandial time points (78). In
patients with FCHL, abnormalities in post-
prandial lipoprotein metabolism have been
extensively described (79; 80), indicating the
presence of elevated plasma levels of apoB-
48-containing and apo B-100 containing TG-
rich lipoprotein fractions. No data on plasma
RLP-C levels are yet published, but we may
speculate that RLP-C will be an additional
marker for the postprandial lipid response.
RLP in secondary dyslipidemia
Insulin Resistance and type II diabetes mellitus
The insulin resistance state is associated with
abnormalities in lipid metabolism, such as
elevated plasma TG and decreased plasma
HDL-C levels, and in glucose homeostasis.
Metabolic defects includes an impaired Free
Fatty acid (FFA) metabolism, saturation of
TRL remnant removal and disruption of the
regulation of hepatic secretion of VLDL par-
ticles into the circulation. Kinetic studies
have shown that acute hyperinsulinemia in
healthy men suppresses hepatic VLDL-1
production. This phenomenon does not
occur in patients with type 2 diabetes melli-
tus (81; 82). Elevated plasma RLP-C (RLP-
C>7.5 mg/dl) concentrations were found
more frequently in individuals with insulin-
resistance (IR) than in healthy individuals.
Moreover, in a multiple regression analysis,
the HOMA-ratio (an index for insulin resist-
ance) was closely related to plasma RLP-C
(83). In insulin-resistant, postmenopausal
women, the postprandial elevations of plas-
ma RLP-C were lower than in the insulin-
sensitive women. ref
Type II diabetes mellitus is associated with a
marked increase in cardiovascular disease. A
characteristic clinical feature of type 2 Dia-
betes Mellitus is dyslipidemia with elevated
plasma levels of TG, presence of small dense
LDL, and decreased levels of HDL-C (84).
Patients with the metabolic syndrome (i.e.
patients with visceral obesity, hypertension
and insulin resistance) have a similar abnor-
mal lipoprotein profile. It is therefore not
surprising that a number of studies have been
published to analyse the contribution of
RLP-C in the atherogenic lipoprotein profile
in DM. In patients with type II diabetes mel-
litus, postprandial RLP-C levels were elevat-
ed (58; 63; 85-90). Interestingly, the impact of
type 2 DM on the lipoprotein phenotype and
the risk on CAD is relatively worse in women
as compared to men. Women with type II DM
have a higher proportion of small dense LDL
(91), relatively higher plasma RLP-C levels
(58). Both parameters significantly contribute
to the athreogenic lipoprotein phenotype as
seen in patients with type II DM.
In patients with renal disorder the expression
of an atherogenic lipid phenotype is associat-
ed with increased plasma levels of TRL, and
consequently increased plasma RLP-C con-
centrations Indeed, glomerular disease and
the presence of albuminuria (defined as >2
grams / 24 hour collected urine), lead to an
increase in plasma RLP-C levels (18,9 mg/dl
vs 7,7 mg/dl in matched control subjects).
Plasma RLP-C concentration was not related
to renal function (assessed as calculated crea-
tinine clearance), but associated closely with
plasma TG levels (92). Patients with a fatty
liver or steatosis had significantly higher plas-
ma RLP-C levels as compared to control sub-
jects (16 mg/dl vs 5 mg/dl, respectively) (93).
RLP and atherosclerosis
It has been shown in a number of studies that
the presence of elevated plasma RLP-C levels
and endothelial dysfunction, as a marker for
atherosclerotic disease, are significantly asso-
ciated (94). Patients with established coro-
nary heart disease have elevated plasma levels
of RLP-C (95; 96). The intima media thick-
ness of the carotid artery was positively relat-
ed to baseline plasma RLP-C concentrations
in a secondary intervention study with
patients, aged 50 years and older, after their
first cardiovascular event (94). This associa-
tion was independent of plasma TG and
LDL-C levels. In the LOCAT study (97) the
mean plasma on-treatment RLP-C concen-
tration was significantly associated with the
42
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progression of minimum luminal diameter
(P<0.004). However, this association was
not independent upon plasma TG levels. In
addition, a significant association was found
between the plasma RLP-C concentration
and occurrence of new lesions in vein grafts.
In patients with vasosoatic angina with or
withour myocardial infarction, plasma RLP-
C was a major risk factor for predictio of
myocardial infarction (98). Elevated levels of
plasma RLP-C were predictive for future
coronary events in Japanes patients with
CAD independent of other risk factors
(99;100). In the postprandial period, arterial
relaxation (as assessed by flow mediated dila-
tion) in healthy young normolipidemic sub-
jects decreased in parallel with the plasma
peak concentration of TG and RLP-C (101).
Additional evidence for a relationship
between postprandial increase in plasma
RLP-C and endothelial function was
observed in a small study by Wilmink et al
(62), wherein the increase in plasma RLP-C
and decrease in endothelial function was atten-
uated by short term statin treatment, inde-
pendent upon the differences in plasma TG
and cholesterol. Human studies therefore sug-
gest a direct effect of RLP on atherogenesis.
In-vitro studies have further elucidated the
role of RLP the atherosclerotic process.
Incubation of triglyceride rich particles with
isolated rabbit aorta showed that RLP inhib-
ited arterial relaxation by acetylcholine in a
dose-dependant manner (102). Pretreatment
of rat aortas with L-NAME completely
downregulated vasorelaxation of thoracic rat
aortas, indicating the involvement of a nitric
oxide (NO) mediated pathway. Moreover,
inhibition of cell surface glycoproteins with
heparin and lactoferrin did not affect RLP-
induced impairment of vasorelaxation. These
results suggest that RLP exert a direct effect
on endothelial function without binding to
glycoproteins that are located at the apical
site of the endothelium. Incubation with
RLP (0,1 mg cholesterol/ml), but not VLDL
TG-rich lipoproteins (d<1,006) or LDL
(1,019<d<1,063) that are separated by ultra-
centrifugation, induced an increased expres-
sion of ICAM-I, VCAM-I and Tissue Factor
(TF) in a HUVEC cell model partly through
a redox-sensitive mechanism (103). Incuba-
tion with alpha-tocopherol suppressed the
RLP-induced mRNA and protein expression
of these molecules in a dose dependent man-
ner. In addition, treatment of subjects with
higher plasma RLP-C levels (RLP-C > 5,1
mg cholesterol/dL) for 4 weeks with alpha-
tocopherol (300 mg/day) prevent the rise in
plasma levels of adhesion molecules, such as
sICAM-I and sVCAM-I. (103). Incubation
of RLPs with HUVEC and monocytes in a
flow conditioned model results in enhanced
expression of CD11a, CD18 and CD49d and
IL1β (104), indicating a role of remanant
lipoproteins in vascular inflammation. Pro-
inflammation is a key step in progressive ath-
erosclerosis and a pro-inflammatory pheno-
type is closely associated with a high
cardiovascular mortality. Macrophages and
subsequently foam cells are frequently found
in both human and animal atherosclerotic
plaques. The interaction of RLP with
macrophages and the consequent atherogenic
response is still under investigation, but RLP
may induce foam cell formation according to
previous studies in animal models ref.
Effect of treatment on plasma RLP-C
Only limited intervention studies are avail-
able to evaluate potential therapeutic reduc-
tions of increased plasma levels of RLP-C.
Effect of statin treatment
Although evidence exist that statin treatment
result in a reduced cardiovascular mortality
that may be explained by plasma LDL-cho-
lesterol lowering, the effect of statin treat-
ment on elevated plasma RLP-C levels is not
consistently observed. Pravastatin, atorvas-
tatin or simvastin exert its own effect on
plasma RLP-C lowering in a randomized
cross-over study in patients with combined
hyperlipidemia (105). Plasma RLP-C reduc-
tion did not occur after pravastatin (40
mg/d), whereas Simvastatin (20 mg/d; medi-
an reduction of 6%) and Atorvastatin (10
44
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mg/d; median reduction of 26%) lowered
plasma RLP-C levels significantly. Although
high dose Simvastatin therapy in heterozy-
gous FH patients also reduces plasma RLP-C
concentrations significantly, only 25 % of
FH patients reached plasma RLP-C levels
comparable with aged and sex matched nor-
molipidemic subjects (66). In a small FH
population, a significant reduction in baseline
and postprandial RLP-C levels were found by
statin treatment (106; 107). No dose-
dependent decrease in plasma RLP-C (-33%,
-34%, -32%) from atorvastatin (20 mg/day,
40 mg/day and 80 mg/day) in patients with
CHD was found, in contrast to plasma levels
of LDL-cholesterol (-38%, -46%, and -52%)
and TG (-22%, -26%, and -30%) (108). This
is not surprising since the primary target for
lipid lowering with a statin will be plasma
LDL-cholesterol. The decrease in plasma TG
after statin therapy is much less pronounced
and is mostly not dose-dependent (109; 110).
Additional intervention studies are needed to
compare different statins with respect to
their potency to reduce plasma RLP-C levels
in distinct patient groups with disturbances
of lipid metabolism.
Fibrates
The principal effect of fibrates is lowering of
plasma TG and increase of plasma HDL-C.
The working hypothesis is that fibrates alter
the expression of PPAR-α. Several genes
involved in triglyceride metabolism, such as
apo C-III and LPL have a PPAR regulating
element in the promoter region. Apo C-III
expression is downregulated by fibrates,
whereas LPL gene expression is upregulated
(111). As stated before, plasma RLP-C con-
centrations are closely associated with plasma
TG, VLDL-cholesterol and VLDL-TG levels,
but not with LDL-cholesterol. It is therefore
likely to expect a significant lowering effect
of fibrate therapy on plasma RLP-C levels. In
patients after coronary artery bypass graft-
ing, a two year treatment with Gemfibrozil
(LOCAT study; 1200 mg/day) reduced
median plasma RLP-C levels with 34 %
(from baseline 0.24 [0.17-0.42] to 0.15 [0.13-
0.20] mmol/l ) (97). In patients with protein-
uric renal disease, no effect of cerivastatin
(100 or 200 µg once a day for 2 months) on
plasma RLP-C was found, in contrast to
fenofibrate (200 mg once a day for 2
months) that results in a 35 % decrease in
plasma RLP-C levels (112). In line with the
reduction of plasma TG during fenofibrate
treatment, the TG reduction correlated with
a decrease in VLDL1 and and a shift towards
less dense, less atherogenic LDL subfraction.
In addition, the reduction in VLDL-1 was
associated with the decrease in plasma RLP-
C. Therefore, treatment with fibrate is
favored above treatment with statins with
respect to plasma RLP-C reduction in
patients with a nephritic-range proteinuria.
In patients with combined hyperlipidemia
the threat of rhabdomyolysis occurs when
both a statin and a fibrate are subscribed.
Therefore a direct comparison was made
between the effect of statin versus gemfi-
brozil on plasma lipid phenotype. However
there was a significant decrease in plasma TG
on gemfibrozil treatment and no effect with
the statin. Statin treatment results in a signif-
icant decrease in plasma LDL-C, whereas no
change was seen in gemfibrozil treated
group. Plasma RLP-C decrease was similar in
both treatment groups (113).
Diet intervention
The effect of diet intervention on plasma
RLP-C levels are still not studied extensively.
In contrast to long-term intervention stud-
ies, short-term dietary intervention studies
with either a high fat or a high carbohydrate
intake in healthy adults did not result in
changes in plasma TG levels (114). More-
over, in type IV hyperlipidemic patients who
consume a low fat diet for three months, no
changes in fasting plasma TG levels were
found (115). In a short-term diet interven-
tion study, in which carbohydrate was added
to mixed meals, even in large amounts, no
increase in de-novo lipogenesis was found
(116;117). A diet of 20 grams of soy protein
isolate during 3 weeks reduced baseline plas-
ma RLP-C levels by 9,8% (118). A replace-
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ment of diacylglycerol by triacylglycerol in
the oral fat load, increased postprandial plas-
ma RLP-C levels (119).
Conclusion
The importance of atherogenic lipoprotein
remnants in the development of premature
and progressive atherosclerosis, beyond
LDL-cholesterol have now been extensively
documented. It remains however to be stud-
ied in large epidemiological studies to what
extend the measurement of plasma RLP-C
provides additional knowledge for the treat-
ment goals of the individual patients. In
comparison to a plasma TG measurement,
plasma RLP-C analyses is expensive and
time-consuming. The samples should be
stored at -80°C and not for a period longer
than one or two years. Furthermore, the
standardization of the assay is very important
and critical for the outcome of the plasma
RLP-C levels. It is still striking that plasma
RLP-C levels in Japan are so much lower
than in Caucasian countries. In conclusion,
plasma RLP-C analyses further completes
the atherogenic profile of the patient at risk
and can be used as a specific target for treat-
ment. Assessment of RLP-C, in addition to
LDL-cholesterol and the calculated non-
HDL cholesterol, may therefore complete
the atherogenic lipid profile with a view to
estimation of the risk of coronary events.
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bnormal postprandial lipoproteins are
associated with an increased risk for
cardiovascular disease (1; 2). Dietary
fat enters the small intestine and is packed in
apoB48 containing chylomicrons in the ente-
rocyte (3;4). These particles are heteroge-
neous of composition and size. Upon secre-
tion into the circulation chylomicron
triglycerides are lipolyzed by the direct
action of lipoprotein lipase (LPL) in periph-
eral tissues, leading to the formation of free
fatty acids and remnant particles (1). Rem-
nants have a reduced triglyceride content and
are enriched in cholesterol and apolipopro-
teins B and E (5). Increased levels of these
remnant particles have already been associat-
ed with the presence and progression of car-
diovascular disease.
Most studies on the relationship between
cardiovascular disease and lipoproteins
metabolism have been based on fasting
lipoprotein levels. Given the fact that a per-
son is in the postprandial state a great period
of the day, it appeared to be more appropriate
to analyze lipoprotein metabolism postpran-
dially using a standardized fat intake or a
standardized meal. Postprandial remnant
lipoprotein metabolism was typically meas-
ured in humans by incorporation of retinyl
esters into chylomicron particles as a core
label during an oral fat loading test (6; 7). As
chylomicrons undergo lipolysis and become
a smaller remnant particle the palmitate ester
label remains in the core and is cleared from
the plasma. Therefore, monitoring the retinyl
ester label during an oral fat loading test pro-
vides data about chylomicron appearance and
clearance. The evaluation of data using
retinyl esters as marker have been discussed
extensively, because of the possible exchange
of the label with other non-intestinally
derived lipoprotein fractions (8; 9). It is thus
important to search for a more reliable
method to assess remnant lipoprotein con-
centrations. Recently, the development of a
novel immunoseparation method by Nakaji-
ma et al (10) enables a new approach for rem-
nant analysis both in fasting and postprandial
plasma samples. This assay is based on the
specificity of two antibodies used to isolate
non-remnant lipoproteins. The apo B100
monoclonal antibody (mab JI-H) recognizes
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Abnormal postprandial lipoproteins are associated with an increased risk for car-
diovascular disease. Postprandial remnant lipoproteins were usually analyzed indi-
rectly using retinyl esters (RE) as a chylomicron core label during an oral fat load-
ing test. Apo B-100 containing VLDL remnants in addition to apo B48 containing
chylomicron remnants can also be directly quantified using the RLP-Cholesterol
Immunoseparation Assay. This recently available method uses monoclonal anti-
bodies to apo A-I and apo B-100 to remove non-remnant lipoproteins and quanti-
fies cholesterol in the remaining apo E-rich remnant fraction. In the present study
we compared the analysis of retinyl ester with the immuno-based RLP-Cholesterol
(RLP-C) analysis in measuring postprandial remnant lipoproteins in healthy nor-
molipidemic subjects.
Sixteen healthy normolipidemic subjects were selected for this study. Postprandial
plasma retinyl esters peaked at 5.0 ± 1.2 hr, whereas plasma RLP-C showed a peak
significantly earlier (P<0.001) at 3.5 ± 0.6 hr. In comparison, postprandial plasma
TG and FFA peaked at 3.3 ± 1.1 hr (P<0.005 compared to retinyl esters). 
In conclusion, levels of RLP-C changed, during the postprandial phase, in parallel
with plasma TG and FFA concentrations and peaked significantly earlier than
retinyl esters. Postprandial measurements of RLP-C can be considered as a fast
alternative method for the more laborious retinyl ester analysis in clinical studies.
A
an epitope near apo B51 enabling the isola-
tion of all LDL and most VLDL particles. A
monoclonal antibody against apo AI removes
all HDL particles. In the remaining unbound
fraction apoB 48 remnant particles and a
small portion of apo E containing VLDL
remnant particles are present. This fraction is
called ‘remnant-like particles’ (RLP). Cho-
lesterol RLP-C) and triglycerides (RLP-T)
are measured using an enzymatically assay.
Increased levels of RLP-C has been found in
a number of disorders related to increased
risk for atherosclerosis like diabetes, type III
dyslipoproteinemia, chronic kidney insuffi-
ciency, and hypertriglyceridemia. 
In the present study we evaluate the classical
approach of postprandial lipid kinetics by
retinyl palmitate incorporation into intesti-
nally derived lipoprotein particles with rem-
nant analysis using the new immunosepara-
tion technique in measuring postprandial
remnant lipoproteins in normolipidemic
individuals.
Methods and Materials
Subjects
Normolipidemic healthy control subjects,
matched for age, gender, BMI and apo-E
genotype, were selected for this study by
advertisement in the local newspaper. Exclu-
sion criteria included the presence of dia-
betes, hepatic -, renal -, thyroid dysfunction
and a positive family history for cardiovascu-
lar diseases. The human investigation review
committee of the University Medical Center
Utrecht approved the study protocol and
written informed consent was obtained from
all participants. 
Oral fat loading test
After an overnight fast of 12 hrs, participants
were admitted to the metabolic ward at 7.30
h am. Cream (consisting of 40% fat (w/v)
with a P/S ratio of 0.06, 0.001% cholesterol
(w/v) and 2.8% carbohydrates (w/v)), sup-
plemented with 120.000 IU Vitamin A, was
given as a single fat load in a dose of 50 g fat
per m2 body surface area. Prior to the test
meal blood samples were obtained for base-
line values. After ingestion of the cream
venous blood samples were taken hourly
from an indwelling catheter in the ante
cubital vene during 8 hours. During the test
only water or tea without sugar were allowed
to drink. Blood was collected in EDTA
(2mM) containing tubes. All blood samples
were immediately put on ice and immediately
centrifuged at 4°C, 3000 rpm for 15 min. 
Analytical Methods
Plasma triglyceride and total cholesterol were
measured by enzymatic assays (Monotest
cholesterol kit no. 237574 and GPO-PAP no.
701912, Boehringer Mannheim, Germany).
HDL cholesterol was determined using
heparin-manganese precipitation of non-
HDL lipoproteins (11). Plasma free fatty
acids (FFA) were analyzed by an enzymatic
assay (WAKO chemicals, Neuss, Germany).
Plasma apo E and plasma apo CIII concen-
trations were analyzed with a commercial
available immunoelectrophoretic assay
(Hydragel LP E and LP CIII, Sebia, Issy-les-
Moulineaux, France). Apo E genotype was
determined as described before (12). ApoB
was measured using an enzymatic assay
(UNIMATE 3 APOB kit, Roche Diagnos-
tics Systems, France) using a Cobas Mira S
auto-analyzer (ABX Diagnostics, Montpelli-
er, France). Retinyl esters were analyzed on
the HPLC (LC 10A, Shimadzu, Japan) (13)
using retinyl palmitate as a standard. 
Preparation of chylomicron and non-chy-
lomicron fractions
Lipoproteins were separated in a single ultra-
centrifugation step by flotation in a Sf>1000
fraction which contains chylomicrons, large
chylomicron remnants and large hepatic
triglyceride rich lipoproteins, and a remain-
ing infranatant fraction (Sf<1000) contain-
ing small chylomicron remnants and all the
other lipoproteins (14). Plasma samples were
adjusted to d=1.006 g/L using and overlay-
ered with d=1.006 g/L NaCl solution. Ultra-
centrifugation was performed in a SW 50.1Ti
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swinging bucket rotor at 40.000 rpm for 4h
at 15°C in a Beckmann Optima Ultracen-
trifugation.
Analysis of postprandial RLP-C.
The RLP fraction was prepared using an
immune separation technique described by
Nakajima et al (15). Briefly, 5 µl of serum
was added to 300µl of mixed immunoaffinity
gel suspension containing monoclonal anti-
human apo A-I (H-12) and anti-human Apo-
B-100 (JI-H) antibodies (Japan Immunore-
search Laboratories, Takasaki, Japan). The
reaction mixture was gently shaken for 120
minutes at room temperature on a special
mixer (RLP-mixer J100-A, Photal, Otsuka
Electronics, Japan). After 15 minutes, 200µl
of the supernatant was used for the measure-
ments of cholesterol (RLP-C) by an enzy-
matic assay included in the assay kit using a
Cobas Mira S auto-analyzer (ABX Diagnos-
tics, Montpellier, France). The interassay
variability was 1.3 %. 
Statistical Analysis
Data are presented as means ± SD, unless
shown otherwise. Paired student’s t-test was
used to test the significance of the difference
between the peak times of the various post-
prandial analyses. Pearson correlation test
was used for correlation analysis. P<0.05 was
considered statistically significant. An Area
under the integrated Curve (AUC) was cal-
culated using GraphPad Prism software (ver-
sion 3.1, San Diego, California, USA).
Results
Population characteristics
All subjects were normolipidemic according
to the latest European recommendations.
The baseline characteristics are presented in
(Table 1). The subjects were middle-aged
men (8) and women (8) on a free-living diet.
No difference in age, body mass index, plas-
ma lipid and apolipoprotein levels was
observed between male and female subjects.
As a consequence we analyzed the data for
males and females together.
Postprandial profiles in normolipidemic sub-
jects
Postprandial plasma, chylomicron (Sf>1000)
and non-chylomicron (Sf<1000) levels of
TG, FFA, retinyl esters, apo B and RLP-C
were analyzed. Plasma TG and FFA levels
increased after ingestion of the cream (Fig-
ure 1, panel A and B). The maximal post-
prandial plasma TG concentration (peak: 1.8
± 1.2 mmol/l, baseline: 0.9 mmol/L;
p<0.001) and maximal postprandial plasma
FFA concentration (peak: 0.62 ± 0.23
mmol/L; baseline: 0.36 ± 0.23 mmol/L
p<0.05) occurred between 3 and 4h, respec-
tively. After 8h the plasma triglyceride curve
returned to its baseline levels, whereas the
plasma FFA curve remained elevated
throughout the whole test period. Plasma
apo B levels did not change during the post-
prandial test (Figure 1C). Plasma retinyl
ester concentration (baseline: 0.62 ± 0.73
mg/L) increased, with a delay over the first
two hours, (Figure 2, panel A) to the maxi-
mal postprandial plasma retinyl ester
response of 7.65 ± 5.15 mg/L (p<0.0001) at
around 5h. Plasma retinyl ester concentra-
tions remained elevated until 7h after the
start of the oral fat load test, and did not
return to its baseline levels after 8h. The
retinyl ester concentrations in the Sf<1000
fraction (baseline: 0.33 ± 0.23 mg/L) and the
Sf>1000 fraction (baseline: not detectable)
showed curves comparable to the plasma
retinyl ester curve (Figure 2, panel A). The
maximal postprandial retinyl ester concentra-
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tion in the Sf<1000 (2.59 ± 2.00 mg/L;
p<0.001 in comparison with baseline con-
centrations) and in the Sf>1000 (5.08 ± 2.43
mg/L) was reached around 5h. 
Plasma RLP-C (baseline: 0.18 ± 0.06
mmol/L) and RLP-T concentration (base-
line: 0.25 ± 0.14 mmol/L) gave an immediate
response upon ingestion of the dietary fat
load (Figure 2, panel B). The maximal post-
prandial plasma RLP-C concentration (0.48
± 0.31 mmol/l; p<0.05 versus baseline) was
reached at 3.6 h, comparable to the plasma
triglyceride peak. The RLP-T and the RLP-C
profile, are similar, although we were unable
to measure the 3-hour RLP-T point. The
peak of Sf<1000 retinyl ester was significant-
ly later than the plasma RLP-C peak (Figure
3 and Table 2, p<0.0001), and plasma TG
peak (p<0.0001) (Table 2). The baseline val-
ues, integrated area under the curve (AUC)
and incremental AUC of plasma RLP-C,
plasma TG, Sf<1000 retinyl ester are pre-
sented in Table 3. 
To determine which parameters were best
predictive for plasma RLP-C levels a correla-
tion analysis was performed (Table 4). Base-
line RLP-C was positively correlated with
BMI (0.54; p<0.05), plasma TG (0.79;
p<0.001), plasma cholesterol (0.52; p<0.05),
apo B (0.73; p<0.001) and apo E (0.61;
p<0.05). The integrated AUC of RLP-C
showed similar correlations but an additional
correlation with apo CIII (0.59; p<0.05) was
found. The incremental AUC of RLP-C was
positively correlated with apo CIII (0.53;
p<0.05) and with baseline plasma cholesterol
(0.49; p=0.05). The integrated AUC of RE
(Sf<1000) was positively correlated with
plasma TG (0.55; p<0.05), plasma choles-
terol (0.60; p<0.05) and apo B (0.64;
p<0.05). The incremental AUC of RE
(Sf<1000) was positively correlated with
plasma TG (0.53; p<0.05) and apo-B (0.61;
p<0.05).
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Table 1: Baseline characteristics of the subjects
Parameter
N 16
Age (y) 49 ± 9
BMI (kg/m2) 25.30 ± 3.22
WHR 0.83 ± 0.09
Cholesterol (mmol/L) 5.16 ± 0.70
HDL-chol (mmol/L) 1.53 ± 0.37
Triglycerides (mmol/L) 0.90 ± 0.38
ApoB (g/L) 0.95 ± 0.25
ApoAI (g/L) 1.20 ± 0.22
ApoE (mg/dL) 4.76 ± 1.1
Apo CIII (mg/dL) 3.0 ± 0.7
NEFA (mmol/L) 0.36 ± 0.16
ApoE genotype
E3E3 10
E3E4 2
E4E4 3
E2E3 1
Values are expressed as mean ± SD.1
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Figure 1. Postprandial plasma TG (panel A), plasma FFA
(panel B) and plasma apo B (panel C) curves. All data are
expressed as mean ± SEM. Peak versus baseline: * p<0.05
and ** p<0.001 as tested with a student’s T-test.
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Table 2: Differences in peak time of plasma TG, Sf<1000 RE and plasma RLP-C during the
oral fat load. 
Time (hr) p-value
RLP-C vs. TG 3.56 ± 0.63 vs. 3.25 ± 1.13 ns
Sf<1000 RE vs. TG 5.14 ± 1.10 vs. 3.25 ± 1.13 0.0001
RLP-C vs. Sf<1000 RE 3.56 ± 0.63 vs. 5.14 ± 1.10 <0.0001
Values are expressed as mean ± SD. P-values were determined using the Student’s t-test. 
Table 3: Baseline values and postprandial integrated areas under the curve (AUC) of plasma
RLP-C, plasma TG, Sf<1000 RE and plasma TG/Apo-B ratio. 
RLP-cholesterol TG Sf<1000 RE
Baseline 0.18 (0.06) 0.89 (0.37) 0.33 (0.23)
AUC 0-8 h 2.59 (0.89) 11.41 (4.81) 13.36 (9.50)
∆AUC 0-8 h * 1.14 (0.61) 4.49 (2.41) 10.70 (8.68)
Values are expressed as mean ± SD. P-values were determined using the Student’s t-test. * ∆AUC means incremental area
under the curve. RLP-C and TG are expressed as mmol/L, retinyl esters as mg/L. 
Table 4: Correlation coefficients of variance of baseline lipid parameters and BMI with plasma
RLP-C (Baseline, AUC and incremental AUC) Sf<1000 RE (AUC and incremental AUC). 
RLP-C Sf<1000 RE
Baseline AUC 0-8 h ∆AUC 0-8 h † AUC 0-8 h ∆AUC 0-8 h †
BMI 0.54 * - - - -
TG 0.79 ** 0.53 * - 0.54 * 0.54 *
Cholesterol 0.52 * 0.61 * 0.49 * 0.60 * -
Apo-B 0.73 ** 0.56 * - 0.64 * 0.61 *
Apo-CIII - 0.59 * 0.53 * - -
Apo-E 0.61 * 0.58 * - - -
† ∆ AUC 0-8h indicates area under the curve incremental curve after substraction of baseline concentrations. Correlations
were determined using Pearson’s correlation coefficient test.  *P<0.05, ** P<0.001.
Discussion
In the present postprandial study, the charac-
terization of chylomicron/VLDL-remnants
by immunoseparation or by retinyl ester
analysis in the Sf<1000 fraction after an one-
step ultracentrifugal separation revealed dif-
ferent postprandial chylomicron remnant
profiles in normolipidemic subjects. Fasting
plasma RLP-C concentrations in our nor-
molipidemic subjects (mean RLP-C 7.0
mg/dl, 0.18 mmol/L) were in the higher
range of the 75th percentile RLP-C concen-
trations when compared to a general North
American population (6.6 mg/dL, 0.17
mmol/L) (16) and were in the lower range
when compared to the Framingham study
population (7.2 mg/dL, 0.19 mmol/L) (17).
Post-hoc analysis in the Framingham study
population resulted in gender differences for
fasting RLP-C concentrations (males vs.
females: 8.02 mg/dL (0.21 mmol/L) vs. 6.80
mg/dL (0.18 mmol/L) respectively). In our
study, fasting RLP-C tended to be higher in
males than in females, but due to the small
number of subjects it did not reach signifi-
cance. Fasting RLP-C was positively correlat-
ed with BMI, fasting plasma TG, and fasting
plasma cholesterol (17). In the present study
BMI, plasma TG and cholesterol were lower
compared to the Framingham study popula-
tion and could explain the relatively lower
RLP-C levels. 
Enhanced postprandial chylomicron-rem-
nant levels are a feature of premature athero-
sclerosis (18). Measurement of retinyl esters
in the triglyceride-rich lipoprotein fraction
has been proposed as a marker for chylomi-
cron remnants (6; 19-22). However, retinyl
ester label does not specifically resembles
chylomicron clearance due to the exchange
of the label between lipoprotein species in
plasma (8; 9; 23). Up to 25% of the retinyl
ester in the postprandial state was due to
retinyl ester in the apo B100 TRL fraction.
The apo B100 peak occurred at a later time
point than the apo B48 peak that is in favor
of a precursor - product relationship. Brun-
zell et al (24) already proposed that VLDL
and chylomicrons are catabolized by a com-
mon pathway by competition for the enzyme
lipoprotein lipase at the capillary endotheli-
um surface. Increased presence of apo B48
containing remnants could explain the
increased levels of triglycerides in apo B100
particles. On the other hand evidence is
available that in the fed state an increase in
the production rate of triglyceride-rich apo
B100 containing lipoprotein particles
occurred (25). 
In the enterocyte, retinyl esters are incorpo-
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Figure 2. Plasma retinyl esters (l), Sf>1000 RE(n) and
Sf<1000 RE (s)responses(panel A). Postprandial RLP-C (u;
left y-axis) and RLP-T (l; right y-axis)(panel B). All data are
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Figure 3. Postprandial RLP-C (left y-axis) curve and the
postprandial Sf<1000 RE (right y-axis) are shown. All data
are expressed as mean (SEM). ** P<0.001 compared to
baseline value. The peaks of the RLP-C and RE curve are
significantly different (p<0.0001).
rated in chylomicrons proportionally to the
size of chylomicrons (26). Postprandially, the
numbers of chylomicron particles, measured
as apo B48 concentration, do not increase.
However, during the postprandial phase the
size of chylomicrons is distributed in a
bimodal way (27). In the early postprandial
phase smaller primordial lipoproteins (apo-
B48) are assembled independently from the
formation of triglyceride-rich lipid droplets,
whereas at later time points (6-8 hours) larg-
er chylomicrons, formed by fusion of TG-
rich lipid droplets and primordial lipopro-
teins, are secreted by the enterocyte. This
means that the postprandial retinyl ester
peak in most studies, with an average at 5
hours after ingestion of the test meal, reflect-
ed the capacity of large chylomicron particles
to incorporate the retinyl esters. The post-
prandial retinyl ester response, with a delay
in the first hour in oral fat-loading test, in
our normolipidemic subjects confirmed this
hypothesis. An additional support was
derived from the fact that plasma retinyl
esters and retinyl esters in the remnant frac-
tion (Sf<1000) peaked significantly later
than plasma triglycerides and the RLP-C
peak. Moreover, the postprandial RLP-C
curve changed in parallel with plasma TG and
FFA concentrations. 
In summary, we have presented a novel appli-
cation for the elegant and fast immunosepa-
ration technique to quantify remnant parti-
cles in the postprandial phase. Although both
RE and RLP-C can be used to study post-
prandial lipoprotein metabolism, they meas-
ure different remnant lipoprotein fractions.
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Susceptibility to Oxidative Stress
Preliminary report
emnants of triglyceride-rich particles,
including chylomicrons and very low-
density lipoprotein (VLDL), (TRP)
are associated with an increased risk for car-
diovascular disease. A recent method to
analyse these lipoprotein remnants (RLP) in
a suitable way was introduced by Nakajima et
al (1). Elevated plasma levels of RLP-C are
found in patients with coronary artery dis-
ease. In patients with an adult-onset growth
hormone deficiency (AGHD), an athero-
genic lipoprotein phenotype was reported,
together with elevated plasma RLP-C levels
that have similarities with a mild form of
type II-B dyslipidaemia (2). This atherogenic
lipid phenotype is characterized by elevated
plasma levels of total cholesterol and triglyc-
eride (>250 and > 200 mg/dL, respective-
ly)(3), reflecting elevated plasma VLDL and
IDL concentrations, and in addition, subnor-
mal plasma HDL-cholesterol levels. An
increased mortality due to cardiovascular dis-
ease is observed in these patients. Although
direct negative effects of the RLP fraction on
endothelial function was found, the mecha-
nism underlying this effect remains to be
established Moreover, the physical-chemical
properties of the RLP fraction and its rela-
tion to the atherogenic properties of this spe-
cific TRP fraction are not totally elucidated.
In this preliminary report, our objective was
to analyse the physicochemical composition
of the RLP fraction and to evaluate its sus-
ceptibility to oxidative stress in Type IIB
patients.
Patients/Methods
Patients
Patients (n= 50) were selected who had a
combination of hypercholesterolemia and
hypertriglyceridemia, a phenotype termed
combined or “mixed” hyperlipidemia (type
II-B). Plasma samples were obtained from
the patients after an overnight fast and
pooled. Mean plasma cholesterol and triglyc-
eride (TG) levels were 296 ± 28 mg/dl and
253 ± 32 mg/dl, respectively. Plasma samples
were stored at minus 80°C for subsequent
analyses.
Lipoproteins
The lipid content of plasma and isolated
lipoprotein fractions was quantified enzy-
matically by using kits from Roche Molecu-
lar Biochemicals (Meylan, France) for total
cholesterol (TC) and free cholesterol. CE
mass was calculated as (TC-FC) x 1.67 and,
thus, represents the sum of esterified choles-
terol and fatty acid moieties (4). Kits from
Bio-Mérieux (Marcy-l’Etoile, France) were
used for determination of TGs and phospho-
lipids. Bicinchoninic acid assay reagent
(Pierce Chemical Co., Rockford, IL) was
used for protein quantification. Lipoprotein
mass was calculated as the sum of the mass of
the individual lipid and protein components
for each lipoprotein fraction.
TRP fraction analysis
Subfractions of triglyceride-rich lipopro-
teins, i.e. VLDL-1 (Sf 60-400), VLDL-2 (Sf
20-60) and IDL (Sf 12-20) were isolated
from plasma (2 ml) by cumulative flotation
following non-equilibrium density gradient
ultra centrifugation using a Beckman SW41
Ti rotor (5). All lipoprotein fractions were
analysed for their protein and lipid content.
RLP isolation
Isolation of the RLP fraction was performed
as described before, using an immunosepara-
tion technique described by Nakajima et al
(1) with some modifications (1; 6). From
each pool of plasma, 10 ml plasma was added
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to 20 ml mixed immunoaffinity gel suspen-
sion containing monoclonal anti-human apo
A-I (H-12) and anti-human Apo-B-100 (JI-
H) antibodies (Japan Immunoresearch labo-
ratories, Takasaki, Japan). The reaction mix-
ture was gently shaken during the night at
4°C. The gel mixture was applied in a col-
umn, and washed with PBS EDTA, pH 7.4.
The unbound fraction was collected, and fur-
ther isolated by ultracentrifugation (40.000
rpm, 24h) in a SW 60 rotor in a Beckman
ultracentrifuge at a density of 1.063 g/ml to
reduce contamination with plasma proteins,
such as albumin. The top fraction (5 ml) was
collected and concentrated five fold by using
Millipore centrifugal filter device (Mw cutt
off 100.000) and dialysed extensively against
PBS pH 7.4 (24 h, 4°C). The RLP fraction
was analysed for protein and lipid content.
Oxidation studies
The same procedure was performed, as
described earlier (7). Lipoproteins were
extensively dialysed against PBS pH 7.4
(three changes over 24 h, 4°C) before the
oxidation studies. In short, lipoproteins were
incubated at a final concentration of 50 µg
protein/ml; with 5.0 µM CuSO4 at a final
volume of 500 ml. Conjugated diene absorp-
tion (234 nm, each 10 min, at 37°C) was
measured by spectrophotometry over a peri-
od of 20 h. As a positive control, a LDL-3
fraction from normolipidemic subjects was
oxidised in parallel. The oxidative curve typi-
cally reveals three phases; specifically the lag,
propagation and decomposition phase (8).
Propagation rate is the average oxidation rate
in the propagation phase.
Chromatographic size exclusion
To estimate the size range of RLP, in compar-
ison with VLDL-1, VLDL-2 and IDL, we
used the Duo Flow system (Biorad), that
consists of two Superose 6HR 10/30
columns in series with a flow rate of 0.4
ml/min. Both the RLP fraction and the dis-
tinctive TRP fractions (each 200 µL) were
injected separately in the Duo Flow system.
Fractions of 2 ml were collected and used for
the determination of TG and cholesterol
content. From the RLP profile, the total area
under the curve (AUC) and partial AUCs,
corresponding to the TRP subfraction, was
calculated with GraphpadPrism (version 3.1,
2002).
Statistical Analysis
All values are presented as means ± SD. Two
sided paired student t-tests were used with a
p value of <0.05, as significant. The Graph-
padPrism (version 3.1, 2002) was used as sta-
tistic software.
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Results
Plasma lipoprotein profile and chemical
composition
Table 1 summarizes the percent weight
chemical composition of the different TRL
fractions (VLDL-1, VLDL-2 and IDL) and
RLP, isolated from four different plasma
pools obtained from type II-B patients. The
RLP fraction is distinguished by its high cho-
lesteryl ester content, compared to the other
TRP fractions.
Physical characteristics
Figure 1A and 1B show distinctive chro-
matographic (size exclusion) profiles from
the RLP fraction and each fraction of TRPs
(VLDL-1, VLDL-2 and IDL). The first peak
that could be detected was RLP, followed by
VLDL-1, VLDL-2 and IDL. Although the
elution position of the peak of RLP-TG was
similar to that of VLDL-1, the RLP choles-
terol peak was broader and overlapped partly
the VLDL-2 and IDL fractions. The frac-
tions were well separated by the column in
the different runs. The RLP-C peak was sub-
sequently detected in the same chromato-
graphic (size exclusion) profiles (fraction 77
± 2). The part of the RLP curve that is in the
size range of VLDL-1 (fraction 76-89) is
56% (RLP-C), and 82% (RLP-TG), 25%
(RLP-C) and 23% (RLP-TG) is in the size
range of VLDL-2 (fraction 86-118); and 12
% (RLP-C) and 14% (RLP-TG) in the size
range of IDL (fraction 99-126). These data
indicate that the particle size range of RLP
closely resembles that of the VLDL-1 sub-
fraction.
Oxidizability
Both the RLP fraction and the TRP frac-
tions, like LDL-3, were susceptible to oxida-
tive modification after exposure to CuSO4 as
assessed by the formation of conjugated
dienes (figure 2). The conjugated diene
curves were analysed for lag time, T1/2 and
maximal conjugated diene concentration.
The RLP fraction (compared to LDL-3 from
normolipidemic subjects) was found to have
a six fold longer lag-phase (Table 2), with no
68
0
0
80-5
5
10
15
20
25
Fractions
C
ho
le
st
er
ol
 le
ve
l (
m
g/
dl
)
RLP
VLDL 1
VLDL 2
IDL
100 120 140
Figure 1B. The RLP-C profile of RLP and the content of
cholesterol in the VLDL-1, VLDL-2 and IDL in type II-B
dyslipidemic subjects after size exclusion chromatography.
0
0
80
-10
10
20
30
40
50
60
Fractions
T
G
 le
ve
l (
m
g/
dl
) RLP
VLDL 1
VLDL 2
IDL
100 120 140
Figure 1A. The RLP-TG profile of RLP and VLDL-1,
VLDL-2 and IDL in type II-B dyslipidemic subjects after
size exclusion chromatography.
0
0
200
-02
0.2
0.6
0.8
1.0
1.6
1.4
time (min)
O
D
(2
34
nm
)
RLP
VLDL 1
VLDL 2
LDL 3
400 600 1000800
Figure 2. Conjugated diene curves generated from the oxida-
tion of RLP, VLDL-1, VLDL-2 and LDL-3. The conjugat-
ed diene curves were produced by incubating (room temper-
ature) the lipoprotein preparations (50 mg protein/ml) with
CuSO4 (5mM) in EDTA-free PBS and continuously mon-
itoring the changes in absorbance at 234 nm for 20h.
difference in maximal diene production. Oxi-
dation of RLP produced a conjugate diene
curve that had a similar lag time , and took
the same time to reach maximal diene pro-
duction, as that of VLDL-1 and VLDL-2.
The overall pattern of oxidative susceptibility
increased in the order of LDL-3>VLDL-
2>RLP(VLDL-1
Discussion
This preliminary report shows that RLP ,
among the other TRP fractions including
VLDL-1, VLDL-2 and IDL, is characterized
by increased content of cholesteryl esters
(CE) and a size range that overlapped mostly
with the VLDL-1 fraction. Moreover, this
RLP fraction is susceptible to oxidative
stress, but to a lesser degree as the LDL-3
fraction from normolipidemic subjects.
Remnant lipoproteins, such as RLP, originate
from chylomicrons and VLDL in the circula-
tion where they are processed intravascularly
by lipoprotein lipase, hepatic lipase and cho-
lesteryl ester transfer protein (CETP).
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Table 1: Chemical composition of plasma RLP , and plasma RLP of normolipidemic healthy
subjects (RLP N), and VLDL-1, VLDL-2 and IDL fractions from subjects with Type II-B dys-
lipidemia. 
% Weight
Free Cholesteryl tri- phospho- Total mass
cholesterol ester glycerides lipids protein (mg/dl)
RLP (N) 4.2±0.9 8.9±1.2 72.2±5.9 7.8±2.9 6.7±1.3 93.2±1.7
RLP (II-B) 3.6±0.7 18.9±5.4 52.5±9.5 16.8±3.3 9.4±1.7 150.0±5.3
VLDL-1 1.8±0.2 2.5±0.5* 70.4±0.8 20.5±0.9 4.8±1.2 194.2±27.7
VLDL-2 3.4±0 4.5±0.4* 60.6±0.5 20.6±1.2 13.5±0.5 127.7±32.8
IDL 12.7±1.8* 15.7±1.3 18.1±2.4* 24.8±6.5 28.8±2.0* 68.8±14.6*
Values are expressed as means ± SD of four different fasting plasma pools in type IIB and 2 pools in the normolipidemic
healthy subjects. * p<0.05 vs. RLP (IIB)
Table 2: Comparison of oxidative susceptibility of triglyceride-rich lipoprotein particle sub-
fractions in type II-B subjects, and LDL-3 from normolipidemic healthy subjects.  
Lag phase Propagation Propagation Max diene 
(min) rate time (min) production
RLP 251.6 ± 83.7* 1.1± 0.75 154.1± 84.8 181.1±111.7
VLDL-1 302.6±52.2** 1.48±0.81 153.1±42.2 232.2 ± 83.6
VLDL-2 121.5±41.4* 3.7±1.8 59.6±14.1 231.6 ± 76.4
LDL-3 39.6±0.35 3.2±0.3 51.0±1.0 162.8 ± 15.9
Values are expressed as means ± SD of four different plasma pools. * p<0.05 and **p<0.01 vs. LDL-3, 
Indeed, the TG content in RLP is lower
(although not significantly) and the CE con-
tent is higher than that of VLDL-1 and VLDL-
2 in type II B patients. Indeed, the effect of
CETP and LCAT on an incubation with mild-
ly hypertriglyceridemic plasma showed a
marked increase in CE content and a decrease
in TG content in the TRP fraction (9).
The size of RLP from type IIB patients is
close to the VLDL-1 and chylomicron frac-
tion. Also in type III, and type IV dyslipi-
demia, the size of the RLP was within the
range of TRP (6; 10). In case of lipoprotein
disturbances (such as in insulin resistance),
the regulation of the amount of VLDL-1
(that is a precursor for dense LDL) towards
VLDL-2 is often disturbed, with consequent-
ly a higher plasma pool of VLDL-1 (11;12).
The increased plasma levels of RLP-C that
are found in these populations with an
increased cardiovascular risk may therefore
reflect an increased plasma VLDL-1 pool.
Moreover, the elevated content of CE in RLP
make the RLP more atherogenic than VLDL-
1, as CE is the lipid which accumulate in
macrophage foam cells. Recently, native
VLDL-1 was shown to induce foam cell for-
mation without first being oxidized, in con-
trast to LDL-cholesterol that results in less
intracellular cholesterol accumulation in its
native form (13-15). So far, no reports exist
about the effect of RLP on foam cell forma-
tion. We found that RLP (compared to
VLDL-1) leads to a similar accumulation of
TG and cholesterol in a human monocyte
macrophage model. However, incubation of
human monocytes macrophages with RLP
tends to increase cell cytotoxicity (compared
to VLDL-I), with no increase in apoptosis.
(preliminary results, ThB Twickler). These
results support a relation between the
lipoprotein remnants and atherogenesis.
Oxidative stress is an important event in
atherogenesis. In contrast to chylomicrons,
lipoprotein remnants can accumulate prefer-
entially in the subendothelial space due to
their smaller size. After accumulation in the
extracellular matrix, their susceptibility to
oxidative stress may contribute to the devel-
opment of atherosclerotic plaques. The RLP
fraction from type IIB patients was less sus-
ceptible to oxidation, than LDL-3 from nor-
molipidemic subjects. Nonetheless, it is still
easily oxidized in vitro. Our observation is in
line with Huff et al who showed that artifi-
cially produced remnants in vitro could be
oxidized, but that oxidation of TRP rem-
nants was not a key factor for the induction
of foam cells (16). The explanation of the
mechanism behind the oxidative profiles that
we found is not simple. Additional analyses
that will focus more in extents on the sepa-
rate levels of fatty acids and antioxidants
which are major factors determining lipopro-
tein oxidizability, will give more insight; this
work is under investigation now. A first step
to explain may be in the elevated surface free
cholesterol/protein ratio in both VLDL-1
and RLP, compared to VLDL-2. Increased
free cholesterol content is known to decrease
the susceptibility of lipoproteins for in-vitro
oxidation (17; 18). However, the CE/protein
ratio, that is closely associated to the suscep-
tibility for oxidative stress is higher in RLP
(19). Therefore, although a definite answer
on the mechanism is not there, this observa-
tion indicated that RLP are readily oxidized
in-vitro and this support their effect in the
process of atherosclerosis.
In conclusion, our results show that the RLP
fraction obtained from type II-B patients,
have atherogenic properties and may be an
important lipid in addition to the atherogeni-
clipid phenotype.
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complex relationship exists between
disease of the cardiovascular system
and a spectrum of neural and
humoral factors. Recently, the modulating
role of hormones, such as thyroid hormone
(1-4), in the atherosclerotic process has been
emphasized. However, several other hor-
mones, in addition to thyroid hormone, may
contribute to atherogenesis, thereby consti-
tuting a key element in the concept of car-
diovascular endocrinology (5). Recently, evi-
dence has been provided to suggest that
disturbances of the pituitary growth hor-
mone (GH) axis and its mitogenic partners,
including insulin-like growth factor-1 (IGF-
1) and IGF-binding proteins (IGFBP), are
critical actors in the initiation of the athero-
sclerotic process (6-8). Indeed, disturbances
in the GH axis/ IGF system appear to be
intimately related to the perturbed postpran-
dial lipoprotein metabolism which is typical
of subjects presenting premature atheroscle-
rosis (9;10). Furthermore, a high baseline
plasma GH concentration is associated with
increased cardiovascular mortality (11;12).
These observations suggest a U-shaped rela-
tionship between disturbances in the GH
axis/IGF system and increased cardiovascu-
lar morbidity and mortality.
In the present review, we explore the key
pathways of lipid metabolism in adult-onset
GH deficiency (AGHD) that may be involved
in the initiation of atherosclerosis, and which
result in elevated cardiovascular risk.
AGHD and the GH axis/IGF system
In the last 15 years, GH deficiency in adult-
hood has been focused on (pan-) hypopitu-
itarism (depletion of (all) hormones that
originate in the pituitary as a consequence of
pituitary damage) or on transition from
childhood-onset GH deficiency. In such
cases of GH deficiency, one deals with an
absolute deficiency state. Nowadays, a new
group of patients with disturbances in the
GH/IGF system have been defined that are
characterized by a relative deficiency in opti-
mal GH secretion, and which includes sub-
jects displaying obesity and NIDDM (13).
Moreover, ageing is associated with reduc-
tion in plasma GH and IGF-1 levels; indeed,
subjects with a low serum IGF-1 level display
an increased risk of ischemic heart disease
(IHD)(14). In addition, patients with heart
failure in a catabolic condition, or with pro-
gression of cancer, or with end-stage renal
failure (15;16) were characterized with GH
resistance.
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With the growing clinical importance of GH
deficiency, knowledge of the physiological
function of the GH/IGF system has pro-
gressed. The GH axis originates in the cere-
brum with the hypothalamus and the pitu-
itary as regulation centers (figure 1). GH,
whose release is induced by growth hor-
mone-releasing-hormones (GHRH) from
the hypothalamus, is secreted by the pitu-
itary in a diurnal pattern with the highest
serum GH levels occurring early during the
night. After secretion into the circulation,
GH is primarily bound to GH binding pro-
tein (GHBP). The circulating bound fraction
of GH is thought to be biologically inactive,
and for expression of biological activity, GH
must be present in an unbound configura-
tion. GH stimulates a spectrum of metabolic
processes and is a major factor in the genera-
tion of IGF-I and its binding proteins. The
liver secretes IGF-I into the circulation; by
contrast GH stimulates IGF-I gene expres-
sion in a wide range of tissues, leading to
local autocrine and paracrine actions of the
biological active IGF-1 in tissues such as the
endothelium, and is active in cellular process-
es such as cell proliferation and protection
from apoptosis. Recent data from hepato-
specific IGF-I knock-out mice indicate that
circulating IGF-I should be considered more
as a ‘marker’ of GH action in the liver.
The IGF system consists of two major
growth factors, IGF-I and IGF-II, and six
IGF binding proteins (IGFBP1-6) (figure 1).
IGF-1 (17) and IGF-II are primarily synthe-
sized in the liver. IGF-I and IGF-II are bio-
logical active in the unbound form. When
IGF-I or IGF-II are bound to IGFBPs, then
loss of biological activity occurs. Recently, it
has been shown in a twin study that serum
levels of IGFBPs are primarily genetically
determined (18), but fine-tuning control of
the GH axis is needed in order to respond to
local tissue requirements of IGF-I and IGF-
II (19;20). The majority of circulating IGF-1
in healthy subjects is bound to IGFBP-3
together with the acid labile subunit (ALS) in
a 140 kDa complex with a relatively long res-
idence time. In GH deficiency, IGF-1 shifts
toward a IGFBP-IGF complex with a molec-
ular weight of 40kDa, which does not con-
tain the acid labile subunit, and which is
capable of crossing the capillary endothelium
(21). In addition to elevated circulating levels
of IGFBP-3-bound IGF1, local tissue levels
of biologically active IGF-1 are increased by
proteolysis of the IGF/IGFBP3 complex;
this process is mediated by proteases on the
apical side of the capillary endothelium and
in plasma. Plasma levels of biologically active
IGF-I are inversely related to age. In AGHD,
this relationship is not present. Despite the
fact that total IGF-1 levels are lower in
AGHD than in healthy subjects, the IGF-
1/intact IGFBP-3 ratio is similar (22).
Accelerated atherosclerotic disease in AGHD
In several retrospective studies, cardiovascu-
lar mortality in AGHD is increased in com-
parison with a matched healthy population.
The first report by Rosèn and Bengston
revealed increased cardiovascular mortality in
subjects with panhypopituitarism substituted
with adrenal, gonadal and thyroid hormones,
as compared to an age- and gender-matched
control population (standard mortality rate,
1.8) (23). Subsequent reports have confirmed
this observation (24-26). In another Scandi-
navian population displaying panhypopitu-
itarism supplemented with adrenal, gonadal
and thyroid hormones, the standard mortali-
ty rate was increased (2.2), but female GH-
deficient subjects displayed a higher mortali-
ty rate than male subjects, while athero-
sclerosis-related events originated more in
cerebrovascular than in coronary arteries
(27). These results were confirmed in a
Swedish population with pituitary adenoma
in which the increased cardiovascular mortal-
ity was higher among women than men, and
in which atherosclerosis was preferentially
located in the cerebrovascular than in the
coronary vascular region (24).On the other
hand, no increase in cardiovascular mortality
was observed in an AGHD population in the
United Kingdom (28). In conclusion, most
retrospective observational reports noted an
increased cardiovascular mortality in subjects
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with panhypopituitarism substituted with
adrenal, gonadal and thyroid hormones, but
with GH deficiency. One prospective obser-
vational study found a limited effect of GH
on the increased mortality in hypopitu-
itarism. However, no extended data on GH
status were presented (29). These limitations
may have underestimated the effect of GH.
Long term randomized follow-up GH inter-
vention trials will definitively answer the
question as to whether GH treatment will
result in reduced cardiovascular mortality in
AGHD.
Mechanisms
Direct proatherogenic effects of components
of the GH/IGF system
Atherosclerotic disease is a complex disorder
involving several co-existing features, such as
dyslipidemia, inflammation and a pro-throm-
botic state (30). Disturbances in the
GH/IGF system may be directly related to
the progressive development of atherosclero-
sis. In GH deficiency, increased intima-media
thickness in both the femoral and carotid
artery were found (30) and endothelial func-
tion is impaired (31; 32). Endothelial dys-
function is considered as an early feature of
atherogenesis (33-35) and involves reduced
availability of endothelial NO, a vasodilatato-
ry compound (36; 37). It has been shown
that IGF-I has a direct NO-releasing effect
on NO in cultured human endothelial cells
(38), and that low basal IGF-I levels in serum
are associated with low basal urinary nitrate
and cyclic camp excretion (17). Decreased
biological activity of NO in the endothelium
may account for the increased occurrence of
hypertension in AGHD, another risk factor
for development of premature atherosclerot-
ic disease (39).
The composition of the extracellular matrix
is relevant to the development of atheroscle-
rosis (40; 41). Proteoglycans, key compo-
nents of the extracellular matrix, accumulate
in the intimal layer of the artery. Based on
earlier studies, it has been proposed that the
small IGF-I/IGFBP-3 complex in GH defi-
ciency is capable of crossing the capillary
endothelium, leading to enhanced concentra-
tions of IGF-I in the subendothelial space
(22). However, in-vitro studies with cultured
human smooth muscle cells have revealed
that GH increased the accumulation of both
hyaluronan and chondroitin sulfate proteo-
glycans (42), whereas administration of IGF-
I in cell cultures in-vitro is without effect
(43). Thus, IGF-1 does not affect the com-
position of the extracellular matrix. On the
other hand, paracrine and autocrine IGF-1
and insulin (44) play a role in smooth muscle
cell hypertrophy and the local secretion of
angiotensinogen. This observation is sup-
ported by studies in a diabetic rat model,
with the restriction that only high systemic
levels of IGF-1 promote growth of SMC. In
addition, no change in elastin and collagen
content of the thoracic aorta media layer was
found (45). As stated above, plasma IGF lev-
els in AGHD are decreased, but the biologi-
cally active free IGF-1 available in AGHD is
not reduced, thereby suggesting that local
IGF-I concentrations in tissues are distinct
from plasma levels. The induction of smooth
muscle cell growth may therefore account
for the increased intima-media thickness of
the carotid artery in GH deficiency.
Impact of GH treatment on direct proathero-
genic effects of the GH/IGF system
The rapid regression of the thickened intima
media layer measured with carotid IMT at
three and six months post GH treatment is
impressive (7 46; 47). In comparison with
previous results from dyslipidemic popula-
tions, such a reduction can only be obtained
after extensive lipid lowering involving a
decrease of 30-40% in LDL-cholesterol (48-
50). In general, generation of a similar reduc-
tion in endothelial dysfunction by LDL-cho-
lesterol reduction requires three to four years
of therapy (48; 50). 
After 6 to 12 months of GH treatment in
AGHD, brachial artery function (measured
by Flow Mediated Dilation) is improved
compared to pre-treatment FMD values
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(51). In patients with long term GH substi-
tution, improvement in arterial performance
is maintained (46).
It is established that GH directly affects the
expression of the hepatic LDL-receptor and
of key enzymes implicated in bile acid
metabolism with effects on intracellular cho-
lesterol homeostasis in the liver. This may be
linked to metabolism of triglyceride-rich par-
ticles (VLDL and remnants particles) (52).
The indirect, metabolic effects of the GH
deficient state correspond more closely to
factors that continuously interact with local
arterial structures and may have pro-athero-
genic effects, such as the induction of eleva-
tion in plasma VLDL- and chylomicron rem-
nant levels during the postprandial period.
The GH/IGF system, atherogenic lipoprotein
phenotype and the arterial wall (fig. 2).
The dyslipidemia of adult-onset GH deficien-
cy is characterized by lipid disturbances in
LDL-cholesterol and triglyceride-rich lipopro-
tein particles as illustrated in figure 2 (53).
LDL-cholesterol
In most published studies, plasma levels of
LDL-cholesterol are only moderately
increased (3.5-4.5 mmol/l) in adult-onset
GH deficiency, as compared to healthy age-,
and gender-matched control subjects (54-
59). In GH-deficiency, hepatic LDL-receptor
activity is decreased, a process which can be
reversed by GH substitution. A small (10%),
but significant decrease in plasma LDL-cho-
lesterol levels occurs during GH therapy (60-
64). Several studies detected no effect of
short term GH therapy on total and LDL
cholesterol levels (64-68), whereas one
report even noted no difference in plasma
lipid levels in AGHD after 7 years of GH
therapy (69). The LDL-cholesterol profile
shifted from atherogenic dense particles
towards larger, less-dense particles after GH
therapy (70). All these beneficial changes
contribute to attenuation of the atherogenic
phenotype (71), which is characterized by
elevated levels of LDL cholesterol, small
dense LDL, triglycerides, and decreased lev-
els of HDL cholesterol.
Triglyceride rich particles
In AGHD, elevated levels of baseline plasma
TG were found, which are considered to con-
stitute an independent risk factor for cardio-
vascular disease (72). Elevated plasma levels
of TG and TG-rich lipoprotein particles
(TRP), consisting of VLDL containing apo
B100 of hepatic origin and of chylomicrons
containing apo B48 of intestinal origin, are
associated with increased carotid intima-
media thickness and cardiovascular mortality
(73-77). It has been shown in AGHD that
VLDL apo B100 secretion is increased and
that VLDL particles are enriched in TG (78).
Enrichment of VLDL with TG in AGHD
gives rise to a dyslipidemic lipoprotein pat-
tern including the presence of more small
dense LDL (79). Zilversmit (80) postulated
some decades ago that the increased suscepti-
bility to premature atherosclerosis may be
related to atherogenic factors occurring as a
result of a continuous postprandial state that
is a consequence of the consumption of a
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Figure 2. The effect of GH therapy on lipid metabolism in
AGHD before and during GH therapy . Abbreviations:
VLDL: very low density lipoprotein, LPL: lipoprotein
lipase, TRP:triglyceride-rich proteins, LDLr, LDL receptor,
LRP, LDL-receptor like protein, 7-OH –ase: 7 alpha
hydroxylase, LDL, low density lipoprotein.
minimum of three meals a day in Western
Societies (81). Indeed, elevated postprandial
levels of TRP and especially of TRP rem-
nants have been observed in subjects with
cardiovascular disease, as compared to age-,
gender- and BMI-matched control subjects
(76; 82-85) and their postprandial lipemia is
positively associated with atherosclerotic dis-
ease (86). The analyses of determinants of
postprandial lipemia requires distinctive and
laborious techniques, such as the determina-
tion of apoB48 or apoB100 in VLDL density
fractions isolated by ultracentrifugation. The
availability of an immuno-isolation method
based on a Sepharose gel coated with apoAI
and apoB100 monoclonal antibodies greatly
improved the analysis of TRP remnants
(remnant-like particle cholesterol;  RLP-C)
(87). In a Japanese population with coronary
artery disease, fasting plasma RLP-C levels
above the 90th percentile predicted the occur-
rence of cardiovascular events more strongly
than LDL-cholesterol. In an in-vitro study,
RLP induced a dose-dependant impairment
of vasorelaxation in rat thoracic aorta (88).
RLP may interact with the endothelial nitric
oxide system, thereby accounting for the
observed endothelial dysfunction (89). The
postprandial rise in RLP-cholesterol levels in
healthy normolipidemic subjects is associated
with impairment of endothelial function (90).
In patients with AGHD, postprandial levels
of RLP-cholesterol are higher than in
matched healthy control subjects. Postpran-
dial plasma RLP-C levels in GH deficiency
rose from 0.41 mmol/L to 0.70 mmol/L
(from baseline to 4 h) after ingestion of an
oral fat load. Such levels induced endothelial
dysfunction in isolated rat aortas (91) and in
healthy human subjects (90). Such elevated
levels of postprandial RLPs are in accordance
with the observations of Al-Shoumer et al
(92) , who noted an increase in postprandial
plasma TG levels in AGHD after three con-
secutive meals during the day. A significant
reduction in postprandial plasma RLP-C
(towards 0.42 mmol/L) was observed during
GH substitution (93).
To account for the marked postprandial
increase in RLP-C levels in adult-onset GH
deficiency (AGHD), several steps in post-
prandial TRP metabolism require evaluation.
Although hepatic apoB100 secretion is
increased (70) in AGHD, no decrease in pos-
theparin LPL activity in AGHD humans has
been found (94). The accumulation of post-
prandial RLP-C in AGHD may be explained
by a decrease in their removal from the circu-
lation via hepatic lipoprotein receptors (95;
96). Indeed, the expression of several hepatic
surface receptors, such as LDL- and LRP
receptors, is lower in GH deficient states
than in healthy subjects (97). The substitu-
tion of GH results in increased expression of
these surface receptors. For example, the GH
deficient LDL-receptor knock-out mouse
benefits from GH substitution despite lack
of the LDL-receptor. Thus treatment with
GH resulted in increased expression of key
enzymes involved in cholesterol synthesis
(HMG co-A reductase) and bile acid metab-
olism (7 α-hydroxylase), resulting in an
increased transport of intracellular choles-
terol towards the bile acid pool with an
enrichment in the faeces with bile acids (98).
The intracellular pathway of cholesterol
excretion is positively linked to the synthesis
and secretion of VLDL in hepatocytes. In
man, reduction of intracellular hepatic cho-
lesterol content may reduce secretion of the
cholesterol-rich VLDL-2 subfraction but not
the larger TG-enriched VLDL-1 (99).
HDL
Decreased levels of HDL-cholesterol are
associated with an increased risk of CAD
(100). Plasma levels of HDL-cholesterol in
AGHD are decreased as compared to healthy
controls (101) or remained unchanged (93).
It has also been shown by Beentjes et al (102)
that mainly HDL cholesteryl ester concen-
tration is significantly decreased in AGHD,
whereas free cholesterol remained
unchanged. HDL plays a major role in the
process of reverse cholesterol transport,
thereby transporting cholesterol from the
peripheral tissues towards the liver for excre-
tion into the bile. CETP and PLTP are key
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lipid transfer proteins which play an impor-
tant role in intravascular HDL remodelling.
CETP transfers TG from TG-rich lipopro-
tein particles to HDL in exchange for choles-
teryl esters from HDL. Plasma CETP activi-
ty is lower in AGHD than in healthy
subjects, whereas no difference was found
for LCAT and PLTP activity(102). We con-
firmed the presence of lower circulating
CETP mass in AGHD and found a signifi-
cant increase during GH therapy (figure 3).
This strongly suggest that the decrease in
CETP activity resulted in impaired transfer
despite higher concentration of TG-rich
lipoprotein particles, resulting in impaired
reverse cholesterol transport from peripheral
cells back to the liver (103). Upon treatment
with rhGH, plasma HDL cholesterol levels
increase with accompanying increase in HDL
cholesteryl ester concentration and increase
in plasma CETP mass (figure 3). This is in
contrast to data from Beentje et al (104) who
showed a decrease in cholesteryl ester trans-
fer activity upon long term GH replacement
therapy. It is evident that more studies have
to be performed to establish the role of GH
treatment in AGHD upon improvement of
the atherogenic lipoprotein profile.
Arterial wall and lipoprotein remnants
Interaction of postprandial atherogenic
lipoprotein particles with the endothelium
may result in an inflammatory response.
Indeed, addition of antioxidants in the form
of α-tocopherol leads to a decrease in the
inflammatory response after incubation of
endothelial cells with RLP with subsequent
attenuation of endothelial dysfunction (105;
106). RLP particles are able to penetrate the
endothelium with retention in the suben-
dothelial or extracellular matrix (107). Con-
sequently, elevated amounts of lipoproteins
retained in the subendothelium space can no
longer be efficiently removed, resulting in
enhanced formation of macrophages (foam
cells), and induction of local vascular inflam-
mation (108; 109). Indeed, when elevated
concentrations of RLP are present as in the
postprandial state, plasma Il-6 and TNF-α
levels in GHD are increased (figure 4.) (110).
RLP may bind to human monocyte-
macrophages through surface receptors (for
example LRP), but uptake of RLP via a
receptor-independent mechanism may also
occur (111).
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Figure 3. Plasma CETP mass was increased significantly
after rh-GH substitution (from 1.63 ± 0.34 to 2.38 ± 0.54
mg/mL, P<0.05)
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Figure 4. The hypothetical atherogenic pathway of RLP that
gives rise to (a) retention in subendothelial space of RLP,
and (b) a direct interaction with the endothelium resulting
in induction of vascular inflammatory response. After reten-
tion in the subendothelial space, macrophages engulf the
RLP with subsequent foam cell formation that gives rise to
proinflammatory and prothrombogenic responses interacting
with surrounding local vascular structures. 
GH/IGF Axis in association with other hor-
monal balances
To understand the role of the GH/IGF axis
in the pathogenesis of accelerated atheroscle-
rosis, knowledge of the interplay of this axis
with other hormonal systems is essential. We
limit the discussion of this topic to the inter-
action with the glucocorticoid system.
Glucocorticoid system (25).
Patients with AGHD who present a defect in
the GH-IGF-1 axis additionally display a
deficit in circulating corticosteroid levels.
Daily cortisol production, measured in stable
isotope studies, is overestimated by a factor
of 2 to 3 (112; 113). Based on recent
research, physiological cortisol levels are in
the range of 6-7 mg/m2/day. As a conse-
quence, AGHD patients are often treated
with doses of corticosteroids far above daily
requirements. In addition, glucocorticoid
metabolism is altered in AGHD. The
enzyme 11-β-hydroxysteroid dehydrogenase
1 (11β-HSD 1) activates cortisol via its
action on inactive cortison and enforces the
action of cortisol in the liver and adipose tis-
sue. GH inhibits 11β-HSD activity. There-
fore, the increased activity of 11β-HSD 1 in
GH deficient patients (not substituted with
GH) results in an increase in central omental
fat subsequent to increased conversion of
cortison to cortisol (114). The increase in
abdominal fat creates additional active meta-
bolic compartments that are discussed below.
Postprandial action of adipose tissue
A decade ago, adipose tissue was considered
as an inactive tissue. Recent research howev-
er has shown that adipose tissue, especially in
the intra-abdominal cavity, possesses elevated
metabolic activity and may secrete factors
(such as adiponectin and TNF-α) with hor-
monal action. Moreover, in terms of their
differentiation and maturation, adipocytes
are under the control of many growth fac-
tors, such as IGF-I (115). These cellular
processes in adipocytes may therefore be
directly influenced when disturbances in the
GH/IGF system occur. In the postprandial
period, there is an influx into adipocytes
from free fatty acids and catecholamines, in
addition to efflux from adipocytes of other
biologically active factors, including
adiponectins, TNF-α and IL-6 (116; 117).
The postprandial balance of adipocyte
influx/efflux is mainly regulated by the
adrenergic system and insulin. Increased
amounts of visceral fat in AGHD patients
have been reported, but little is known about
the degree of differentiation and maturation
of adipocytes in these patients, and conse-
quently the properties of adipocytes in this
GH deficient condition. Due to the lipolytic
effects of GH therapy on the accumulated
visceral fat, intra-abdominal fat decreases sig-
nificantly during GH therapy (118). Despite
quantitative decrease in intra-abdominal fat
in AGHD as a result of GH treatment, the
influence of GH substitution on adipocyte
capacity is not totally clear and therapy with
GH may therefore exert additional effects to
that of lipolysis. Studies in obese subjects
have shown that increased amounts of intra-
abdominal fat are associated with higher plas-
ma TNF-α levels, and that plasma TNF-α
levels are higher in obese than in lean sub-
jects (119). TNF-α secretion by adipocytes is
a function of differentiation and maturation,
with optimal secretion capacities limited to
highly differentiated adipocytes. Although
the amounts of intra-abdominal fat in
AGHD patients are equal to those of obese
patients, baseline plasma TNF-α levels in
AGHD are lower than in obese patients.
However, after GH therapy, baseline plasma
TNF-α levels reach similar levels in both
AGHD and obese patients. The induction of
increased expression of TNF-α suggests
additional effects of GH substitution on
adipocytes, such as an increase in adipocyte
maturation. In addition, the metabolic activi-
ty of the intra-abdominal fat may be influ-
enced by circulating GH levels. Increased
intra-abdominal fat may therefore exert an
additional aggravating effect on accelerated
atherosclerosis.
Atherosclerosis is considered to be a part of a
pro-inflammatory condition (120-122) and
the increased postprandial release of these
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cytokines by the adipose tissue in GH defi-
ciency could influence glucose homeostasis
via an increase in insulin resistance, a
decrease in macrophage response and an
altered differentiation of fibroblasts into
smooth muscle cells (123; 124). Moreover,
secretion of de novo remnant particles from
visceral adipose tissue may contribute to the
catabolism of RLP (125). Therefore, part of
the beneficial effect of GH on the athero-
genic lipoprotein phenotype may be due to
altered metabolic properties of intra-abdomi-
nal adipocytes. Moreover, the visceral
adipocyte compartment in AGHD is in con-
tinuous interplay with the metabolic profile
that is attained in the postprandial period.
Both aspects may therefore be considered as a
therapeutic target in order to attenuate an
atherogenic lipid phenotype in GH deficiency.
In conclusion, epidemiological observational
studies in AGHD patients have revealed
increased cardiovascular morbidity and mor-
tality, due to accelerated atherosclerotic dis-
ease. The precise atherogenic mechanisms in
GH deficiency are not, however, fully eluci-
dated, but a dyslipidemic phenotype, which
is exacerbated during the postprandial period
together with a lack of endothelial NO are
considered to be key factors. The role of hor-
monal and growth factor disturbances in the
development and progress of atherosclerotic
disease is part of a new and rapidly growing
field in medical practice, that of cardiovascu-
lar endocrinology.
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Effect of growth hormone therapy in adult-
onset growth hormone deficiency on home
measured capillary triglyceride status. 
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dult-onset growth hormone deficien-
cy (AGHD) is associated with pre-
mature atherosclerosis and an
increased cardiovascular mortality (1-4).
Although LDL-cholesterol has been consid-
ered as the most atherogenic factor, the
importance of triglyceride-rich lipoprotein
particles is recently emphasized (5). Prema-
ture atherosclerosis is associated with elevat-
ed fasting plasma TG levels (6; 7) and post-
prandial TG levels (8; 9). As a result of our
daily food intake, plasma levels of circulating
TG-rich lipoprotein particles have the prop-
erty to accumulate (10). Therefore, an assess-
ment of a daytime TG profile provides us with
data on the actual lipid load during the day.
Postprandial levels of plasma TG are elevated
in GH deficiency after one single oral fat
load, and remain elevated during GH substi-
tution, although GH treatment improves the
atherogenic phenotype (11). These observa-
tions are in line with Al-Shoumer et al (12)
who found elevated postprandial TG levels in
AGHD, that were even more prominent in
female AGHD. In both studies, disturbances
in TG profiles in GH deficiency were found.
These studies have both been performed in a
metabolic ward in a strictly controlled in-
hospital setting under fasting conditions.
Under these circumstances, it is not possible
to study variation in TG throughout the day
in ordinary life. Recently a new method to
assess the capillary TG (TGc) levels during
the day by self-measurements with the
Accutrend apparatus became available (13).
In the present study we evaluated the day
time capillary TG levels before and during
GH treatment in GH deficiency (in compari-
son to matched control subjects).
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Adult-onset growth-hormone deficiency (AGHD) is characterised by presence of
an atherogenic lipoprotein profile and associated with an increased cardiovascular
mortality. Recently, an individual self-monitoring method for triglycerides
became available. We evaluated this method in a case controlled intervention study
in an out-of-hospital setting (AGHD patients: n=10 versus controls: n=10), in
relation to dietary intake and composition in patients with adult growth hormone
deficiency (AGHD), and the effect of 6 months of rhGH therapy.
Baseline plasma cholesterol and HDL-cholesterol levels were similar, but baseline
plasma triglycerides were significantly elevated in AGHD patients versus controls
(2.30 ± 0.9 mmol/l vs 0.92 ± 0.3 mmol/l, P<0.05). Fasting capillary TG (TGc),
measured with the Accutrend®, was similar in controls and patients at baseline
(1.60 ± 0.59 mmol/l vs 1.49 ± 0.46 mmol/l). Area under day Curve of the TGc
(AUC TG-c) was significantly elevated in AGHD patients (14.6 ± 7.7 mmol*h/L)
compared to controls (7.14 ± 3.8 mmol/L*h; p=0.01). After rhGH therapy, the
incremental AUC TG-c decreased towards control levels (11.88 ± 7.5 mmol*h/L).
At baseline, AGHD patients consumed less total calories (1703 Kcal vs 2210 Kcal),
mainly as carbohydrates (208±86 g/d vs 309 ± 127 g/d; P<0.05) and fat (56.3 ±
22.2 g/d vs 86 ± 32g/d; P<0.05) than the control subjects. After rhGH therapy the
dietary intake of carbohydrates, and fat was comparable to controls.
In conclusion, the increased capillary TG profile during the day in AGHD, in
spite of lower calorie and fat intake, improved upon rhGH treatment.
A
Materials and Methods
Subjects
Ten adult-onset GHD patients from the out-
patient clinic of the Utrecht University Hos-
pital were included after giving written
informed consent. The protocol had been
approved by the local ethical committee. The
results were calculated on the basis of 9
patients. One patient dropped out of the fol-
low up due to recurrence of the pituitary. All
GHD patients suffered from hypopitu-
itarism after surgical removal of a pituitary
adenoma. Deficient pituitary hormones,
except GH, were adequately supplemented
for a minimum of three months. GH defi-
ciency was diagnosed with a growth hor-
mone releasing hormone-arginin test and an
insulin tolerance test. 
After baseline measurements, all subjects
participated in the TG self measurement pro-
tocol, followed by a period of 6 month rhGH
treatment (0.8-1.1 IU/day for GH deficient
patients with a repeat of the TG self meas-
urement protocol. The definite daily dosage
of rhGH was aimed at reaching the recom-
mended plasma IGF-1 levels, adjusted for age
and sex. All patients were stable with regard
to GH status during the last three month.
Exclusion criteria for patients were: smoking,
alcohol intake > 2 U/day, renal and liver dis-
ease, apo E2/E2 genotype, use of lipid lower-
ing drugs and a family history for premature
cardiovascular disease. Normolipidemic
matched (for body mass index (BMI), age,
sex and apo E genotype) controls without a
family history of cardiovascular and metabol-
ic diseases, were included. None of the par-
ticipating subjects was unable to perform in
the TG protocol due to cognitive, visual or
motility disabilities.
Study design
Anthropometric values, lipid, glucose and
hormone levels were determined in the con-
trol subjects at the start of the study and in
the AGHD patients before and after six
months of rhGH treatment. Venous blood
samples were collected into EDTA-contain-
ing tubes, were put on ice immediately, cen-
trifuged and stored at - 80°C for further
analysis.
TG protocol
At the first visit, all subjects were thoroughly
trained to use the Accutrend GCT (Roche,
Basel, Switzerland) according to the manu-
facturer’s instructions, and to administer the
dietary records. The Accutrend GCT
(Roche) is a home glucose meter that has
been modified to measure adequately triglyc-
erides (TGc) (14). TGc’s are measured in
fresh capillary blood using a reflection-pho-
tometric method. A sample volume of 12-45
µl is required and the operating time is 45-
174s, depending on the TG concentration. A
range of measurement between 0.8 mmol/l
(70 mg/dl) and 6.86 mmol/l (600 mg/dl) is
achieved. At six fixed time points,1) at wake-
up, 2) at lunch, 3) three hours after lunch, 4)
at dinner, 5) three hours after dinner, 6)
before sleep, the capillary triglyceride levels
(TGc) were measured for two separate days
(except week-end days and Monday).
Fasting blood samples at start of the study
Plasma was obtained by centrifugation at
3000 rpm for 15 min at 4°C. TG and choles-
terol were analysed in duplicate in total plas-
ma with a colorimetric assay (Monotest cho-
lesterol kit no. 237574 and GPO-PAP no.
701912, Boehringer Mannheim, Germany).
HDL-Cholesterol was determined after pre-
cipitation of apoB-containing lipoproteins
with the heparin-MnCl2 dextrane-sulphate
precipitation method (15). Low-density
lipoprotein (LDL) cholesterol was calculated
with the Friedewald Formula (16). Apolipo-
protein (apo) B concentrations were analysed
automatically on a Cobas Mira autoanalyzer
(Unimate 3 Apo B, Roche Diagnostics,
Basel, Switzerland). Plasma Insulin and IGF-
1 concentrations were determined with a
radio-immuno assay test (17). Insulin resist-
ance was estimated by calculating HOMA-
index (fasting insulin * fasting plasma glu-
cose/22.5) (18). Apo E genotype was
determined as described before (19).
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Body composition measurements
Body fat was assessed by bioelectric imped-
ance analysis (BIA) (tetrapolar BIA-101 ana-
lyzer: RJL-Systems, Detroit), on the basis of
resistance and reactance measurements.
Resistance and reactance were measured (in
Ω) after application of an alternating current
of 800 µA at 50 kHz with the electrodes
placed (20). Body fat was calculated with the
use of the manufacturer-supplied equation.
Analysis of dietary intake
During the days of TG measurements, the
intake of food and beverages (including alco-
hol) were carefully recorded in a diary. The
food record was reviewed by a physician in a
personal consultation within one week of
return. Energy and nutrient intakes from the
food items were calculated using Becel nutri-
tion program, version NL03a, 1987 (Unilever,
Vlaardingen) based on the Dutch Nutrient
Data Base. The evaluation of the results was
performed in collaboration with the depart-
ment of Clinical Nutrition UMC Utrecht.
Estimated nutrients (total fat, unsaturated fat,
saturated fat, carbohydrates, protein and alco-
hol) were grouped for the different time
points at the two consecutive days of TGc
measurements and averages were calculated.
Statistical analyses
All values are presented as means ± SD. The
capillary TG concentrations of the two con-
secutive days were grouped for each time
point and averaged. The area under the day-
time TGc curve (AUC TGc) was calculated
as a total (AUC TGc) and as an incremental
(or delta) AUC (dAUC TGc) with the use
of GraphPad Prism Software (Inc, San
Diego,1994). Testing for differences between
the patients and controls were performed
with an unpaired Student t-test. Paired stu-
dent t-tests were used to test if differences
before and after treatment exist. Parameters
were log transformed before analyses in case
of non-normality, if appropriate. A p<0.05
was considered as significant. The SPPS PC
program (version 8.0, SPPS, Inc, Chicago,
USA) was used as statistic software.
Results
Population characteristics
No differences were observed in the anthro-
pometric characteristics (BMI, WHR, fat
mass (FM) and FM as a percentage of total
body weight (FM%) between the AGHD
patients, before and after rhGH treatment,
and control subjects (table 1). Two AGHD
patients had an apo E3/4 genotype and eight
subjects had an apo E3/3 genotype. The con-
trol subjects were matched for apo E geno-
type. Average duration of hypopituitarism
was 3 years. All patients were substituted
with thyroxin, 8 patients with hydrocortison,
2 patients with cortison acetate, 8 patients
with sex hormones and 8 patients with
desmopressin. All patients were treated with
rhGH during minimally 3 months with an
average of 7 ± 2 months.
Fasting plasma TG concentrations were sig-
nificantly higher in the AGHD patients com-
pared to controls (2.30 ± 0.92 mmol/l vs 0.9
± 0.3 mmol/l, p<0.05), without any differ-
ence in fasting plasma total cholesterol,
HDL-cholesterol and LDL-cholesterol lev-
els. Upon treatment with rhGH, both plasma
TG and cholesterol concentrations decreas-
ed. Fasting plasma glucose levels were similar
in the AGHD patients and controls. The
HOMA index increased significantly
(P<0.05) after rhGH treatment. In AGHD
patients. Plasma IGF-1 levels were signifi-
cantly lower than in the control subjects.
After treatment with rhGH, plasma IGF-1
levels increased towards normal levels.
Daytime capillary triglyceride concentrations
The mean daily capillary TG concentrations
(TGc) are presented in figure 1. The TGc
levels at 8.00 am were similar in AGHD
patients and controls. This is in contrast to
the plasma TG measurements. The daily TGc
profiles were different in AGHD patients
than in controls. In AGHD patients, the
TGc increased after the breakfast meal, and
remained elevated during the day. At 10 pm
the maximum TGc level (3.22 ± 0.49
mmol/l) was reached. In controls no increase
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in TGc was observed until 10.00 pm (maxi-
mum: 2.22 ± 0,23 mmol/l). Treatment with
rhGH treatment only resulted in a small
improvement in daily TGc profile. The
curves were still higher than in the control
subjects.
The integrated areas under the TG curve
(AUC TGc) were significantly elevated in
the AGHD patients (+ 47%; P<0.05) com-
pared to controls (table 2). After correction
for fasting TGc concentrations, the dAUC
TGc in AGHD was still significantly elevated
(P<0.05). After rhGH therapy, a 19% reduc-
tion in dAUC TGc was found (p<0.05).
Daily dietary intake and composition
In AGHD patients, total daily energy (E)
intake was lower than in controls (1720 ±
603 vs. 2209 ± 650 kcal; p=0.09) (table 3).
The absolute intake of total dietary fat,
monounsaturated fat and polyunsaturated fat
were significantly lower in AGHD patients
than in the control subjects (P<0.05), but as
a percentage of total daily energy intake, no
differences were found. Upon rhGH therapy,
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Table 1: Baseline characteristics of AGHD patients before (GH-) and after GH treatment
(GH+), and control subjects
controls AGHD AGHD
GH (-) GH (+)
N (M/F) 10 (6/4) 9 (5/4) 9 ( 5/4)
Age (y) 48 (7.2) 48 (7.8) 48 (7.8)
BMI (kg/m2) 27.7(2.3) 27.6(3.9) 26.5(4.1)
WHR (cm/cm) 0.89 0.92 0.93
Cholesterol (mmol/l) 5.09(0.93) 5.48(1.1) 5.19(0.72)
Triglycerides (mmol/l) 0.92(0.3) 2.30(0.9)* 1.62(0.44)*
HDL-cholesterol (mmol/l) 1.17(0.29) 1.15(0.48) 1.17(0.51)
LDL-cholesterol (mmol/l) 3.51 (0.32) 3.21 (0.63) 3.35 (0.44)
Total IGF-1 (nmol/l) 173(56) 105(52) * 204 (57)#
FT4 (nmol/l) nd 16.1(3.1) 17.5(4.6)
Glucose (mmol/l) 5.80(0.59) 4.70(0.34) 5.02(0.11) 
HOMA-index 2.85(2.27) 1.55(0.94) 3.14(0.82)#
FM (kg) 22 (5.6) 19.7(5.2) 18.45(6.7)
FM % 25.8 (6.7) 24.3 (6) 22.96(6.7)
Values are presented as mean (SD). * p< 0.05 vs. control subjects, # p<0.05 vs. before GH treatment.
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Figure 1. Capillary triglyceride concentrations (TGc) dur-
ing the day in controls (open circles) and adult-onset GHD
patients before (closed triangles) and after GH (open trian-
gles) (* P< 0.05, TGc in the day vs baseline, # P < 0.05,
TGc in the day in GHD patients vs TGc in the day in con-
trol subjects). TGc concentrations are expressed as a mean of
a two-day measurement (±sem).
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Table 2: Fasting capillary TG (TGc) and daytime capillary TG profiles calculated as integrated
area under the triglyceride curve (dAUC TGc; mmol/l*h) in AGHD before (GH -) and after
GH (GH+) treatment, and in control subjects.
controls AGHD AGHD
GH (-) GH (+)
TGc 1.49  (0.46) 1.60  (0.59) 1.41  (0.68)
AUC TGc 23.55(4.67) 34.71(13.05)† 28.77(12.97)
dAUC TGc 7.14  (3.78) 14.61(7.67)† 11.88 (7.46)
Values are presented as mean (SD).  †p < 0.05 vs. control subjects.
Table 3: Daily nutrients intake in AGHD before (GH -) and after GH (GH+) treatment, and
in control subjects. 
controls AGHD AGHD
GH (-) GH (+)
Energy (Kcal) 2209 ± 649 1720 ± 535 1929 ± 787
Fat 
(g) 86 ± 32 56 ± 24# 76±45*
(% of energy) 34 29 34
Saturated 
(g) 31 ± 12 22 ± 11 32 ± 20*
(% of energy) 12 11 14
Polyunsaturated
(g) 15 ± 6 9 ± 4# 9 ± 5*
(% of energy) 6 5# 4
Monounsaturated
(g) 33 ±13 21 ± 8# 31 ± 18*
(% of energy) 13 11 15
Carbohydrates
(g) 264 ± 73 213 ± 89 217 ± 95
(% of energy) 48 49 47
Protein
(g) 96 ± 32 85 ± 18 88 ± 33
(% of energy) 18 22 19
Cholesterol (mg) 216±67 150±76 197±120 
Values are based on the daily food records. Values are presented as mean (SD) # p<0.05 vs. control subjects, * p< 0.05
vs. before GH treatment.
the intake of total calories increased although
the difference was not statistically signifi-
cant. The absolute intake of total dietary fat,
saturated fat and monounsaturated fat were
significantly higher (56 g, 22 g and 21 g vs. 76
g, 32 g and 31 g, respectively; p<0.05). On a
percentage basis, only the intake of PUFA
remained significantly decreased. No associa-
tion was found between the difference in day
time TGc profiles and the daily food intake
in AGHD patients after rhGH treatment.
Discussion
In the present study, the day-time TGc pro-
file in AGHD patients, measured with the
Accutrend in a natural home situation, was
impaired as compared to healthy matched
control subjects with a slight, but significant,
improvement during rhGH therapy. This
improvement in TGc profile was independ-
ent of the dietary intake.
Dyslipidemia, characterized by elevated plas-
ma TG and low plasma HDL levels, is
thought to be an important risk factor for
initiation of premature atherosclerosis in GH
deficiency (21). Indeed, fasting plasma TG
levels in AGHD are most frequently slightly
elevated (1.5-3.0 mmol/l). In the present
study different levels of baseline TGc and
plasma TG were found. A similar variability
in capillary and plasma TG levels has previ-
ously been noted (22). The explanation for
this observation is not yet known, but may
be due to the use of different analytical
methods. The analytical method for TG
analyses is standardised, whereas the dry
chemistry technology used in the Accutrend
methodology is new. The observed difference
in plasma and capillary TG is too large to be
explained only by differences in fatty acid
trapping in the capillary beds (23). Critical
evaluation of the method of self-measure-
ment of TGc levels in AGHD patients
reveals a day to day TGc variation of 25%
(range 1.44-72.71) (24), that may limit a gen-
eral use of this method. In general, the use of
out-of-hospital TGc method looks very
promising despite the methodological
caveats that have to be improved.
TG-rich lipoproteins, reflected by total plas-
ma TG levels, accumulate during the day. An
exaggerated profile is found when distur-
bances in lipoprotein metabolism occurs
(25). Because the close association between
an atherogenic lipoprotein profile and
increased cardiovascular mortality, a day-time
TG profile may provide additional informa-
tion for the characterization of the athero-
genic lipoprotein phenotype (26). Indeed,
several studies found elevated levels of post-
prandial plasma TG in patients with coronary
artery disease (27; 28). Moreover, postpran-
dial hypertriglyceridemia is related with
enhanced platelet aggregation (29; 30),
endothelial dysfunction (31) and with intima
media thickness (IMT) of the carotid artery
(32).
Beneficial effects of rhGH treatment in
AGHD on the proatherogenic phenotype
have already been reported (33; 34). Despite
an increase in insulin resistance (determined
by HOMA-index), we observed a decrease in
day-time TGc profile during rhGH treat-
ment. A transient decrease in insulin sensitiv-
ity with improvement of the initial dyslipi-
demia has also been reported in AGHD
during rhGH treatment (35-37), however the
exact mechanisms remained unclear.
The amount of TG accumulation during the
day may be dependent upon the daily food
intake. Increased fasting plasma TG levels
were found when diets were restricted in fat
content (38), because a shift towards
increased carbohydrate intake occurred to
meet the adequate daily energy intake (39).
However, in the present study, the GH defi-
cient patients consume less total calories per
day with a normal proportion of fat and car-
bohydrates. Snel et al (40) reported a lower
daily energy intake and a lower basal meta-
bolic rates (BMR) in AGHD. In contrast to
the long-term intervention studies, the
short-term dietary intervention studies in
healthy adults, show no change in plasma TG
levels with either a high fat or a high carbo-
hydrate intake (41). In type IV hyperlipi-
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demic patients who consume a low fat diet
for three months, no changes in fasting plas-
ma TG levels were found (42). The lack of
association between day-time TGc profile
and diet composition is therefore in accor-
dance with previous reports (43).
In conclusion, despite a lower total daily
food intake, an increased day-time TGc pro-
file was observed in AGHD patients that
contributes to a proatherogenic phenotype.
During rhGH treatment, the day-time TGc
profile improved. Although promising, the
feasibility of TGc measurement in a natural
home environment needs further investiga-
tion before it is implemented in daily clinical
practice as part of the assessment of cardio-
vascular risk.
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dult-onset growth hormone deficient
patients (AGHD) suffer from pre-
mature atherosclerosis in the coro-
nary and in the peripheral arteries (femoral
and cerebral arteries) (1; 2) and increased
cardiovascular mortality (3). After six month
of substitution with synthetic growth hor-
mone (rh-GH) regression of lesions have
been found (4). Abnormalities in plasma
cholesterol and LDL cholesterol levels have
been observed in AGHD patients which
could be improved by treatment with
Growth hormone for at least three months
(5-9). However, improvement of endothelial
dysfunction and decrease in intima-media
thickness in AGHD patients after growth
hormone substitution could not fully be
explained by decreased concentrations of
plasma LDL cholesterol (4). Triglyceride-
rich lipoproteins, particularly lipoprotein
remnants, have been shown to be involved in
atherogenesis (10; 11). Disturbances in post-
prandial lipoprotein remnant levels were
found in patients with premature coronary
atherosclerosis like Familial Combined
Hyperlipidemia, Familial Hypercholes-
terolemia and type 2 diabetes (12-14). Al-
Shoumer et al (15) observed an increase in
plasma triglyceride (TG) levels in AGHD
patients during daily regular meals, suggest-
ing abnormalities in postprandial clearance of
lipoprotein particles. No data are yet avail-
able on detailed analyses of postprandial rem-
nant lipoproteins in AGHD patients.
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Premature atherosclerosis is a clinical feature in adult-onset growth hormone defi-
ciency (AGHD). Evidence is accumulating that disturbances in triglyceride
metabolism, reflected by abnormalities in circulating remnant lipoproteins, are
associated with increased atherogenic potential. In a case-controlled intervention
study, we investigated postprandial lipoprotein metabolism using a new remnant
lipoprotein method based on immunoseparation principle (RLP-Cholesterol). In
addition we analyzed retinyl ester (RE) analysis in plasma and in Sf<1000 fraction.
Endothelial function was assessed as flow mediated dilatation (FMD). Eight
patients diagnosed with acquired adult-onset growth hormone deficiency and
eight controls matched for gender, age, BMI and apo E genotype were enrolled in
the study. Oral vitamin A fat loading tests were performed at baseline in both
groups and after six month of treatment with rh-Growth Hormone (rh-GH) in
the AGHD patients. AGHD patients had significantly higher fasting RLP-C,
postprandial RLP-C concentrations (plasma RLP-C: 0.29 ± 0.14 mmol/L and
incremental AUC-RLP-C: 2.13 ± 1.60 mmol*h/L, respectively) than controls
(0.19 ± 0.06 mmol/L and 1.05 ± 0.72 mmol*h/L (P<0.05), respectively). They also
had significantly higher postprandial RE in plasma and Sf<1000 fraction. Treat-
ment with rh-GH significantly reduced postprandial RLP-C concentrations
(incremental AUC-RPL-C 0.73 ± 0.34 mmol*h/L; p<0.05) but had no effects on
the fasting RLP-C concentrations (0.317 ± 0.09 mmol/L, P<0.05), nor on the
postprandial RE in plasma and in Sf<1000 fraction. Endothelial function meas-
ured as FMD was improved from 5.9 ± 3.3% to 10.2 ± 4.0% (p<0.05) in patients
treated with rh-growth hormone.
It is concluded that patients with AGHD have increased levels of fasting and post-
prandial RLP-Cholesterol and an impaired endothelial function as measured as
FMD. Treatment with rh-GH resulted in a decrease of postprandial RLP-C con-
centration thereby improving the postprandial atherogenic lipoprotein profile
and improvement of endothelial function, however the clearance of large chy-
lomicron particles as reflected by RE remained disturbed.
A
In the present study, we used both the classi-
cal RE analysis and a new remnant lipopro-
tein method based on the immunoseparation
principle to study remnant metabolism
developed by Nakajima et al (16). Apo AI-
containing and apo B100-containing particles
were bound to a sepharose gel coupled with
specific monoclonal antibodies against Apo
B100 and Apo AI. In the remaining super-
natant fraction, remnant particles were found
with only apo B48 or with apoB100/apoE.
Lipoprotein remnants isolated with this
method maintained their pathological prop-
erties in in-vitro studies (foam cell forma-
tion, decreased endothelial dilatation) (17).
Remnant lipoprotein particles, isolated in
this way, were associated with endothelial-
dependent vasomotor function (17) and
restenosis of coronary arteries after PTCA
(18). The clearance of remnant particles was
also assessed by incorporation and analysis of
exogenous vitamin A (retinyl esters, RE) as
core label for lipoprotein particles of intes-
tinal origin. The suitability of vitamin A as a
marker for chylomicrons and its remnants
has been criticized (19; 20). Incorporation of
RE occurs mostly in the late postprandial
period as reflected by the delayed postpran-
dial RE response compared with apoB48
analysis in the VLDL/chylomicron fraction
(21). Furthermore RE label has been shown
to exchange to other lipoprotein particles at
later postprandial time points.
In this case-controlled intervention study, we
investigated whether disturbances in post-
prandial lipoprotein metabolism were associ-
ated with the atherogenic lipoprotein profile
observed in AGHD patients, and whether
rh-GH treatment was capable of improving
the atherogenic profile thereby decreasing
the risk for coronary artery disease in
AGHD patients. 
Methods
Subjects
Patients with adult onset growth hormone
deficient (AGHD) were recruited from the
out patient clinic of the Department of
Endocrinology from the University Hospital
Utrecht. All patients had acquired growth
hormone deficiency in adult life due to
recent (within one year) treatment of a pitu-
itary adenoma with surgery and/or radiother-
apy. Other deficient pituitary hormones were
supplemented for at least six months and
were at a stable level at the start of the study.
GH deficiency was defined as a peak plasma
growth hormone concentration < 5 µg/L
after the arginine infusion test. Recombinant
human growth hormone (rh-GH was) sub-
stituted to plasma IGF-1 levels within the
age-related normal range (22; 23). Exclusion
criteria were presence of lipoprotein disor-
ders such as familial hypercholesterolemia
and familial combined hyperlipidemia, Body
Mass Index (BMI) > 30, renal and/or liver
disease, diabetes mellitus, Apo E2/E2 geno-
type and a positive family history of prema-
ture atherosclerosis. Eight healthy control
subjects, matched for age, gender, BMI and
ApoE genotype, were selected for this study
by advertisement. They had no diabetes, no
hepatic, renal, thyroid or cardiac dysfunction
and a negative family history for cardiovascu-
lar disease. Post-heparin lipoprotein lipase
(LPL) and hepatic lipase (HL) activities were
measured at baseline in controls and before
and after 6-month rh-GH treatment in
AGHD patients. Oral fat load tests with RE
were performed on a separate day.
The human investigation review committee
of the University Hospital Utrecht approved
this protocol and written informed consent
was obtained from all participants.
Oral fat loading vitamin A test
After an overnight fast (12 hrs), participants
were admitted to the metabolic ward at 7.30
am. Cream (consisting of 40% fat (w/v) with
a P/S ratio of 0.06, 0.001% cholesterol (w/v)
and 2.8% carbohydrates (w/v)) was given as
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a single fat load in a dose of 50 g fat per m2
body surface area, After ingestion of the
cream supplemented with 60.000 IU aqueous
vitamin A per 125 ml cream, 10 hourly
venous blood samples were collected from an
indwelling catheter in the ante cubital vene
into EDTA containing tubes. All blood sam-
ples, protected from light, were immediately
put on ice, centrifuged and analyzed. During
the postprandial period, the subjects were
allowed to drink only water or tea without
sugar. None of the subjects experienced gas-
trointestinal complaints after drinking the
cream.
Laboratory measurements
Plasma was obtained by centrifugation at
3000 rpm for 15 min at 4°C. TG and choles-
terol were measured with a colorimetric assay
(Monotest cholesterol kit no. 237574 and
GPO-PAP no. 701912, Boehringer
Mannheim, Germany). Cholesterol was ana-
lyzed in the HDL fraction isolated by the
heparin-MnCl2 dextran-sulphate precipita-
tion method (24). LDL cholesterol was cal-
culated with the Friedewald Formula (25).
Plasma apo B concentrations were analyzed
automatically on a Cobas Mira autoanalyzer
(Unimate 3 Apo B, Roche Diagnostics).
Plasma Apo E and Apo CIII concentrations
were determined with a commercial test kit
using the immunoelectrophoresis technique
(Sebia Inc. USA). The coefficient of variance
for plasma Apo E and Apo C III analysis was
< 7.5%. The plasma Insulin and IGF-1con-
centrations were determined with a radio-
immuno assay (26). Apo E genotype was
determined as described by Dallinga-Thie et
al (27). Plasma for LPL and HL was obtained
20 minutes after an intravenous injection of
50 IU/kg of heparin. Postheparin Lipopro-
tein Lipase and Hepatic Lipase activity were
assayed as described previously (28; 29). Non
esterified fatty acids (expressed as nmol free
fatty acids (FFA) min-1 (mU)/mL) were
measured with an enzymatic assay (WAKO
chemicals, Neuss, Germany). HOMA-index
(fasting glucose*fasting insulin/22.5) was
calculated to estimate the insulin sensitivity.
Body composition was assessed with bio-
impedance analysis.
Assessment of lipoprotein remnants
Lipoproteins were separated by flotation
using a single ultracentrifugation step in a
Sf>1000 fraction which contains chylomi-
crons, large chylomicron remnants and large
hepatic triglyceride-rich lipoproteins, and a
remaining infranatant fraction (Sf<1000)
containing small chylomicron remnants and
all the other lipoproteins (30; 31). Retinyl
ester concentrations in plasma and in the Sf
> 1000 and Sf<1000 fraction were measured
with high-performance liquid chromatogra-
phy (HPLC) as described by Ruotolo et al
(32). Recoveries of retinyl esters in the
Sf>1000 and Sf<1000 were between 80 and
105%.
The RLP fraction was prepared using an
immunoseparation technique described by
Nakajima et al (16; 33). Briefly, 5 µl of serum
was added to 300 µl of mixed immunoaffinity
gel suspension containing monoclonal anti-
human apo A-I (H-12) and anti-human apo
B-100 (JI-H) antibodies (Japan Immunore-
search Laboratories, Takasaki, Japan). The
reaction mixture was gently shaken for 120
minutes at room temperature followed by
standing for 15 minutes. Then 200 µl of the
supernatant was withdrawn for the assay of
RLP-C and RLP-TG. Cholesterol (CV
<3%) and triglycerides (CV<3%) in the
RLP fraction were measured by an enzymatic
assay using an automatic chemistry analyzer
(ABX Diagnostics, Montpellier, France).
Forearm vasomotion study
Prior to the test meal blood samples were
obtained for baseline values and a forearm
vasomotion test was performed. The ultra-
sound measurements were performed in a
supine position at the elbow of the right arm
using a vessel wall-movement system (Wall
Track System, Pie Medical, Maastricht, The
Netherlands) consisting of an ultrasound
imager with a 7.5 MHz linear array transduc-
er connected to a data acquisition system and
a personal computer. In short, an optimal
100
two dimensional B-mode image of the
brachial artery was obtained. An M-line per-
pendicular to the vessel was selected. Next,
the ultrasound system was switched to M-
mode, after which storage of data started.
The vessel movement detector system
repeatedly registered end-diastolic vessel
diameter during a period of 5 to 6 cardiac
cycles. This procedure was performed three
times. The measurements were averaged to
provide for a baseline diameter measurement.
By inflation of a blood pressure cuff for 4
minutes at a pressure of 100 mmHg above
the systolic blood pressure, ischemia was
applied to the forearm distal to the location
of the transducer. Ultrasonography contin-
ued for 3 minutes after cuff release with
measurements at 30 seconds intervals. The
widest lumen diameter was taken as a meas-
ure for maximal diameter. Measurements
were obtained for another 5 minutes, at 1-
minute intervals. Flow Mediated Dilatation
(FMD) was expressed as a percentage change
relative to baseline diameter. The intersession
variability was 3.4%.
Statistical Analysis
Data are presented as means ± SD, unless
shown otherwise. Area under the integrated
curve was calculated using data from the first
8 hours after the start of the oral fat loading
test for postprandial TG, retinyl esters and
RLP-C using GraphPad Prism software (ver-
sion 3.1, San Diego, California, USA).
Effects of rh-GH substitution in AGHD
patients and differences between untreated
AGHD patients and controls were analyzed
by two-tailed unpaired Student’s t-test. Pear-
son’s correlation or Spearman’s rank correla-
tions were applied to evaluate relationships
between parameters. A two-sided p-value of
0.05 was considered to be significant. Statis-
tical analysis was performed with Graphpad
InStat version 3.00 for Windows 95, Graph-
pad Software, San Diego, California, USA.
Results
Characteristics of the subjects
Table 1 shows characteristics of the subjects.
Average duration of hypopituitarism was 40
± 8 month. All 8 patients were substituted
with thyroxine, 6 patients with hydrocorti-
sone, 2 patients with cortisone acetate, 7
patients with sex hormones (males: testos-
terone esters; females: cyclic estrogen and
progesterone) and 7 patients with desmo-
pressin. Seven patients had an apo E3/E3
genotype and 1 patient had an apo E3/E4
genotype. All patients were treated with rh-
GH during minimally 6 months with an aver-
age of 7 ± 1 month.
Fasting plasma TG and LDL cholesterol lev-
els were significantly elevated in AGHD
patients as compared to control subjects.
After treatment LDL cholesterol levels
decreased, whereas plasma TG levels
remained significantly elevated. Plasma apo
B, apo E and apo CIII levels were similar in
all groups. The fasting plasma insulin levels,
plasma IGF-1 levels and the HOMA-index
were significantly lower in the AGHD
patients than in controls (P<0.05). After rh-
GH treatment plasma insulin levels and the
HOMA-index increased and were not distin-
guishable from control levels. In contrast
plasma IGF-1 levels increased and were sig-
nificantly higher than in controls (P<0.05).
In AGHD patients, fasting plasma IGF-1
concentrations were positively correlated
with the HOMA-index (r=0.67; p<0.01),
fasting plasma insulin concentration (r=0.63;
p=0.01) and fasting plasma glucose concen-
tration (r=0.52; p=0.046). Plasma LPL
activity was similar in AGHD patients and
controls, but treatment with rh-GH resulted
in a significant decrease in LPL activity. No
differences were observed for plasma HL
activities.
Postprandial TG responses
After the oral fat load, maximum postprandi-
al plasma TG levels were reached at 3 hours
in control subjects and between 4 and 5
hours in AGHD patients (Figure 1).
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They were significantly higher in AGHD
patients than in matched control subjects,
3.17 ± 1.51 mmol/L vs. 1.93 ± 0.69 mmol/L
(P<0.05). Area under the TG curve (AUC-
TG), analyzed over an 8-hour postprandial
interval, was significantly higher in AGHD
patients (21.29 ± 8.91 mmol*h/L; p<0.05)
than in controls (11.65 ± 3.66 mmol*h/L,
P<0.05, Table 2). After correction for base-
line TG levels (incremental AUC-TG) this
difference disappeared (8.62 ± 5.92
mmol*h/L versus 4.71 ± 2.42 mmol*h/L).
Treatment with rh-GH did not result in
improvement fasting plasma TG levels.
Postprandial RLP-Cholesterol response
Fasting RLP-Cholesterol concentrations
were significantly elevated in AGHD
patients (0.29 ± 0.14 mmol/L) as compared
to in control subjects (0.19 ± 0.06 mmol/L;
p<0.05, Figure 2). The maximum postpran-
dial RLP-C concentration was reached
between 2 and 4 hr in control subjects and
between 4 and 6 hr in AGHD patients and
was significantly higher in AGHD patients.
The AUC-RLPC (table 2) and the incremen-
tal AUC-RLPC were significantly elevated in
AGHD patients (4.46 ± 2.0 mmol*h/L
respectively 2.13 ± 1.60 mmol*h/L) than in
control subjects (2.59 ± 1.08 mmol*h/L
respectively 1.05 ± 0.72 mmol*h/L; p<0.05).
Growth hormone treatment resulted in a sig-
nificant decrease of AUC-RLPC and incre-
mental AUC-RLPC (Table 2), suggesting an
improvement of postprandial clearance of
remnant-like particles after normalization of
the growth hormone axis, although the peak
time for RLP-C was unchanged (Figure 2). It
is important to note that despite the fact that
a strong correlation existed between baseline
TG and RLP-C, they seemed to have differ-
ent metabolic properties in AGHD patients.
In AGHD patients, positive correlations
were observed for incremental AUC-RLPC
and baseline plasma cholesterol concentra-
tions (r = 0.63; p<0.05), plasma TG concen-
trations (r = 0.62; p<0.05), LDL cholesterol
(r = 0.62; p<0.05), and Apo B concentra-
tions (r = 0.63; p<0.05), whereas IGF-1
concentrations showed a negative correlation
(r = -0.54, p<0.03).
Postprandial retinyl ester response
Maximum postprandial plasma RE concen-
trations were reached at 4 hours in control
subjects and between 5 and 8 hours in
AGHD patients and were higher, albeit not
statistically significant, in AGHD patients
(Figure 3A). Similarly the area under the
retinyl ester curve (AUC-RE) was higher in
AGHD patients (Table 2) but the difference
did not reached the level of statistical signifi-
cance. Growth hormone treatment resulted
in even higher maximal postprandial RE lev-
els and the difference with the control sub-
jects now reached the level of significance
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Figure 1. Postprandial response for plasma TG in untreated
AGHD patients (‡), AGHD patients with rh-GH treat-
ment(u) and control subjects (m ). Data are presented as
mean ± SEM.
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Figure 2. Postprandial remnant-like particle cholesterol
(RLP-C) response in untreated AGHD patients (‡),
AGHD patients with rh-GH treatment (u) and control
subjects (m ).
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Table 1: Characteristics of AGHD patients before and after treatment with rh-GH and
matched control subjects
AGHD AGHD Controls
rhGH (-) rhGH (+)
N 8 8 8
Male/Female 5/3 5/3 5/3
Age (yrs) 49 (8.0) 49 (8.0) 47 (7.7)
BMI (kg/m2) 27.5 (2.3) 27.5 (3.7) 25.7 (1.6)
FM (kg) 20.58 (4.2) 22.64 (6.67) 19.7 (4.6)
FM% 25.4 (5.6) 27.1 (6.7) 24.9 (6.4)
Waist to hip ratio 0.92 (0.04) 0.93 (0.03) 0.88 (0.06)
Cholesterol (mmo/L) 5.51 (0.96) 5.04 (0.66) 4.98 (0.72)
TG (mmol/l) 1.55 (0.68)# 1.75 (0.37)## 0.91 (0.27)
HDL-cholesterol (mmol/L) 1.31 (0.43) 1.24 (0.52) 1.42 (0.32)
LDL-cholesterol (mmol/L) 3.63 (0.92)$ 3.07 (1.12) 3.07 (0.70)
Apo-B (mg/L) 1.01 (0.28) 0.97 (0.09) 0.90 (0.21)
Apo-CIII (mg/L) 27.63 (9.76) 26.17 (5.8) 27.80 (8.67)
Apo-E (mg/L) 43.9 (8.17) 43.67 (7.32) 53.6 (10.7)
Insulin (mU/L) 5.57 (0.79)# 9.43(4.65) 9.25 (3.4)
HOMA-index 1.17 (0.29)# $ 2.09 (1.01) 2.14 (0.89)
IGF-1 (nmol/L) 111 (49)# $ 222 (43)# 169 (28)
fT3 (nmol/L) 1.35 (0.44) 1.34 (0.35) 1.52 (0.27)
LPL activity (mU/mL) 149 (40)$ 112 (27)# 149 (26)
HL activity (mU/mL) 472 (268) 499 (316) 357 (131)
All values are expressed as mean ± SD. rhGH (-) indicates without rh-GH treatment and rhGH(+) indicates with rh-
GH treatment.  AGHD vs controls: # P<0.05 and ## P<0.01; AGHD patients treated vs. not treated: $ P<0.05.<0.01
Table 2: Postprandial data for triglycerides, RLP-C, and retinyl esters in the Sf<1000 fraction.
AGHD AGHD Controls
rhGH (-) rhGH (+)
Fasting TG 1.55 (0.70)# 1.75 (0.37) 0.91 (0.27)
AUC-TG 21.29 (8.91)# 19.99 (6.72) 11.65 (3.66)
∆AUC-TG* 8.62 (5.92) 7.51 (2.88) 4.71 (2.42)
AUC-RE 56.26 (35.41) 66.11 (14.47)# 29.91 (21.88)
Sf<1000 AUC-RE 18.36 (12.93) 25.71 (6.04)# 12.69 (9.66)
Fasting RLP-C 0.29 (0.14) 0.32 (0.09)# 0.19 (0.06)
AUC-RLPC 4.46 (2.0) # $ 3.21 (1.07) 2.59 (1.08)
∆AUC –RLPC* 2.13 (1.60) # $ 0.73 (0.34) 1.05 (0.72)
All values are expressed as mean ± SD. rhGH (-) indicates without rh-GH treatment and rhGH(+) indicates with rh-
GH treatment.  AGHD vs controls: # P<0.05; AGHD patients treated vs. untreated: $ P<0.05. AUC and incremental
(∆) AUC were calculated over a period from 0 – 8 hours. *∆AUC indicates area under the incremental curve after correc-
tion for baseline concentrations.
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(P<0.05). The AUC-RE in the Sf<1000
fraction increased after rh-GH treatment in
AGHD patients and was significantly elevat-
ed as compared to control subjects (P<0.05,
Table 2).
Endothelial function in AGHD patients
To assess the atherosclerotic burden of the
AGHD patients we measured the flow-medi-
ated diameter of the brachial artery. No
measurements were performed in control
subjects. Rh-GH treatment in AGHD
patients resulted in an increase in the flow
mediated diameter in the brachial artery as
shown in Figure 4 (from 5.9 ± 3.3% to 10.2
± 4.0%, P<0.05). The basal diameter of the
artery was similar in AGHD patients before
treatment: 4.4 ± 0.8 mm and after rh-GH
treatment: 4.3 ± 0.7 mm. 
Discussion
In the present study postprandial lipoprotein
remnant concentrations, measured as rem-
nant-like particle cholesterol was significant-
ly increased in AGHD patients. Rh-GH
treatment resulted in a significant decrease in
postprandial remnant-like particle choles-
terol, and improvement of endothelial func-
tion, although due to the small samples size
the correlation did not reach the level of sig-
nificance. Other pituitary hormone deficien-
cies were sufficiently treated throughout the
study and no shift in plasma free T3 concen-
trations were found, stressing the effect of
the rh-GH intervention.
Postprandial remnant lipoprotein particles
have to be considered important mediators
into the atherogenic process (34; 35). We
used two different approaches to assess
lipoprotein remnant metabolism. A new iso-
lation method based on immunoseparation
of remnant lipoproteins with sepharose coat-
ed with specific antibodies against apo B100
and Apo AI was applied, resulting in the
scavenging of all HDL and most of the LDL
and VLDL particles from the plasma. In the
supernatant fraction the remnant-like parti-
cles (apo B48-containing and apo B100/Apo
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Figure 3. Postprandial RE responses for untreated AGHD
patients (‡), AGHD patients with rh-GH treatment(u)
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Figure 4. Flow mediated dilatation (%) before and after rh-
GH substitution in 8 AGHD patients.
E enriched particles) were recovered. Analy-
sis of postprandial remnant-like particles
consisting mostly of Apo B48 particles is in
agreement with assessment of postprandial
apo B48 in Very-Low Density lipoprotein/
intermediate density fractions (Dallinga-
Thie, unpublished data). Furthermore, the
classical analysis of vitamin A (retinyl
esters), which is incorporated into the core
of the newly synthesized chylomicron parti-
cle, was used. Assessment of retinyl ester
concentrations in the plasma and in the
Sf<1000 and Sf>1000 fractions over a period
of 8 hours will provide evidence for in-vivo
chylomicron remnant clearance.
Our results show for the first time that in
AGHD patients abnormalities in postprandi-
al response were characterized by decreased
clearance of RLP-C and retinyl esters in the
Sf<1000 fraction, whereas fasting levels of
RLP-C were also significantly increased.
Treatment with rh-GH resulted in significant
improvement of RLP-C clearance but no
effects were observed in retinyl ester meta-
bolic behavior and in fasting plasma RLP-C.
Incorporation of vitamin A occurred mostly
at later time points during the postprandial
phase into larger chylomicron particles (36).
After ingestion of dietary fatty acids the vol-
ume of the newly formed chylomicron parti-
cles increased thereby improving the capacity
to carry vitamin A. Larger chylomicrons and
its remnants were considered to be less
atherogenic particles than smaller, early post-
prandial remnants (35). It has been shown
that in rat enterocytes the secretion of chy-
lomicrons occurred in a bimodal way. De
novo secreted chylomicrons in the late post-
prandial period and the continuous secretion
of smaller chylomicrons predominantly in
the fasting and early postprandial period,
albeit some degree of secretion of smaller
particles remained throughout the later peri-
od. We hypothesize that apo B 48 and RLP-C
reflects particles with identical behavior,
whereas RE marks the properties of intestin-
al postprandial lipoprotein particles with a
different metabolic behavior. Our results
suggest that the secretion of large chylomi-
cron particles remained abnormal after
growth hormone substitution. Growth hor-
mone therapy resulted in an upregulation of
the hepatic expression of the LDL-receptor
(37), resulting in improved clearance of apo
B containing lipoprotein particles. In fact we
observed a significant decrease in plasma
LDL-cholesterol level and concomitant
decrease in VLDL-cholesterol. Both apo
B100 and apo B48 containing particles share
the same degradation pathways (38), involv-
ing either the LDL-receptor pathway or
alternative pathways involving the LDL
receptor related protein (LRP) and proteo-
glycans. The preferential improvement of
only the RLP-C fraction is in support of a
role of the LDL-receptor pathway in apo B48
remnant particle clearance. No correlations
were found between changes in LPL activity
and postprandial parameters. It has been
reported that growth hormone supplementa-
tion results in a specific decrease of LPL
activity in adipose tissue but not in a change
in LPL activity in skeletal muscle tissue (39;
40), that has been shown to be correlated
with a beneficial lipoprotein profile.
We hypothesize that fasting plasma RLP-C
levels resembles the presence of circulating
apoB100 remnant particles enriched with
apoE. Due to conformational changes in the
particles they do not bind to the monoclonal
antibody and remained in the supernatant
fraction (16). The fact that its concentration
remained elevated after growth hormone
treatment is in favor for a different metabolic
behavior of these remnant particles as com-
pared to apo B48 containing remnants. Fur-
ther studies are required to dissect the meta-
bolic behavior of these different remnant
fractions. Increased cardiovascular mortality
due to accelerated atherosclerosis is a clinical
feature in AGHD (1-3). Impaired endothe-
lial dependent vasodilatation in response to
flow is associated with early atherogenesis
(41.42) Different interventions in the athero-
sclerotic process, including growth hormone
substitution in AGHD, have shown to
directly modulate endothelial functions (43-
45). In the present study a significant
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increase in flow mediated dilatation after
treatment with rh-GH was observed, which
is in agreement with an improvement of the
atherogenic profile in response to growth
hormone treatment in AGHD patients (4).
It has been recognized that RLP-C offered
independent assessment for CHD risk in
addition to TG. Incubation with an isolated
remnant-like particle fraction reduced
endothelial-dependent vasorelaxation in
vitro, which could be reversed by interven-
tion with α-tocopherol (46; 47). In humans,
plasma RLP-C concentrations were negative-
ly associated with plaque regression of the
coronary artery (17).
In conclusion, we showed a significant
decrease in postprandial RLP-C concentra-
tion and improvement of the endothelial
function in AGHD patients after growth
hormone replacement therapy. We were not
able to show a direct relationship between
the improved endothelial function and
improvement of the plasma lipoprotein pro-
file, probably due to the small sample size.
Improved postprandial lipoprotein remnant
levels and improved endothelial function
reflect a less atherogenic state and support
the beneficial effect of early growth hormone
replacement therapy in AGHD patients.
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atients with an adult-onset GH defi-
ciency (AGHD) have a higher risk on
cardiovascular and cerebrovascular
death due to progressive atherosclerotic dis-
ease. This increased susceptibility for athero-
sclerosis may be explained by the presence of
a dyslipidemia (1). Although dyslipidemia in
GH deficiency is characterized by a moder-
ate elevated plasma LDL-cholesterol, also
plasma levels of triglyceride-rich particles
(TRPs) are increased (2). Recent develop-
ments show that elevated plasma levels of
TG and apolipoprotein B levels complete the
atherogenic lipid phenotype and are there-
fore an independent risk factor for athero-
sclerotic disease (3;4). Among the triglyc-
eride-rich particles, lipoprotein remnants or
Remnant-Like Particle-Cholesterol (RLP-C)
are increasingly considered as high athero-
genic particles (5-7)and their plasma levels
are found increased in populations with a
high risk for cardiovascular disease, such as
familial hypercholesterolemia (8). In a previ-
ous report, we showed that GH therapy had
no effect on fasting plasma RLP-C levels,
while postprandially the plasma RLP-C accu-
mulation decreased (9). In the background of
an increasing interest of the TRPs in the
atherogenic lipid phenotype, the effect of
GH therapy in AGHD on both plasma levels
of LDL-cholesterol and TRP need to be elu-
cidated.
In order to focus more on the mechanism
behind the plasma levels of LDL-cholesterol
and RLP-C in AGHD and the effects of GH
therapy on it, the relation between choles-
terol synthesis and VLDL-cholesterol, as a
common precursor of LDL-cholesterol and
RLP-C, needs to be analyzed. Hepatic secre-
tion of VLDL apo B100 is modulated by cho-
lesterol synthesis (10). In GH deficient sub-
jects, synthesis of VLDL apo B100 is
elevated (11; 12)which may give rise to ele-
vated plasma levels of both LDL-cholesterol
and TRPs. However, in hepatocytes, expres-
sion of HMG co A reductase is determined
by several growth factors, such as IGF-1,
which is decreased in AGHD (13). Whole
body cholesterol synthesis is in general
reflected by plasma levels of the several cho-
lesterol precursors, such as lanosterol, meval-
onic acid (MVA), squalene, and/or lathos-
terol. Previous reports noted that plasma
levels of squalene reflect plasma VLDL-cho-
lesterol concentrations, whereas plasma lev-
els of lathosterol (or lathosterol expressed
per cholesterol) is a most reliable marker for
whole body cholesterol synthesis (14; 15).
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Adult-onset Growth Hormone deficiency (AGHD) is associated with an athero-
genic lipid profile that ameliorates during growth hormone therapy. We aim to
study the effect of adequate GH substitution in AGHD patients on lipids and total
cholesterol synthesis (by lathosterol/cholesterol ratio; LC ratio).
Nine AGHD patients (5 males, 4 females, age: 49.3 ± 7.8 y, BMI: 26.9 ± 2.7
kg/m2), and 13 matched (for age, sex, BMI and apolipoprotein E genotype) con-
trol subjects were included. Plasma levels of TG, RLP-C and of the L/C ratio were
significantly higher in GH deficient subjects compared to control subjects. During
GH therapy, plasma TG (1.62 ± 0.41 mmol/L), L/C ratio (1.31 ± 0.40), VLDL-
cholesterol (0.83 ± 0.38 mmol/L) and RLP-C (11.8 ± 3.5 mg/dL) levels remained
elevated, while plasma LDL-cholesterol decreased significantly from 3.63 ± 0.93 to
3.05 ± 1.12 mmol/L.
In conclusion, GH treatment in AGHD resulted in a 30 % decrease in plasma LDL-
cholesterol levels, but TG levels, total cholesterol synthesis and plasma RLP-C lev-
els did not change and persisted during GH therapy. Beneficial effects of GH thera-
py in AGHD is mostly due to increased expression of LDL receptors, although
with minimal effect on plasma levels of atherogenic lipoprotein remnants.
Moreover, plasma lathosterol levels are inde-
pendent of cholesterol synthesis induced by
dietary cholesterol (16).
We performed a case control intervention
study, with the aim to determine the effects
of GH therapy on the atherogenic lipid phe-
notype in adult-onset GH deficient adults
and its relation with whole body cholesterol
synthesis.
Subjects and Methods
Subjects
Patients and normolipidemic controls
Adult-onset growth hormone deficient
(AGHD) patients were recruited from the
out patient clinic of the department of Inter-
nal Medicine and Endocrinology from the
University Medical Center Utrecht. The GH
deficient patients and control subjects partic-
ipated in a larger project that concerns the
atherogenic metablic phenotype in GH defi-
ciency and were also part of a previous pub-
lished study (9). All patients had an acquired
AGHD due to recent (within one year) neu-
rosurgery (pituitary adenoma) and/or irradi-
ation. Other deficient pituitary hormones
than GH were supplemented for at least six
months and were at a stable level at the start
of the study. Three months stable GH thera-
py was reached before patients were tested
again for the lipid profile. GH deficiency was
defined as a peak plasma GH concentration
< 5 µg/L after the combined administration
of Arginin plus GH-Releasing Hormone
(GHRH) intravenously. GH was substituted
to plasma IGF-1 levels within two standard
deviations of age- and gender related normal
range (17;18). Exclusion criteria were
lipoprotein disorders (as familial hypercho-
lesterolemia and familial combined hyperlipi-
demia), Body Mass Index (BMI) > 30
kg/m2, renal and/or liver disease, diabetes
mellitus (DM), apolipoprotein E genotype
(apoE): E2/E2 and family history of prema-
ture atherosclerosis.
Healthy control subjects, matched for age,
gender, BMI and apoE genotype, were select-
ed for this study by advertisement. They had
no diabetes, no hepatic-, renal-, thyroid- or
cardiac dysfunction and had a negative family
history for cardiovascular disease. The proto-
col had been approved by the human investi-
gation review committee of the University
Medical Center Utrecht and written
informed consent was obtained from all par-
ticipants.
Methods
Fasting blood samples were obtained for
baseline values. Plasma was obtained by cen-
trifugation at 3000 rpm for 15 min at 4°C.
TG and Cholesterol were measured with a
colorimetric assay (Monotest cholesterol kit
no. 237574 and GPO-PAP no. 701912,
Boehringer Mannheim, Germany). Coeffi-
cient of variance for TG and Cholesterol was
<5%. Cholesterol was determined in the
HDL fraction isolated by the heparin-MnCl2
dextran-sulphate precipitation method. Low-
density lipoprotein (LDL) -cholesterol was
calculated with the Friedewald Formula.
Apolipoprotein (apo-) B concentrations
were analysed automatically on a Cobas Mira
autoanalyzer (Unimate 3 Apo B, Roche
Diagnostics). VLDL-cholesterol was calcu-
lated with the equation: (Total cholesterol-
(HDL-cholesterol + LDL-cholesterol)). The
plasma Insulin and IGF-1 concentrations
were determined with a radio-immuno assay
(19). HOMA-index (fasting glucose x fast-
ing insulin/22.5) was calculated to estimate
the insulin sensitivity. Apo E genotype was
measured as described (20). The amount of
fat mass (FM) was assessed with bio-imped-
ance analysis. The RLP fraction was prepared
using an immunoseparation technique
described by Nakajima et al (21; 22). Briefly,
5 µl of serum was added to 300 µl of mixed
immunoaffinity gel suspension containing
monoclonal anti-human apo A-I (H-12) and
anti-human apo-B-100 (JI-H) antibodies
(Japan Immunoresearch Laboratories,
Takasaki, Japan). The reaction mixture was
gently shaken for 120 minutes at room tem-
perature followed by standing for 15 min-
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utes. Then 200 µl of the supernatant was
withdrawn for the assay of RLP-C. Choles-
terol (CV < 6%) in the RLP fraction were
measured by an enzymatic assay using a
Cobas Mira S auto-analyzer (ABX Diagnos-
tis, Montpellier, France).
Cholesterol Precursors
Plasma samples were collected and stored
frozen at -20°C in the dark until use. For the
extraction of the sterols, 500 µl of plasma was
mixed with 100 µl 0.01 mg/ml stigmasterol
and saponified for 60 min. at 60°C in 1 ml of
4 % (w/v) KOH in 90 % ethanol. After
saponification, the samples were mixed with
1 ml of water and extracted two times with 2
ml of hexane. The pooled hexane extracts
were dried under nitrogen and derivatized
with 50 µl BSTFA/pyridine (v/v 5:1) at 60°C
for 60 min.
For SIM-GC-MS, 2 µl of the derivative mix-
ture were delivered by automatic injection to
an HP-5890 gas chromatograph split injec-
tion port (1:20) leading to a 0.2 mm x 25 m
Chrompack CP-sil 19 CB (WCOT Fused
Silica) capillary column. The injection port
contained a glass wool liner. The carrier gas
was helium at a linear rate of 1 ml/min. The
oventemperature starts at 120°C and was
raised to 260°C at 20°C/min, then to 280°C
at 2°C/min and finally to 300°C at 40°C/min
and held for 5 min. An HP-5989B mass spec-
trometer was used as detector. Measurements
were done in the electron impact mode at 70
eV with an ion source temperature of 250°C.
The quadropole temperature was 150°C.
Mass spectrometric data were collected in the
selected ion mode at m/z = 136 and 341 for
squalene, m/z = 325 and 351 for 7-dehydroc-
holesterol (7-DHC), m/z = 255 and 213 for
lathosterol, m/z = 306 and 355 for dihydroc-
holesterol, m/z = 241 and 393 for lanosterol,
and m/z = 255 and 394 for stigmasterol. Cal-
ibration curves were constructed by mixing
100 µl of 0.01 mg/ml stigmasterol with a
series of 0 to 500 µl samples of a standard
solution containing 30 µmol lathosterol, 10
µmol desmosterol, 2 µmol squalene, 2 µmol
lanosterol, 15 µmol dihydrocholesterol and
1.5 µmol 7-DHC.
High purity solvents were purchased from
Merck, Germany. Bis-trimethylsilyltrifluo-
roacetamide (BSTFA) was obtained from
Sigma-Aldrich (the Netherlands) and pyri-
dine from Pierce (USA). Squalene
(2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-
tetracosahexaeen), dihydrocholesterol (5α-
cholestan-3β-ol), lathosterol (5β-cholest-
7en-3β-ol) and lanosterol (3β-hydroxy-8,24-
lanostadieen) were purchased from Sigma,
cholesterol (5δ-3β-cholestenol) from ICN
Biomedicals Inc. (the Netherlands), 7-dehy-
drocholesterol (5,7-cholestadien-3β-ol) from
Sigma-Aldrich and stigmasterol from Laco-
clau AB Sweden.
Statistical Analysis
Data are presented as mean ± SD, unless
shown otherwise. Comparison of effects
after GH substitution in AGHD patients
was assessed by a paired Student’s t-test.
Comparisons between AGHD and control
subjects were performed by two-tailed
unpaired Student’s t-test. Spearman’s rank
correlation were applied to assess the rela-
tionship between different variables and cho-
lesterol precursors. P<0.05 (two-tailed) was
considered to be significant. Statistical analy-
sis was performed with Graphpad InStat ver-
sion 3.00 for Windows 95, Graphpad Soft-
ware, San Diego, California, USA.
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Results
Characteristics of the subjects
Table 1 shows characteristics of the subjects.
The AGHD patients were strictly matched
with the control subjects for age, gender,
BMI and apo-E genotype (table 2). Average
duration of hypopituitarism was 3.4 years ±
9 months. All 9 patients were substituted
with L-thyroxine. Additionally, 7 patients
were substituted with hydrocortisone, 2
patients with cortisone-acetate;  7 patients
were substituted with sex hormones and 5
with desmopressin. All patients were treated
with GH for 6 months. The fasting plasma
insulin levels, plasma IGF-1 levels and the
HOMA-index were lower in AGHD
patients before GH substitution compared
with control subjects and significantly lower
compared to the value obtained after GH
treatment.. After GH treatment, insulin and
HOMA-index increased to the control lev-
els, while IGF-1 concentration increased into
the age-and gender related normal range.
Plasma lipids
Table 2 shows the lipoprotein levels of
AGHD patients before (GH(-)) and after
treatment with GH (GH(+))and the levels
of the matched control subjects. Fasting
plasma TG levels were significantly higher in
the AGHD patients before and after rhGH
treatment compared to control subjects
(table 2). No differences were found in fast-
ing plasma cholesterol and LDL-cholesterol
between the AGHD patients after treatment
and control subjects. The plasma LDL-cho-
lesterol decreased significantly (p=0.03),
while the plasma HDL-cholesterol tended to
increase (p=0.05) during GH therapy. Fast-
ing levels of RLP-C were higher in AGHD
patients before and after GH therapy, com-
pared to control subjects (p<0.05). Apo B
levels were not significantly different
between patients and control subjects. The
plasma RLP-C levels in control subjects and
in GH-substituted patients were positively
associated with TG/apo B ratio (r=0.57;
p<0.01) and VLDL-C (r=0.53; p<0.05).
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Table 1: Characteristics of the AGHD patients before (GH(-)) and after treatment with GH
(GH(+)) and of the matched control subjects
AGHD AGHD Control
GH(-) GH(+) Subjects
No. 9 9 13
Male/Female 5/4 5/4 7/6
Age (yr) 49.3 (7.8) 49.7 (7.6) 50.0(8.8)
BMI (kg/m2) 26.9 (2.7) 26.9(4.0) 26.2 (2.8)
FM(kg) 21.2 (5.3) 22.5 (5.8) 20.0 (4.9)
FM (%) 25.9 (5.3) 25.4(6.9) 25.2 (6.7)
Waist/Hip ratio 0.92 (0.04) 0.94 (0.03) 0.83 (0.09)
Insulin (mU/L) 5.78 (1.01) 8.89 (4.20)c 8.58 (3.18)
HOMA-index 1.15 (0.28) 1.97 (0.92)c 1.88 (0.74)
IGF-1 (nmol/L) 105.22 (48.80) 215.30 (40.46)c 162.80(26.93)a
All values are expressed as mean ± SD. GH (-) indicates without GH treatment, and GH(+) indicates with GH treat-
ment. AGHD vs. Controls:a P<0.05 ;  AGHD patients treated vs. untreated:c P<0.05.<0.01
Cholesterol Precursors
Table 3 shows that the plasma levels of all
measured cholesterol precursors (squalene,
lanosterol, dihydrocholesterol (cholestanol),
7-dehydrocholesterol (7dhc) and lathos-
terol), were higher in the patient group com-
pared to control subjects. No significant
change in the plasma levels of the cholesterol
precursors was found after GH therapy, 
although they tend to increase with the
exception of squalene. The plasma lathos-
terol levels in controls were positively associ-
ated with the plasma RLP-C levels (r=0.57;
p<0.01) and in all subjects (r=0.42; p<0.05).
Plasma lathosterol levels were positively
associated with TG/Apo B ratio in all sub-
jects (r=0.49; p<0.01).
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Table 3: Cholesterol precursors in plasma of the AGHD patients before and after treatment
with GH and in the matched control subjects
AGHD AGHD Control
GH(-) GH(+) Subjects
Squalene (µmol/L) 1.25 (1.02)b 1.02 (0.37)b 0.45 (0.22)
Lanosterol (µmol/L) 0.16(0.06)a 0.19(0.06)a 0.13(0.07)
Dihydrocholesterol 3.78(1.15)b 4.13(1.89)b 3.37 (0.98)
(cholestanol) (µmol/L)
Lathosterol (µmol/L) 6.52(2.90)b 7.32(2.36)b 4.05(1.72)
Lathosterol/cholesterol ratio 1.21(0.52)+ 1.31(0.40)a 0.78(0.34)
7-dehydrocholesterol (µmol/L) 0.41(0.15)b 0.52(0.18)b 0.22(0.09)
All values are expressed as mean ± SD. GH (-) indicates without GH treatment, and GH(+) indicates with GH treat-
ment.  AGHD vs. Controls:a P<0.05 and b P<0.01; AGHD patients treated vs. untreated:c P<0.05.
Table 2: Plasma lipoprotein levels of the AGHD patients before and after treatment with GH
and of the matched control subjects
AGHD AGHD Control
GH(-) GH(+) Subjects
Cholesterol (mmol/L) 5.43(0.93) 4.98 (0.64) 5.23 (0.73)
LDL-cholesterol (mmol/L) 3.63(0.93) 3.05 (1.12)c 3.28 (0.73)
HDL-Cholesterol (mmol/L) 1.11 (0.20) 1.30(0.38) 1.52 (0.40)
VLDL-Cholesterol (mmol/L) 0.83 (0.38)a 0.80 (0.36)a 0.43 (0.17)
TG (mmol/L) 1.44(0.72)a 1.62 (0.41)a 0.96 (0.37)
RLP-C (mg/dL) 11.47(4.89)a 11.80(3.51)a 7.59 (2.16)
Apo-B (g/L) 1.06(0.29) 1.00(0.13) 0.98 (0.18)
Apo E Genotype
E3/E3 7 7 10
E3/E4 1 1 1
E4/E4 1 1 2
All values are expressed as mean ± SD. GH (-) indicates without GH treatment, and GH(+) indicates with GH treat-
ment. AGHD vs. Controls:a P<0.05 ; AGHD patients treated vs. untreated:c P<0.05.
Discussion
The increased cardiovascular mortality in
adult-onset GH deficiency is mostly
explained by a pro-atherogenic lipid profile,
that ameliorates during GH therapy. In this
study, the elevated plasma LDL-cholesterol
levels reduced significantly during GH thera-
py, but no effect was found on elevated plas-
ma levels of TG, VLDL-cholesterol and
RLP-C. In addition, the elevated plasma lath-
osterol levels and the elevated lathosterol/
cholesterol ratio in GH deficient subjects,
which reflects an elevated whole body cho-
lesterol synthesis, were not decreased by GH
therapy. The persistent elevated cholesterol
synthesis and plasma levels of TG, VLDL-
cholesterol and RLP-C in AGHD patients
indicate that the effect of GH therapy is
mostly mediated by an increased expression
of hepatic LDL-receptors.
In general, plasma LDL-cholesterol levels in
GH deficient subjects are mostly found to be
in a moderate higher cholesterol range with a
significant decrease during GH therapy (23;
24). In line with previous observations, we
also found a 16% decrease after 6 months
GH therapy. Reductions in plasma LDL-cho-
lesterol levels in GH treated GH deficient
subjects have been also reported in other
intervention studies (1; 25; 26). The sus-
tained elevated plasma TG and especially the
RLP-C levels in GH treated AGHD patients
is of clinical relevance (27). Cross-sectional
studies found that the 90th percentiles of
plasma RLP-C levels was 8.5 mg/dL in
healthy subjects, and 10.9 mg/dL in coronary
artery disease (CAD) patients (28). More-
over, a value above 75th percentile of distri-
bution of RLP-C levels in CAD patients
explored a higher mortality compared to
those with a plasma RLP-C levels lower than
50th percentile of distribution of RLP-C lev-
els in a three year follow-up trial (29). The
RLP-C levels above the 90th percentile of dis-
tribution are a significant risk factor for the
presence of CAD independent of LDL-cho-
lesterol, HDL-cholesterol, TG and other tra-
ditional risk factors (30; 31). In this study,
plasma levels of RLP-C in AGHD patients
were above the high 90th percentile of distri-
bution and remained elevated during GH
therapy. From our results, we propose an
additional lipid lowering strategy in individ-
ual GH deficient patients with elevated plas-
ma RLP-C and TG levels. Gemfibrozil may
be a candidate drug as it proved to prevent
progression of coronary and vein graft ather-
osclerosis by lowering increased plasma RLP-
C levels (32), in favour of statin intervention
that had limited reducing effects (8).
In order to understand more the direction of
the lipid pathways in AGHD that are influ-
enced by GH therapy, the relationship
between the L/C ratio (that reflects whole
body cholesterol synthesis;  CS) and plasma
levels of both LDL-cholesterol and TRP
were studied. The secretion of apo B100
VLDL is associated with CS. In this study,
CS and estimated plasma VLDL-cholesterol
levels in AGHD patients was increased com-
pared to control subjects, and remained ele-
vated during GH therapy. Our observation is
in contrast with Russell-Jones et al (24)who
found a decrease in plasma mevalonic acid
(MVA) levels during one month of GH ther-
apy. However, plasma MVA levels, as an indi-
cator of whole body CS is less reliable than
plasma lathosterol levels, due to significant
diurnal intra-individual variations (33; 34).
Our observation of an increased CS and esti-
mated plasma VLDL-cholesterol level in
AGHD is line with Kearney et al, who also
found an increased VLDL synthesis (35).
Notwithstanding the sustained increase in
CS and plasma VLDL-cholesterol levels dur-
ing GH therapy, the decrease in plasma LDL-
cholesterol can be explained by a GH-
induced increased expression of LDL-
receptors on the surface of the hepatocytes
(36)and our study confirms this possible
mechanism in LDL-lowering as a cause of
GH therapy. In addition, GH substitution in
LDL-receptor deficient mice increases the
activity of 7-alpha hydroxylase, which
increases the flux of intracellular cholesterol
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towards bile acids, and subsequently GH
additionally lower plasma LDL-cholesterol
levels (37). On the other hand, the effect of
GH therapy on TRPs is less than on LDL-
cholesterol. In a previous study, we already
showed a limited effect of GH therapy on
post heparin lipoprotein lipase and hepatic
lipase activity, and therefore disturbances in
lipolytic pathways cannot explain the persist-
ent rise in plasma TRPs in AGHD. Probably,
the hepatic receptors (such as scavenger
receptors) in humans, that are responsible
for the TRP removal are not influenced by
GH therapy. This observation is line with
results from cultured mesengial cells that
also found no effect of IGF-I on the scav-
enger receptor activity, but only on the LDL-
receptor expression and non-receptor medi-
ated endocytosis (38). Plasma TRPs are only
for a small part removed by the hepatic LDL-
receptor. Plasma concentration of lathosterol
were positively associated with plasma RLP-
C levels, and this observation may indicate
that the RLP fraction is a preferable trans-
porter for lathosterol. Probably, GH modu-
lates VLDL secretion by altering the amount
of phospholipids- and/or apo B availability
for formation of the VLDL particle (39). The
decrease in insulin sensitivity with GH thera-
py, as determined by an increase in HOMA-
index, may have contributed to the higher
apoB VLDL levels in GH treated AGHD
patients and consequently to the relatively
higher plasma TRP levels (40).
In conclusion, the dyslipidemic profile in
AGHD patients is characterized by increased
plasma LDL-cholesterol levels and TRPs,
such as RLP-C, which both are associated
with an increased total body cholesterol syn-
thesis. Plasma LDL-cholesterol levels
decreased during GH therapy, indicating a
significant effect of GH therapy on catabolic
pathways of LDL-cholesterol. On the other
hand, the increased whole body CS and ele-
vated plasma levels of TG, RLP-C and
VLDL-cholesterol persisted during GH ther-
apy. Due to more evidence that TRPs play an
important role in atherosclerotic disease,
more research on the effect of GH therapy
on TRP pathways in AGHD is needed, and
additional lipid-lowering therapy besides GH
therapy needs to be envisioned in those GH
deficient subjects with persistent elevated
plasma TG and RLP-C levels.
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he syndrome of growth hormone
deficiency is characterized by
increased cardiovascular morbidity
and mortality due to premature and progres-
sive atherosclerosis (1-5). Endothelial dys-
function in GHD, that occurs early in ather-
osclerotic disease, is probably a consequence
of low circulating levels of GH and IGF
(that both are known to produce endothelial
nitric oxide that cause vasodilation (6-8).
Besides those direct effects of GH deficiency
on the endothelial lining, disturbances in
lipoprotein (9; 10) and lipoprotein remnant
metabolism (11) are considered to be an indi-
rect atherosclerotic process. Postprandially,
lipoprotein remnants dominate (12)and they
are atherogenic lipoproteins (13), that give
rise to foam cell formation and inflammation
in-vitro (14) Inflammation is an evident key
factor in premature atherosclerosis (reviewed
in ref (15-17)), but although its strong asso-
ciation the definite interaction of an inflam-
matory state and premature atherosclerosis is
still under debate (18; 19). The pathophysio-
logical explanation may be an excessive
lipoprotein retention in the extracellular
matrix with increased uptake of lipoproteins
by macrophages (20-22). Consequently,
atherogenic processes are initiated (23; 24).
Reports in animal models support this reten-
tion hypothesis for TG-rich apo B lipopro-
teins, such as lipoprotein remnants. The plas-
ma levels of these diet-derived-lipoproteins
were associated with inflammatory compo-
nents with increased intracellular nuclear fac-
tor κB (NF-κB) levels in stripped endotheli-
um of rat aorta that subsequently activates
pro-inflammatory genes and secretion of
subsequent pro-inflammatory cytokines
(25). Hitherto only an increase in postpran-
dial hydroperoxides (26) has been reported.
In this study, we hypothesize that the pres-
ence of atherogenic lipoproteins in the post-
prandial period in GH deficiency may be
associated with an inflammatory response.
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Increased cardiovascular mortality due to premature atherosclerosis, is a clinical fea-
ture in the adult-onset growth hormone deficiency (AGHD) syndrome. Inflamma-
tion is a key feature in atherogenesis and may be triggered by postprandial lipoprotein
remnants. We hypothesized that increased postprandial lipoprotein remnant levels in
AGHD may be associated with an inflammatory response. In this case-control study,
10 AGHD patients (6 male, 4 female, age: 48 ± 9 y, BMI: 26.9 ± 2.6 kg/m2) and 10
healthy control subjects (matched for age, BMI, gender, baseline lipid levels and apo E
genotype) were included. They all ingested an oral fat load. Fasting and postprandial
levels of plasma RLP-C (0.31 ± 0.13 mmol/l and 4.14 ± 1.37 mmol/l*h in GHD; 0.18
± 0.06 mmol/l and 2.56 ± 1.02 mmol/l*h in controls, respectively) were significantly
increased in AGHD patients compared to control subjects. The median inflammatory
cytokines, Interleukin-6 and TNF-a were higher in the fasting (3,9 (3.1 - 11.9) pg/ml
and 6.8 (2.5 - 27.6) pg/ml) and postprandial state (151.7 (87.0 - 294.3) pg/ml*24h and
289.9 (87.5 - 617.6) pg/ml*24h) in AGHD than in controls (0.9 (0.2 - 5.2 pg/ml and
2.8 (2.5 - 5.7) pg/ml and postprandial: ( 54.5 (11.50- 126.5) and 118.3 (81.2 - 243.1)
pg/ml*24h). In addition, postprandial profile of RLP-C and IL-6 in AGHD and in
the total group were significantly associated (r2: 0.44; p<0.05 and r2: 0.38; p<0.01,
respectively). In conclusion, the increased postprandial RLP-C level in GH deficiency
is associated with an inflammatory response, that may result in increased susceptibili-
ty for premature atherosclerosis.
T
Patients and Methods
Patients
Adult onset growth hormone deficient
(AGHD) patients were recruited from the
out patient clinic of the department of Inter-
nal Medicine and Endocrinology from the
University Hospital Utrecht. All AGHD
patients had an acquired AGHD in adult life
due to recent (within one year) neurosurgery
(pituitary adenoma) and or irradiation.
Other deficient pituitary hormones were
supplemented for at least six months and
were at a stable level at the start of the study.
GH deficiency was defined as a peak plasma
growth hormone concentration < 5 µg/l
after the argnine infusion test. Exclusion cri-
teria were the presence of lipoprotein disor-
ders (as familial hypercholesterolemia and
familial combined hyperlipidemia), Body
Mass Index (BMI) > 30, renal and/or liver
disease, diabetes mellitus (DM), apo E geno-
type: E2/E2 and family history of premature
atherosclerosis.
Normolipidemic controls.
Healthy control subjects, matched for age,
gender, BMI and Apo E genotype, were
selected for this study by advertisement.
They had no diabetes, no hepatic, renal, thy-
roid or cardiac dysfunction and had a nega-
tive family history for cardiovascular disease.
The protocol had been approved by the
human investigation review committee of the
University Hospital Utrecht and written
informed consent was obtained from all par-
ticipants
Oral fat loading test (OFLT)
Matched controls and AGHD patients
underwent an OFLT. After a 12h overnight
fast, participants were admitted to the meta-
bolic ward at 7.30 h am. They ingested a test
meal (consisting of 40% fat (w/v) with a P/S
ratio of 0.06, 0.001% cholesterol (w/v) and
2.8% carbohydrates (w/v)) of 50 g fat per m2
body surface area. Venous blood samples
from the antecubital vein were obtained prior
to the test meal and hourly after ingestion of
the cream up to 24 hours. All blood samples
were immediately put on ice. Only water or
tea without sugar was allowed to drink dur-
ing the OFLT. None of the subjects had gas-
trointestinal complaints after drinking the
cream.
Baseline measurements.
Prior to the test meal blood samples were
obtained for baseline values. Plasma was
obtained by centrifugation at 3000 rpm for
15 min at 4°C. TG and cholesterol were
measured with a colorimetric assay
(Monotest cholesterol kit no. 237574 and
GPO-PAP no. 701912, Boehringer
Mannheim, Germany). Coefficient of vari-
ance for TG and Cholesterol was <5%. Cho-
lesterol was determined in the HDL fraction
isolated by the heparin-MnCl2 dextran-sul-
phate precipitation method. Low-density
lipoprotein (LDL) -cholesterol was calculat-
ed with the Friedewald Formula. Apolipo-
protein (apo-) B concentrations were
analysed automatically on a Cobas Mira
autoanalyzer (Unimate 3 Apo B, Roche
Diagnostics). The plasma Insulin and IGF-1
concentrations were determined with a
radio-immuno assay (27). HOMA-index
(fasting glucose*fasting insulin/22.5) was
calculated to estimate the insulin sensitivity.
Body composition was assessed with bio-
impedance analysis. Apo E genotype was
determined as described (28).
RLP-C analysis
The RLP fraction was prepared using an
immunoseparation technique described by
Nakajima et al (29; 30). Briefly, 5 µl of serum
was added to 300 µl of mixed immunoaffinity
gel suspension containing monoclonal anti-
human apo A-I (H-12) and anti-human Apo-
B-100 (JI-H) antibodies (Japan Immunore-
search Laboratories, Takasaki, Japan). The
reaction mixture was gently shaken for 120
minutes at room temperature followed by
standing for 15 minutes. Then 200µl of the
supernatant was withdrawn for the assay of
RLP-C. Cholesterol (CV% <3) in the RLP
fraction were measured by an enzymatic
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assay using a Cobas Mira S auto-analyzer
(ABX Diagnostis, Montpellier, France).
Interleukin analysis
IL-6, IL-10 and TNF-α (in pg/ml) were
analysed in fasting and in postprandial plas-
ma samples with a commercial available
ELISA-kit (CLB, Amsterdam, the Nether-
lands). Both the inter- and intra-assay coeffi-
cients of variation were below 10%.
Statistical analysis
Data are presented as means ± SD. In case of
a skewed distribution, the median plus mini-
mum and maximum value is presented. Total
area under integrated curve (AUC) was cal-
culated for postprandial plasma RLP-C, post-
prandial IL-6,TNF-α and IL-10 using Graph-
Pad Prism software (version 3.1, San Diego,
California, USA). In case of significant dif-
ference in baseline levels, the incremental
(with correction for baseline levels) AUC
was calculated. Differences between AGHD
and controls were analyzed by unpaired t-
test. Pearson’s correlation or Spearman’s
rank correlation was calculated to assess the
relationships between different variables.
P<0.05 (two-tailed) was considered to be
significant. Statistical analysis was performed
with Graphpad InStat version 3.00 for Win-
dows 95, Graphpad Software, San Diego,
California, USA.
Results
Subjects
Table 1 shows characteristics of the subjects.
The AGHD patients were strictly matched
with the control subjects for age, gender and
BMI and apo E genotype. Average duration
of hypopituitarism was 28 ± 8 months. All 10
patients were substituted with T4, 8 patients
with hydrocortison, 2 patients with cortisone
acetate, 9 patients with sex hormones (males,
testosterone esters; females, cyclic estrogen
and progesterone) and 8 patients with
desmopressin. The distribution of the Apo E
genotype in AGHD was as followed: E3/E3
(n=8), E2/E3 (n=1) and E3/E4 (n=1).
Fasting plasma TG levels were significantly
higher in AGHD patients (1.44 ± 0.68
mmol/l) than in control subjects (0.88 ± 0.26
mmol/l; p<0.05). No differences were found
in baseline plasma cholesterol, Apo B and
LDL-cholesterol (table 1). Baseline plasma
IGF-1 levels were lower in AGHD than in
controls. No difference was found in free T3
levels.
Postprandial responses
Postprandial RLP-C response
After the oral fat load, the time course of
postprandial plasma RLP-cholesterol (RLP-
C) concentrations is shown in figure 1. Fast-
ing levels of RLP-C were significantly higher
in AGHD patients (0.31 ± 0.13 mmol/l) than
in control subjects (0.18 ± 0.06 mmol/l;
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Figure 1. Postprandial plasma RLP-C response for the GH
deficient patients (l) and control subjects (‡) Values are pre-
sented as mean (SD).
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Table 2: Postprandial data for RLP-C, IL-6, TNF-a and IL-10 
Control AGHD
RLP-C (mmol/l) 0.18 (0.06) 0.31 (0.13)a
AUC RLP-C (mmol/l*h) 2.56 (1.02) 4.14 (1.37)a
dAUC RLP-C (mg/dl*24h) 0.90(0.35) 1.86 (0.92)a
Il-6 (pg/mL) 0.9 (0.2 - 5.2) 3.9 (3.1 - 11.9)b
AUC Il-6 (pg/mL*24 h) 54.5 (11.5 - 126.5) 151.7 (87.0 - 294.3)b
dAUC-IL-6 (pg/mL*24 h) 8.0 (0.3 - 45.8) 34.9 (18.6 - 169.8)a
TNF-a (pg/mL) 2.8 (2. - 5.7) 6.8 (2.54-27.6)
AUC TNF-a (pg/mL*24 h) 118.3  (81.2 - 243.1) 289.9 (87.5 - 617.6)a
Il-10 (pg/mL) 6.1 (5.0-15.1) 16.7 (5.3-24.2)a
All values are expressed as means (SD). RLP-C, remnant-like particle-cholesterol, AUC, integrated Area under the
Curve; dAUC, incremental AUC; IL-6, interleukin-6; IL-10, interleukin-10. AGHD vs. controls: a P < 0.05 and b P
<0.01
Table 1: Baseline characteristics 
Control AGHD
(n=10) (n=10)
Male/Female 6/4 6/4
Age (yr) 48,60 (7,73) 47,90(8,66)
BMI (kg/m2) 25,43 (1,62) 26,87(2,59)
WH ratio 0,86 (0,06) 0,93 (0,04)a
FM (kg) 19,70 (4,55) 20,58 (4,19)
FM (%) 24,9 (6,44) 25,35 (5,63)
Cholesterol (mmol/L) 4,99 (0,64) 5,30 (0,97)
LDL-Chol (mmol/L) 3,04 (0,61) 3,49 (0,97)
HDL-chol (mmol/L) 1,49 (0,33) 1,28 (0,43)
TG (mmol/L) 0,88 (0,26) 1,44 (0,68)a
ApoB 0,88 (0,19) 0,97 (0,29)
IGF-1 (nmol/L) 161,78 (31,18) 106,7 (46,28)a
Free T3 (nmol/L) 1,53 (0,27) 1,32 (0,43)
All values are expressed as means (SD). WH, waist to hip; FM, fat mass; LDL, low-density-lipoprotein; HDL, high-den-
sity-lipoprotein; TG; triglyceride; IGF-I, insulin-like growth factor-I. AGHD vs. controls: a P < 0.05 and b P <0.01
p<0.05). The postprandial peak time of RLP-
C was between 2 and 4 h in control subjects
and between 4 and 6 h in AGHD patients,
with a maximum level of 0.43 ± 0.2 mmol/l,
in controls, and 0.70 ± 0.34 mmol/l in
AGHD patients ( p<0.05). The AUC RLP-
C (table 2) was enhanced in AGHD (4.14 ±
1.37 mmol*h/l) compared to control sub-
jects (2.56 ± 1.02 mmol*h/l; p<0.05).
Postprandial cytokines
After the oral fat load, the time course of
postprandial plasma IL-6 concentration is
shown in figure 2. Median fasting levels of Il-
6 were higher in AGHD patients (3.9 pg/ml
(range: 3.1 - 11.9) than in control subjects
(0.9 pg/ml; range: 0.2 - 0.5; p<0.01). In con-
trols, the postprandial IL-6 response
remained low with maximum levels of 3.4 ±
2.3 pg/ml at 10 hr. In GH deficiency, a dis-
tinctive peak level was reached at 10 hr of
13.1 ± 4.6 pg/ml (p<0.01). The AUC IL-6
(table 2) was enhanced in AGHD (151.2
pg/ml *24h, range: 87.0 - 294.3) compared to
control subjects (54.5 pg /ml*24h; range:
11.5 - 126.5; p<0.05).
After the oral fat load, the time course of
postprandial plasma TNF-α concentration is
shown in figure 2. Fasting levels of TNF-_
were not significantly higher in AGHD
patients than in control subjects. The post-
prandial peak time of TNF-α was between 4
and 8 hr in control subjects and at 10 hr in
AGHD patients with a maximum level of 4.7
± 3.4 pg/ml, respectively, 20.4 ± 7.2 pg/ml;
p<0.01. The AUC TNF-α (table 2) was
enhanced in AGHD (289.9 pg/ml* 24h;
range: 87.5 - 617.6) compared to control sub-
jects (118.3 pg/ml *24h, range: 81.2 - 243.1;
p<0.05).
After the oral fat load, a decrease in post-
prandial IL-10 was found in AGHD while a
significant increase in postprandial IL-10 was
found in the control subjects (figure 2). Fast-
ing levels of IL-10 were higher in AGHD
patients (16,7 pg/ml, range: 5.3 - 24.2) than
in control subjects (6.1 pg/ml, range: 5.0 -
15.1; p<0.05). The postprandial peak time of
IL-10 was at 10 h in control subjects (14.6 ±
8.7 pg/ml) and the lowest level of postpran-
dial IL-10 was reached at 12 h in AGHD
patients (10.5 ± 4.8 pg/ml).
Correlations
The integrated area under the IL-6 and RLP-
C curves (AUC IL-6 vs AUC RLP-C) were
significantly associated in all the subjects
together (r2 = 0.38; p<0.01), and in only the
AGHD patients (r2 = 0.44; p<0.05; Figure
3).Also, the incremental postprandial
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Figure 2. Postprandial plasma cytokine response for the GH
deficient patients (l) and the control subjects (‡). Inter-
leukin-6 (IL-6), TNF-alpha and IL-10. Values are present-
ed as mean (SD).
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Figure 3. Scatter plot for the relationship between the post-
prandial plasma RLP-C response (AUC RLP-C) and post-
prandial IL-6 response (AUC IL-6). GH deficient patients
(l) and control subjects (r). Correlations were calculated
with the use of SPSS as indicated in the method section.
response of IL-6 (dAUC IL-6) and RLP-C
(dAUC RLP-C) were positive associated in
the GHD patients (r2 = 0.24; p<0.05) and
all the subjects together (r2 = 0.34; p<0.01).
No correlations between AUIC TG and
AUIC IL6 or AUIC TNF-α could be
demonstrated (data not shown).The AUC
TNF-α was significantly associated to waist
to hip ratio (r2 = 0.21; p<0.05) and plasma
IGF-1 (r = -0,57; p<0.05) in all subjects
together and in AGHD patients (for both
waist to hip ratio and plasma IGF-1 r2 =
0.30; p<0.05). Baseline plasma IL-6 or IL-10
levels were not associated with baseline IGF-
1 levels, waist to hip ratio or RLP-C levels.
Discussion
In this report, we found evidence that the
presence of atherogenic lipoproteins in the
postprandial period in GH deficiency may be
responsible for the induction of an inflam-
matory response. Recent observations stress
the importance of a pro-inflammatory profile
in the development of progressive athero-
sclerosis (31), but the origin of inflammation
is still under debate. These observations sug-
gest that the postprandial period in GH defi-
ciency may be an atherogenic interval that
needs a supplemental approach in treatment.
We realize that deficiencies in other pituitary
hormones, such as TSH and ACTH, may
have an effect on the postprandial inflamma-
tory response. However, currently no sup-
port is available for such an influence in
human, in contrast to reported effects in ani-
mal models and in-vitro cell culture systems.
Moreover, the patients were adequately sub-
stituted for all end-organ hormone deficien-
cies. Substitution with end-organ hormones,
albeit adequate, does not mimic completely
the diurnal variations of these hormones.
In previous studies, atherosclerotic disease in
GH deficiency present as endothelial dys-
function (post-ischemic dilation of brachial
artery) or increased intima media thickness
(IMT) of femoral or carotid artery (32).
During rhGH treatment, initial increased
IMT decreased with a marked progress. Par-
allel results in IMT decrease were estimated
to be equal to 3 to 4 years’ aggressive lipid
lowering treatment in dyslipidemic patients
(33-35). Therefore, it is of general impor-
tance to get more insight into the pathways
that give rise to this accelerated atherogene-
sis and that could be reversed so adequately
by GH therapy.
Negative influence by the GH deficient state
on metabolic pathways (such as the lipopro-
tein remnant) with a high atherogenetic
potential is an example of an indirect implica-
tion in atherosclerosis. In line with earlier
observations, elevated postprandial lipopro-
tein remnant levels are counteracted by
rhGH therapy with additionally an improve-
ment in flow mediated dilation (FMD) of the
brachial artery after 6 months’ therapy. Fur-
thermore, IMT of carotid arteries and the
angiographically verified progression of focal
coronary atherosclerosis were positively
associated with the plasma RLP-C levels,
even independently from plasma LDL-cho-
lesterol and TG levels (36; 37). In a statin-
fibrate cross-over study in healthy subjects,
fluctuations of postprandial levels of plasma
lipoprotein remnants are closely related to
post-ischemic changes in diameter of the
brachial artery, a marker for early atheroscle-
rosis (38). Additionally, in a model with rat
aortic rings, incubation with RLP-C results
in endothelial dysfunction that was mediated
through the NF-κB upregulation, resulting in
an enhanced endothelial response (39-41).
The intracellular NF-κB pathway is part of
the inflammatory response. Moreover, incu-
bation of beta-VLDL with endothelial cells
indeed increases the expression of endothe-
lial TNF-α. This observation is in line with
the presence of elevated fasting plasma RLP-
C levels in AGHD, and increased fasting
plasma levels of TNF-α and IL-6. Moreover,
in the present study, we show in humans,
that plasma levels of pro-inflammatory
cytokines (such as IL-6 and TNF-α) are
increased during the postprandial period and
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are related to the presence of elevated levels
of lipoprotein remnants. The plasma levels of
these inflammatory cytokines are a result of
spilling into circulation. Endothelial cells and
monocyte/macrophages are secretors of
cytokines, whereas TG-rich lipoproteins, of
which lipoprotein remnants are a subset
from, are able to induce an inflammatory
response in endothelial cells and
macrophages through specific receptors on
their surface (42; 43). The postprandial
response of RLP-C was closely associated
with the postprandial IL-6 response, which
suggests that lipoprotein remnants may
induce an inflammatory response. Inflamma-
tion is a key feature in atherogenesis (44). In
several clinical studies, strong correlations
between mortality from coronary artery dis-
ease (CAD) with other inflammatory mark-
ers, such as fibrinogen and C-reactive protein
(CRP), was found (45; 46). Moreover, TNF
induce apoptosis of endothelial cells, block-
ade of TNF-α accelerates functional
endothelial recovery after balloon angioplas-
ty and plasma TNF-α levels are associated
with the carotid IMT in humans (47-49). As
a consequence, three meals a day, as occurs in
Western diet, result in several postprandial
inflammatory responses during the day. The
inflammatory response consists of a pro-
inflammatory and a anti-inflammatory path-
way that are both fine tuned (50). An exag-
gerated pro-inflammatory response is also
found in animal models and in patients with a
defect in the anti-inflammatory response, for
example a deficiency in the IL-10 secretion.
In rat models with IL-10 deficiency, the area
of the atheromatous plaque is more extensive
and more suspicious to rupture and restora-
tion of plasma IL-10 levels decreased the ath-
erosclerosis (51; 52). In the present study,
baseline plasma IL-10 levels were elevated in
AGHD patients as compared to controls,
revealing an induction of anti-inflammatory
factors during an ongoing inflammatory con-
dition in AGHD. This explained the observa-
tion that the postprandial IL-10 response in
the patients is absent. Currently we are con-
ducting in vitro experiments to elucidate fur-
ther these observations.
In conclusion, we observed a pronounced
postprandial inflammatory response in GH
deficiency in relation to the presence of ele-
vated plasma levels of postprandial RLP-C.
This observation offer an additional
approach for studying the importance of
increased susceptibility of premature athero-
sclerosis in AGHD patients.
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DL-cholesterol and atherogenesis
Familial Hypercholesterolemia (FH)
is an autosomal dominant disorder of
lipoprotein metabolism (1) Mutations in the
LDL-receptor gene are the cause of this dis-
ease and lead to a reduction in the clearance
of LDL-cholesterol (LDL-C), which conse-
quently causes a rise in LDL-C levels and
predisposes to the development of athero-
sclerosis (2) Therefore, FH patients are at
great risk of developing premature coronary
artery disease (CAD). However, there is a
wide variation of coronary risk among FH
patients (3)
Remnant lipoproteins and atherogenesis
Increasing experimental and clinical evidence
suggests that triglyceride-rich lipoproteins
(TRL) and in particular remnant-like parti-
cles (RLP) contribute to atherogenesis and
consequently to cardiovascular disease pro-
gression. High levels of remnant lipoproteins
of both hepatic (very-low-density lipopro-
teins (VLDL)) and intestinal (chylomicron)
origin are associated with the progression of
coronary atherosclerosis.(4-7) In a study of
Phillips et al, it was found that neither LDL-
C nor triglyceride (TG) levels correlate well
with lesion progression or clinical events.(7)
TRL remnant levels, however, did correlate
with both lesion progression and cardiac
events. Recently, Nakajima et al developed a
simple technique to analyze remnant-like
particle cholesterol (RLP-C) using an
immune-affinity gel containing anti-
apolipoprotein (apo) A-I and anti-apoB100
monoclonal antibodies.(8-10) This unique
anti-apoB100 monoclonal antibody was
shown to recognize apoB100 in LDL and
most VLDL but not in apoE-enriched
VLDL, whereas anti-apoA-I recognizes and
binds all HDL particles. This technique iso-
lates apoE-rich VLDL particles containing
apoB100 together with chylomicron rem-
nants containing apoB48, neither of which
binds to the immunoaffinity gel. Increased
levels of these remnant particles have already
been associated with the presence and pro-
gression of cardiovascular disease (CVD)
and with endothelial dysfunction.(11-18)
However, it should be stressed that these
previous results are examined in non-FH
patients. Evidently, these patients have a dif-
ferent lipid profile compared to the extreme-
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Remnant lipoproteins (RLP-C) are considered important in atherogenesis. Hence,
this study was designed to assess RLP-C levels and the effect of statin therapy in
patients with familial hypercholesterolemia (FH). Elevated RLP-C levels have
been associated with the presence and progression of atherosclerotic disease and
their presence in FH patients has been proposed but never established in a large
cohort, or their response to statin therapy. FH patients were recruited from 36
Lipid Clinics. After a washout period of 6 weeks, all patients were started on
monotherapy with 80 mg simvastatin for two years. RLP-C levels were assessed by
an immune-separation assay. In 327 FH patients RLP-C measurements could be
performed before and after treatment. Mean total (10.55 ± 2.17 mmol/L), mean
LDL cholesterol (8.40 ± 2.13 mmol/L) and median RLP-C (0.47 mmol/L) levels
were all severely elevated at baseline. After treatment, RLP-C levels were reduced
by 49% (0.24 mmol/L; p<0.0001). Even patients with normal TG levels had elevat-
ed RLP-C levels at baseline and those with high RLP-C levels were generally char-
acterized by a very atherogenic lipoprotein profile.Baseline RLP-C levels are
severely elevated in FH patients, are reduced by simvastatin, but do not return to
normal. These elevated RLP-C levels could be the consequence of impaired func-
tion of the LDL-receptor in FH. RLP-C levels in FH contribute to an atherogenic
lipoprotein profile and could identify patients who require additional treatment.
L
ly elevated LDL-C levels seen in FH
patients. Therefore, this association between
elevated levels of RLP-C and CVD cannot be
extrapolated to FH patients as such.
Levels of remnant particles could be relevant
for the understanding of the heterogeneity in
coronary risk among FH patients. RLP-C
levels have so far not been assessed in a large
FH population. Up to now only two small
studies (in 15 and 7 FH patients, respective-
ly) reported RLP-C levels of FH patients and
did indeed show increased RLP-C lev-
els.(19;20) In the current study we aimed to
assess accumulation of RLP-C and also to
evaluate whether RLP-C levels will be low-
ered by statin therapy in a large and well-
defined cohort of FH patients.
Methods
Subjects
The present study is a substudy of the
ExPRESS FH (Examination of Probands and
Relatives in Statin Studies with Familial
Hypercholesterolemia) study, in which effi-
cacy, safety and pharmacogenomics of sim-
vastatin 80 mg was assessed in 526 heterozy-
gous FH patients. For this open label
multicenter study FH patients were recruited
from 36 Lipid Clinics in the Netherlands.
Patients were included if they met the fol-
lowing criteria: all patients had to have either
a molecular diagnosis for FH or were diag-
nosed with definite FH and had to have 6 or
more points, according to an algorithm (to
allow standardization of the diagnosis of FH
based on clinical findings, personal and famil-
ial clinical history and biochemical parame-
ters)(21); at least 18 years of age; and
patients with a history of myocardial infarc-
tion (MI), coronary artery bypass graft
(CABG) or percutaneous transluminal coro-
nary angiography (PTCA) could be included
if the physician thought it was medically
allowed for the patient to have a washout
period. Patients were excluded if they: were
pregnant or nursing women, or pre-
menopausal women not using adequate con-
traceptives; had acute liver disease, hepatic
dysfunction, or persistent elevations of
serum transaminases; had hypersensitivity or
intolerance to simvastatin or any of its com-
ponents; had hyperlipidemia Type I, III, IV
or V or homozygous FH; had a recent histo-
ry of alcohol or drug abuse; had secondary
hypercholesterolemia due to any cause; had
inadequately controlled diabetes, unstable
angina or intermediate coronary syndrome or
clinically significant ventricular arrhythmia at
study entry or MI within the past 3 months;
were on concurrent use of erythromycin and
similar drugs affecting the cytochrome P450
enzyme; had a history of cancer.
Controls
Controls for the 327 FH patients, in whom
RLP-C levels were measured, were recruited
post-hoc from their families and matched for
age and sex. In these 77 individuals we
obtained demographic characteristics, lipids
and lipoproteins.
Study design
After a washout period of six weeks, patients
were started on monotherapy with simvas-
tatin 80 mg. No other lipid lowering medica-
tion was allowed. Medical history, physical
examination and additional risk factors for
cardiovascular disease as well as laboratory
analysis of lipid and lipoprotein levels and
routine safety parameters were obtained in all
patients. The biochemical analyses of lipid
levels and safety parameters were performed
in the hospitals themselves and were stan-
dardized by a virtual central laboratory. The
apolipoprotein determinations were per-
formed in the Academic Medical Center in
Amsterdam and the RLP determinations in
the University Medical Center in Utrecht.
The Ethics Committees of all the 36 centers
approved the protocol and written informed
consent was obtained from all participants.
Biochemical analysis
Blood samples were taken in the morning
after an overnight fast. Total cholesterol
(TC), HDL-cholesterol (HDL-C) and
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triglycerides (TG) were routinely determined
in the different laboratories and standardized
by a virtual central laboratory. LDL-C was
calculated using the Friedewald formula.(22)
Apolipoprotein A-I (apoA-I) and apolipo-
protein B (apoB) were determined by an
immunological rate-nephelometric procedure
using a polyclonal goat anti-human antibody
(Array protein system, Beckman Coulter,
Netherlands).(23)
The RLP fraction was prepared by use of an
immune-separation technique described by
Campos, Nakajima and colleagues.(24;25)
Briefly, 5 µL of serum was added to 300 µL of
mixed immunoaffinity gel suspension con-
taining monoclonal anti-human apoA-I (H-
12) and anti-human apoB100 (JI-H) antibod-
ies (Japan, Immunoresearch Laboratories,
Takasaki, Japan). The reaction mixture was
gently shaken for 120 minutes at room tem-
perature. After the supernatant was left
standing for 15 minutes, 200 µL was with-
drawn for the assay of RLP-C. Cholesterol in
the RLP fraction (coefficient of variation
<3%) was measured by an enzymatic assay
on a Cobas Mira S auto analyzer (ABX Diag-
nostics, Montpellier, France). Apo E geno-
typing was performed as described by
Reymer et al.(24)
Statistical analysis
Data were expressed as mean ± standard
deviation. Skewed data distributions were
presented as median and the interquartile
range. Mean and median cholesterol levels in
FH patients compared to controls were test-
ed by the independent sample t-test and the
Mann-Whitney test, respectively. Mean val-
ues in lipids, lipoproteins before and after
treatment were compared using the paired
sample t-test. TG and RLP-C were compared
by the non-parametric Wilcoxon test,
because they had a skewed distribution.
Mean values in baseline characteristics and
lipids for the different groups were compared
using the one-way ANOVA test. Parameters
with a skewed distribution (TG, RLP-C and
RLP reduction) were compared using the
Kruskal-Wallis test. Chi-square tests were
applied for comparing distributions of
dichotomous data (gender, diabetes and
apoE2). All statistical analyses were per-
formed using the SPSS package (version 10.1,
Chicago; Illinois). A p-value of less than 0.05
was considered to be statistically significant.
Results
From the 526 patients, participating in the
ExPRESS FH study blood samples were
stored in 327 patients. Consequently, these
patients were available for RLP-C analyses
and comprised our study group. This group
did not differ from the source population
with regard to baseline characteristics and
lipid parameters. Ages ranged from 18 to 80
years. Mean age was 47.4 years (standard
deviation (SD) ± 13.2). Slightly more males
(54%) than females (46%) were included.
Mean body mass index (BMI) was 25.8
kg/m2 (SD ± 3.6). Lifestyle and physical
characteristics such as dietary adherence,
BMI, alcohol intake and physical exercise did
not change over the course of the trial.
Mean lipid, lipoprotein and RLP-C levels at
baseline and one year after therapy with sim-
vastatin 80 mg are shown in table 1. As
expected, mean TC (10.55 ± 2.17 mmol/L)
levels were severely elevated in FH patients
compared to their family controls (4.58 ±
0.77 mmol/L; p<0.0001) and this could
largely be attributed to elevated LDL-C lev-
els (8.40 ± 2.13 mmol/L). Mean HDL-C lev-
els were lower in FH patients compared to
the controls (1.25 ± 0.35 mmol/L vs. 1.39 ±
0.38 mmol/L; p=0.04), whereas median TG
levels were elevated compared to the controls
(1.80 mmol/L vs. 0.97 mmol/L; p<0.0001).
Median RLP-C levels (0.47 mmol/L) were
severely elevated in FH patients. Median
RLP-C levels in controls were 0.20 mmol/L,
which indicates that FH patients have a
twofold elevation of RLP-C levels
(p<0.0001). After simvastatin treatment,
plasma cholesterol, LDL-C, TG and apoB
decreased, and HDL-C and apoA-I
increased, all significantly. RLP-C levels
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decreased significantly from a median of 0.47
mmol/L to 0.24 mmol/L (p<0.0001), which
is consistent with a 49 % median reduction.
At baseline, only 5 FH patients (1.5%) had
normal RLP-C levels (≤ 0.20 mmol/L); in
contrast after simvastatin therapy 84 patients
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Table 2: Lipids, RLP, ApoE2 and clinical features in FH patients with baseline RLP-C levels
divided in 3 equal groups (all in mmol/l)
RLP-C <0.39 0.3≤ RLP-C <0.65 RLP-C ≥ 0.65
Variable n = 109 n = 109 n = 109 p-value
Age (years) 44.0 ± 14.2 46.6 ± 13.2 51.5 ± 11.0 <0.0001
Male gender (N) 41 (45.0%) 47 (51.4%) 60 (65.1%) 0.009
BMI (kg/m2) 24.6 ± 3.7 25.6 ± 3.2 27.3 ± 3.5 <0.0001
Diabetes (N) 0 (0%) 1 (0.9%) 5 (4.6%) 0.029
TC (mmol/L) 9.50 ± 1.70 10.68 ± 2.08 11.47 ± 2.23 <0.0001
LDL-C (mmol/L) 7.58 ± 1.63 8.64 ± 2.13 8.99 ± 2.32 <0.0001
HDL-C (mmol/L) 1.37 ± 0.36 1.29 ± 0.35 1.09 ± 0.27 <0.0001
TG (mmol/L) 1.10 (0.90-1.50) 1.80 (1.30-2.05) 2.80 (2.10-3.60) <0.0001
ApoA-I (g/L) 1.28 ± 0.21 1.25 ± 0.24 1.18 ± 0.19 0.004
ApoB (g/L) 1.74 ± 0.35 2.00 ± 0.39 2.17 ± 0.49 <0.0001
RLP-C (mmol/L) 0.32 (0.26-0.34) 0.47 (0.43-0.53) 1.06 (0.79-1.62) <0.0001
RLP reduction (%) 29.0 (14.9-41.0) 50.5 (39.8-57.7) 67.5 (57.2-76.8) <0.0001
ApoE2 allele (N) 5 (4.6%) 4 (3.7%) 17 (15.6%) 0.001
FH, familial hypercholesterolemia; RLP-C, remnant-like particle cholesterol; BMI, body mass index; TC, total choles-
terol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; Apo,
apolipoprotein. All values are given as mean with SD or (%), except that TG, RLP-C and RLP-C reduction are given as
median with interquartile range.
Table 1: Lipid, Lipoprotein and RLP-C Levels in controls and in FH patients at baseline and
after one year of therapy
Variable Baseline Simvastatin 80 mg p-value
(n = 327) (n = 327)
TC (mmol/L) 10.55 ± 2.17 6.36 ± 1.37 <0.0001
LDL-C (mmol/L) 8.40 ± 2.13 4.32 ± 1.30 <0.0001
HDL-C (mmol/L) 1.25 ± 0.35 1.39 ± 0.39 <0.0001
TG (mmol/L) 1.80 (1.20-2.40) 1.20 (0.90-1.73) <0.0001
ApoA-I (g/L) 1.24 ± 0.22 1.36 ± 0.24 <0.0001
ApoB (g/L) 1.97 ± 0.45 1.19 ± 0.31 <0.0001
RLP-C (mmol/L) 0.47 (0.34-0.80) 0.24 (0.20-0.31) <0.0001
RLP-C, remnant-like particle cholesterol; FH, familial hypercholesterolemia; TC, total cholesterol; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; Apo, apolipoprotein.
All values are given as mean with SD except that TG and RLP-C are given as median with interquartile range.
(25.7%) were below this RLP-C level.
In table 2 baseline RLP-C levels are divided
into three equal groups using the 33rd and
66th percentiles. FH patients in the highest
third were older, more often male, had a
higher BMI and had more often diabetes. To
address whether FH patients with type 2 dia-
betes were outliers in terms of remnant accu-
mulation and caused significant shifts of the
medians in the different 3 groups we calcu-
lated median RLP-C levels with these indi-
viduals included or excluded. However,
results indicated no significant changes in the
medians of these three groups (data not
shown). In addition, the statistically signifi-
cant increase in total cholesterol, LDL-C and
TG levels and the decrease in HDL-C, illus-
trates the association between plasma RLP-C
and the presence of a severe atherogenic
lipoprotein profile. RLP-C levels were also
correlated to HDL-C levels, the Spearman’s
rank correlation coefficient was r = -0.37 at
p<0.0001. In the lowest third of baseline
RLP-C, median TG levels were normal (1.10
mmol/L) whereas in that third median RLP-
C levels were still above normal (0.32
mmol/L). Moreover, significantly more
patients in the highest RLP-C third had an
apoE2 allele compared to the two lower
thirds (p=0.001). Lastly, RLP-C levels were
more reduced in the highest third compared
to the lower thirds. Since pre- and post treat-
ment measurements on the variable of inter-
est are, in general, not perfectly correlated,
the evaluation of treatment effects must be
adjusted for regression to the mean. Chen et
al. proposed 4 models, which included either
or both additive and multiplicative
effects.(25) We have applied this model to
evaluate RLP-C changes. The model, which
included both additive and multiplicative
effects fit better than that with only additive
effects (regression to the mean) for RLP-C
change (p<0.0001). Therefore, changes in
RLP-C could not be attributed to regression
to the mean only, but indeed exhibit a rela-
tionship with baseline levels. FH patients in
the highest versus the lowest third of RLP-C
suffered from CVD in 53 (48.6%) versus 30
(27.5%) of cases (χ2=10.5, p=0.005). How-
ever, upon multiple logistic regression analy-
sis with age, gender, BMI and major lipids in
the model this relation was no longer statisti-
cally significant (p=0.32).
In table 3 the data were stratified according
to baseline TG levels in quartiles. Patients in
the lowest quartile had completely normal
median baseline TG levels (0.90 mmol/L),
however the corresponding RLP-C levels
were already strongly elevated (0.32
mmol/L), whereas plasma LDL-C levels were
similar in all groups (p=0.09).
Discussion
RLP-C increase at baseline
In this study we observed that median RLP-
C levels in FH patients are severely elevated
compared to their siblings (0.47 mmol/L vs.
0.20 mmol/L; p<0.0001). Elevated RLP-C
levels were reported before in FH patients,
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Table 3: Lipids and RLP-C Levels in FH patients with baseline TG levels divided in quartiles
(all in mmol/L)
TG≤ 1.10 1.10<TG≤ 1.80 1.80<TG≤ 2.40 TG>2.40 p-value
(n=80) (n=91) (n=76) (n=80)
LDL-C 8.03 ± 1.90 8.81 ± 2.17 8.48 ± 2.30 8.23 ± 2.07 0.09
TG 0.90 (0.80-1.00) 1.50 (1.30-1.70) 2.10 (1.90-2.20) 3.25 (2.73-4.10) <0.0001
RLP-C 0.32 (0.25-0.41) 0.42 (0.33-0.49) 0.52 (0.42-0.75) 1.16 (0.79-1.80) <0.0001
RLP-C, remnant-like particle cholesterol; FH, familial hypercholesterolemia; TG, triglycerides; LDL-C, low-density
lipoprotein cholesterol. LDL-C is given as mean with SD; TG and RLP-C are given as median with interquartile range.
albeit in very small cohorts. Twickler et al
measured RLP-C levels in 7 FH patients and
found significantly elevated mean RLP-C
levels compared with 7 controls (42.10 mg/dl
(1.09 mmol/L) vs. 7.49 mg/dl (0.19
mmol/L); p<0.01). Dane-Stewart et al also
found elevated median RLP-C levels in 15
FH patients compared with 15 controls (16.2
mg/dl (0.42 mmol/L) vs. 8.5 mg/dl (0.22
mmol/L); p=0.003).(19) In our cohort,
mean age and BMI increase from the lowest
to the highest RLP-C thirds. Why RLP levels
rise with age is unknown, but older people
have higher BMI ‘s often combined with
higher TG levels. This association points to
increased synthesis of VLDL, which could
consequently lead to higher RLP levels.(26)
We also found a higher prevalence of apoE2
allele carriers in the highest RLP-C third.
ApoE is the major ligand for hepatic lipopro-
tein receptors and mediates chylomicron and
VLDL remnant uptake.(27) ApoE2 is one of
the three E isoforms and exhibits a very low
affinity to the LDL-receptor.(28) It is there-
fore not unexpected to find more apoE2 alle-
les in the highest third of RLP-C levels. The
apoE allele distribution was in Hardy Wein-
berg equilibrium (χ2 =3.59, p>0.1) in our
FH sample but the frequency of the (2 allele
was lower compared to the general Dutch
population as previously reported (0.047 and
0.082, respectively).(29) It is therefore
unlikely that an overrepresentation of the ε2
allele of the apoE gene will have contributed
to our findings.
These elevated RLP-C levels might play an
important role, in addition to elevated LDL-
C levels, in the acceleration of atherosclero-
sis in FH. This idea is supported by the find-
ings of Karpe et al who did not find an
association between LDL-C and new lesions
in vein grafts in 395 patients with coronary
artery disease (CAD), but did find a strong
trend for higher RLP-C concentrations.(17)
RLP-C reduction after statin intervention
RLP-C levels are significantly decreased by
simvastatin. Median RLP-C levels almost
returned to normal, but remained slightly
elevated. This observation was previously
reported in 7 FH patients.(20) Recently, two
studies in patients with combined dyslipi-
demia showed similar results.(30;31) Stein et
al found that median elevated RLP-C levels
of 0.34 mmol/L were reduced by simvastatin
20 mg (6.0%) and by atorvastatin 10 mg
(25.9%), but not by pravastatin 40 mg in 22
patients in a crossover study.(30) In addition,
Sasaki et al found that atorvastatin 10 to 20
mg reduced RLP-C levels from 0.31 mmol/L
to 0.16 mmol/L.(31) These studies also illus-
trate a treatment effect of statins on the
RLP-C fraction.
Accumulation as the proposed mechanism
The central abnormality in heterozygous FH
is an impaired function of the LDL receptor.
As a consequence, plasma levels of LDL-C
are severely elevated, and levels of RLP-C as
well. Moreover, these elevated RLP-C levels
are significantly reduced by simvastatin treat-
ment. Statins likely improve RLP clearance
by upregulating LDL-receptors and by
decreasing hepatic VLDL synthesis.(32;33)
Both mechanisms lead to less competition
for the clearance mechanisms shared by chy-
lomicrons and VLDL.(34) The reductions in
apoB and LDL-C were very consistent with
those of RLP-C, as is anticipated since by
upregulating the LDL (apoB, E) receptor all
apoB (LDL) as well as apoE (RLP-C) con-
taining lipoproteins will be reduced in essen-
tially similar proportions.
The raised TG levels in the higher RLP-C
thirds support the accumulation of TG-rich
lipoproteins. The conclusion could therefore
be drawn that TG levels measured in FH
patients primarily reflect atherogenic rem-
nant lipoproteins. However, even patients
with normal TG levels had elevated RLP-C
levels. This observation was also made previ-
ously.(20) All these data indicate the pres-
ence of remnant particle accumulation in FH
patients, irrespective of concomitant TG ele-
vation. Likewise, stratification of the data
according to baseline TG into quartiles
resulted in an association between TG and
RLP-C levels, but LDL-C levels were equally
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elevated in all quartiles. This suggests that
despite the fact that plasma LDL-C levels are
strongly elevated in FH patients, RLP-C lev-
els could further contribute to the athero-
genic lipoprotein profile over and above
LDL-C measurements. We, therefore,
hypothesize, that remnant accumulation in
FH might be explained by a combination of
factors such as the LDL-receptor mutation,
VLDL production associated with advancing
age, central obesity and glucose intolerance,
carriership of an ε2 allele of the apo E gene
and possibly by defective LDL-receptor
related protein function. These findings may
raise the need to prescribe combination ther-
apy with simvastatin 80 mg and either nico-
tinic acid or fenofibrate or with more power-
ful statins to lower the risk associated with
the residual remnant increase.
In conclusion, baseline RLP-C levels are
severely elevated in FH patients. Treatment
with high dose simvastatin resulted in a
strong reduction of RLP-C, but in the major-
ity of the patients RLP-C levels remained
elevated. RLP-C levels in FH contribute to
an atherogenic lipoprotein profile and could
identify patients who require additional
treatment.
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rowing evidence exists that a dis-
turbed plasma triglyceride (TG)
metabolism plays an important role
in the development of premature atheroscle-
rosis (1; 2). Disturbances in triglyceride
metabolism are characterized by postprandial
accumulation of lipoprotein remnants and
were observed in various populations with
elevated cardiovascular risk (3-7). Patients
with Familial Hypercholesterolemia (FH)
and disturbances in postprandial lipoprotein
metabolism have higher risks for coronary
artery disease (8). Animal studies have
shown that a deficiency in the LDL receptor
(LDL-R) is associated with a delayed chy-
lomicron remnant removal (9-11). Castro
Cabezas et al (12) have demonstrated a small
but significant postprandial increase in
retinyl palmitate concentration in the chy-
lomicron remnant fraction (Sf<1000) in het-
erozygous FH patients compared to nor-
molipidemic control subjects. However
Rubinsztein et al (13) did not observe any
accumulation of vitamin A labeled chylomi-
crons, IDL-sized remnants or chylomicron
remnants in homozygous FH patients. Addi-
tionally Kowal et al.(14) reported that only
5% of the binding capacity of the LDL
receptor was needed to remove chylomicron
particles, suggesting only a minor role for the
LDL receptor in the removal process of
lipoprotein remnants.
Several laborious methods, i.e. incorporation
of vitamin A as core label and HPLC analy-
ses of retinyl esters (RE) in isolated lipopro-
tein fractions or measurements of apo B48
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Both Familial Hypercholesterolemia (FH) and disturbances in postprandial
lipoprotein metabolism are both associated with premature atherosclerosis. The
effect of HMG-CoA reductase inhibitors on plasma cholesterol levels in patients
with Familial Hypercholesterolemia is well established, however, it is not known
whether postprandial lipoproteins are also influenced. In this case-controlled
intervention study, we investigated the effects of high dose Simvastatin on post-
prandial lipoproteins. We used a new method to analyze remnant lipoproteins
based on immunoseparation principle (RLP-Cholesterol assay), as well as the well
established measurement of retinyl ester (RE) analysis in plasma and in the
Sf<1000 fraction. Seven heterozygous FH patients and seven controls matched for
gender, age, BMI, TG and apo E genotype were enrolled in the study. Oral vitamin
A (retinyl ester, RE) fat loading test was performed at baseline in both groups and
after 3 month of high dose Simvastatin (80 mg/day) treatment in the FH patients.
Before treatment, FH patients had significantly higher fasting and postprandial
concentrations of lipoprotein remnants (plasma RLP-C: 42 ± 19 mg/dL and
AUC-RLPC: 415 ± 82 mg. L-1.h-1, respectively) than in controls (7 ± 3 mg/dL and
101 ± 35 mg. L-1.h-1; respectively, p<0.05), suggesting a delayed clearance of chy-
lomicron remnant particles in the FH patients. Treatment with Simvastatin signif-
icantly reduced both fasting and postprandial remnant lipoprotein cholesterol
concentrations (13 ± 3 mg/dL and 136 ± 53 mg. L-1.h-1; respectively, p<0.05 for
both). Postprandial RE in the Sf<1000 fraction, not total RE in plasma, were also
significantly higher in FH patients than in controls (24 ± 10 mg. L-1.h-1 vs. 6.3 ±
5.9 mg. L-1.h-1 P<0.05), but treatment with Simvastatin did not result in improve-
ment of the postprandial RE response, either in the Sf<1000 fraction or in plasma.
It is concluded that heterozygous FH patients have increased fasting and post-
prandial remnant lipoprotein concentrations. Treatment with Simvastin signifi-
cantly reduced the fasting and postprandial remnant-like particle cholesterol con-
centrations but did not result in improved postprandial RE response.
G
and apo B100 concentration in the different
lipoprotein fractions using SDS-PAGE, have
been used to study postprandial lipoprotein
remnant metabolism. The suitability of vita-
min A as a marker for chylomicrons and its
remnants has been criticized (15; 16). Incor-
poration of vitamin A by the enterocyte
occurs mostly in the larger sized chylomi-
cron particles in the late postprandial period
(17) as reflected by the delayed postprandial
RE response compared with the Apo-B48 in
the VLDL/chylomicron density fraction. A
new remnant lipoprotein method based on
immunoseparation principle (RLP-Choles-
terol assay) offers the possibility to separate
lipoprotein remnant particles using an
immunoaffinity gel with coupled monoclonal
antibodies against Apo B100 and Apo AI
(18; 19). In the unbound fraction cholesterol
and triglyceride concentrations in apo B48
particles (chylomicron-remnants) and apo E
enriched apoB100 (β-VLDL and IDL) parti-
cles are detected (20).
HMG-CoA reductase inhibitors (statins)
upregulate the LDL receptor and partly
inhibit hepatic apoB secretion (21) resulting
in an increased removal of LDL particles
from the circulation thereby improving the
atherogenic lipid profile. Their effects on
postprandial remnant metabolism have not
been completely established. Most studies
showed a tendency to decrease postprandial
triglyceride concentrations that appear to
correlate with the degree of fasting plasma
triglyceride reduction (22). Therefore we
investigated postprandial lipoprotein rem-
nant metabolism in heterozygous FH
patients and the effect of Simvastatin treat-
ment using RE analysis and the RLP-C assay
for remnant characterization. 
Methods
Subjects
This study was a substudy from the Express
multi-center study in which the safety and
efficacy was assessed of a high dose Simvas-
tatin (80 mg once a day) in heterozygous
patients with Familial Hypercholesterolemia
(FH). Patients were recruited from the lipid
clinic of the University Hospital Utrecht.
Diagnosis of heterozygous FH was made on
the basis of existing hypercholesterolemia (>
6.50 mmol/L), presence of tendon xanthomas
and hypercholesterolemia in at least one first-
degree relative (23). These patients were asked
to stop all lipid lowering drugs at least 8 weeks
before the study (washout period). At the end
of the washout period, patients were given
intravenous injection of heparin and then
blood samples were collected for lipoprotein
lipase (LPL) and hepatic lipase (HL) activity
measurements. On a separate day, patients
were given an oral fat loading test followed by
a 4-month treatment with Simvastatin in a
dose of 80 mg a day. Oral fat loading test was
repeated at the end of the treatment period.
Healthy, normolipidemic subjects with fasting
plasma cholesterol < 6.0 mmol/L and TG <
2.0 mmol/L were recruited by advertisement
to match the FH patients in their age, gender,
BMI, apoE genotype and fasting plasma TG
concentration. Exclusion criteria included dia-
betes, hepatic, renal or thyroid diseases and a
positive family history for cardiovascular dis-
eases and type 2 diabetes mellitus. Control
subjects also had an oral fat loading test. The
human investigation review committee from
University Hospital Utrecht and a national
committee representing the Express multi-
center study approved this study protocol and
written informed consent was obtained from
all participants.
Oral fat loading test
After an overnight fast (12 hrs), participants
were admitted to the metabolic ward at 7.30
h am. Cream (consisting of 40% fat (w/v)
with a P/S ratio of 0.06, 0.001% cholesterol
(w/v) and 2.8% carbohydrates (w/v)) was
given as a single fat load in a dose of 50 g fat
per m2 body surface area. After ingestion of
the cream supplemented with 120. 000 IU
aqueous vitamin A, 10 hourly venous blood
samples were collected from an indwelling
catheter in the antecubital vein into EDTA
containing tubes. All blood samples, protect-
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ed from light, were immediately put on ice,
centrifuged and analyzed. During the post-
prandial period, the subjects were allowed to
drink only water or tea without sugar. None
of the subjects experienced gastrointestinal
complaints after drinking the cream.
Laboratory measurements
Plasma was obtained by centrifugation at
3000 rpm for 15 min at 4°C. Plasma TG and
cholesterol were analyzed in duplicate and
measured with an enzymatic colorimetric
assay (Monotest cholesterol kit no. 237574
and GPO-PAP no. 701912, Boehringer
Mannheim, Germany). LDL cholesterol was
calculated with the Friedewald formula (24)
in the control subjects and determined with
ultracentrifugation as described by Redgrave
et al (25) in FH patients. Cholesterol was
analyzed in the HDL fraction isolated by the
heparin-MnCl2 dextran-sulphate precipita-
tion method (26). Plasma apo E concentra-
tions (mg/L) and plasma apo CIII concen-
trations (mg/L) were determined with a
commercial test kit using the electroimmuno-
diffusion technique (CV < 7.5%) (Hydragel
LP E Ref. 4058 and LP CIII, Sebia Inc.
USA). Apo E genotype was determined as
described by Dallinga-Thie et al (27). Plasma
for LPL and HL was obtained 20 minutes
after intravenous injection of 50 IU/kg of
heparin. Postheparin Lipoprotein lipase
activity and hepatic lipase activity were
assayed as described previously (28; 29).
Non-esterified fatty acids (expressed as nmol
free fatty acids (FFA) min-1 (mU) per mL)
were measured with an enzymatic assay
(WAKO chemicals, Neuss, Germany).
Assessment of lipoprotein remnants
Lipoproteins were separated in a single ultra-
centrifugation step by flotation in a Sf>1000
fraction which contains chylomicrons, large
chylomicron remnants and large hepatic
triglyceride rich lipoproteins, and a remain-
ing infranatant fraction (Sf<1000) contain-
ing small chylomicron remnants and all the
other lipoproteins (30; 31). In both fractions
retinyl-ester concentrations were determined
using high-performance liquid chromatogra-
phy (HPLC) as described by Ruotolo et al
(32).
The RLP fraction was prepared using an
immunoseparation technique described by
Nakajima et al (18; 19). Briefly, 5 µl of serum
was added to 300 µl of mixed immunoaffinity
gel suspension containing monoclonal anti-
human apo A-I (H-12) and anti-human apo
B100 (JI-H) antibodies (Japan Immunore-
search Laboratories, Takasaki, Japan). The
reaction mixture was gently shaken for 120
minutes at room temperature. After standing
for 15 minutes 200 µl of the supernatant was
withdrawn for the assay of RLP-C. Choles-
terol in the RLP fraction (CV% <3) was
measured by an enzymatic assay using an
automatic chemistry analyzer (Cobas Mira
autoanalyzer, ABX, USA).
Statistical Analysis
Data are presented as means ± SD, unless
stated otherwise. Area under the integrated
curve was calculated using data from the first
8 hours after start of the oral fat loading test
for postprandial TG, RE and RLP-C using
GraphPad Prism software (version 3.1, San
Diego, California, USA). Normality was
tested with the Kolmogorov-Smirnov test. If
non-Normality occurred, data were normal-
ized by log-transformation. The effects of
Simvastatin treatment was tested by a paired
Student’s t-test. Comparisons between FH
patients and controls were tested by two-
tailed unpaired Student’s t-test. Pearson’s
correlation or Spearman’s rank correlations
were applied to evaluate relationships
between parameters. A two-sided p-value <
0.05 was considered to be significant. Statis-
tical analysis was performed with Graphpad
InStat version 3.00 for Windows 95, Graph-
pad Software, San Diego, California, USA.
Results
Study Population
Characteristics of the subjects were summa-
rized in Table 1. Both FH patients and con-
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trol subjects were normotriglyceridemic. FH
patients have significantly increased fasting
plasma cholesterol, LDL cholesterol, apo B
and apo E concentrations and decreased
HDL cholesterol concentrations compared
to control subjects. After Simvastatin treat-
ment plasma cholesterol, LDL cholesterol
and apoB concentrations significantly
decreased, whereas plasma apo E levels
remained significantly elevated. Due to sub-
ject selection criteria, fasting TG concentra-
tions did not differ significantly between the
FH and control groups. No significant dif-
ferences in postheparin LPL and HL activi-
ties were found in FH patients and control
subjects. Simvastatin treatment did not
change the LPL and HL activities.
Postprandial responses
Postprandial TG responses
After the fat load, maximal postprandial plas-
ma TG concentrations were reached at 4
hours and were higher in FH patients than in
matched control subjects, 2.61 * 0.50
mmol/L vs. 1.66 * 0.53 mmol/L (P=0.02).
(Figure 1). Area under the TG curve (AUC-
TG) was also significantly higher in FH
patients, after correction for baseline plasma
TG concentrations the ∆AUC-TG in FH
patients was not significantly different from
that in control subjects (Table 2). Simvastatin
treatment did not result in improvement of
postprandial plasma TG concentration,
AUC-TG and ∆AUC-TG.
Postprandial RLP-C responses
Fasting plasma RLP-cholesterol concentra-
tions (RLP-C) were significantly higher in
FH patients than in control subjects
(P<0.05, Figure 2). After Simvastatin treat-
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Table 1: Characteristics of patients with Familial Hypercholesterolemia and control subjects.
FH FH Controls
Simva (-) Simva (+)
n 7 7 7
Male 4 4 4
Age (y) 46.7 (6.9) - 47.7 (6.9)
BMI 25.5 (1.5) 25.8 (1.7) 25.23 (1.63)
Cholesterol (mmol/L) 12.12 (1.86)##  $$ 6.34 (1.11)# 5.11 (0.640
TG (mmol/L) 1.39 (0.4) 1.36 (0.4) 0.91 (0.3)
HDL-cholesterol (mmol/L) 0.94 (0.22)#  $$ 1.03 (0.32) 1.51 (0.47)
LDL-cholesterol (mmol/L) 10.28 (1.6)##  $$ 4.78 (0.91)## 3.18 (0.64)
Apo B (mg/L) 210 (21) ##  $$ 140 (15)## 92 (14)
Apo CIII (mg/L) 25.82 (7.56) 21.36 (7.44) 27.44 (9.88)
Apo E (mg/L) 62.29 (8.88)# 60.30 (12.63)# 43.48 (10.10)
LPL activity (mU/mL) 171 (50) 164 (48) 158 (33)
HL activity (mU/mL) 543 (269) 398 (146) 343 (174)
All values are expressed as mean ± SD. Simva (-) indicates without Simvastatin treatment and Simva(+) indicates with
Simvastatin treatment.  FH vs controls: # P<0.05 and ## P<0.01; treated vs. untreated: $ P<0.05 and $$ P<0.01.
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Figure 1. postprandial TG responses in patients with FH
without Simvastatin (‡), with Simvastatin (u) and the
matched control subjects (m ). Values are expressed as mean "
SEM. 
ment fasting plasma RLP-C concentrations
normalized and were similar to control sub-
jects. Fasting RLP-C correlated positively
with baseline plasma cholesterol (r=0.80;
p<0.01), TG (r=0.52; p<0.05), LDL-choles-
terol (r=0.79; p<0.01), apo B (r=0.84;
p<0.01) and apo E concentrations (r=0.52;
p<0.05). The maximal postprandial plasma
RLP-C concentration was reached between 2
and 4 hours and was significantly higher than
in control subjects (72.15 * 8.77 mmol/L vs.
18.00 * 2.63 mmol/L; P=0.004). So were the
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Table 2: Postprandial data for TG, retinyl esters and RLP-C
FH FH Controls
Simva (-) Simva (+)
Fasting plasma TG 1.39 (0.4) 1.36 (0.4) 0.91 (0.3)
AUC-TG 0-8h 16.4 (2.6)## 15.7 (4.8) 10.06 (3.3)
DAUC-TG 0-8h 5.35 (1.6) 4.96 (2.2) 3.62 (1.4)
Fasting RLP-C 42.10 (19.2)## 12.48 (10.8)$ 7.49 (7.8)
AUC-RLPC 414.82 (81.7)## 135.64 (52.9)$$ 101.22 (35.2)
DAUC-RLPC 120.77 (67.2)# 40.83 (29.1)$ 42.21 (22.2)
RE-AUC 51.35 (25.9) 50.48 (21.0) 28.00 (21.8)
Sf>1000 RE-AUC 19.07 (12.0) 27.60 (10.8) 17.29 (7.8)
Sf<1000 RE-AUC 24.05 (9.5)# 22.65 (11.4)# 6.34 (5.9)
All values are expressed as mean ± SD. Simva (-) indicates without Simvastatin treatment and Simva(+) indicates with
Simvastatin treatment. FH vs controls: # P<0.05 and ## P<0.01; FH patients treated vs. not treated: $ P<0.05 and $$
P<0.01. † DAUC indicates area under the incremental curve, after correction for baseline concentrations, calculated over
the first 8 hours..
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Figure 2. Postprandial remnant-like particle (RLP) respons-
es in FH patients without Simvastatin (‡), with Simvas-
tatin (u) and the matched control subjects (m ). Total plas-
ma RLP-cholesterol (panel A) and the incremental plasma
RLP-C (panel B) are presented. Values are expressed as
mean ± SEM.
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Figure 3. Postprandial retinyl esters (RE) response of patients
with FH without Simvastatin (‡) and with Simvastatin (u)
and the matched controls (m ). The total plasma RE (Panel
A)and the Sf<1000 RE (panel B) are presented. Data are
expressed as mean ± SEM.
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area under the RLP-C curve (AUC-RLP-C)
and DAUC-RLP-C (Table 2). Simvastatin
treatment resulted in a significant decrease in
maximum postprandial RLP-C concentration,
AUC-RLPC (P<0.01) and DAUC-RLP-C
(P<0.05) in the FH patients.
Postprandial retinyl ester response
Maximal postprandial plasma retinyl ester
concentrations were reached at 4 hours and
were higher, albeit not statistically signifi-
cant, in FH patients than in controls (10.97 *
2.22 mmol/L vs. 6.18 * 1.86 mmol/L; (Figure
3A)). There was no statistical difference in
area under the retinyl ester curve (AUC-RE)
between the FH and control subjects (Table
2). Treatment with simvastatin did not
decrease the maximal postprandial plasma
retinyl ester concentrations, nor AUC-RE in
the FH patients. AUC-RE in the Sf<1000
fraction was correlated with baseline plasma
TG (r=0.61; p<0.05), Apo B (r=0.49;
p<0.05) and Apo E concentrations (r=0.53;
p<0.05). Negative correlation between
AUC-RE in the Sf<1000 fraction and plas-
ma HDL cholesterol concentrations was
found (r= -0.54; p<0.05). Unlike total
retinyl esters, maximum postprandial plasma
retinyl ester concentrations and AUC-RE in
the Sf<1000 fraction were significantly high-
er in FH patients than in control subjects
(Figure 3B). However, like total retinyl
esters, Simvastatin treatment did not result in
improvement of the postprandial retinyl
ester in the Sf<1000 fraction.
Discussion
In the present study, specific monoclonal
antibodies for apo B100 and for apo AI have
been used to isolate remnant like-particles
(RLP). We observed higher fasting RLP-C
concentrations and an increased postprandial
RLP-C response in heterozygous FH
patients compared with matched control
subjects. Treatment with high dose Simvas-
tatin resulted in a significantly decreased
postprandial lipoprotein remnant concentra-
tion. The importance of detecting a disturbed
postprandial lipoprotein metabolism in FH
patients was recently stressed, because these
patients had significantly increased risks for
coronary artery disease (8; 33-37).
Hitherto, contradictory results about possi-
ble abnormalities in postprandial lipoprotein
remnant metabolism in FH patients were
reported. Different methodologies were used
to isolate lipoprotein remnants. Most studies
on postprandial lipoprotein remnant metabo-
lism in FH used vitamin A (retinyl esters) as
a core label for chylomicron particles. Studies
on postprandial lipoprotein remnants with
retinyl esters as a marker in homo- or het-
erzygous FH patients revealed either abnor-
malities (12; 38) or a normal removal of chy-
lomicron remnants (13; 31). We confirmed
an earlier report by Castro Cabezas et al (12)
that postprandial chylomicron remnants
reflected by retinyl esters in Sf<1000 frac-
tion were elevated in heterozygous FH
patients compared to matched control sub-
jects. In the fasting state and the early post-
prandial period (first three hours after a
meal) smaller sized chylomicrons (consid-
ered to be atherogenic) are secreted. Later in
the postprandial period, de-novo formed
larger chylomicrons are secreted. It has been
shown In-vivo that conversion of larger chy-
lomicron particles into smaller sized remnant
particles is a phenomenon that is not occur-
ring very frequently (39). Retinyl esters are
mostly incorporated in larger-sized chylomi-
cron particles. This could be observed in our
study by the delay of retinyl ester appearance
in the blood. A similar observations was
reported for apo B48 and RE (40). We
hypothesize that apo B48 and RLP-C reflects
particles with identical behavior, whereas RE
marks the properties of intestinal postpran-
dial lipoprotein particles with a different
metabolic behavior.
The results suggest that secretion of larger
particles continued to be abnormal in FH
patients even after Simvastatin treatment. An
in vivo study in rats (41) supported the con-
cept that larger chylomicron particles were
removed by the liver via alternative pathways
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involving the LDL receptor related protein
(LRP) and proteoglycans. This process was
not influenced by LDL receptor modulation
(42). Therefore, even after high dose Simvas-
tatin treatment with its positive effects on
plasma cholesterol homeostasis, the periph-
eral pathway through which Sf <1000 retinyl
esters were removed was still saturated. In
contrast the removal of the smaller postpran-
dial plasma RLP-C levels decreased after high
dose Simvastatin therapy.
Our results showed for the first time
increased fasting and postprandial RLP-C
concentrations in heterozygous FH patients
despite normal TG concentrations in these
patients. It has been recognized that there is
a strong correlation between RLP-C and TG
concentrations. Therefore it has been argued
that TG measurements are sufficient to esti-
mate remnant concentrations. However, sev-
eral clinical studies (43; 44) demonstrated
that RLP-C offered independent assessment
for CHD risk in addition to TG. In the pres-
ent study we show that RLP-C and TG clear-
ly had different postprandial responses to
Simvastatin treatment therefore they are not
interchangeable (Figure 1 and 2). Secretion
of VLDL apo B100 was increased and hepatic
removal of VLDL/IDL particles by the liver
was decreased in untreated FH patients. As a
result plasma IDL and LDL concentrations
are increased in untreated FH. Therefore, the
increase in fasting RLP-C levels reflects
increasing levels of circulating IDL-like apo
B100/apo E remnant particles. Since removal
pathways are shared by RLP and IDL, accu-
mulation of IDL could be expected when
influx of RLP increased after a fatty meal.
Our observed postprandial RLP-C peak is a
reflection of this process and is the result of
accumulation of apo B48 remnant particles
and apo B100 / apo E enriched remnants.
The strong association of AUC-RLP-C with
baseline plasma apo B is suggestive for this
concept. After treatment with Simvastatin,
postprandial RLP-C concentrations in FH
patients was comparable to that observed in
control subjects. As a result of Simvastatin
intervention, hepatic secretion of precursor
lipoproteins, that eventually will become
IDL/LDL-density-like particles, decreased
whereas catabolism of apo B containing par-
ticles increased leading to less accumulation.
The role of apo E in this process is less clear.
Elevation of apo E levels in patients with FH
have been reported earlier (45). More exten-
sive studies are required to analyze the effect
of Simvastatin treatment on apo E in FH.
In conclusion, heterozygous FH patients
have a disturbed postprandial lipoprotein
metabolism. After Simvastatin treatment the
postprandial RLPC response was decreased
towards that of matched control subjects.
No differences were observed in postprandial
plasma retinyl ester response after treatment.
This observation stresses the importance of
the different approaches for analysis of post-
prandial lipoprotein remnant metabolism.
Additionally, response of lipoprotein rem-
nants that dominate the early postprandial
period can be modulated by Simvastatin
treatment, whereas the “later” and larger
plasma chylomicron particle concentrations
continued to be elevated. Improvement of
RLP-C response after Simvastatin treatment
in FH reduces the postprandial atherogenici-
ty of plasma in addition to lowering LDL-
cholesterol.
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amilial hyperchylesterolemia (FH) is a
disorder of lipoprotein metabolism
with an autosomal dominant mode of
inheritance. The underlying cause of FH are
mutations in the gene for the LDL-receptor
located on chromosome 19 (1). The athero-
genic lipoprotein phenotype in heterozygous
FH patients is defined by elevated plasma
LDL-cholesterol concentrations (2; 3). The
expression of the clinical phenotype varies
widely even in subjects with the same muta-
tion in the LDL-receptor gene. Recently, evi-
dence has accumulated that triglyceride rich
particles (TRP), such as very low density
lipoproteins (VLDL), VLDL remnants, chy-
lomicrons, chylomicron remnants, and inter-
mediate density lipoproteins (IDL) share
atherogenic properties (4-7). In addition, it
has been shown that plasma triglyceride-rich
lipoproteins remnants concentrations are ele-
vated in FH (8-10). A specific subspecies of
these lipoprotein remnants can be measured 
with the use of an immunoseparation assay
that consist of an immuno-affinity mixed gel
containing anti-apolipoprotein (apo) A-I and
anti-apoB-100 monoclonal antibodies (11;
12). Plasma levels of RLP-C are elevated in
heterozygous FH patients independent from
plasma LDL-cholesterol (13; 14).  The rela-
tionship between elevated plasma RLP-C lev-
els and atherosclerotic disease is supported
by in vitro studies using rat aorta rings show-
ing a direct dose dependent effect of RLP on
endothelial function (15). In addition, plas-
ma RLP-C levels are positively associated
with the extent of carotid arterial wall thick-
ening as measured by intima-media thickness
(IMT), a surrogate marker of atherosclerosis,
in a cohort of healthy 50-year old men (16). 
In the present study, we investigate the rela-
tionship between parameters of the athero-
genic lipoprotein phenotype, including plas-
ma RLP-C, LDL-C and TG, and markers
representing  atherosclerotic burden, such as
carotid and femoral intima-media thickness
IMT in patients with heterozygous FH.
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Triglyceride (TG)-rich lipoproteins, such as remnant-like particles (RLP), are
related to an increased cardiovascular mortality in patients after a first ischemic
event. In patients with established heterozygous familial hypercholesterolemia
(FH) and elevated plasma triglyceride levels, plasma RLP-cholesterol (RLP-C)
concentration is increased, independent from plasma LDL-cholesterol levels. In
the present study plasma RLP-C concentrations were associated with the com-
bined carotid and femoral artery intima-media thickness. The effect of one-year
simvastatin treatment was evaluated. 
Methods and Results From the FH Express study, a subpopulation of 100 het-
erozygous FH patients was investigated. Plasma lipid profile (including total cho-
lesterol (TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), TG and
RLP-C) and IMT were analysed at baseline and after one year simvasatin treatment
(80 mg once daily). Plasma levels of TG, Cholesterol LDL-C and RLP-C decreased
with 35%, 37%, 46%, and 50% respectively  (all p<0.001) and HDL-C increased
with 11% (p=0.001). Baseline plasma RLP-C (r=0.29), TG (r=0.28), and LDL-C
(r=0.23) were positively associated with IMT (all p<0.001), and HDL-C and the
RLP-C/TG ratio did not show a significant correlation with IMT. In a multivariate
analyses both LDL-C and RLP-C were associated with IMT.  
Conclusions  Plasma RLP-C concentrations are increased in FH patients, and are
positively associated with IMT, but not independent from LDL-cholesterol. Con-
sequently, an increase in plasma RLP-C will extent the atherogenic lipoprotein
phenotype in FH patients and may play a role in the progression of atherosclerotic
disease in addition to LDL. Simvastatin reduces cardiovascular risk by decreasing
plasma lipid parameters including LDL-C and RLP-C.
F
Material and Methods
Patients
The present study is a sub-study (n=100
patients) of the FH ExPRESS study (Exami-
nation of Probands and Relatives in Simvas-
tatin Studies with Familial Hypercholes-
terolemia). This is an open label, multicenter
study, in which efficacy, safety, and pharma-
cogenetics of simvastatin 80 mg were
assessed in 526 heterozygous FH patients
(10; 17; 18). In short, patients were included
if they met the following criteria: all patients
had to have either a molecular diagnosis for
FH or the clinical diagnosis of FH. All par-
ticipating FH patients were informed thor-
oughly about the content of the study and
had to sign an informed consent. The study
protocol was approved by the ethical Review
Boards of the participating centres.   
Measurements of Lipoproteins
Fasting venous blood samples were obtained
at baseline and after one year simvastatin
therapy. Plasma was obtained by centrifuga-
tion at 3000 rpm for 15 min at 4∞C and
stored at -800C. TC, HDL-C, and TG were
routinely determined in the different labora-
tories and standardized by a virtual central
laboratory. LDL-C was calculated using the
Friedewald formula (19). Apolipoprotein A-I
(apo A-I) and apo B were determined by an
immuno rate-nephelometric procedure using
a polyclonal goat anti-human antibody
(Array protein system, Beckman Coulter,
Netherlands).
Measurements of RLP-C
The RLP fraction was prepared using an
immuno-affinity separation technique
described by Nakajima et al (11; 12). Briefly,
5 µl of serum was added to 300µl of mixed
immunoaffinity gel suspension containing
monoclonal anti-human apo A-I (H-12) and
anti-human apo B-100 (JI-H) antibodies
(Japan Immunoresearch Laboratories,
Takasaki, Japan). The reaction mixture was
gently shaken for 120 minutes at room tem-
perature followed by standing for 15 min-
utes. Then 200µl of the supernatant was
withdrawn for the assay of RLP-C. Choles-
terol (CV% <6%) in the RLP fraction were
measured by an enzymatic assay using a
Cobas Mira S auto-analyzer (ABX Diagnos-
tics, Montpellier, France).
Assessment of IMT 
The ultrasound scanning protocol was simi-
lar to that used in the ASAP study (20; 21).
In summary, all examinations were per-
formed by the same sonographer. A
Biosound phase-II ultrasound instrument
equipped with a 10 mHz transducer
(Biosound Esaote, USA) was used. Scans
were done at baseline and after one year of
statin therapy. Carotid arteries were scanned
bilaterally. Three 10 mm segments were
scanned: the distal portion of the common
carotid artery, the carotid bifurcation, and
the proximal portion of the internal carotid
artery. The 10 mm proximal to the femoral
dilatation, the common femoral artery seg-
ment, was scanned in the right femoral
artery. Images of segments were stored on
optical disk. IMT measurements of far walls
were performed. The image analysis was
done with Eurequa (Eurequa; TSA Company,
Meudon, France). Ultrasound images were
analysed by one reader blinded to any patient
information. Repeated scans were performed
regularly by the sonographer. The repeatabili-
ty had a coefficient of variation less than 5%. 
Statistical Analysis
Data are presented as mean ± SD, unless
shown otherwise. Treatment effect of simvas-
tatin on plasma RLP-C, other lipid parame-
ters, and IMT was assessed using Wilcoxon’s
matched-pairs signed-rank test. Association
between IMT on the one hand and baseline or
follow-up levels of plasma RLP-C and other
lipid parameters on the other was quantified
using Spearman’s rank correlation coeffi-
cient. Multivariant analysis of IMT on plasma
RLP-C and other plasma lipid parameters
jointly was done after rank transformation.
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Results
Only patients from the FH ExPRESS cohort
with available data on plasma RLP-C levels
and IMT data were included in the present
analysis. This subset of patients was not sig-
nificant different from the complete cohort
with regards to all measured parameters.
Characteristics and plasma lipid levels  at
baseline and after one year high dose simvas-
tatin treatment, are given in table 1. Baseline
plasma LDL-cholesterol and total cholesterol
were significantly elevated. Plasma triglyc-
eride levels ranged from 0.5 – 7.9 mmol/L.
Median plasma RLP-C levels were 0.40
mmol/L (range: 0.2-0.8). Upon simvastatin
80 mg, plasma TG (35%), TC (37%), LDL-
C (46%) levels decreased significantly ,
whereas plasma HDL-C and apo A-I levels
increased after treatment. Plasma RLP-C lev-
els decreased significantly to 0.2 mmol/L
(range 0.1-1.0 mmol/L), but only 34 patients
(34/100 patients) reached plasma RLP-C lev-
els within the normal range in our laboratory
(<0.2 mmol/l). 
Baseline mean combined IMT of the carotid
and femoral arteries was increased (1.05 ±
0.25 mm, Table 1). The femoral far wall
accounted for most of this increase. No sta-
tistically significant decrease in carotid and
femoral IMT was observed after one year
simvastatin treatment. A positive relation-
ship between baseline plasma RLP-C levels
and both IMT  parameters  was found (Fig-
ure 1). A linear association between plasma
RLP-C levels and far wall IMT was observed
for plasma RLP-C levels in a range from 0.2
to 0.6 mmol/l (table 2). Positive associations
were also found for plasma LDL-C and TG.
In a multivariate analysis (including plasma
TG, LDL-C and HDL-C), the significant
association between RLP-C and IMT was
lost when LDL-C was included into the
analyses. On the other hand, the association
with LDL-C was lost when RLP-C was
added to the equation.
After therapy, no association was found
between the decrease in plasma RLP-C levels
and change in IMT (p>0.20). However,
baseline and far wall IMT 1.02 (SD 0.22 mm,
p=0.03) was found to be lower in 34/100
patients who respond upon treatment with a
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Table 1: Characteristics of 100 patients with baseline RLP-measurement and IMT measurements.
Baseline after treatment P-value*
Male gender: n (%) 53 (53%) - -
Age (year): mean (SD) 45.4 (13.6) - -
BMI (kg/m2): mean (SD) 24.7 (3.1) - -
TC (mmol/L): mean (SD) 10.2 (2.0) 6.4 (1.6) <.0001
TG (mmol/L): median (min-max) 1.7 (0.5 – 7.9) 1.1 (0.4 – 7.1) <.0001
HDL-C (mmol/L): mean (SD) 1.4 (0.3) 1.5 (0.4)
LDL-C (mmol/L): mean (SD) 8.0 (1.9) 4.3 (1.5) <.0001
ApoA-I (g/L): mean (SD) 1.3 (0.2) 1.4 (0.3)
ApoB (g/L): mean (SD) 2.0 (0.4) 1.2 (0.4) <.0001
RLP-C (mmol/L): median (min-max) 0.4 (0.2 – 3.2) 0.2 (0.1 – 2.7) <.0001
IMT total (mm): mean (SD) 0.99 (0.21) 0.98 (0.20) 0.11
Far wall IMT (mm): mean (SD) 1.05 (0.25) 1.03 (0.23) 0.09
Near wall IMT (mm): mean (SD) 0.87 (0.20) 0.87 (0.21) 0.80
CFA IMT (mm): mean (SD) 1.82 (0.75) 1.85 (0.62) 0.94
* P-value of paired t-test, or Wilcoxon matched-pairs signed-ranks test; CFA = common femoral artery.
decrease in  plasma RLP-C below normal lev-
els (<0.20 mol/L) as compared to 66/100
patients who responded upon therapy with a
decrease in plasma RLP-C levels which did
not reach the normal value (plasma RLP-C >
0.20 mmol/L). Similar results were found for
CFA IMT (p=0.04). 
Discussion
In this study, we showed that baseline plasma
RLP-C levels in patients with FH are associ-
ated with IMT as a validated marker for ath-
erosclerosis. However, in multivariate analy-
sis, both LDL-C and RLP-C were correlated
with endothelial function, but either one or
the other sufficed for predicting IM level.
Univariately RLP-C correlated stronger with
IMT than LDL-C, but the difference was not
statistically significant. A one-year treatment
period with simvastatin (80-mg od)
decreased plasma RLP-C levels significantly,
as has been shown before (13; 22). 
Lipoprotein remnants are involved in the
progression of atherosclerotic disease and are
related to later occurring cardiovascular
ischemic events (23). Inclusion of triglyc-
eride-rich particles as an additional risk fac-
tor in the atherogenic lipoprotein profile has
Remnant lipoprotein levels and carotid intima media thickness in patients
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Table 2: Mean (SD) of IMT data in quartiles of baseline RLP-C
Plasma RLP-C IMT Far wall Near wall CFA 
total IMT IMT IMT
<0.34 mmol/L 0.93 (0.23) 0.98 (0.25) 0.85 (0.22) 1.66 (0.74)
0.34 – 0.47 mmol/L 0.94 (0.17) 1.01 (0.20) 0.81 (0.14) 1.78 (0.72)
0.47 – 0.80 mmol/L 1.07 (0.20) 1.14 (0.24) 0.93 (0.20) 2.07 (0.78)
> 0.80 mmol/L 1.06 (0.22) 1.12 (0.27) 0.92 (0.22) 1.85 (0.77)
P-value* 0.03 0.04 0.11 0.31
* P-value of one way ANOVA; CFA = common femoral artery.
Table 3: Spearman correlation coefficients of baseline IMT with baseline RLP-C, TG, LDL-C,
HDL-C, and RLPC/TG ratio
Plasma RLP-C IMT Far wall Near wall CFA 
total IMT IMT IMT
RLP-C 0.31 ** 0.29 ** 0.24 * 0.20 *
TG 0.27 ** 0.28 ** 0.11 0.22 *
LDL-C 0.28 ** 0.23 * 0.34 ** 0.18
HDL-C -0.08 -0.07 -0.02 -0.21 *
RLP-C/TG 0.04 -0.01 0.18 -0.09
* p<0.05; ** p<0.001.
proven to be a better indicator for cardiovas-
cular risk in patients with CVD or type II
diabetes mellitus than plasma LDL-C alone
(24). Elevated baseline plasma RLP-C levels
in patients with coronary artery disease
(CAD) predict future coronary events, inde-
pendently of other risk factors (including
plasma LDL-C). This observation is in line
with Karpe et al (16), who also showed a
relationship between plasma lipoprotein rem-
nants in CAD patients and carotid IMT,
independent of plasma TG and LDL-C. 
In this study, a positive association between
plasma RLP-C levels and IMT was found,
that was linear up to a plasma RLP-C con-
centration of 0.6 mmol/l after which this lin-
earity disappeared. A saturation of the pro-
atherogenic pathways (such as a maximal
amount of subendothelial retention of lipo-
protein remnants, and/or a limited possibility
to interact with other pro-atherogenic com-
ponents, i.e. smooth muscle cells) is suggest-
ed as a possibility to explain this relationship.
In vitro, RLP induce a dose dependent posi-
tive response in endothelial cells on the
expression of inflammatory markers (25) and
a negative effect on the expression of NO
synthesis. Moreover, lipoprotein remnants
were able to induce foam cells (26) .
In a cohort with patients with CAD (16) ,
the association of plasma RLP-C with IMT
was independent of plasma LDL-C. In the
present study we were not able to find an
association of RLP-C with IMT independent
from plasma LDL-C. In multivariate analyses
both contributed to a similar extend but not
independent from each other. It is therefore
interesting, that a twofold decrease in plasma
LDL-C levels after 1 year of treatment was
not beneficial for to both carotid and femoral
IMT. Significant IMT decrease was observed
after two years of treatment, but plasma
RLP-C levels were not determined at this
time point. IMT at two years was related to
baseline plasma RLP-C, but IMT change not.
In the ASAP study (21) a lower dose simvas-
tatin treatment (40 mg once a day) in het-
erozygous FH patients on the IMT was
observed, despite a reduction of 41 % in plas-
ma LDL-C levels. On the other hand, ator-
vastatin treatment (80-mg od) result in a
decrease in LDL-C 50% together with a
decrease in IMT. This small difference in
LDL-C reduction may not account for the
beneficial effect of atorvastatin on IMT. In
the ASAP study, baseline plasma TG concen-
trations were positively associated with IMT
and may explain part of the observed differ-
ences. 
In conclusion, we observed an association
between plasma RLP-C levels and combined
carotid IMT in heterozygous FH patients.
This observation further supports the
hypothesis that a complete atherogenic lipid
phenotype in FH patients should include
analysis of plasma RLP-C levels. Simvastatin
lowered significantly plasma TC, TG, RLP-C
and LDL-C. The decrease in cardiovascular
disease risk may therefore be augmented by
statin induced RLP-C reduction.
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1.12
The atherogenic plasma remnant-like
particle cholesterol (RLP-C) concentration
is increased in the fasting and postprandial
state in active acromegalic patients
Departments of Internal Medicine and Endocrinology, University Medical Center Utrecht
(UMCU), Utrecht, the Netherlands
cromegalic patients suffer from an
increase in cardiovascular mortality
(1) that is related both to an impair-
ment of heart function (2) and premature
atherosclerosis (3). The etiology of prema-
ture atherosclerosis in acromegaly is related
to unfavorable changes in lipoprotein metab-
olism, insulin resistance and a disturbed fibri-
nolysis (4) (elevations of t-PA, PAI and fib-
rinogen (5)). Increased plasma levels of total
cholesterol, LDL-cholesterol and triglyc-
erides, as observed in patients with active
acromegaly, characterize the dyslipidemia. In
addition, there is increased evidence that
lipoprotein remnants, dominating in the
postprandial state, are highly atherogenic and
related to increased susceptibility of coro-
nary artery disease. In in vitro studies,
lipoprotein remnants have an equivalent
potency as oxidized-LDL to induce foam
cells (6;7). In patients with manifest coro-
nary artery disease (8) and patients with an
increased cardiovascular risk (9-13) the post-
prandial TG-rich lipoprotein remnant levels
were increased. No data are available yet on
postprandial lipoprotein remnant metabo-
lism in patients with acromegaly. We hypoth-
esize that postprandial lipoprotein remnants
in patients with active acromegaly are related
to the etiology of premature atherosclerosis.
162
Premature atherosclerosis is a clinical feature in untreated acromegaly. Increased
postprandial lipoprotein remnant levels are associated with premature atheroscle-
rosis. In most studies, remnants were measured indirectly using retinyl esters (RE)
as a chylomicron core label. Remnants can also be directly quantified by
immunoseparation using monoclonal antibodies to apo AI and apo B100 to
remove non-remnant lipoproteins. Cholesterol is quantified in the remaining apo
E-rich remnant fraction (RLP-C). The outline of the present study is to investi-
gate the role of postprandial lipemia in patients with acromegaly to further define
abnormalities leading to increased susceptibility for atherosclerosis. In a case-con-
trolled study, the plasma postprandial lipoprotein remnant fraction (RLP-C and
RE) were analyzed in 6 patients with active acromegaly (F/M: 2/4; age: 53 ± 9;
BMI: 29 ± 4 kg/m2) and in 6 normolipidemic control subjects (matched for age,
gender, BMI and apo E genotype). They underwent an oral vitamin A fat loading
test. Baseline plasma triglycerides (TG) were not significant different in patients
(1.75 ± 0.71 mM) and controls (1.15 ± 0.46 mM). Lipoprotein Lipase (LPL) activi-
ty was significantly lower in patients than in controls (108 ± 21 vs.141 ± 19
mU/mL, respectively; p<0.05). Baseline plasma apo E levels were higher in
patients (60.8 ± 7.9 mg/L) than in controls (48.3 ± 5.9 mg/L; p<0.05). No differ-
ences were found in the area under the postprandial TG curve (AUC-TG), the
incremental AUC-TG (DAUC-TG) and AUC-RE in the Sf<1000 remnant frac-
tion. However, fasting plasma RLP-C concentrations, isolated by immunosepara-
tion, were increased in patients with active acromegaly (0.41 ± 0.13 mM) as com-
pared to control subjects (0.20 ± 0.07 mM; p<0.05). Incremental postprandial
RLP-C response (corrected for fasting values) was also significantly elevated in
patients (2.14 ± 1.19 mM*h) than in the controls (0.86 ± 0.34 mM*h; P<0.05). In
both groups, the maximal RLP-C concentration was reached between 2 and 4
hours. In conclusion, the atherogenic postprandial remnants, represented by RLP-
C, were significantly elevated at baseline and in the postprandial period, whereas
the larger-sized remnants, represented by RE (Sf<1000), were not different from
controls. The disturbances in the postprandial RLP-C response increased the sus-
ceptibility for premature atherosclerosis as observed in patients with acromegaly.
A
Most studies on postprandial dyslipidemia
used retinyl-ester (RE) as a marker for chy-
lomicrons and its remnants. However, the
specificity of retinyl-esters as marker is
under debate, as it appears that RE transfer
to other lipoprotein fractions in the post-
prandial period. Recently, a separation proce-
dure for lipoprotein remnants based on
immunoseparation with specific apo B100
and apo AI antibodies (14;15) was intro-
duced. This separation method enables us to
isolate more specifically the remnant-like
particles (RLP). We recently showed
(Schreuder et al, Atherosclerosis in press)
that remnant-like particle cholesterol (RLP-
C) is an excellent marker for postprandial
lipemia in vivo. Increased plasma postprandi-
al RLP-C levels in untreated patients with
heterozygous familial hypercholesterolemia
(FH) were found, whereas statin treatment
completely normalized fasting and postpran-
dial plasma RLP-C levels (Twickler et al
2000). Furthermore, in patients with growth
hormone deficiency we observed increased
levels of fasting and postprandial RLP-C
accompanied by an impaired endothelial
function. Treatment with recombinant
Growth Hormone resulted in a significant
decrease of postprandial RLP-C and
improvement of endothelial function (Twick-
ler et al 2000).
In the present case-controlled study we
investigated, whether in patients with active
acromegaly, disturbances in postprandial
lipoprotein remnant metabolism after an oral
fat loading test, as reflected by abnormalities
in RLP-C, occurred.
Patients and Methods
Patients
Acromegalic patients had been recruited from
the outpatient clinic of the department of
Internal Medicine and Endocrinology from
the University Hospital Utrecht. Active
acromegaly was defined as non suppressibility
of (increased) plasma GH concentrations
after an oral glucose load. The purpose of the
present study is to study the effects of the
presence of excess growth hormone on lipid
metabolism, specifically on disturbances in
postprandial lipoprotein remnant metabo-
lism. Therefore we excluded patients with
increased fasting plasma lipids (fasting plasma
cholesterol > 6.5 mM and/or TG > 2.3 mM),
Body Mass Index (BMI) > 30, renal and/or
liver disease, diabetes mellitus (DM),
apolipoprotein E2/E2 genotype, and a family
history of premature atherosclerosis and/or
non-insulin dependent diabetic mellitus.
Before the start of the study, all patients had
been on treatment with a short term acting
Sandostatin®. The study was performed when
the patient was at the end of a six-week off
treatment period to restart a long acting San-
dostatin Lar®. The hormone levels were meas-
ured at 13.00 pm. Because of the skewed dis-
tribution we present the average data and the
range: cortisol: 0.24 µM (range: 0.1 - 0.4 µM,
testosteron: 14.7 nM (range: 8.8 - 20 nM),
TSH: 1.06 mU/L (range: 0.13 - 2.4 mU/L),
and f-T4: 13.4 pM (range: 9 - 16 pM). Nor-
molipidemic (fasting plasma cholesterol <
6.0 mM and TG < 2.3 mM) healthy control
subjects, matched for age, gender, and BMI
were selected by advertisement. They had no
diabetes, no hepatic, renal, thyroid or cardiac
dysfunction and a negative family history for
cardiovascular diseases. The study protocol
was approved by the human investigation
review committee of the University Hospital
Utrecht. Written informed consent was
obtained from all participants.
Oral fat tolerance test
After an overnight fast of 12 h, participants
were admitted to the metabolic ward at 7.30
h am. Cream (consisting of 40% fat (w/v)
with a P/S ratio of 0.06, 0.001% cholesterol
(w/v) and 2.8% carbohydrates (w/v)) was
given as a single fat load in a dose of 50 g fat
per m2 body surface area. Vitamin A was
added to the cream in a dose of 60.000 IU
aqueous retinyl palmitate (RP) per 50 g fat
(125 ml cream). After ingestion of the cream,
venous blood samples were taken hourly
from an indwelling catheter in the antecu-
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bital vene during 10 hours. Blood was col-
lected in EDTA containing tubes. All blood
samples were immediately put on ice. During
the test only water or tea without sugar were
allowed to drink. None of the subjects vom-
ited or suffered from diarrhea after drinking
the cream.
Analytic methods
Plasma was obtained by centrifugation at
3000 rpm for 15 min at 4°C. Plasma TG and
cholesterol were analysed with a colorimetric
assay (Monotest cholesterol kit no. 237574
and GPO-PAP no. 701912, Boehringer
Mannheim, Germany). Cholesterol was
determined in the HDL fraction isolated by
the permangate precipitation method (16).
Low-density lipoprotein (LDL)-cholesterol
was calculated with the Friedewald Formula
(17). Apolipoprotein (apo) B concentrations
were analysed on the Cobas Mira autoanalyz-
er (Unimate 3 Apo B, Roche Diagnostics).
Plasma apo E concentrations and plasma apo
CIII concentrations were determined with
the use of electroimmunodiffusion
(Hydragel LP E Ref. 4058 and LP CIII Ref.,
Sebia Inc. USA). The coefficient of variance
for plasma total apo E and plasma apo CIII
concentrations was less than 7.5%. Plasma
Insulin and IGF-1 concentrations were
determined with a radio-immuno assay. Apo
E genotype was analysed as described (18).
Postheparin lipolytic enzyme activities were
measured as described before (Twickler et al
2000). HOMA-index (fasting glucose*fast-
ing insulin/22.5) was calculated to estimate
the insulin resistance. Body composition was
performed with the bioimpedance measure-
ments, as described before (19). The waist to
hip ratio (WHR) was determined as the ratio
of the circumference at the waist and hip
level.
Assessment of postprandial lipoprotein rem-
nants
Lipoproteins were separated by flotation in a
Sf>1000 fraction which contains chylomi-
crons, large chylomicron remnants and large
hepatic triglyceride rich lipoproteins, and a
remaining infranatant fraction (Sf<1000)
containing small chylomicron remnants and
all the other lipoproteins (20;21). Retinyl
Ester (RE) concentrations in plasma and in
the Sf > 1000 and Sf<1000 fraction were
measured with the high-performance liquid
chromatography (HPLC) as described (22).
Recoveries of RE in the Sf>1000 and
Sf<1000 in comparison with plasma RE were
between 80 and 105%.
The RLP fraction was prepared using an
immunoseparation technique described by
Nakajima et al (14;15). Briefly, 5 µl of serum
was added to 300 µl of mixed immunoaffinity
gel suspension containing monoclonal anti-
human apo AI (H-12) and anti-human apo
B100 (JI-H) antibodies (Japan Immunore-
search Laboratories, Takasaki, Japan). The
reaction mixture was gently shaken for 120
minutes at room temperature followed by
standing for 15 minutes. Then 200 µl of the
supernatant was withdrawn for the assay of
RLP-C. Cholesterol (CV% <3) in the RLP
fraction was measured with the use of an
enzymatic assay on a Cobas Mira S auto-ana-
lyzer (ABX Diagnostis, Montpellier, France).
Statistical Analysis
Data are presented as means ± SD, unless
shown otherwise. Area under the integrated
curve (and corrected for baseline values) was
calculated for the postprandial TG, RE and
RLP-C response using GraphPad Prism soft-
ware (version 3.1, San Diego, California,
USA). Baseline values between patients with
acromegaly and control subjects were com-
pared with the use of the unpaired t-test.
Pearson’s correlation or Spearman’s rank cor-
relation were applied to evaluate relation-
ships between parameters. A two-sided P
value of 0.05 was considered significant.
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Results
Characteristics of the subjects
The patients with active acromegaly were
strictly matched with the control subjects for
age, gender, and BMI. Baseline characteristics
are shown in table 1. No significant differ-
ences were found in fasting plasma choles-
terol, plasma LDL-cholesterol, plasma HDL,
plasma apo B and apo C-III between patients
and controls. Although plasma triglycerides
levels were higher in patients with active
acromegaly than in controls, this difference
did not reach the level of statistical signifi-
cance. Total plasma apo E concentration was
significantly higher in the acromegalic
patients (60.8 ± 7.9 mg/L) than in the con-
trol subjects (48.3 ± 5.9 mg/L; p<0.05). The
fasting plasma insulin levels and the HOMA-
index were similar in both groups. As expect-
ed, the plasma IGF-1 levels were significantly
higher in acromegalic patients than in the
controls. Plasma IGF-1 concentration was
positively correlated with HOMA-index
(r=0.64;p=0.02), and plasma apo E concen-
tration (r=0.72;p=0.01). Plasma postheparin
HL activity was similar in both groups but
the plasma postheparin LPL activity was sig-
nificantly decreased in patients with active
acromegaly (P < 0.05).
Postprandial TG responses
After the oral fat load, the maximal postpran-
dial plasma TG levels (2.25 ± 0.80 mM) were
reached at 3 hrs in the control subjects,
whereas in the acromegalic patients maximal
TG levels (2.97 ± 1.20 mM) were reached at
4 h as shown in Figure 1A. The areas under
the curve (AUC-TG) and the incremental
area under the curve (∆AUC-TG) measured
over an 8 h postprandial interval for plasma
TG were not significant different between
the acromegalic patients and the control sub-
jects (Table 2). The postprandial plasma RE
Fasting and postprandial RLP-C in acromegaly
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Table 1: Characteristics in the acromegalic patients and the control subjects. 
Acomegaly Controls
n 6 6
Male/Female 4/2 4/2
Age (yrs) 53 (9) 54 (10)
BMI (kg/m2) 28.5 (3.7) 27.5 (2.9)
FM (kg) 21.38 (5.1) 20.3 (3.7)
FM% 24 (6) 25 (6)
W/H ratio 0.93 (0.18) 0.89 (0.07)
Cholesterol (mMl) 5.07 (0.86) 5.20 (0.90)
TG (mM) 1.75 (0.71) 1.15 (0.46)
HDL-cholesterol (mM) 1.27 (0.23) 1.40 (0.28)
LDL-cholesterol (mM) 3.03 (0.90) 3.33 (0.80)
Apo-B (g/l) 0.98 (0.22) 0.96 (0.27)
Apo-CIII (mg/l) 32.90 (6.62) 32.51 (5.28)
Apo-E (mg/l) 60.77(7.94)* 48.25 (5.93)
Insulin (mU/l) 12.0 (3.52) 10.7 (2.42)
HOMA-index 2.81 (1.07) 2.46 (0.52)
IGF-1 (ng/ml) 717(365)* 172 (29)
LPL(mU/ml) 108 (21)* 141 (19)
HL(mU/ml) 413 (204) 459 (187)
All values are expressed as mean (SD). Acromegaly vs controls: * P<0.05 .
response reached its maximum level at 5 h
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Table 2: Integrated areas under the curve (AUC) of the postprandial TG response,  postpran-
dial plasma RE and non-chylomicron RE Sf<1000 response and postprandial RLP-C response. 
Acomegaly Controls
Plasma TG 1.75 (0.71) 1.15 (0.46)
AUC-TG 17.09 (6.57) 14.14(6.01)
∆AUC-TG 5.31 (3.6) 5.40 (2.55)
AUC-RE 42.00 (19.03) 39.05 (28.46)
Sf<1000 AUC-RE 16.65 (7.03) 14.18 (10.76)
Plasma RLP-C 0.40 (0.13)** 0.20 (0.07)
AUC RLP-C 4.78 (1.70)* 2.48 (0.74)
∆AUC RLP-C*** 2.14 (1.19)* 0.86 (0.34)
All values are expressed as mean (SD). Acromegaly  vs controls: * P<0.05 and ** P<0.01. *** ∆AUC indicates area under
the response curve after correction for baseline concentrations.
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Figure 1. Postprandial responses for the acromegalic patients
(u) and control subjects (m ). Total plasma-TG (panel A),
the incremental plasma RE (panel B) and RE concentra-
tions in the non-chylomicron fraction (Sf<1000) (panel C)
are presented. Values are presented as mean ± SEM
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Figure 2. Postprandial remnant-like particle (RLP-C)
responses for the acromegalic patients (u) and control sub-
jects (m ). Total plasma RLP-C (panel A) and the incremen-
tal plasma RLP-C (panel B) are presented. Values are pre-
sented as mean ± SEM.
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after the oral fat load in the control subjects
and at 4 h in the acromegalic patients (Figure
1B). The area under the curve during an 8 hr
postprandial interval (AUC-RE) for plasma
RE was similar in the acromegalic patients
(42 ± 19 mg*h/L) as compared to the con-
trol subjects (39.1 ± 28.5 mg*h /L). RE lev-
els in the Sf<1000 remnant fraction (Table 2)
were similar in controls and patients with
active acromegaly. The AUC-RE (Sf<1000)
was positively correlated with the BMI (r =
0.74; p<0.05).
Fasting plasma concentrations of RLP-cho-
lesterol (RLP-C) were significantly elevated
in acromegalic patients (0.41 ± 0.13 mM)
compared to control subjects (0.20 ± 0.07
mM; P<0.05). Fasting plasma RLP-C con-
centrations were positively correlated with
plasma apo E concentrations (r= 0.67; p =
0.02) and plasma triglycerides (r=0.88,
P<0.02). In both groups, the maximum level
of plasma RLP-C was reached between 2 and
4 hours after the oral fat load. The maximum
concentration was 0.40 ± 0.14 mM in con-
trol subjects and 0.76 ± 0.27 mM in
acromegaly patients (P<0.05). The AUC-
RLP-C was significantly increased (4.78 ±
1.70 mM*h/L) compared to control subjects
(2.48 ± 0.74 mM*h/L; P<0.05). If the
AUC-RLP-C data were corrected for base-
line values (∆AUC-RLPC) the differences
still remained statistically significant (Table
2). Positive correlations for AUC-RLPC
were found for fasting plasma TG (r = 0.62;p
= 0.03) and fasting RLP-C concentrations (r
= 0.77; p = 0.003) and a negative correlation
for postheparin LPL activity (r = -0.62; p =
0.04). Identical correlations were found for
the ∆AUC RLP-C.
Discussion
In the present study, we showed that patients
with active acromegaly, but without second-
ary causes of dyslipidemia, had elevated fast-
ing and postprandial lipoprotein remnant
(RLP-C) concentrations, whereas fasting
concentrations of total, LDL-cholesterol,
and HDL-cholesterol were similar to those
measured in control subjects matched for
age, gender, and BMI. The plasma TG levels
were elevated in acromegaly although this
did not reach the level of statistically signifi-
cance. The importance of RLP-C as an
atherogenic risk factor was established in a
number of different studies. In patients with
occlusive coronary artery disease the regres-
sion of the coronary diameter was strongly
associated with the decline in plasma RLP-C
(6). Moreover, increased fasting levels of
RLP-C were found in patients with coronary
artery disease and in non-insulin dependent
type 2 diabetic patients with microalbumin-
uria (23). Increased fasting RLP-C concen-
trations were also found in non-diabetic,
insulin-resistant, female subjects in contrast
to insulin-sensitive subjects (24). In line with
these observations, the increased fasting plas-
ma RLP-C levels in our study could con-
tribute to the increased susceptibility for
atherogenesis leading to premature athero-
sclerosis in patients with acromegaly. We
postulate that the increased fasting plasma
RLP-C, in active acromegaly, could be partly
explained by the relative increased state of
insulin insensitivity in our patients. The plas-
ma IGF-1 levels were positively associated
with the homeostasis model insulin resist-
ance index (HOMA-R). The HOMA-R
index was highly correlated with the data
obtained with euglycemic clamp studies in
both non-diabetic and diabetic individuals
(25) and is a simple measure for the state of
insulin sensitivity. Additionally, insulin
resistance decreased the activity of the hepat-
ic LDL-receptor that plays an important role
in the removal of lipoprotein remnants (26).
Simultaneously, the secretion of VLDL apo B
is increased (27). This phenomenon has
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already been observed in acromegaly (28),
although in our subset of patients no differ-
ences in plasma apo B levels were found. The
elevation of fasting plasma RLP-C levels in
patients with active acromegaly may also be
the results of the slightly increased plasma
triglyceride levels. It has been shown that
plasma triglycerides are a major determinant
for RLP-C levels because a correlation with
increasing plasma triglyceride level was
found (r=0.88, P<0.02). However, in a
recent published study in healthy elderly
men, it was found that RLP-C quantification
is a better assessment for cardiovascular risk
than measurements of LDL-cholesterol and
plasma triglycerides (Karpe et al 2001). This
observation is further established in the pres-
ent study.
The postprandial RLP fraction consisted of
apo B48 containing chylomicron remnants
and of apo B100 containing triglyceride-rich
remnants. Both apo B48 and apo B100 con-
taining lipoprotein particles share the same
lipolytic pathway mediated by LPL. Howev-
er, apo B48 containing particles exert a higher
affinity for LPL (29). We observed signifi-
cant decreased postheparin LPL activities in
patients with acromegaly. This is in agree-
ment with an earlier observation of decreased
LPL activity in acromegaly by Simsolo et al
(30). The incremental area under the post-
prandial RLP-C curve was negative correlat-
ed with postheparin LPL activity, indicating
that a low LPL activity is associated with an
increased postprandial presence of RLP-C.
No difference in postprandial profiles for
retinyl esters as well as total triglycerides was
found between the patients with active
acromegaly and control subjects. This fur-
ther showed that RLP-C measurement is a
more specific marker for postprandial
lipaemia than either total TG or retinyl
esters. In patients with heterozygous Famil-
ial Hypercholesterolemia we observed an
effect of statin treatment on the postprandial
RLP-C levels but not on the postprandial
Sf<1000 RE levels. Similarly, in patients with
growth hormone deficiency, abnormalities in
postprandial lipoprotein metabolism were
found that were linked to specific abnormali-
ties in RLP-C metabolism. Furthermore
Karpe et al (31) found that only the early
peak of ApoB48 remnants correlated to the
severity of coronary atherosclerotic lesions
and not the later postprandial peak of RE.
Moreover Kugiyama et al showed a close
association of the RLP-C with the impair-
ment of endothelium-dependent vasomotor
function in human coronary arteries (8).
Taken together, recent studies established the
importance of remnant-like particles in
atherogenesis. In the present study, we clear-
ly demonstrated that in active acromegaly
more remnant-like particles were present in
both the fasting and the postprandial state.
We postulated that the increased fasting
RLP-C levels could be a result of relative
insulin insensitivity and increased plasma
triglyceride levels, while the increased post-
prandial RLP-C levels could be additionally
explained by the lower postheparin LPL
activity. The increase in RLP-C levels may
contribute to the increased susceptibility of
premature atherosclerosis in acromegaly.
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ype 2 diabetes mellitus is generally
due to a combination of insulin resist-
ance and an impairment in insulin
secretion by the pancreatic B-cell (1). Origi-
nally, the insulin secretion capacity of the
pancreatic B-cell was considered as a commu-
nicative process of biological signals, such as
derived from meal composition and neural
input (2). Insulin secretion is known to adapt
to systemic needs for insulin, and in humans
systemic insulin profiles mostly reflect
peripheral sensitivity to insulin action (3).
We will here describe the importance of
growth factors, especially insulin-like growth
factors I and II, and their signalling pathways
for pancreas beta cell growth and function,
which have become more clear by the use of
animal models, and explore recent findings in
humans.
Plasticity of high differentiated cells
Recent ontological studies show a high plas-
ticity of highly differentiated cells with
respect to maturation and differentiation. In
contrast of what was thought before, highly
differentiated cells have an ability to reenter
the cell growth cycle on stimulation with
specific growth factors; pancreatic beta cells
have been shown to possess these properties
(4). It has not been elucidated whether this
interval of cell plasticity is limited in time
(prenatal or also later in adult life). Barker
hypothesized that especially the prenatal
period is of importance for the development
of functional tissues or organs and that dis-
eases later in adult life (such as hypertension
and type 2 diabetes) may have their origin in
disturbances of growth and the development
of functional tissue capacity (5). This would
also imply that a disease later in life may
result from a maladaptation due to reduced
capacity of functional tissues (6). In support
of Barker’s hypothesis, lower birth weight
has been shown to be associated with a
prevalence of type 2 diabetes (7). Since overt
diabetes mellitus results from a failure of
pancreatic beta cells to adapt to environmen-
tal demands, i.e. insulin insensitivity (1), the
effects of growth factors on pancreas beta
cells are of growing interest. But also in case
of a high plasticity of cells that continue to
form functional tissue during adult life,
defects in growth factors, such as the insulin-
like growth factor system, may potentially
give rise to a less adaptive capacity and there-
fore an increased susceptibility to disease (8).
A prerequisite in this situation is an increase
of a specific burden, i.e. insulin resistance
related to obesity, that needs to be compen-
sated for by functional tissues (i.e. B-cells)
which are limited by a reduced capacity,
and/or are limited in their adaptive growth.
Growth Factors in Humans
Expression of growth factors
GH, IGF-I and IGF-II are the principal
growth factors in humans. Their biological
action is dependent from the balance in the
total IGF system, that consists of IGF-I,
IGF-II and six IGF binding proteins (IGF
BP 1-6). The growth hormone (GH) axis is
functionally superimposed on the balances
that exist in the IGF system. Primary distur-
bances in the secretion of GH are therefore
associated with shifts in the balance of the
IGF system. GH is secreted by the adenopi-
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In this review, we highlight recent findings of the roles of various growth factors
for pancreas beta cell function with emphasis on the Insulin-like Growth Factors
(IGF). Signalling of insulin and the IGF system uses parallel (and interrelated)
pathways. There is a complex interplay between insulin receptor-dependent sig-
nalling and the signalling of the IGF-system in the development of the islet cells,
which has become apparent by various animal knock-out models. Recent know-
ledge about the influence of human gene polymorphisms relating to islet cell
function also sheds more light on the importance of the IGF system for pancreas
B-cell function.
T
tuitary in a 24 hours pulsatile secretion pro-
file, with a peak in the early morning. Other
cerebral structures (such as hypothalamus)
are involved in the regulation of GH secre-
tion; stimulation by GH Releasing Hormone
and ghrelin, and a reduction by somatostatin.
GH increases the expression of IGF-I in the
circulation (systemic IGF expression) and in
many tissues (local IGF expression), while
its effects on IGF-II are less clear. Moreover,
plasma levels of IGFBP-3 are increased by
GH stimulation. IGFBP-3 is the IGF bind-
ing protein that binds most of both IGF-I
and IGF-II. Due to the fact that IGF-II is
bound more avidly by IGFBP3, total plasma
IGF-II levels are roughly three times higher
than total plasma IGF-I in humans, and the
IGF-II pool is therefore larger than the IGF-
I pool. IGF-I has a negative feedback on GH
secretion.
Shared receptors for insulin and IGF network
The distinctive molecules IGF-I, IGF-II and
insulin bind to specific cell surface receptors.
Due to structural homologies among these
molecules, IGF-I also binds to insulin-recep-
tors (but with a lower affinity than insulin),
and recto-versa, IGF-I and IFG-II both bind
to IGF-1 receptors. In addition to these
cross-talks on the cell surface, insulin and
IGF-1 receptors share common (post-recep-
tor) intracellular signalling pathways, that
were presented in recent reviews (9-12).
The insulin receptor is a transmembranous
receptor, consisting of 2 extra-cellular alpha-
subunits, that display the epitope for insulin,
two membrane spanning beta-subunits and
an intracellular tyrosine kinase related part.
The IGF-receptor is related to the insulin
receptor, with a subsequent 80% structural
homology in the kinase domains (10).
Although the receptors are very common in
structure, the distributions over the various
tissues that are involved in the human insulin
resistance syndrome differ. In adipose tissue,
no IGF receptors are detected, in contrast to
the liver and muscle. These non-equal distri-
butions over several tissues have various
implications, and especially in a system that
is in imbalance, since signals may be become
effective in tissues that are not “allowed” to
receive.
I/IGF signaling
Insulin
Upon binding of insulin to extracellular
domains of the insulin receptor, the signal
transduction is mediated through intracellu-
lar beta-subunits that undergo autophospho-
rylation of tyrosine residues. After phospho-
rylation of these submembranous structures,
a cascade of phosphorylations of so-called
insulin receptor substrates (IRS) starts (13).
An intracellular distribution of insulin-like
signals is mediated along these IRS sub-
strates. Hitherto, four intracellular IRS (IRS
1-4) proteins have been isolated and the dis-
tinctive IRS proteins direct to different intra-
cellular pathways. In short, IRS-1 regulates
somatic cell growth and is involved in insulin
activity of muscle and adipose tissue (12).
IRS-2 is involved in insulin activity mainly in
liver, in brain growth, in reproduction, and in
pancreas beta-cell growth (14). The pathways
that are related to IRS-3 and IRS-4 are still
not elucidated, but these IRS proteins are
expressed in tissues of neuroendocrine and
adipose origin. IRS-3 and IRS-4 disruption
gives rise to normal (or even slightly lower)
plasma glucose and normal insulin levels
(13).
Upon phosphorylation of IRS proteins, the
Phospho-Inositol 3’ Kinase (PI3K) pathway
is activated. This pathway consists of multi-
ple subsequent phosphorylations, and gives
rise to the expression of insulins effects on
glucose homeostasis, such as enhancement of
glucose uptake and glycogen synthesis in
peripheral skeletal muscle, and inhibition of
gluconeogenesis and glycogenolysis in hepa-
tocytes, and inhibition of lipolysis in adipose
tissue (9). Moreover, the signal transduction
towards more downstream pathways of the
PI3K pathway results in additional insulin-
related effects, such as on protein synthesis,
gene expression, mitogenesis, and cell
growth (Table 1). Besides insulin-specific
glucose metabolism related pathways (like
IGF system and b-cell function, review
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PI3K), several other intracellular cascades are
activated. After the phosphorylation step of
PI3K, several major pathways involves acti-
vation of grb2, SOS, RAS, and MAPK,
whereas another pathway involves mTOR
(mammalian Target Of Rapamycin) and PKB
(PhosphoKinase B) activation (10).
IGF-I
IGF-I mainly acts via the IGF-1 receptor
(IGF-1r). IGF-I has a critical role in fetal and
post-natal growth. Knock-out mice homozy-
gous null for either IGF-I or the IGF1R
weigh only half the size of the wild-type ani-
mals (15). The IGF-1R has structural homol-
ogy with the insulin receptor, and upon its
activation, partly identical transduction path-
ways as for insulin are activated via IRS-2,
followed by activation of PI3K and mTOR,
but also of MAPK, both leading to mitogen-
esis (Table 1).
IGF-II
IGF-II can also bind to IGF-1R, but in addi-
tion also to the so-called Type-2 insulin-like
growth factor receptor (IGF2R, also known
as the IGF-6 mannose or IGF-M6 receptor),
that has four distinct binding domains, which
can bind IGF-II, mannose-6-phophate con-
taining lysosomal enzymes, retinoic acid, and
urokinase-type plasminogen activator recep-
tor (16). This receptor has a role in the
degradation of IGF-II, and may function as a
tumor suppressor gene (16). In epigenetic
phenomena occurring during gametogenesis,
leading to silencing of either a maternal or a
paternal allele, the expression of IGF-II and
IGF-II related genes were recently found to
be key factors in the development of tumors,
such as Wilm’s tumor and adenocarcinoma of
the colon (17). However, also in adjacent
colon tissue these epigenetic processes are
found, which may suggest a more general
field defect. So far, no extrapolation of these
epigenetic results with IGF-II have been
made to the field of insulin secretion or
resistance.
Relationship with GH
As stated before, GH is a regulator of
expression of IGF-I and IGF BP-3, in both
circulation, liver and other tissues. Whether
GH also regulates IGF-II production in
humans has not been elucidated yet. Exoge-
nous administration of growth hormone to
healthy adults during 14 days, did not lead to
appreciable changes in plasma IGF-II (18);
on the other hand GH appears to stimulate
the promoter region of IGF-II gene (19).
Interestingly, GH has also cell growth pro-
moting properties without the necessity to
induce the local expression of IGFs. GH
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Table 1: Simplified scheme of  insulin/IGF signaling. Pathways used only by insulin signaling
are given in italics; pathways presumably shared by both insulin and IGF are given in bold
Insulin Receptor / IGF-receptor
IRS1 / IRS2 
PI3K Grb2/SOS
PKC PKB/akt mTOR ras
GSK 3 p70S6K MAPK
Glucose Glycogen Cell Protein Gene
Transport synthesis survival synthesis expression
binding to the GH receptor leads to phos-
phorylation of the Janus kinase 2 (JAK2),
which will activate signal transducer and acti-
vator of transcription 5 (STAT 5). STAT 5
will then lead to mitogenesis. GH can there-
fore stimulate cell growth via various mecha-
nisms, both more directly via its own recep-
tor and/or indirectly via the IGF system.
Interestingly, while cross talk between
insulin-receptor and IGF receptor dependent
mechanisms exist in various levels, there
appears to be little or no cross talk between
the JAK-STAT and the other pathways, at
least in pancreas beta cells (20).
Growth factors and adaptive effects in adult
pancreatic B-cells
Animal studies
Pancreatic beta cells are under influence of
growth factors not only during the prenatal
period. Also later in adult life, the influence
of growth factors on the insulin secreting
cells is considerable. Especially, knowledge
about the involvement of the PI3K cascade
in survival of pancreatic beta cells and the
positive effect of MAPK activation on gene
transcription show relationships between
insulin receptor-mediated and IGF receptor-
mediated effects with respect to beta-cell
growth (9). Although insulin-secreting beta
cells are well-differentiated in adult human
life (less than 1% of pancreatic beta cells are
in mitosis), they are still capable to undergo
proliferative changes (9). Beta cell prolifera-
tion is stimulated by IGF-I via the activation
of the post receptor IRS-2 proteins (21). In
animal models, the IRS-2 knock-out mice
have been shown to have not only impair-
ment of insulin action, but also of beta cell
development, with consequent development
of diabetes (22). Those mice have a 60%
reduction in pancreas islet cell mass with a
relative beta cell deficiency; the number of
islets is also half of normal. Disruption of the
IRS-1 pathway, however, leads to a mild
insulin resistance in peripheral muscle tissue
with a two-fold increase in beta cells, that is
associated with an hyperinsulinemia
(10;12;13). IRS-1 binds with high affinity to
calmodulin, a calcium-binding protein
involved in insulin-secretion (23). IRS-1
deficient beta cells fail to increase the con-
tent of calcium in the cytosolic compart-
ment, while the overexpression of IRS-1 pro-
tein increases the calcium levels in INS-1
beta cell lines (13). These observations sug-
gest that a disruption in the IRS-1 pathway
results in adaptation by doubling the pancre-
atic beta cells to overcome the decrease in
calcium-driven secretion of insulin. Trans-
genic mouse models have indicated that sub-
sequent phosphorylation of PI3K, Akt and
mTOR are necessary for the transduction of
this IGF-I signaling (21;24;25)(Table 1),
while glucose has a strong modifying effect
(26). Recent studies in mice with a beta-cell
specific knockout of the IGF1Receptor indi-
cate, that the mice showed normal growth
and development of beta-cells but had a
defective glucose-stimulated insulin secre-
tion (with hyperinsulinemia) and had
impaired glucose tolerance. These studies
indicate that, even if IGFRI is not crucial for
islet cell development, it is of importance for
beta cell function (27).
Much less is known about the role(s) of
IGF-II in pancreas beta cell mass and func-
tion. IGF-II is known to have anti-apoptotic
properties. At least part of the effects of
IGF-II may relate to its capability to bind to
IGF-1 receptors. Recently, it was found that
the Goto-Kakizaki (GK rat), which has been
widely studied since it is a model for dia-
betes, displays defective IGF-II synthesis
which may causative for its insufficient beta-
cell development (28). However, transgenic
mice overexpressing IGF-II develop fre-
quently diabetes in spite of an increased beta
cell mass, possibly due to an increase in
glucagon producing alpha cells (13;29). Pan-
creas cells are capable of producing IGF-II
themselves (30).
Other growth factors than IGF are presum-
ably also at play. Fibroblast growth factors
(FGF) have been proposed to be implicated
already very early in the embryonic pancreas
development (31). In-vitro studies suggest
that they may influence the intestinal differ-
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entiation program and the development of
the dorsal and/or ventral part of the develop-
ing pancreas (32). FGF bind to extracellular
FGF-receptors (FGFR) also belonging to
the tyrosine kinase family. Recently, it was
shown in in vitro studies, that FGF7 could
control the development of exocrine pancre-
atic tissue, while removal of the FGF7 led to
proliferation of endocrine tissue (33). Stud-
ies with transgenic mouse models, expressing
a dominant negative version of FGFR1 show
that these animals develop diabetes (34).
These animal models have not only a reduced
number of beta-cells, but they have also an
impaired expression of the glucose trans-
porter 2 (Glut-2), the most prominent glu-
cose transporter of the pancreas and of the
liver. Moreover, the expression of PC1/3,
prohormone convertase 1/3, which is the
enzyme catalyzing the final conversion of the
prohormone proinsulin into the actual hor-
mone insulin in the pancreas, is also
decreased. Interestingly, the production of
FGFs occurs in the beta-cells themselves
under the influence of other transcription
factors, notably Ipf1/Pdx1, insulin promoter
factor1 or pancreatic duodenal homeobox
gene 1. Ipf1 is known to stimulate insulin
gene transcription and Glut 2 expression
(30). In humans, a nonsense mutation of the
Ipf1 gene is a known cause of Maturity
Onset Diabetes of the Young type 4
(MODY4) (35).
Human studies
Recently, several reports mention the effect
of disturbances in the expression of the IGF
system on beta cell function in humans in
relation to glucose metabolism (Table 2).
Although still limited to some studies, most
of them show an association between plasma
levels of the IGF system or the presence of
certain common gene polymorphisms and
the release of insulin that are estimated by
plasma insulin profiles during an oral glucose
tolerance test (OGTT). However, plasma
glucose levels change constantly during an
OGTT. The use of hyperglycemic glucose
clamping during which plasma glucose is
kept constant, enables studying relationships
between beta cell insulin release and influ-
encing factors, such as the IGF system.
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Table 2: Effect of IGF plasma levels or of common polymorphisms in the Insulin/IGF signal-
ing molecules on beta cell function (or glucose homeostasis) in humans. Reference numbers
are given in brackets
Variant Beta Cell Function Glucose 
homeostasis
IRS1 Gly972Arg contradictory findings (46;47) possibly worsening (44)
IRS2 Gly1057Asp no effect (47;47;49)
IGF-I level no effect (38) present (36)
IGF-I gene no data no effect (39)
Promoter IGF-I gene no data possibly (40)(low birth weight)
IGF-1 receptor GAG1013GAA no effect (39)
IGF-II level Stimulating  (Twickler) augmentation glucose (Twickler)
IGF-II gene no data
promoter IGF-II  IGF2-APA-I possibly no effect
IGF2 receptor no data 
Relationship with IGF-I
The presence of low plasma IGF-I levels has
been associated with an increased risk to
develop IGT and type 2 diabetes (36). Both
IGT and type 2 diabetes are related to a rela-
tive insufficiency of insulin secretion (37). In
line with this observation, we also observed a
negative correlation of the free IGF-I index
with baseline and 2-h glucose response after
an OGTT. However, we did not find a rela-
tionship of IGF-I with pancreas beta cell
function as assessed with hyperglycaemic
clamps in normal-glucose-tolerant subjects
(38). In view of the above-mentioned find-
ings in IGF1 receptor knock-out mice (27),
it could well be that the role of this polymor-
phism in insulin secreti1on is more subtle,
and would only become apparent during the
development of IGT. It is of note, that the
development of type 2 diabetes mellitus gen-
erally is the result of a combination of distur-
bances in insulin secretion and in sensitivity
(35). Therefore, it could also be that the role
of IGF-I in the development of IGT might
possibly relate to an effect of IGF-I on
peripheral tissue insulin sensitivity. Follow-
up studies may be of relevance to clarify this
point.
Relation with IGF-II
Very recently, we observed a significant asso-
ciation between both plasma IGF-II and
IGFBP-3 levels and measures of beta cell
function in subjects who have a normal glu-
cose tolerance; these subjects were on aver-
age around 45 years of age, and were mildly
obese (Twickler TB, de Sain- van der Velden
MGM, van Doorn J, van Haeften TW. Rela-
tionship of insulin secretion with plasma
Insulin-like Growth Factor-II. Submitted).
Obesity (and age to a minor extent) is relat-
ed to a certain amount of insulin resistance,
but may also have an impact on beta-cell
function. It is of note that the relationship of
IGF-II with insulin secretion was still appar-
ent after correction for obesity and age. It
has previously already been shown that
insulin secretion is elevated even in subjects
with a BMI within normal ranges as com-
pared to lean subjects (3). Our observation
that IGF-II levels relate with beta-cell func-
tion in mildly obese subjects might therefore
indicate a positive effect of IGF-II on beta-
cell growth during embryogenesis which is in
line with the Barker hypothesis. On the
other hand, IGF-II may also have adaptive
effects on adult pancreatic beta cells, which
would compensate for changes related to
increase of age and/or changes in glucose
homeostasis due to obesity. However, to our
knowledge, no additional data that deals with
IGF-II plasma levels and beta cell function at
a (very) young age in humans are available.
Gene polymorphisms and the relationship
with glucose homeostasis
IGF-I
Several studies in type 2 diabetes patients
have looked for the importance of common
polymorphisms in genes involved in the IGF
system. In a Danish study, DNA analysis of
82 probands of type 2 diabetes families
showed no nonsense, frameshift or missense
mutations in the IGF-I or IGF-1receptor
genes; however, a number of silent or intron
variants were noted (39). The most prevalent
polymorphism (GAG1013GAA) of the IGF-
receptor was not related to neither birth
weight or insulin sensitivity index in a group
of 349 healthy subjects. In addition, its
prevalence was not higher in subjects with
type 2 diabetes mellitus than in subjects with
a normal glucose tolerance. Another com-
mon polymorphism in the IGF1 promoter
region, however, has been reported to influ-
ence the weight at birth (40). A low birth
weight is related to increased risks of insulin
resistance, Impaired Glucose Tolerance and
type 2 diabetes mellitus (6;41). Although
insulin resistance is generally known to be
the most important risk factor for the devel-
opment of type 2 diabetes, disturbances in
insulin secretion are almost always found in
type 2 diabetes subjects (42). However,
recent preliminary results from our group
did not indicate any relationship between the
presence of an IGF-1 gene polymorphism
and beta cell function, neither in subjects
IGF system and b-cell function, review
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with normal glucose tolerance nor in subjects
with IGT.
IGF-II
Little is known about the biological impact
of polymorphisms in the IGF-II gene and
the expression of a diabetic phenotype. In a
recent study in a small group of subjects, a
relatively frequent polymorphism of the
untranslated part of the IGF2 gene was
found to be associated with lower plasma
insulin levels after an oral glucose tolerance
test. (43). However, in preliminary studies in
three groups of subjects we could not find a
consistent effect of the polymorphism on
either glucose levels after an OGTT or on
insulin secretion during hyperglycemic glu-
cose clamps.
Intracellular IRS proteins
Recent observations in humans indicate that
carriers with a Gly972Arg substitution in
IRS-1 proteins have a slightly decreased
insulin sensitivity, and a slightly increased
prevalence of type 2 diabetes mellitus
(13;44). Conformational in-vitro studies
show that RIN cells that have an increased
expression of this variant have a reduced glu-
cose-induced insulin release (45). Although
one series of hyperglycemic clamps describes
a marginally decreased beta cell function in
humans (46), we were not able to confirm
that observation in two larger cohorts (47).
Very recently, in vitro studies point to a
decreased conversion of proinsulin to insulin
in human beta cells with the Gly972Arg vari-
ant. However, these data were obtained in
cells from only two subjects with the variant,
and compared to cells from only two con-
trols (48), while insulin secretory function is
known to differ markedly between subjects.
Similarly, a common polymorphism
(Gly1057Asp) in the IRS2 molecule does not
appear to have an appreciable influence on
pancreas beta cell function in man neither in
subjects with normal glucose tolerance nor in
subjects with IGT (46;49).
Conclusion
Taken together, animal studies showed a sig-
nificant impact of growth factors, such as
IGF-I and IGF-II, in physiological develop-
ment of prenatal pancreatic beta cells, and in
adaptive properties of beta cells on environ-
mental changes in the postnatal period. In
humans, the observation of a relationship
between a low birth weight and an increased
prevalence of impaired glucose tolerance and
type 2 diabetes has prompted research into
the effect of the IGF system on adult insulin
secretion and the occurrence of derange-
ments of glucose homeostasis. IGF-I levels
have been shown to relate to the develop-
ment of IGT. We have recently found evi-
dence that plasma levels of IGF-II and
IGFBP-3 are positively associated with
insulin secretion. Others have observed a
relationship with a promoter gene polymor-
phism of the IGF-I gene with (low) birth
weight. However, no direct relationship has
been found with type 2 diabetes, so far.
A major area of further research relates to
the question whether the impact of growth
factors on the insulin secretion capacity in
humans is limited to the prenatal period or
whether it is also related to coping processes
of the beta cell in the postnatal period.
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ir-Norbert Vaessen and colleagues
(March 23, p 1036)(1) describe the
interesting observation that a poly-
morphism of the insulin-like growth factor-I
(IGF-I) gene is closely associated with low
birth weight and an increased incidence of
type 2 diabetes mellitus.
It is relevant in this context that a phenotyp-
ic association between low birthweight and
increased incidence of type 2 diabetes is sup-
ported by a large Scandinavian study (2).
From their results, Vaessen and colleagues
propose that a specific IGF-I polymorphism
is related to the extent of plasma IGF-I
expression, a key factor in the development
of pancreatic insulin-secreting cells. This
proposal is supported by previous animal
knock-out and transgenic models in which
the concentration of plasma IGF-I is a deter-
minant of the development and maturation
of the insulin secreting B-cells in fetal life,
and consequently affect insulin-secreting
properties of the B-cells in adult-life (3).
Most IGF-I in plasma is bound to IGF-bind-
ing protein-3 (IGFBP-3).
Due to the heritability of expression of IGF-
I and IGFBP-3 (more with respect to
IGFBP-3 than IGF-I (4)), we have assessed
whether the relation between plasma IGF-I
concentration, IGFBP-3 expression in
insulin-secreting cells, or both is conserved
in adult-life. We did a standard oral glucose
tolerance test (75 g glucose), and a hypergly-
caemic clamp (10 mmol/L during 180 min)
with measurement of first and second (aver-
age plasma insulin in 140-80 min period)
phase insulin secretion in 53 non-diabetic
individuals (mean age 46 years, SD 6; 13 men,
40 women; mean body-mass index 25·9
kg/m2, SD 3·8).
Plasma IGF-I concentrations were not relat-
ed to parameters of insulin secretion, but
plasma concentrations of IGFBP-3 were sig-
nificantly correlated with second-phase
insulin secretion (p=0·025) in the clamp, and
with baseline (p=0·056) and 120 min plasma
insulin after the oral glucose tolerance test
(p=0·037). Multiple linear regression
showed that the effect of IGFBP-3 on insulin
secretion could be accounted for by body-
mass index.
Thus, IGFBP-3 concentrations are closely
related to insulin secretion in the adult pan-
creas. Several factors, including growth hor-
mone status, age, nutrition, and hepatic func-
tion affect plasma concentrations of
IGFBP-3. However, the variation between
individuals of IGFBP-3 in the circulation of
adults seems to be largely determined by a
genetic component (4). Hence, at least to a
certain extent, IGFBP-3 concentrations at
the tissue level are also affected by genetic
factors. IGFBP-3 plays an important part in
the modulation (inhibitory or stimulatory)
of IGF action at the cellular level.
During fetal development, local concentra-
tions of IGF and IGFBP-3 may affect the
balance between cell apoptosis and the
maturing of functional B-cells (3), and hence
the insulin secretory capacity in adult life.
This may explain the intriguing finding that a
relation exists between plasma IGFBP-3 and
insulin secretion by the adult pancreas. The
apparent effect of body-mass index on this
relation remains puzzling. Considered
together with the data of Vaessen and col-
leagues, we suggest that pancreatic B-cell
function may be primarily determined early
in life.
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ype 2 diabetes mellitus is generally
due to a combination of insulin resist-
ance and an impairment in insulin
secretion by the pancreatic B-cell (1). A key
step in the development of pancreatic B-cell
function in animal studies, is the insulin /
insulin-like growth factor (I-IGF) signalling
pathway (2). Both IGF-I and IGF-II can
activate this pathway through IGF-1 recep-
tors (IGF-1r) resulting in cell processes,
such as proliferation, differentiation, and
prevention of apoptosis (2). In addition,
IGF-II is also able to activate the type-2
insulin-like growth factor receptor (IGF2R),
or IGF-6 mannose or IGF-M6 receptor. It
has become apparent from these studies that
pancreas B-cells are more plastic than was
previously appreciated. A type II diabetes rat
model without obesity (the Goto-Kakizaki
(GK) rat) displays a defective IGF-II synthe-
sis, which may account for its insufficient
beta-cell development (3).
In humans, in accordance with Barker’s
hypothesis, it has been reported that aberrant
foetal and infant growth is related with glu-
cose homeostasis in adult life (4). Decreased
plasma IGF-I levels are related to type II dia-
betes. Both IGF-I and -II are mostly bound
to the IGF-binding proteins, mainly to
IGFBP-3, and the biological activity of both
growth factors is dependent on the not-
bound fraction. In a preliminary report we
noted that adult insulin secretion is related to
IGFBP-3 (5); however, this significant asso-
ciation could be explained by the positive
relation of plasma IGFBP-3 levels with BMI,
presumably illustrating the well-known aug-
menting effect of overweight on insulin
secretion (6). In the present studies, we aim
to elucidate a possible relationship of plasma
IGF-II levels with pancreatic insulin secre-
tion in healthy non-diabetic adult subjects, as
assessed by both an oral glucose tolerance
test and a hyperglycemic glucose clamp.
Subjects, materials, methods
Subjects
Fifty healthy non-diabetic (OGTT) subjects
took part in this study (Table 1). They are
part of studies reported in earlier papers
(7;8). The local Ethical Committee had
approved the study, and informed written
consent was obtained from each participant.
All subjects had normal values for routine
laboratory measurements for hematology,
HbA1c (upper normal limit 6.1%), lipids,
and kidney, liver, thyroid and adrenal func-
tion.
Oral glucose tolerance test (OGTT)
Blood samples for glucose and insulin deter-
minations were taken at baseline and at 30
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To study the relationship between plasma IGF-II and insulin secretion in adult
non-diabetic humans.
Methods. We evaluated relationships between plasma IGF-II and insulin secretion
in 50 non-diabetic adults, estimated using an oral glucose tolerance test, and a
hyperglycemic clamp (10 mmol/L, 180 minutes) with determination of first and
second phase insulin secretion. Plasma IGF-II levels were positively associated
with fasting plasma glucose (r=+0.37, p=0.004) and fasting insulin (r=+0.33,
p=0.021) levels, and with second phase insulin secretion (r=+0.38; p=0.007).
Multiple linear regression (with gender, age, BMI and waist-hip ratio as covari-
ates) indicated that plasma IGF-II concentrations contributed significantly to the
variance of baseline plasma glucose levels (partial coefficient r=+0.27, p=0.037),
and of second phase insulin secretion (partial r= +0.28; p=0.044). Plasma IGF-II
levels are significantly related to adult pancreas B-cell function.
T
minute intervals after the oral administration
of 75 grams glucose (in 300 ml water), and
put on ice.
Hyperglycemic glucose clamp
A hyperglycemic glucose clamp was per-
formed during 180 minutes aiming at a glu-
cose level of 10 mmol/l (arterialized blood
sampling, 55°C). Blood samples for insulin
determination were taken at 2 minute inter-
vals during the first 10 minutes, and at 20
minute intervals thereafter, for determination
of first phase (summation from 0 to 10 min-
utes) and second phase (average plasma
insulin levels from 140 to 180 minutes)
insulin secretion.
Laboratory measurements
Blood glucose was determined immediately
with a glucose analyzer (YSI, Yellow Springs,
Ohio, USA). Plasma insulin was determined
by radioimmunoassay with 125I-labelled
insulin (IM 166, RC Amersham, UK). Plas-
ma IGF-II (nmol/L) was determined by a
specific RIA, as described previously (9).
Plasma IGF-II was also expressed as standard
deviation score (SDS) corrected for age and
gender, as reported previously (9).
Statistical analysis
Data are presented as mean with SD. Linear
correlations of plasma IGF-II, and its SDS,
with plasma glucose and insulin levels before
and after the OGTT, and with first and sec-
ond phase secretion during the clamp were
investigated. Multiple linear regression
(MLR) analysis was also performed with the
use of age, gender, body mass index (BMI)
and waist-hip (WH-) ratio, as covariates. 
Results
Plasma IGF-II levels were positively corre-
lated with baseline plasma glucose
(p=0.004), and with baseline plasma insulin
levels (p=0.021) (Table 2).
Multiple linear regression indicated, that
plasma IGF-II contributed significantly to
the variance of basal glucose (partial coeffi-
cient r=+0.27, p=0.037), but not to that of
plasma insulin levels.
In the univariate analysis, no significant asso-
ciations were found between the first phase
insulin secretion and IGF-II, while second
phase insulin secretion was positively related
to plasma IGF-II levels (p=0.007) (Table 2).
Multiple linear regression analysis indicated
Plasma IGF-II elates  to insulin secretion
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Table 1: Baseline characteristics of 50 subjects, fasting, 30 minute and 120 minute plasma glu-
cose and insulin levels after an OGTT, and first and second phase insulin secretion as deter-
mined during a 3 hour hyperglycemic clamp (10 mmol/L, 180 minutes) in 50 healthy subjects.
Data is Mean ± SD.
Gender (f/m) 38/12
Age (year) 46.2 ± 6.2
BMI (kg/m2) 25.7 ± 3.5
Waist-Hip ratio 0.82 ± 0.07
Basal plasma Glucose (mmol/L) 5.2 ± 0.5
120 min plasma Glucose (mmol/L) 6.7 ± 1.6
Basal plasma Insulin (pmol/L) 41.3 ± 20.3
30 min plasma Insulin (pmol/L) 303 ± 182
120 min plasma Insulin (pmol/L) 337 ± 282
First phase (pmol/L*10min) 836 ±505
Second phase (pmol/L) 347 ±216
Plasma IGF-II (nmol/L) 54.4 ± 9.9
that BMI has the largest impact on second
phase secretion (partial coefficient r= 0.38,
p=0.015). Plasma IGF-II levels contributed
significantly to the variance of second phase
insulin secretion (r=+0.28, p=0.044).
In general, the use of Standard Deviation
Scores (SDS) for univariate and multiple linear
regression led to the same results (Table 2).
Discussion
To our knowledge, the present studies are the
first to evaluate the relationships between
IGF-II and pancreas B-cell function. They
indicate that plasma IGF-II levels and second
phase insulin secretion are related, also after
correction for age, gender, BMI, and waist to
hip ratio. Pancreas beta cell function is close-
ly and negatively related with insulin sensi-
tivity: in obesity, insulin sensitivity is
decreased with a marked increase in the pan-
creatic beta-cell function (up till two- to
three-fold) (6). Therefore, body weight is a
major determinant of beta-cell function. In a
preliminary report, we already showed that
the relationship of IGFBP-3 with beta cell
function is mainly due to an interaction with
BMI (5).
The IGF system (and thus IGF-I and IGF-
II) in both transgenic rat and mice models, is
closely involved in the development of the
fetal pancreas. The present observation is the
first supporting this relationship in humans.
Both IGF-I and IGF-II affect positively pro-
liferation and maturation of developing B-
cells, although partly through different
receptors. In both fetal and neonatal life, the
synthesis of IGF-II, is a common feature of
isolated human islets cells (2). The role of
IGF-II in the pancreas of the fetus and
neonate is likely to be that of a paracrine or
autocrine mitogen and anti-apoptosis agent,
acting through the type 1 IGF-receptor.
Human plasma IGF-II levels increase moder-
ately during early childhood and remain on a
stable level during adult life, reaching plasma
values exceeding those of plasma IGF-I more
three-fold. Since the estimated heritability of
plasma IGF-II concentrations is around
66%, there must be important genetic traits
for the expression of IGF-II (10). Moreover,
the expression of IGF-II specific receptors in
fetal life is higher than IGF-I receptors (2),
and it is thus plausible that the impact of
(changes in) IGF-II on the definite function-
al properties of the pancreatic cells is impor-
tant. (1).
We conclude that beta cell function is related
with IGF-II, independent from other known
key factors such as obesity. Although it is
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Table 2: Linear correlation coefficients of relationships of IGF-II with fasting and post-glu-
cose load glucose and insulin levels (OGTT), and first and second phase insulin secretion
parameters as determined with a hyperglycemic clamp (10 mmol/L, 3 hours) in 50 non-diabet-
ic subjects.  SDS IGF-II denotes Standard Deviation Score for IGF-II according to previously
determined SDS IGF-II values for age, gender and BMI.
IGF-II SDS IGF-II
Fasting Glucose +0.37 c +0.38 c
120 min Glucose +0.05 +0.08
Fasting Insulin +0.33 a +0.34 b
30 min Increment Insulin +0.19 +0.19
120 min Insulin +0.18 +0.21
First Phase -0.11 -0.15
Second Phase +0.38 c +0.35 b
a p<0.05 , b p<0.02, c p<0.01
tempting to speculate that properties of the
insulin secreting cells are determined in early
life, obesity has also a marked influence on
actual B-cell function. Therefore, IGF-II
may have a role in B-cell adaptation to obesi-
ty (induced insulin resistance) during adult
life. Consequently, a thorough analysis of the
IGF system, from fetal to adult life, with
respect to the properties of the insulin
secreting cells may improve the understand-
ing of (adult) insulin secretion, and possibly
also shed new light on the disturbances of B-
cell function related to the development of
type 2 diabetes mellitus.
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ecently, clinical concern arose about
the increased IR in short-term substi-
tution studies with recombinant
growth hormone (rhGH) in adult-onset
growth hormone deficiency (AGHD)
patients. In several studies, the incidence of
diabetes mellitus type II is higher in GH sub-
stituted patients with adult and/or childhood
onset GHD (1) and it is known for a long
time that an increased IR is associated with
increased cardiovascular morbidity and mor-
tality (2). On the opposite, increasing clinical
evidence showed that premature atheroscle-
rosis is a clinical feature in the AGHD syn-
drome and that rhGH substitution improved
the initially increased femoral intima media
thickness (IMT) and endothelial dysfunction
(measured with Flow Mediated Dilation;
FMD) (3-6). If IR increase after rhGH sub-
stitution, the beneficial effect of rhGH upon
the cardiovascular parameters could conse-
quently be counteracted. Nowadays, the sub-
stitution of rhGH is only according to sex
and age (7;8) without a regular follow-up of a
subsequent IR.
In this short communication, we report the
observation that baseline plasma IGF-1 level
in AGHD could prospect the insulin sensi-
tivity that result after 6 months of rhGH
substitution.
Subjects and Methods
Subjects
Eleven adult GHD patients (9 men and 2
women), aged 49 ± 5 years, BMI 28.3 ± 3.1
kg/m2 (Mean ± SD) participated in this
intervention study. After being optimally
substituted for other deficient pituitary hor-
mones, the patients were treated with daily
subcutaneous rhGH during 6 months.
Before the start and after six months of
rhGH substitution venous blood was drawn
to analyse. Dosages of rhGH were titrated
upon the adjusted plasma IGF-1 levels,
according to their age and sex. The daily
adminestered rhGH was similar in all
patients (between 0.8 and 1.1 IU/day). None
of the patients had additional treatment in
the study period, had a positive family histo-
ry for type II Diabetes or suffered from renal
and or liver disease. All patients obtained
written information about the protocol
(approved by the ethical committee) and
from all patients an informed consent was
obtained.
Methods
In fasting conditions, plasma glucose, insulin
and IGF-1 concentrations were assessed
before and after rhGH replacement. The IR
was estimated by calculating HOMA index
(fasting insulin times fasting plasma glucose
divided by 22.5) (9). Measurement of insulin
and IGF-1 were performed in plasma samples
with a radio-immuno assay (10).
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Increased insulin resistance (IR) has been reported in patients with adult-onset of
GH deficiency (AGHD) after starting rhGH therapy and this could oppose the
beneficial cardiovascular effects of GH substitution. Therefore, a useful marker
that predicts the increase of IR during rhGH therapy could be of clinical value. In
11 AGHD patients, baseline plasma IGF-1 levels (before rhGH substitution) were
negatively correlated with the delta HOMA index. Moreover, the delta plasma
IGF-1 levels were positively correlated with the delta HOMA index. In conclu-
sion, a baseline plasma IGF-1 level already gives an impression of the level of IR in
AGHD patients that is obtained during rhGH treatment and, additionally, the
rhGH dosage need to be titrated to avoid an exaggerated increase in IR.
R
Statistical analysis
Data are presented as median (range). Effects
of rhGH substitution in AGHD patients
were analyzed by a paired (two tailed) t-test.
Pearson’s correlation or Spearman’s rank cor-
relations were applied to evaluate relation-
ships between parameters. Correlations are
mentioned in the text if they reached statisti-
cally significance. Differences between
before and after rhGH treatment are
expressed as delta. A P value of 0.05 was con-
sidered significant. Statistical analysis was
performed with Sigma Stat (Jandel Corpora-
tion).
Results
The increase in insulin secretion (C-peptide
was also increased) was not sufficient to pre-
vent the small but statistically significant
increase in fasting glucose (4.6 vs. 5.1
mmol/L) (Table 1). Although, the plasma
insulin levels increased it did not reach the
level of significance. Overall insulin resist-
ance as determined by HOMA index,
increased after rhGH. As expected, a signifi-
cant increase in plasma IGF-1 levels was
observed after treatment with rhGH.
Plasma IGF-1 levels, before rhGH substitu-
tion, were negatively correlated with the
delta HOMA index (delta HOMA index= -
0.01 * (basal IGF- I level) + 1.96; r = 0.56)
(Figure 1).
The delta plasma IGF-1 levels were positively
correlated with the delta HOMA index
(delta HOMA index = 0.01(delta IGF-1) -
0.40; r = 0.73).
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Table 1: Effect of six months rhGH treatment on various plasma parameters
Parameter Baseline on rhGH treatment
Glucose (mmol/L) 4.6 (4.0-6.0) 5.1 (4.6-6.0) #
Insulin (mIE/L) 6 (3-17) 9 (2-21)
HOMA index 1.3 (0.7-4.5) 1.8 (0.6-5.6) #
IGF-1 (ng/ml) 102 (30-182) 212 (180-280) #
Results are Median (range). # P<0.05.
3
-2
-1
1
2
0
0 100
Delta IGF-1
200 0 100
Baseline IGF-1
200
D
el
ta
 H
O
M
A
 in
de
x
Figure 1. Relationships (with 95% confidence limits) between delta HOMA index and delta IGF-1 (ng/ml) (left) and between
delta HOMA index and basal IGF-1 (ng/ml) (right).
Discussion
In the present study, we showed that pre-
treatment plasma levels of IGF-1 in AGHD
patients could partially account for the defi-
nite change in HOMA index (basal insulin
sensitivity) after rhGH therapy (r2 = 0.32).
Moreover, a decrease in insulin sensitivity in
AGHD patients during treatment was asso-
ciated with the incremental in plasma IGF-1
levels. Knowledge of plasma profiles of IGF-
1 before and during rhGH substitution could
therefore help in the individual titration of
rhGH, and may optimize beneficial effects of
rhGH treatment.
An increase in HOMA-index, due to eleva-
tion of both the plasma glucose and insulin
levels, observed after rhGH substitution,
reflect a decrease in insulin sensitivity. Short-
term rhGH infusion results in hyperinsuli-
naemia, in impairment of insulin to suppress
the hepatic de-novo glucose production and
in stimulation of the peripheral glucose
uptake and oxidation in skeletal muscles
(11;12). Decreased insulin sensitivity is
already described to be an independent car-
diovascular risk factor, even in non-diabetic
populations (13). The relation between
hyperinsulinemia and cardiovascular mortali-
ty was confirmed in a large population during
a 15-year follow-up study. In that study, the
calculated HOMA index in subjects who
died from cardiovascular disease was 2.11
(14). As previously noted the AGHD syn-
drome is associated with an increased mortal-
ity. While in the present study only one
untreated patient exhibit a HOMA index
above 2, the HOMA index was >2 in five
patients on rhGH treatment. Therefore, the
HOMA index in AGHD that results from
GH substitution needs to be of concern dur-
ing clinical follow-up.
In this study, lower plasma IGF-1 levels at
the start of rhGH substitution result in more
IR in rhGH treated AGHD patients. Plasma
IGF-1 levels are for 35% genetically deter-
mined. A possible explanation could be a less
intrinsic insulin secretion capacity by the
pancreas due to initially low plasma IGF-1
levels. Prenatal, the development of pancreat-
ic β cells is influenced by IGF-1; low plasma
IGF-1 in the prenatal period result in a lower
insulin secreting capacity. IGF-1 is an impor-
tant regulator in the differentiation and pro-
liferation of the pancreatic β cell (15). From
index subjects and family members with IR, a
genetically determined low IGF-1 expression
was associated with a 7.5 fold increased risk
for diabetes (95 percent confidence interval
of odds ratio 2.8 to 16.2 (16). Therefore, the
increase in IR after rhGH substitution may
be interpreted as an in-born capacity reduc-
tion of the pancreatic gland that is not capa-
ble to oppose the increased glucose load
(possibly due to increased gluconeogenesis
that is related to rhGH substitution) in the
general circulation. Therefore, the enhanced
insulin response of the pancreatic β cell may
be primarily considered to be genetically
determined and only in a secondary manner,
after the substitution of rhGH and the con-
sequent elevation of the systemic glucose
load will lead to IR.
From our results, one could consequently
derive that less concern about IR is needed in
these AGHD patients with higher plasma
baseline IGF-1 levels. In line with this,
AGHD patients with lower baseline IGF-1
levels will possibly need additional treatment
to lower the insulin resistance by for example
drugs like biguanides (Metformin) or insulin
therapy. The increase in IR is also associated
with the IGF-1 elevation after rhGH substi-
tution and this observation advocate an opti-
mal titration of rhGH substitution with spe-
cial attention to the AGHD patients with
initially lower plasma IGF-1 levels.
In conclusion, the increase of insulin resist-
ance in AGHD after substitution of rhGH
could be optimally managed with special
attention to the baseline plasma IGF-1 levels.
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lthough results are conflicting, most
reports note distinctive changes in
glucose homeostasis in AGHD
patients during GH therapy, such as a
decrease in insulin sensitivity (1-3). Conse-
quently, this may indicate a reduced availabil-
ity of glucose for tissue metabolism (if not
compensated by higher plasma insulin lev-
els). An impaired glucose metabolism, and
especially glycolysis, will limit cognitive
functions, physical activity, and other glucose
dependent processes. In humans, optimal
plasma levels of endogenously derived glu-
cose (in a range of 5 to 8 mmol/L) are main-
tained in a well-regulated balance in GNG,
GL and glycolyse. In order to understand
better the consequences of GH therapy on
the molecular level of glucose metabolism,
thorough analysis of both GNG and GL,
with respect to EGP in AGHD patients, may
therefore be of interest.
So far, no studies with a direct assessment of
GNG and GL in AGHD patients are per-
formed, or the effects of GH therapy on it.
Moreover, the previous used methods to ana-
lyze GNG were insufficient and were an
important limitation in the progress of
knowledge about GNG and GL in humans.
In healthy subjects who receive a 12 h GH
infusion, Butler et al (4) measured carbon
dioxide incorporation into glucose as quanti-
tative estimation of GNG. However, this
method is not sufficient, mainly due to dilu-
tion of marked labels at the oxalo-acetate
level. This dilative effect can be avoided by
recent developed method that uses deuteri-
um incorporation into glucose (after oral
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GH therapy in adult-onset growth hormone deficiency (AGHD) is associated
with changes in glucose homeostasis. The circulating availability of glucose results
from gluconeogenesis (GNG) and glycogenolysis (GL). In order to investigate
GNG and GL in AGHD, GNG and GL in AGHD patients (n=5) were analyzed,
before and after 6 and 12 months of GH therapy, in comparison to mild obese
healthy volunteers (n=5), matched for age, sex and BMI. The total glucose turn-
over was estimated after intravenous infusion of 6,6 2H2 glucose, with a fractional
contribution of gluconeogenesis after oral ingestion of 2H2O. The contribution of
GNG via pyruvate pathway was determined through 2H enrichment in C6/body
water, and via pyruvate + glycerol pathways through 2H enrichment in C5/body
water. Glycogenolysis was calculated as the difference between glucose production
and gluconeogenesis. On baseline, fasting plasma levels of insulin, glucose, C-pep-
tide and HOMA did not differ between AGHD patients and control subjects.
During GH therapy, insulin sensitivity decreased, but not significant. Total glu-
cose turn-over in AGHD was not increased compared to control subjects and
remained constant during GH therapy. Pretreatment, GL in AGHD was increased
(and inverse for GNG), compared to control subjects. Due to GH therapy, the per-
centage contribution of GL decreases (from 34 % on baseline to 25% on rhGH
(+12)), in favor for GNG (with pyruvate as a major substrate). Plasma glutamate
levels increased during GH therapy. GNG was inversely associated with plasma
IGF-2 levels (r= -0.61, p< 0.01).
Insulin sensitivity in AGHD patients tends to decrease during GH therapy. The
total glucose turnover in AGHD patients remained stable, GL continue to be the
major source of glucose in the postabsorptive phase, before and during GH thera-
py (in comparison to mild obese control subjects). Simultaneously, an increase in
GNG (with pyruvate as a major precursor) is observed during GH therapy that
may explained by an increase in fatty acid oxidation due to GH lipolytic effects.
A
administration of 2H2O) that provides whole
body estimate of total GNG (and by calcula-
tion GL).
In this study, we aim to analyze in AGHD
patients the contribution of GNG and GL, in
the total EGP, compared to that in matched
healthy control subjects, and in AGHD
patients during 6 and 12 months GH therapy.
Subjects and methods
Patients
The study population consisted of 5 male
patients with AO-GH deficiency with a
mean age of 50 years (range 44-58) and a
mean body mass index of 29.2 kg/m2 (range
25.0-33.8 kg/m2). Patients were recruited
from the department of endocrinology in
UMC Utrecht, the Netherlands. The origin
of the GH deficiency was panhypopitu-
itarism after neurosurgery for a pituitary ade-
noma (time interval after surgery was at least
6 months). GH deficiency was confirmed by
at least two GH stimulation tests. All
patients were substituted for additional defi-
cient pituitary axes, such as with thyroxin,
corticosteroids, sex hormones and 3 patients
receive desmopressin. Patients were only
included in this study, if these hormones
were optimally substituted. None of them
were known with diabetes. The clinical char-
acteristic are shown in table 1.
After inclusion and baseline measurements
(including stable isotope studies), GH hor-
monal replacement (Norditropin, Novo,
Nordisk) was started. After 6 months and 12
months GH therapy, the patients were sub-
jected to a study day for the second time and
third time, respectively. One patient could
not complete the whole study because of sur-
gery after 8 months of rhGH therapy. A
weight maintaining diet has been described
for three days prior to the study day to both
the patients and control subjects. While on
diet, excessive exercise and alcohol intake
was not allowed.
The dietary compliance was evaluated from a
diary record, which reports three days’ diet
prior to investigation in the metabolic ward.
At baseline, the total energy intake in
AGHD was 2088 ± 228 kcal/day, compared
to 2150 ± 151 in control subjects (not signif-
icantly different). Moreover, GHD patients
consumed 42 ± 3 % of carbohydrates, 36 ±
2 % fat and 21 ± 2 % protein (percentages
were similar in control subjects). The
patients following GH treatment (6 months)
consumed a total of 2513 ± 188 kcal/day, 43
± 3 % carbohydrates, 36 ± 2 % fat and 21
±4 % protein. The patients following long
term GH treatment (12 months) consumed a
total of 2122 ± 188 kcal/day with a 44 ± 0 %
carbohydrates, 36 ± 1 % fat and 21 ± 2 %
protein.
Control subjects
The control subjects consisted of 5 men with
an average age of 52 years (range 45-58) and
BMI of 28.2 kg/m2 (range 24.0-29.4 kg/m2).
The control subjects consumed 45 ± 1 % of
carbohydrates, 35 ± 1 % fat and 19 ± 1 %
protein.
The institutional Ethical committee
approved the study protocol and each subject
gave his or her informed written consent to
participate.
Methods
Recently, a method has been developed in
which Deuterium oxide (2H2O) can be used
as tracer to measure gluconeogenesis (5;6).
Briefly, the principle is as follows: 2H is
bound to the C3 of Phosphoenolpyruvate
(PEP) that becomes eventually the C6 of
glucose. GNG from glycerol also results in
labeling of the C5 of glucose via incorpora-
tion of the label into C2 of glyceralaldehyde-
3-P, which equilibrates with dihydroxyace-
tone-3-P. Because of rapid cycling between
Glucose-6-P and fructose 1,6-P, there is an
addition of hydrogen from body water to C2
by both GNG and glycogenolysis. Enrich-
ment at C2 of glucose was approximately
equal to the enrichment in body water in
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both control subjects (5;5;7), in patients with
malaria falciparum and cirrhosis (8;9) and in
subjects in whom effects of fatty acids eleva-
tion on GNG was examined (10). Thus,
enrichment of the deuterium bound to car-
bon 6 of glucose to that in body water fol-
lowing 2H2O administration equals the frac-
tion of glucose formed by gluconeogenesis
via pyruvate while enrichment of the deuteri-
um bound to carbon 5 of glucose to that in
body water equals the fraction of glucose
formed by gluconeogenesis including glyc-
erol. Use of non-recycling [6,6 2H2] glucose
label provide a value for total hepatic glucose
production. Because plasma deuterated glu-
cose is analyzed, there is no discrimination
between renal and hepatic GNG and thus
whole body gluconeogenic fraction is meas-
ured.
Experimental design
One day before the study day, all subjects
collected 24 hours urine specimen, which was
analyzed for nitrogen (N) and for back-
ground of body water. Before the study day,
participants have their last oral intake at 6.00
P.M. On the study day, subjects were admit-
ted to the University Medical Center
Utrecht, between 07.00 and 07.30 am. To
avoid physical activity during the study, sub-
jects came by bus or by car and were trans-
ported in a wheel chair in the hospital. Body
weight was measured and a dorsal hand vein
was cannulated for “arterialized” venous
blood sampling (drawn from a hand vein in a
heated box (60°C). Blood samples were
drawn for measurement of basal enrichments
and other parameters for insulin sensitivity
(glucose, glucagon, HbA1c, insulin, C-pep-
tide), additional hormones (free T4, free T3,
cortisol), the IGF system (IGF-1, IGF-2,
IGFBP-1, IGFBP-3), the precursors for
GNG (pyruvate, lactate, alanine, glutamate,
glutamine) and the lipolytic products (free
fatty acids, glycerol).
A cubital vein in the contralateral arm was
cannulated for the infusion of 6,6 2H2 glu-
cose which started at 10.00 AM. At t=10.00
a priming 6,6 2H2 glucose 98% (26.4
µmol/kg prime) and a maintenance dose of
0.33 µmol/kg/hr min was given for two
hours to determine the total rate of glucose
appearance (Ra). Both catheters were flushed
with heparin. During the study day, no food
was given and subjects were allowed to drink
water that was enriched to 0.5% with 2H2O
to maintain steady state. To achieve an
enrichment of 2H in body water of approxi-
mately 0.5%, they were given orally 2H2O
(1g/kg body water) (>99.8 % enriched;
Cambridge Isotopes, Andover, MA) at t=
8.00, 8.30, 9.00, 9.30 en 10.00 AM. The next
two hours were allowed for equilibration of
the 2H2O. After emptying the bladder at
t=12.00, urine have been collected between
t=12.00 and t=13.00. At t= 10.00 AM, a
blood sample for background enrichment
was drawn. At t=12.00, 12.15 and 12.30 hr
heparin blood samples were drawn from
“arterialized” venous blood for the measure-
ment of deuterium enrichments in blood glu-
cose. After the last blood sample, the intra-
venous lines were removed and the subjects
were given a regular meal.
Standard Analytical procedures
Plasma glucose was measured with standard
laboratory methods on a Vitros 950 (Johnson
& Johnson, Clinical Diagnostics, NY, USA).
HbA1c was measured using a high-per-
formed liquid chromatography method. Free
T4 was measured with a full automatic com-
petitive micro particle chemolumnisence
immuno-assay. Free T3 was measured using
an immuno enzymetric assay (a competitive
ELISA using streptavidin technology per-
formed on a ES300, Roche Diagnostics
GmbH, D-68298 Mannheim). Glucagon was
measured after alcohol extraction followed
by a competitive radioimmmnoassay using a
polyclonal antibody raised in rabbit against
Pancreas Glucagon. Cortisol was measured
with immuno chemiluminiscention. IGF1
was measured with an immuno chemolum-
nisence (Nichols Institute Diagnostics, San
Juan Capistrano, USA). Concentrations of
plasma IGF-2, IGFBP-3 (mg/L) and IGFBP-
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1 (µg/L) were determined by specific RIAs,
as described previously (11). Insulin was
measured with a competitive radioim-
munoassay using a polyclonal anti-insulin-
antibody (CARIS46), 125I-Insulin (IM166,
Amersham Nederland bv) as a tracer and
Humuline (YV2632 AMV Lilly, Indpls,USA)
as a standaard. C-peptide was measured with
a competitive radioimmunoassay (MD315,
Euro-Diagnostica, Malmö, Sweden). Pyru-
vate, FFA was measured on a Cobas Fara
(Roche, Germany) using an enzymatical
method. Lactate and glycerol were measured
with standard laboratory method on a
Hitachi-911 (Roche, Germany). Plasma ala-
nine, glutamate and glutamine concentra-
tions were measured on a Biochrom 20 auto-
matic amino acid analyzer (Pharmacia
Biotech, England).
Body composition measurements
Body height was measured to the nearest 1.0
cm by using a wall mounted stadiometer, and
body weight to the nearest 0.05 kg. BMI was
calculated as weight (kg) divided by height
squared (m2). Body fat was assessed by bio-
electric impedance analysis (BIA) (tetrapolar
BIA-101 analyzer: RJL-Systems, Detroit),
based on resistance and reactance measure-
ments. Resistance and reactance were meas-
ured (in ) after appliction of an alternating
current of 800 µA at 50 kHz with the elec-
trodes placed as described by Lukaski et al
(12). Body fat was calculated by using the
manufacturer-supplied equation.
Indirect calorimetry
At t=0.900 A.M., ventilation, oxygen con-
sumption and carbon dioxide production
were calculated breath to breath (Oxycon
Sigma (Mijnhardt, Jaeger)). Gas analyses
were automatically performed by using room
air as a reference. Subjects were asked to
breath normally. Data were recorded at 30
seconds interval during 30 minutes. Before
measuring, two minutes of adaptation period
were introduced.Net glucose and lipid oxida-
tion rates were estimated with the use of for-
mer described method (13) and protein oxi-
dation rates were estimated by the assess-
ment of serum nitrogen (N) concentrations
and urinary excretion rates of N.
Nitrogen measurement
The nitrogen was converted to ammonia by
wet oxidation according to the Kjeldahl tech-
nique in a digestion mixture of sulfuric acid,
sodiumsulphate and mercuric sulphate.
Procedures for measuring glucose metabolism
In order to measure glucose kinetics 5 ml
plasma for enrichment on C5 and 2 ml to
determine enrichment on C6 was immediate-
ly deproteinized using equal volumes of
prechilled 10% perchloric acid and stored at -
20°C. The other samples were immediately
measured or stored below -20°C. The deu-
terium enrichment in bound to carbon 5 and
6 of blood glucose was determined as
described elsewhere (5;6) with some slight
modifications. In short, supernatant obtained
after deproteinizing blood samples was
passed through a mixed cation of AG1-X8
(formate form) and AG 50 w-X8 (H+). Glu-
cose in the effluent was isolated with use of
high pressure liquid chromatography using a
Aminex HPX-87c column (Bio-Rad, the
Netherlands) with water at 80°C as solvent.
In order to isolate C6, 0.5-1mg was oxidized
with periodate to form formaldehyde. This
was converted to hexamethylenetetramine
(HMT). Enrichment at C5 of a portion of
glucose is determined chemically by conver-
sion of glucose to xylose with removal of C6.
The xylose is oxidized with periodate to
form formaldehyde. Plasma glucose enrich-
ment was determined by gas chromatography
mass spectrometry (GC-MS) on a Hewlett-
Packard HP 5890 type II gas chromatograph
interfaced to a HP 5989B mass spectrometer.
The gas chromatograph was equipped with a
coating CP Sil 19CB capillary column
(Chrompack, Bergen op Zoom, the Nether-
lands). Injection (2 µl) was performed in a
split mode (1:20). The flow rate of carrier gas
(helium) was 1 ml/min. Injector temperature
was 240°C and oven temperature was pro-
grammed starting at 210°C for 1 minute,
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then increased from 210°C to 280°C at
25°C/min and maintained at 280°C for three
minutes. The HMT eluted at approximately
4.5 minutes. The source and quadruple tem-
perature were 250°C and 150°C, respectively.
Fragments 140, 141 and 142 were monitored
and enrichment was determined using a cali-
bration curve whereby measured ion abun-
dance ratios are correlated with enrichment
of standards of known isotopic composition.
The distribution of different masses in HMT
was used to calculate deuterium enrichments
by mass isotope distribution analysis(14).
Comparing both methods revealed a correla-
tion of r2=0.995 (y=0.908x-0.0061, n=54).
Since we observed that the tracer/tracee
measurements are affected by the quantity of
HMT analyzed, an initial “pre-run” was per-
formed to determine relative sample concen-
trations. The second run was performed after
adding appropiate volumes of solvent to each
vial in order to narrow sample concentration
within the concentration measured within
the calibration curve. All samples were meas-
ured in duplicate, with a CV<3%.
The enrichment in urinary water was deter-
mined after reaction with calcium carbide to
form acetylene (15). The m/z signal ratio for
acetylene measurements were performed in
triplicate (different vials) with a CV% <4%.
Calculations and statistics
To measure glucose production, an infusion
of [6,6 2H2] glucose is given simultaneously
with 2H2O. The percentages of the HMT
molecules, with two 2H bound to C6, are
determined and are measured as percentage
of the molecules of molecular mass 142
(m+2).Glucose production is calculated as:
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Table 1: Clinical and fasting biochemical characteristics of GHD patients before and after
respectively 6 and 12 months of rhGH replacement therapy compared with age, sex and BMI
matched control subjects
Baseline 6 months 12 months Control 
rGH rGH subjects
N 5 5 4 5
Age 50 ± 2 50 ± 2 50 ± 1 52 ± 2
Body weight (Kg) 96.2 ± 5.1 97.4 ± 6.9 95.7 ± 6.5 85.3 ± 3.6
BMI (Kg/m2) 29.2 ± 1.7 29.5 ± 1.9 29.8 ± 2.4 28.2 ± 1.1
FM (Kg) 23 ± 3 22 ± 3 23 ± 4 22 ± 2
FFM (Kg) 73 ± 5 75 ± 5 73 ± 5 64 ± 3
FM (%) 24 ± 3 23 ± 3 23 ± 4 25 ± 2
FFM (%) 76 ± 3 77 ± 3 77 ± 4 75 ± 2
WHR 0.96 ± 0.03 0.94 ± 0.04 0.93 ± 0.05 0.94 ± 0.02
RQ 0.80 ± 0.02 0.79 ± 0.02 0.78 ± 0.02 0.79 ± 0.03
M (kcal/24hr) 1038 ± 78 1269 ± 139 1242 ± 191 1138 ± 95
Glucose oxidation 
(mg/kg/min) 0.81 ± 0.28 0.81 ± 0.25 0.73 ± 0.24 1.13 ± 0.07
Fat oxidation 
(mg/kg/min) 0.64 ± 0.11 0.81 ± 0.34 0.83 ± 0.18 0.77 ± 0.08
Protein oxidation 
(mg/kg/min) 0.60 ± 0.02 0.51 ± 0.05 0.51 ± 0.11 0.58 ± 0.07
Data respresent Mean ± SEM. BMI= Body mass index, FM= Fat mass, FFM= Fat free mass, WHR=waist-hip ratio,
RQ= respiratoir quofficient, M= Metabolic rate.
Data represent mean ± SEM 
Infusion rate (0.33 µmol/kg/min)/ enrich-
ment (M+2) at blood glucose C-6. The frac-
tion of blood glucose formed by GNG from
pyruvate was calculated by one half of the
enrichment at carbon 6 (M+1) divided by
the enrichment in body water. A factor of 0.5
is used since two hydrogen atoms are bound
to carbon 6. The percent contribution of
GNG from pyruvate + glycerol to plasma
glucose was calculated as the ratio of the
enrichment at C5/enrichment at body water
in each subject. The rate of GNG from both
pyruvate and glycerol and pyruvate was cal-
culated by multiplication of the total glucose
production by fractional GNG. Glycogenol-
ysis was calculated from the difference
between the rates of total glucose production
and GNG (from glycerol and pyruvate).
Data are represented as mean ± SEM,
expressed as %, µmol/kg/min and µmol/kg
FFM/min. Statistically significance (which
was set at p<0.05) of difference was tested
using a paired t-test for patients and a two
sample t-test was used to compare patients
with control subjects. Log transformation
was used in non-normally distributed param-
eters.
Results
Body composition
Body weight (kg), BMI (kg/m2), WHR and
Fat Free Mass (FFM) were not significantly
different between AGHD patients (on base-
line, rhGH (+6) and rhGH(+12)), and con-
trol subjects (table 1).
Indirect calorimetry
The resting metabolic rate in AGHD tended
to increase from 1038 ± 78 kcal/24 h to 1269
± 139 kcal/24 h after 6 months to 1242 ±
191 kcal/24 h after 12 months rhGH therapy
(table 1). No difference in resting metabolic
rate was found at baseline in AGHD, com-
pared to control subjects. Glucose oxidation
was higher than fat oxidation in both AGHD
at baseline and control subjects. The oxida-
tion of fat in AGHD patients increased dur-
ing GH therapy, with a decrease in glucose
oxidation, however not significant (table1).
Circulating metabolites and hormones
Glucose and Insulin 
Fasting plasma glucose levels in AGHD were
not increased, as compared to BMI matched
control subjects. GH therapy tended to
increase plasma glucose levels (table 2). Insu-
line, C-peptide, pyruvate and HOMA-ratio
were not significantly different between
patients (before and during GH therapy) and
control subjects (table 2). Glycosylated
hemogloblin (Glyc-HB) was unchanged dur-
ing GH therapy (table 2). Fasting insulin lev-
els in AGHD tended to increase during GH
therapy, but at baseline no difference with
control subjects was found. Fasting plasma
insulin concentrations correlated positively
with the degree of fat mass (Kg) (r= 0.75,
p<0.0001; grouped results of all partici-
pants).
Hormones 
No change in plasma free T4 and free T3 lev-
els in AGHD was found during GH therapy.
Plasma glucagon and cortisol levels tend to
be higher in GH treated AGHD patients
compared to control subjects, but no signifi-
cant difference was found.
IGF system 
The plasma levels of IGF-1, IGF-2 and
IGFBP-3 were lower in AGHD patients than
in the control subjects. The IGF-1 concen-
tration was significantly higher at 6 months
and at 12 months rhGH therapy, compared
to pretreatment levels (p<0.05), and signifi-
cantly higher at 12 months rhGH therapy,
compared to 6 months rhGH treatment
(p<0.01) (table 2). Both IGF-2 and IGF BP-
3 increased during GH therapy.
Glucose precursors 
FFA (table 2) as well as the other gluco-
neogenic substrate precursors, such as lac-
tate, alanine, glutamine and glycerol (table
3), were not significantly different between
AGHD patients and control subjects and
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these parameters did not change during GH
therapy. In contrast, glutamate was signifi-
cantly higher (P<0.05) at study entry, com-
pared with control subjects, and sustained
higher during GH therapy for 6 and 12
months (table 3). There was a significant
decrease in the urinary N excretion after 6
months therapy (but not after 12 months
GH therapy due to higher variance), com-
pared to pretreatment levels.
Glucose metabolism 
The postabsorptive rates of endogenous glu-
cose production, GNG and glycogenolysis are
presented in table 4. There was no difference
between AGHD patients and control subjects
in endogenous glucose production, expressed
as µmol/kg/min or as as Μmol/kg FFM/min.
During GH therapy, total glucose rate
remained constant. GL, expressed as µmol/kg
FFM/min, was significantly increased in pre-
treatment GH period (2.7 ± 0.3 µmol/kg
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Table 2: Fasting biochemical charactersitics of GHD patients before and after respectively 6
and 12 months of rhGH replacement therapy compared with age, sex and BMI matched con-
trol subjects.
Baseline 6 months 12 months Control 
subjects
Glucose (mmol/L) 5.0 ± 0.3 5.2 ± 0.2 5.6 ± 0.5 5.4 ± 0.2
Gly-Hb (%) 5.8 ± 0.1 5.6 ± 0.2 5.6 ± 0.1 5.5 ± 0.2
Free T4 (pmol/L) 14 ± 2 15 ± 1 15 ± 3 15 ± 1
Free T3 (pmol/L) 6.2 ± 0.4 7.8 ± 1.0 6.9 ± 0.7 6.7 ± 0.3
Glucagon (pmol/L) 29 ± 4 32 ± 6 34 ± 18 & 29 ± 3
Cortisol (µmol/L) 0.60 ± 0.09 0.61 ± 0.12 0.61 ± 0.06 0.45 ± 0.10
IGF-1 (ng/ml) 117 ± 25 198 ± 27 * 154 ± 23 * # 133 ± 12
IGFBP-1 (µg/L) 33 ± 7 28 ± 7 42 ± 25 23 ± 7
IGFBP-3 (mg/L) 1.35 ± 0.15 1.62 ± 0.06 1.76 ± 0.29 1.86 ± 0.18
IGF-2 (ng/ml) 301 ± 27 369 ± 36 330 ± 25 382 ± 23
Insuline (mE/L) 8 ± 3 12 ± 5 13 ± 7 12 ± 3
C-peptide (nmol/L) 0.92 ± 0.19 1.1 ± 0.3 1.1 ± 0.4 0.97 ± 0.12
Pyruvate (µmol/L) 83 ± 14 70 ± 7 74 ± 7 62 ± 5
FFA (µmol/L) 1095 ± 172 1255 ± 73 1244 ± 253 1513 ± 341
HOMA-ratio 1.9 ± 0.7 3.0 ± 1.2 3.6 ± 2.3 3.0 ± 0.5
N (g/day) 12.9 ± 0.8 @ 11.7 ± 0.8 * 10.5 ± 2.9 11.6 ± 0.8
Data represent mean ± SEM
&: 1 data ontbreekt nog (infusie 21)
* p<0.05 compared to basal situation
# p<0.01 compared to 6 months treatment
@ p <0.05 compared to control subjects
=0.61, p<0,01
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Figure 1. The association-curve between the GNG (y-axis)
and plasma IGF-2 levels (x-axis).
G
N
G
(m
m
m
ol
/k
gF
F
M
/m
in
)
FFM/min; p<0.01), and after 6 months thera-
py (2.5 ± 0.3 µmol/kg FFM/min; p<0.05),
compared to control subjects (1.5 ± 0.1
µmol/kg FFM/min). The percent contribu-
tion of GNG from pyruvate to glucose pro-
duction was significantly (P<0.05) lower at
basal situation (44.6 ± 2.4 %) compared to
control subjects (55.7 ± 3.2%). This is also
true when expressed in µmol/kg FFM/min
although this was not statistically different
(table 4). The percent contribution of GNG
from pyruvate + glycerol to glucose produc-
tion was statistically lower at baseline and at
6 months treatment compared to control
subjects (P<0.05) and gradually increased
during rhGH treatment; 66.7 ± 3.1 at base-
line to 68.5 ± 3.8 and 75.6 ± 1.9 at 6 and 12
months of rhGH treatment respectively.
However, when expressed as µmol/kg
FFM/min it was not significantly different.
In the whole data set, GNG (µmol/kg
FFM/min) was negatively associated with
plasma IGF-2 levels (R=-0.605, p=0.006)
(fig.1).
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Table 4: Glucose turnover of GHD patients before and after respectively 6 and 12 months of
rhGH replacement therapy compared with age, sex and BMI matched control subjects
Baseline 6 months 12 months Control 
subjects
Glucose Ra (µmol/kg/min) 10.5 ± 0.3 10.8 ± 0.5 9.5 ± 0.7 10.2 ± 0.3
Glucose Ra 
(µmol/kg FFM/min) 8.0 ± 0.5 8.4 ± 0.7 7.3 ± 0.9 7.6 ± 0.4
GNG Pyruvate (%) 44.6 ± 2.4 @ 47.4 ± 1.2 53.2 ± 4.2 55.7 ± 3.2
GNG Pyruvate 
(µmol/kg FFM/min) 3.6 ± 0.2 4.0 ± 0.3 3.6 ± 0.4 4.3 ± 0.4
GNG  pyruvate+glycerol (%) 66.7 ± 3.1 # 68.5 ± 3.8 @ 75.6 ± 1.9 79.8 ± 2.2
GNG Pyruvate +glycerol 
(µmol/kg FFM/min) 5.4 ± 0.5 5.7 ± 0.4 5.5 ± 0.8 6.1  ± 0.5
Glycogenolysis  
(µmol/kg FFM/min) 2.7 ± 0.3 # 2.5 ± 0.3 @ 1.8 ± 0.2 1.5 ± 0.1
@ p<0.05 compared to control subjects.
# P<0.01 compared to control subjects.
Table 3: Plasma GNG precursors levels in GHD subjects and on respectively 6 and 12 months
treatment on rhGH
Baseline 6 months 12 months Control 
subjects
Lactate (mmol/L) 1.6 ± 0.3 1.5 ± 0.3 1.4 ± 0.1 1.4 ± 0.1
Alanine (µmol/L) 304 ± 16 324 ± 27 335 ± 60 318 ± 14
Glutamate (µmol/L) 125 ± 12 @ 114 ± 11 @ 124 ± 12 @ 78 ± 10
Glutamine (µmol/L) 451 ± 33 400 ± 78 482 ± 17 517 ± 23
Glycerol (mmol/L) 0.16 ± 0.05 0.18 ± 0.03 0.24 ± 0.05 0.13 ± 0.04
Data represent mean ± SEM
@ p<0.05 compared to control subjects
Discussion
Endogenous glucose production in AGHD
patients is maintained on a stable level due to
an increase in gluconeogenesis during GH
therapy. Probably, this increase in GNG dur-
ing GH therapy is the consequence of a
decrease in insulin sensitivity. On the other
hand, less potency to compensate the
decrease in insulin sensitivity (by compo-
nents of the IGF system, such as IGF-2)
during GH therapy may be another explana-
tion. Animal models with defects in the
expression of IGF-2 receptors or with
defects in the related IRS-2 pathway showed
no capacity in the compensation for a prodia-
betic phenotype (16;17). Indeed, in our
study pooled plasma IGF-2 levels were found
to be negatively associated with pooled
GNG.
Although several earlier reports noted
decreased insulin sensitivity during GH ther-
apy (18;19), a recent report found that the
higher start dosages of GH in those early
days of GH treatment were related to these
negative effects on glucose homeostasis (20).
Even opposite effects of GH therapy on
insulin sensitivity were found; a study with a
hyperinsulinemic-euglycemic clamp in
AGHD patient showed that 7 years of GH
treatment may prevent from an age-related
decline in insulin sensitivity (19). Indeed, in
this study no increase in HOMA index was
observed, although a tendency existed for
higher levels of insulin during GH therapy.
In one study, we compared AGHD patients
with BMI- and age matched control subjects
on baseline, and insulin sensitivity was in the
mild obese control subjects higher than in
AGHD patients (although not significant).
The metabolic rate in AGHD patients
increased slightly, but not significantly, dur-
ing GH therapy. In previous studies, rest
metabolic rate (RMR) in AGHD patients
increased after 3 to 6 months of GH therapy,
and the change in RMR could be explained
for about 60% by the change in FFM
(21;22). Moreover, a decrease in FFM in
AGHD patients was observed in the first 6
weeks of the 24 weeks GH therapy, with a
simultaneous increase in RMR (23). In line
with this, we also found no change in FFM
during GH therapy. The glucose oxidation,
as a principal energy source in humans, (as
estimated by RQ measurements) is about
60% in both AGHD patients and control
subjects with only a small decrease during
GH therapy. Fat oxidation in AGHD
patients increased during GH therapy, but
not significant. Recombinant GH substitu-
tion in fasting healthy volunteers increased
oxidation of fatty acids with a related
decrease in serum alanine levels (24). Our
observations are in concordance with Hoff-
man et al, who showed no difference in ener-
gy expenditure (by indirect calorimetry) and
fuel utilization (fat and glucose oxidation)
between AGHD patients and control sub-
jects (25).
In this study, total glucose turnover was not
different between AGHD patients and con-
trol subjects. This observation is in line with
previous reports that explore post absorptive
state glucose metabolic clearance rate and
glucose turnover in AGHD (26), also after
start of GH therapy no significant change in
glucose turnover was found (27). Additional-
ly, so far, no other study showed that the per-
centage of GNG is markedly decreased in
pretreatment AGHD patients in comparison
to mild obese control subjects. On the other
hand, GL in AGHD was increased. In physi-
ological conditions, a decrease in GNG is
directly related to an increase in glycogenoly-
sis to prevent harmful hypoglycemic events.
This inverse relationship between GNG and
GL reflect an autoregulatory pathway, that
activates GL in response to a decreased level
in GNG. Since control subjects were
matched for BMI, the difference in GNG can
consequently not explained by the mild obe-
sity. Other factors, probably induced by GH
and translated towards the IGF system, may
be more adjusted. While previous reports
mention normal insulin sensitivity in GH
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deficient subjects, some other studies report
an increased insulin resistance in obese GH
deficient subjects (28), and an impaired glu-
cose tolerance, in especially female GH defi-
cient subjects. GNG is under influence of
the hormone glucagon, that slightly increases
in parallel with GNG in this study. The
increased amounts of lipolytic products, such
as glycerol and fatty acids, during GH thera-
py will decrease the entry of citrate in the
Kreb cyclus, and favours acetyl-Co A to the
oxaloacetate-malate reaction with formation
of GNG substrate. In line with conditions
that are associated with an accelerated lipoly-
sis, such as a prolonged fasting period (29)
and in diabetes mellitus (30) glycerol acts as a
precursor in gluconeogenic processes.
Although, FFAs serve as a substrate for de-
novo glucose synthesis (31), high FFA levels
also inhibit insulin action on the receptor
level. Consequently, activation of glycogen
synthase by insulin is inhibited (32).
The significant decreased GNG in AGHD
patients may also be due to failure of the
expression of rate determining enzymes in
GNG, such as phosphoenol pyruvate car-
boxy kinase, Gluc-6-phosphatase and fruc-
tose 1,6 biphosphatase, or by reduced supply
of amino acids that serve as glucose precur-
sors in GNG. In AGHD patients, severe
defects of in vivo insulin sensitivity and
skeletal muscle intracellular glucose phos-
phorylation and glycogen synthase activity
persist with 24 months rhGH therapy
(approximately 0.22 IU/kg week) (33;34).
Although limited amounts of glycogene in
AGHD patients are present, GL contributed
most to EGP. After start of GH therapy, the
increase in GNG in AGHD is mostly related
to pyruvate as a C3 GNG precursor. The
amino acid alanin in humans provides most
of the substrate, that is needed to form pyru-
vate with subsequent GNG (Felig cycle), and
plasma levels of alanine in AGHD patients
tend to increase during GH therapy. GH has
a nitrogen sparing effect; and this related to a
decrease in N urine and an increase in gluta-
mate efflux from the liver (35;36). Indeed,
plasma glutamate levels in AGHD patients
were higher and a decrease of N in 24 hour
collected urine was found during GH thera-
py. Interesting, the plasma glutamate levels in
AGHD patients were already increased
before treatment, and this suggests that not
only GH induces the glutamate efflux.
Although baseline plasma levels of alanine
(most important GNG substrate) and lactate
were comparable in AGHD patients and
control subjects, the plasma glutamine levels
were decreased in GHD patients and gluta-
mate significantly increased in those on ther-
apy (table 3). In terms of adding new (non-
glucose derived) carbons to the plasma
glucose pool, glutamine appears to be as
important as lactate (37). In humans in a
postabsorptive condition, glutamine is an
important precursor for renal GNG which
contributes 20% to 25% of the whole body
glucose production (38).
Taken together, in comparison with control
subjects that are matched for BMI, the level
of peripheral insulin resistance, the glucose
production rate and level of glucose oxida-
tion are comparable to AGHD patients,
before and during GH therapy. However, the
contribution of GNG as part of total glucose
production rate in AGHD patients increase
with alanine, pyruvate and glutamine (with a
possible increase of renal GNG) as probable
precursors, in parallel with a decrease in uri-
nary nitrogen excretion (that is a nitrogen
sparing effect of GH). The negative relation-
ship between GNG and plasma IGF-2 levels
is not elucidated yet, but suggests an inter-
esting relationship, also in humans, between
components of the IGF system and glucose
homeostasis.
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any diseases in endocrinology are
characterised by an increase in car-
diovascular mortality. In this Cur-
rent Perspective, we highlight the cardiovas-
cular pathology in active acromegaly
(circulating growth hormone excess) that is
responsible for an increase in cardiovascular
mortality, with recent developments in
molecular endocrinology and cardiology.
Afterwards, possible relationships between
growth hormone (GH) / insulin-like growth
factor (IGF) system and heart function in
ischemic heart failure, in order to underline a
concept of cardiovascular endocrinology, will
be discussed.
Cardiovascular Mortality in Acromegaly
In patients with active acromegaly, clinical
studies noted an increase in cardiovascular
mortality, that is determined mostly by heart
failure (1;2). Premature atherosclerosis, as a
second contributor of the increased cardio-
vascular mortality in acromegaly, may be due
to disturbances in lipoprotein remnant
metabolism or other present cardiovascular
risk factors (1;3).
Aggressive treatment of active acromegaly
may be able to reverse cardiovascular pathol-
ogy. A retrospective study by Orme et al
reported a decrease in cardiovascular morbid-
ity and mortality in acromegaly after lower-
ing the plasma concentration of GH under
7.5 mU/l and of IGF compatible with refer-
ence levels that are age and gender related
(4). In addition to observations, suggesting
that ultimate levels of plasma GH and IGF
determine the cardiovascular and conse-
quently the clinical outcome, also the mode
of treatment and the delay in obtaining “nor-
mal” GH and IGF levels are relevant. Neuro-
surgical treatment with total removal of the
GH-producing adenoma, with supplemen-
tary drug treatment, will result in a reduction
of cardiovascular mortality (5). The highest
death rates are observed in acromegalic
patients with aged over 60 years (75% of the
total deceased patients) and with persistent
acromegaly despite medical treatment (3.5
fold increase in relative mortality rate). Dur-
ing treatment with Octreotide retard “
(Lanreotide) in postoperative persistent dis-
ease, an improvement of the diastolic left
ventricular function (decrease of the isovolu-
metric relaxation time) and geometry
(decrease of left ventricular mass) was found
after 3 months’ treatment period (6). This
improvement in left ventricle function was
stable during a one year follow-up treatment,
but the significance for life expectancy needs
to be evaluated. Unfortunately, treatment
with Octreotide alone lowers the plasma GH
and IGF levels in only 70% of all treated
acromegalic patients (7). In contradiction to
supplementary medical therapy that lowers
systemic plasma GH and IGF-1, pituitary
radiotherapy alone detoriated heart function
(as measured by pulse-wave Doppler
echocardiography and electrocardiography)
over a 10 year’ follow-up treatment period
(8). Probably, the consequence of radiothera-
py on mortality may be explained by the
observation that the threshold for plasma
GH concentration was thought to be under
2.5 microgram/L to obtain similar cardiovas-
cular mortality rates compared to a healthy
unaffected population. However radiothera-
py alone was able to decrease plasma GH
concentrations to those threshold levels in
about 20% of acromegalic patients after a 10-
year treatment period (9).
To consider together, an active and postoper-
ative persistent disease in acromegaly give
rise to increased cardiovascular morbidity
and mortality. Cardiovascular mortality in
acromegaly could be reduced if the threshold
for plasma GH under 2.5 microgram/L is
reached and this limits treatment with a com-
bination therapy or long acting Octreotide.
Development of Cardiomyopathy in
Acromegaly
An untreated acromegaly or persistent post-
operative disease results primarily in a con-
centric hypertrophic cardiomyopathy that
develops over several years (for a short
review (10)). The development of cardiomy-
opathy in active acromegaly is determined by
several periods (figure 1).
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The Hyperkinetic Hemodynamic Period 
At an early phase in acromegaly, cardiovascu-
lar symptoms are explained by a high cardiac
output that is caused by a low systemic
resistance. Such dilation of the peripheral
arterial system is probably due to elevated
plasma levels of GH and IGF that are able to
induce nitric oxide (NO) in endothelial cells;
increased endothelial NO gives rise to signif-
icant vasodilatation (11). This initial period is
called the hyperkinetic hemodynamic period.
The fall in afterload is associated with an
increase in the activation of both the renin-
angiotensin-aldosteron system (RAAS) and
the beta-adrenergic system. High plasma lev-
els of angiotensin II, and also high plasma
levels of aldosteron, have maladaptive effects
on the heart muscle. Therefore, high circulat-
ing levels of angiotensin II and aldosteron
may worsen the cardiac performance by an
increase of myocardial hypertrophy and
fibrosis (12). In addition to after load reduc-
tion, the condition of the cardiac muscle to
respond properly may also be limited. In in
vvo models, GH is required for normal
intrinsic function of cardiac muscle (reflect-
ed by its capacity to contract) by maintaining
Ca(2+)- and beta-adrenergic responsiveness
(13), although no relation was found in a dif-
ferent rat model (14). Moreover, in long
standing acromegaly, no increased adrenergic
activity was found (15).
In conclusion, the increased circulating GH
and IGF-I, that induce high endothelial NO
levels with vasodilation, result through sys-
temic maladaptation in an increased work-
load of the heart muscle. Together with the
trophic effect of the elevated plasma GH and
IGF-1 levels on the myocardium, the heart
chamber in acromegaly is characterised by a
normal size with increased relative wall
thickness (concentric remodelling).
The period of development of concentric hyper-
trophic cardiomyopathy 
As a result of the increased left ventricular
workload and the direct trophic effects of
GH and IGF-1, concentric hypertrophic
changes of the cardiac muscle occur (16). In
parallel with concentric remodelling, local
processes in the ventricular wall result in an
increase of interstitial fibrosis, an influx of
polymorphonuclear cells and a replacement
of (functional) cardiomyocytes (17). The
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Figure 1. Different periods that determine the development
of cardiovascular disease in persistent acromegaly that final-
ly give rise to heart failure.
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GH axis/IGF system, resulting in an increased expression of
myofibrils..
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Figure 3. Possible interventions for future therapy in heart
failure
continuous deposition of interstitial fibrosis
and ventricular hypertrophy in combination
with the hyperkinetic haemodynamic period
result in a left ventricular diastolic dysfunc-
tion, as determined by measurement of the
isovolumetric relaxation time (prolonged)
and an inversed ratio of the early (Ev) and
late (Av) diastolic peak velocity (18). Long
term persistence and inability to compensate
the hemodynamic profile result in a transi-
tion from a compensated hypertrophy to
heart failure (with ultimately an overt dias-
tolic left ventricular incompetence with
accompanying systolic failure)(10) . Not
only the left ventricular function may be
affected, but also the right ventricular func-
tion could be involved in acromegalic car-
diomyopathy (biventricular heart failure).
Pathophysiological Concept of Cardiomyopa-
thy in Acromegaly
In-Vitro and Animal Studies 
The heart, and its functional units the car-
diomyocytes, is integrated in the body by
several extrinsic pathways (such as by the
endocrinological and neurological pathways)
and by the circulation itself. Deprived of
blood plasma in in-vitro experiments, car-
diomyocytes demonstrated increased apop-
tosis that is prevented by addition of IGF-1,
which inhibits apoptosis by activation of Bax
induction and Caspase 3 activation (19). This
action of IGF-1 further progresses the car-
diomyocyte in the cell growth period. This
in-vitro observation supports a relation of
IGF with cell growth and cardiomyocyte
hypertrophy. Indeed, cardiomyocytes pos-
sess large amounts of GH (GH-R) (20)and
GH secretagogue receptors (GHS-R)(21). In
a physiological state, the binding of systemi-
cally circulating plasma GH to the GH-R is a
signal to the cardiomyocyte to produce and
secrete local IGF in an autocrine and/or
paracrine way. This autocrine / paracrine
secreted IGF binds to IGF-receptors of car-
diomyocytes and induces an increase of pro-
tein transcription (myofibrils) and growth of
cardiomyocytes (17). Due to the systemic
high levels of GH in acromegaly, local IGF is
overexpressed with prevention of apoptosis,
but with ventricular hypertrophy (22). Prob-
ably, this inverse relation between apoptosis
and ventricular hypertrophy serves to protect
the early cardiac adaptive system. Therefore,
these previous results confirm that imbal-
ances in systemic and local GH/IGF systems
cause final damage to cardiomyocytes (23).
This may explain the effects of systemic
excess of GH (and IGF-1), occurring in
active acromegaly (24). The contribution of
IGF-I to unfavourable changes in cardiac
performance in acromegaly can be indirectly
confirmed in knock-out animal models for
hepatic IGF-I production. With this model,
no cardiac malfunction is observed, although
plasma GH levels reach excessive levels (25).
The marked contribution of IGF-1 in
acromegaly, and not specifically GH, is once
again proven with these experiments. In the
development of hypertrophic cardiomyopa-
thy, not only systemic IGF-1 but also locally
produced IGF-I may play a role; in vitro
experiments showed an increase in tissue
expression of IGF-I receptor and IGF-I
mRNA of cardiac muscle tissue in the case of
an elevated pressure or volume load (25).
Increase of left ventricular hypertrophy
results in a decrease of wall compliance and
subsequently to an increased end-diastolic
left ventricular pressure. Consequently, local
increase of IGF-I in cardiac muscle gives rise
to further hypertrophic changes, but in addi-
tion to adaptive hypertrophic changes anoth-
er factor need to be present to give rise to
cardiomyopathy, such as a decreased proper-
ty of muscle contraction. GH regulates the
contractility of the heart muscle by its influ-
ence on Ca2+ dependent processes. But in-
vitro, Hexarelin (a synthetic GH secreta-
gogue) had no significant effect on calcium
transients and on the Ca flux measured in
isolated ventricular cells (26). In line with
this observation, acromegaly deteriorates the
cardiac ventricular relaxation (diastolic
phase) while it has no influence on contrac-
tility (systolic phase)(27), and the progres-
sion of cardiomyopathy. Also in concordance
with strict lowering of both GH (because
218
this will decrease local IGF-I) and IGF-I
with aggressive octreotide therapy (such as
Slow Release Lanreotide and Long-Acting
Release Octreotide) that results in improve-
ment of the end-diastolic pressure (after
three months of therapy)(6).
In Humans 
Most previous proposed pathophysiological
mechanisms of the hypertrophic cardiomy-
opathy in acromegaly are constructed from
several non-human models (such as animal
models and in-vitro experiments). On the
other hand, cardiomyocytes obtained from
cardiac muscle biopsies from acromegalic
patients, reveal an increase of apoptosis.
Moreover, the increase of apoptosis is func-
tionally related to a decrease in ejection frac-
tion, but not related to plasma GH or plasma
IGF-1 levels (Fristaci et al 1999 Circulation).
This observation is in contrast with results as
described in animal models: IGF protects for
cardiomyocyte apoptosis, while in GH defi-
ciency an increased apoptosis and increased
occurrence of enhanced heart performance is
found (28). Possibly, this contradiction may
partly be explained by a down-regulated GH-
R, in case of GH excess because that may
give rise to an increased apoptosis although
high circulating GH and IGF levels exist.
Therefore, we hypothesize that increased
plasma levels of GH and IGF may exist, with
a low local expression of GH-R on the car-
diomyocyte, which give rise to a relatively
low local biological activity of IGF-1. The
decrease in GH-R results in a reduction of
intracellular signal transmission towards
intracellular production of IGF-1 and, there-
fore, with few or no release of local and
paracrine and autocrine active IGF-I. In addi-
tion, GH receptors on the surface of car-
diomyocytes are regionally expressed in dif-
ferent amounts, mediated through the
intracellular ubiquitin-proteasome (U-P)
system (29). Increase of the U-P system
activity results in a decrease of GH-R expres-
sion (such as occurs in cachectic patients
with a malignant disease (30)) and by inter-
vention with antagonists of the U-P system,
GH resistance may be corrected. The coex-
isting excessive amounts of systemic IGF-1
are functional in the negative hypothalamic
feedback route and not in local tissue effects.
Hitherto, this analysis of IGF-1 in
acromegaly and its effect on tissue level is
still under study. More efforts need to be
made in human models in order to evaluate
the balance between local and systemic IGF-
1 in cardiomyopathy during acromegaly.
To conclude, the pathophysiological concept
of hypertrophic cardiomyopathy in
acromegaly based on animal models and in
vitro experiments needs to be reassessed with
results that are derived from human studies.
Completion of the pathophysiological basis
of the cardiomyopathy by the rapid develop-
ment of non-invasive techniques (such as
metabolic studies with MRI of the heart) and
the increase of knowledge of GH-R expres-
sion and apoptosis will be an impulse in the
creation of future interventions.
New Insights in Heart Failure Pathophysiolo-
gy: Role for GH/IGF-1 axis?
GH substitution and heart failure 
Cardiomyopathy and subsequent heart fail-
ure, is mostly the consequence of ischemic
heart disease (31). In a recent editorial writ-
ten by Cuneo (32), the substitution of rhGH
in patients with ischemic heart disease was
favourable for cardiac performance, such as
ejection fraction and wall kinetics. Especially
its effect on trophic stimulation of the heart
muscle and the subsequent increase of con-
tractility is put forward to be principally
important. One study showed an additional
effect on ACE inhibition of GH in improv-
ing cardiac performance after mild cardiac
ischemia (33). Although these positive
effects on left ventricular function during
rhGH substitution in short term interven-
tion studies, there are no randomised placebo
controlled studies that show a decrease in
cardiovascular morbidity and mortality after
rhGH substitution in patients with coronary
artery disease (CAD).
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Acquired GH insensitivity in heart failure 
Besides substitution of rhGH in CAD
patients to prevent the definite decrease in
heart performance, subcutaneous substitu-
tion of GHrelin may be cautiously consid-
ered as another progress in the treatment of
heart failure. GHrelin is an endogenous lig-
and of the growth hormone secretagogue
receptor (GHS) (34)and in this way acts
additionally in the GH/IGF-1 axis (35). In a
rat model with ischemic heart failure, left
ventricular dysfunction and cardiac cachexia
ameliorated during long-term application of
subcutanous Ghrelin (36). In patients with
chronic ischemic heart failure, Ghrelin
administration improved cardiac function
without a negative influence on renal func-
tion (21). In other studies, plasma Ghrelin
levels were elevated in patients with conges-
tive heart failure and cachexia, compared to
patients with only congestive heart failure.
These plasma levels of Ghrelin are signifi-
cantly associated with plasma GH and TNF-
alpha levels and body mass index (37). Ele-
vated plasma GH, that suggests a decreased
local GH sensitivity (38), and Ghrelin levels
compensate for low expression of cardiomy-
ocyte GH-R in order to increase intracellular
IGF production. Increased secretion of IGF-
1 will induce trophic changes that may sus-
tain cardiac performance. Therefore, applica-
tion of synthetic Ghrelin in a condition of a
decreased cardiac performance due to
ischemic heart disease, may correct simulta-
neously an acquired GH resistance state on
the level of cardiac tissue. Anand et al (39)
and Anker et al (40)who have shown an
increase in plasma levels of GH and a
decrease in GH-BP, IGF-1 and IGF-BP3 sup-
ported a GH resistant state in case of
ischemic heart failure.
Oxidative stress 
In vitro and animal studies, congestive heart
failure is considered as a state of oxidative
stress. GH has a direct protective effect on
oxidative stress-induced apoptosis in cardiac
myocytes and that the effect of GH is attrib-
uted at least in part to the activation of ERKs
through Ras and PTKs including JAK2, Src,
and EGF receptor tyrosine kinase(41). How-
ever, human studies do not support this
oxidative state as the origin of congestive
heart failure (42).
In conclusion
The GH axis/IGF system is related to hyper-
trophic cardiomyopathy (in acromegaly) and
heart failure (in ischemic heart disease) in
distinctive ways. Although several local
processes in the cardiomyocyte play a role in
the adaptation of heart function, similarities
in coping are observed. Control of apoptosis
appears to be a key factor, and that is partly
related to GH/IGF balances in local heart
tissue. Specific interventions (such as Ghre-
lin administration) may modulate these bal-
ances and give rise to a reversal of deranged
coping mechanism of the heart. Our contri-
bution aims to express the need for a multi-
disciplinary approach in cardiovascular dis-
ease, and its relation with hormonal balances:
the concept of cardiovascular endocrinology
(43).
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Significant improvement of acromegaly-
induced cardiomyopathy after
normalisation of GH levels
- A case report and review -
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ach year, approximately one hundred
patients are candidates to be evaluated
for a cardiac transplantation proce-
dure in the Netherlands, and several thou-
sand patients worldwide. In most patients, an
underlying cardiomyopathy (in 40-74% the
result of ischemic heart disease), is the major
reason for transplantation (1). Although it is
the leading cause, not only ischemic heart
disease may be the reason of (severe) car-
diomyopathy and an elaborate analysis of the
cardiomyopathy may identify reversible
causes. Cardiovascular morbidity and mortal-
ity has been associated with hormonal distur-
bances, such as occurs in subclinical
hypothyroidism (2;3), subclinical hyperthy-
roidism (4) and adult-onset growth hormone
(GH) deficiency (5-7). Although these hor-
monal disturbances are frequently observed
in premature cardiovascular disease, a more
rare but impressive effect of GH excess
(acromegaly) on cardiac function is known.
However, the clinical presentation and recog-
nition of acromegaly and especially its rela-
tion with overt cardiovascular disease is not
easy. In general, careful clinical observation is
necessary to diagnose a possible hormonal
disturbance that underlies cardiovascular dis-
ease, preferably at an early stage.
With this case report, we focus on GH excess
as a primary cause of overt and disabling car-
diovascular disease. In addition, we will dis-
cuss the effects of the GH/IGF system on
the cardiovascular system and its implication
in our understanding of the development
into end stage cardiomyopathy.
Case
A 49-years old woman was referred to our
heart transplantation unit because of an idio-
pathic cardiomyopathy, first diagnosed one
year before the referral. Two months before,
she was hospitalized in a local hospital due to
manifest cardiac failure that was treated with
intravenous dehydration therapy in the acute
period. She continued the medication she
used before the heart failure period such as
diuretics, Angiotensin-Converting-Enzyme
(ACE) inhibitors, oral nitrates, selective
antagonist of alpha 1 and alpha 2 receptors
and lipid lowering medication. In parallel, she
also developed diabetes, which had become
insulin-dependent the moment of presenta-
tion. Before the observation of the cardiomy-
opathy, she had always been “in excellent
health”. She had no other risk factors for car-
diovascular disease besides diabetes. Routine
laboratory tests were within normal limits.
No definite cause for the cardiomyopathy
was found at that time. Echocardiography
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Cardiomyopathy is known to originate from several factors, including hormonal
disturbances. In this report we describe a 49-year old woman that suffered from a
disabling cardiomyopathy, for which she was referred to our heart transplantation
unit. Clinical and laboratory evaluation revealed that the patient suffered from
acromegaly. The subsequent treatment that consisted of neurosurgery, pituitary
irradiation and somatostatin analogue therapy resulted in a significant decrease of
both the plasma IGF-1 and GH levels. In parallel with this decrease, the decreased
left ventricle function improved dramatically to normal. This case shows that
aggressive treatment of acromegaly can result in major improvement of cardiac
dysfunction. The most remarkable results with respect to the cardiac performance
in acromegaly are obtained if plasma GH levels are strictly reduced to less than 2,5
mU/L. Indeed, in this case report we also show an impressive improvement of the
diminished left ventricle function following extensive lowering of plasma GH,
despite the absence of full normalisation of plasma IGF-1 levels. Myocardial dys-
function therefore warrants an extensive analysis of possible hormonal distur-
bances, especially of the GH/IGF system.
E
showed poor left ventricular function and
mild secondary regurgitation of the mitral
and tricuspid valves. The angiographic proce-
dure (performed in the local hospital)
showed a severely dilated left ventricle with
only poor contractions of the left ventricle.
The coronary arteries were normal. The pres-
sure in the right cardiac system was not
increased.
At our heart transplantation unit, extensive
investigations confirmed the dilated left ven-
tricle with a low ejection fraction (figure 1,
period A). Her body mass index was 34 kg/m
2 (height: 1,62 m; weight: 90 kg). Blood
pressure was 110/65 mmHg. Glycosylated
Hb was 9.7% with a fasting plasma glucose
level of 16.6 mmol/l. Baseline fasting plasma
cholesterol, HDL-cholesterol and triglyc-
erides were 6.7 mmol/l, 1.02 mmol/l and 8.5
mmol/l, respectively. As a consequence of
her stable clinical condition, no immediate
measures were taken to prepare her for heart
transplantation and consequently she was
followed in the outpatient clinic. In this peri-
od life style measures, fluid restriction and
optimalisation of her medication improved
further her clinical condition and exercise
tolerance. From the cardiology department,
she was referred to the department of
endocrinology because of increasing dosages
of insulin which were needed to correct the
hyperglycemia.
At the endocrinology department, she com-
plained of increased sweating and diminished
sensitivity in both her feet and hands during
the last year. Also, shoe size had increased
during that time. She did not smoke or drink
alcohol in large amounts (less than 2 units a
day). Menses were regular and she had no
(severe) headaches. At physical examination,
she had an evident acromegalic appearance
that consisted of manifestations of soft tissue
swelling (thickened fingers and no fit of her
rings) and acral overgrowth. In addition, she
had a carpal tunnel syndrome. Previous oph-
talmological evaluations had revealed visual
disturbances that were thought to be related
to the DM type 2; no retinal disease or visual
field defects had been detected. In line with
the clinical diagnosis of acromegaly, both the
plasma levels of plasma insulin like growth
factor-1 (IGF-1) and GH were increased (fig
1A). The MRI scan of the pituitary region
showed an adenoma with a size of 1.5 cm,
which was resected by transsphenoidal sur-
gery after pretreatment with Octreotide
LAR (20 mg during 4 weeks). Histologic
examination revealed a GH and prolactin
secreting adenoma. Both the type 2 diabetes
and the hyperlipidemia with which she ini-
tially presented, were considered to be part
of the acromegaly syndrome.
Postoperative evaluation showed significant
reduction but no normalisation of plasma
GH and IGF-1 levels (fig 1B). MRI scanning
of the pituitary region showed a contrast fill-
ing remnant adenoma tissue next to the left
internal carotid artery. Octreotide LAR
treatment was restarted and she underwent
local radiotherapy (RT: rotation technique,
50 Gy in 25 fractions). In the year following
RT, Octreotide LAR dosages had to be
increased from 20 to 30 mg/weeks and addi-
tional cabergolin (1mg/wk) treatment was
initiated (fig 1C) because of persisting rem-
nant GH overproduction
Echocardiography during the treatment of
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Figure 1. Figure 1. An overview of the several parameters
measured in the patient with acromegaly during clinical fol-
low-up (from A to B to C to D; in the upper part) in the
cardiology and endocrinology department. Plasma levels of
IGF-1 (left y-axis; closed boxes) and of GH (right axis;
open triangles) are shown. The ejection fraction of the left
ventricle is presented by a bar with an indication of its actu-
al value (in percentage). Closed horizontal bars beneath the
graph express the: Oct: Octreotide treatment, Cab: Caber-
golin treatment
the acromegaly showed a dramatic improve-
ment in left ventricular function. Initially, the
left ventricle was severely dilated with an
impaired function (ejection fraction at rest
was 20%, fig 1 period [A]). No significant
abnormalities of the right ventricle were
observed. After one year, the left ventricle
was less dilated in combination with a mild
concentric hypertrophy and a moderate dif-
fuse hypokinesia of the left ventricle. In the
third year of evaluation the left ventricle size
was within normal limits. Only slight con-
centric left ventricle hypertrophy and further
reduction of global hypokinesia were
observed. The ejection fraction of the left
ventricle at rest increased to 45 % (Fig 1
period [C]). The most recent evaluation (Fig
1 period [D]) showed a normalization of the
left ventricle size and left ventricle wall
thickness with only a slightly impaired left
ventricular systolic function with an ejection
fraction of 55%. Fractional shortening
[defined as [(Left Ventricular Intrinsic
Diameter in diastole-Left Ventricular Intrin-
sic Diameter in systole / Left Ventricular
Intrinsic Diameter in diastole)*100%]],
another parameter of contractility, increased
from 18% (period A) to 36% in period D
(figure 2). The left atrium was mildly dilated
during the first two years of evaluation,
which was normalized at the third evaluation.
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"Parasternal long axis M-mode echocardiographic record-
ings. Figure 2a depicts a severely dilated left ventricle with a
global hypokinesia. Fig 2 b demonstrates the normalization
of the left ventricle size, with a slightly impaired left ventric-
ular systolic function. In both ultrasound pictures (figure 2a
and 2b), the left vertical white line indicates the left ventric-
ular intrinsic diameter (LVID) in the diastolic period(d),
and the right vertical white line the LVID in the systolic
period(s)."
A
(s)(d)
Figure 2a
B
(s)(d)
Figure 2b
Discussion
Disturbances in the GH/IGF-1 axis, as in a
deficient (GH deficiency) and excessive
(acromegaly) state, are associated with dis-
turbances in cardiovascular performance, in
body composition and in lipoprotein rem-
nant metabolism (8;9), with a consequent
increased cardiovascular morbidity and mor-
tality (10-12). Suppression of plasma GH
levels below 5.0-7.5 mU/l and lowering of
plasma IGF-1 levels to age and sex adjusted
normal ranges reduce the cardiovascular
morbidity and mortality to that of the gener-
al population (13).
In our patient, all three therapeutic options
(neuro-surgery, radiotherapy and medica-
tion) were needed to control the increased
activity of the plasma GH/IGF-1 axis.
Despite aggressive therapeutic strategy, plas-
ma IGF-1 levels could not be normalised, in
contrast to the plasma GH levels. Limita-
tions of the results of medical treatment after
neuro-surgery and radiotherapy in
acromegaly are well known. Octreotide ther-
apy only reduces plasma IGF-1 levels in at
least 60- 70% of the total acromegalic popu-
lation (14). Suppression of systemic levels of
plasma IGF-1 and GH, such as with
octreotide therapy (slow release lanreotide
and long-acting release octreotide) result in
improvement of diastolic function after 3
months of treatment (15).
In most cases, GH excess (acromegaly)
results in a concentric hypertrophic car-
diomyopathy (16) that slowly develops dur-
ing several years. The origin of this car-
diomyopathy results from a high cardiac
output, due to an initially low systemic vas-
cular resistance, together with a high dias-
tolic capacity of the left ventricle, that is also
described as a hyperkinetic hemodynamic
syndrome (17). The decrease in afterload can
be explained by the inductive effect of IGF-1
on the nitric oxide (NO) system in the arte-
rial endothelium that results in a vasodilation
(18). As a consequence of the high output
state, the workload of the left ventricle is
continuously elevated, resulting in hyper-
trophic changes. In addition, GH excess
induces interstitial fibrosis of the ventricular
myocardium (19). Finally, in chronic GH
excess state, the impairment of diastolic
competence accounts for the definite systolic
dysfunction [16]. In our patient, both the
severe impairment of the contractility (with
an ejection fraction of 20 % at rest) and the
increase in the left ventricle diameter in both
the systolic and diastolic period indicate that
similar processes in the development of left
ventricle dysfunction took place. Although
Fazio et al (20) reported a biventricular
involvement in the cardiac dysfunction in
acromegalic patients, no impairment of the
right ventricle function could be observed in
our patient. Both hypertension (especially
elevated diastolic blood pressure)(21) and
glucose intolerance [16] are aggravating fac-
tors in cardiac dysfunction in acromegaly. In
our patient the insulin resistance progressive-
ly increased; this may have contributed to the
severity of the impaired left ventricle func-
tion at admission. No hypertension was
observed at that stage, probably due to
severely impaired ejection fraction (20%)
and GH-related peripheral vasodilation.
In order to explain in acromegaly the transi-
tion from the initial adaptive hypertrophy
towards heart failure, recent observations
show that local expression of distinctive
growth factors increase the susceptibility of a
failing myocardium. The cross-talk between
these growth factors and the myocardium
determine the definite response of the heart
muscle on haemodynamic changes, with a
different response in case of a volume or a
pressure overload (22;23). Several local
growth factors (such as IGF-I, endothelin-I
and Angiotensin-II) are expressed in a close-
ly coordinated and sequential order (24). In
acromegaly, the early diastolic dysfunction
(with a progressive increase in volume load
and a subsequent overload) is compensated
by hypertrophy of the left ventricle. In the
process of adaptation in case of volume over-
load, the local expression of both the IGF-I
mRNA and protein are necessary (25). After
a certain level of wall stress (threshold) is
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reached, the local expression of IGF-I will
diminish. Reciprocally, with an increase in
transmural tension the local tissue expression
of Angiotensin-II will be upregulated with a
subsequent harmful effect on the function of
the cardiomyocyte (26). Apoptosis of car-
diomyocytes and the development of
myocardial fibrosis are positively associated
with local tissue levels of this inducible
Angiotensin-II (27;28). In line with the
knowledge about local expression of growth
factors in the heart, the transition towards
heart failure in overt acromegaly could be
related to the actual expression of the local
IGF system. An adequate expression of local
IGF-I in the cardiomyocyte prevent the cell
from apoptosis (29;30). The capability to
express the local IGF system may be intrinsi-
cally (such as polymorphisms for IGF-1
receptor)(31) or extrinsically (such as
acquired GH insensitivity) (32) related. The
non-availability of the GH receptor on the
cardiomyocyte is indirectly suggested by
positive effects on the heart function in heart
failure after stimulation of the GH secreta-
gogue receptors (GHS-R). These GHS-Rs
are abundantly, and in parallel with the GH
receptor, expressed on the myocardial sur-
face (33). Stimulation of the GHS-R by the
natural GHS ligand, ghrelin, improves left
ventricle dysfunction in rats (34) and in
humans in end stage heart failure (33;35).
Therefore, in the final stage of heart failure
not GH itself but the GHS ligand is able to
transmit a positive signal directing maladap-
tation towards adaptation of the left ventri-
cle, probably through local induction of
IGF-I.
In conclusion, in case of severe non-ischemic
cardiomyopathy reversible defects in the
activity of hormonal systems (such as the
GH/IGF system) need to be thoroughly
investigated. The cardiac dysfunction as
observed in acromegaly depends on the
effect of the influence of systemic GH on
the local GH/IGF balance in the cardiac tis-
sue. Therefore, plasma GH levels may better
reflect the consequences of acromegaly on
the local equilibrium of the cardiac muscle
than plasma IGF-1 does. Cardiovascular dys-
function is reversible after optimal lowering
of the plasma GH levels, probably as a conse-
quence of normalization of the local
GH/IGF balance in the cardiac tissue.
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